#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=A KCNJ6 gene polymorphism modulates theta oscillations during reward processing
#Text=Event related oscillations (EROs) are heritable measures of neurocognitive function that have served as useful phenotype in genetic research.
1-1	0-1	A	_	
1-2	2-7	KCNJ6	_	
1-3	8-12	gene	_	
1-4	13-25	polymorphism	_	
1-5	26-35	modulates	_	
1-6	36-41	theta	_	
1-7	42-54	oscillations	_	
1-8	55-61	during	_	
1-9	62-68	reward	_	
1-10	69-79	processing	_	
1-11	80-85	Event	_	
1-12	86-93	related	_	
1-13	94-106	oscillations	_	
1-14	107-108	(	_	
1-15	108-112	EROs	_	
1-16	112-113	)	_	
1-17	114-117	are	_	
1-18	118-127	heritable	_	
1-19	128-136	measures	_	
1-20	137-139	of	_	
1-21	140-154	neurocognitive	_	
1-22	155-163	function	_	
1-23	164-168	that	_	
1-24	169-173	have	_	
1-25	174-180	served	_	
1-26	181-183	as	_	
1-27	184-190	useful	_	
1-28	191-200	phenotype	_	
1-29	201-203	in	_	
1-30	204-211	genetic	_	
1-31	212-220	research	_	
1-32	220-221	.	_	

#Text=A recent family genome-wide association study (GWAS) by the Collaborative Study on the Genetics of Alcoholism (COGA) found that theta EROs during visual target detection were associated at genome-wide levels with several single nucleotide polymorphisms (SNPs), including a synonymous SNP, rs702859, in the KCNJ6 gene that encodes GIRK2, a G-protein inward rectifying potassium channel that regulates excitability of neuronal networks.
2-1	222-223	A	_	
2-2	224-230	recent	_	
2-3	231-237	family	_	
2-4	238-249	genome-wide	_	
2-5	250-261	association	_	
2-6	262-267	study	_	
2-7	268-269	(	_	
2-8	269-273	GWAS	_	
2-9	273-274	)	_	
2-10	275-277	by	_	
2-11	278-281	the	_	
2-12	282-295	Collaborative	_	
2-13	296-301	Study	_	
2-14	302-304	on	_	
2-15	305-308	the	_	
2-16	309-317	Genetics	_	
2-17	318-320	of	_	
2-18	321-331	Alcoholism	_	
2-19	332-333	(	_	
2-20	333-337	COGA	_	
2-21	337-338	)	_	
2-22	339-344	found	_	
2-23	345-349	that	_	
2-24	350-355	theta	_	
2-25	356-360	EROs	_	
2-26	361-367	during	_	
2-27	368-374	visual	_	
2-28	375-381	target	_	
2-29	382-391	detection	_	
2-30	392-396	were	_	
2-31	397-407	associated	_	
2-32	408-410	at	_	
2-33	411-422	genome-wide	_	
2-34	423-429	levels	_	
2-35	430-434	with	_	
2-36	435-442	several	_	
2-37	443-449	single	_	
2-38	450-460	nucleotide	_	
2-39	461-474	polymorphisms	_	
2-40	475-476	(	_	
2-41	476-480	SNPs	_	
2-42	480-481	)	_	
2-43	481-482	,	_	
2-44	483-492	including	_	
2-45	493-494	a	_	
2-46	495-505	synonymous	_	
2-47	506-509	SNP	_	
2-48	509-510	,	_	
2-49	511-519	rs702859	_	
2-50	519-520	,	_	
2-51	521-523	in	_	
2-52	524-527	the	_	
2-53	528-533	KCNJ6	_	
2-54	534-538	gene	_	
2-55	539-543	that	_	
2-56	544-551	encodes	_	
2-57	552-557	GIRK2	_	
2-58	557-558	,	_	
2-59	559-560	a	_	
2-60	561-570	G-protein	_	
2-61	571-577	inward	_	
2-62	578-588	rectifying	_	
2-63	589-598	potassium	_	
2-64	599-606	channel	_	
2-65	607-611	that	_	
2-66	612-621	regulates	_	
2-67	622-634	excitability	_	
2-68	635-637	of	_	
2-69	638-646	neuronal	_	
2-70	647-655	networks	_	
2-71	655-656	.	_	

#Text=The present study examined the effect of the KCNJ6 SNP (rs702859), previously associated with theta ERO to targets in a visual oddball task, on theta EROs during reward processing in a monetary gambling task.
3-1	657-660	The	_	
3-2	661-668	present	_	
3-3	669-674	study	_	
3-4	675-683	examined	_	
3-5	684-687	the	_	
3-6	688-694	effect	_	
3-7	695-697	of	_	
3-8	698-701	the	_	
3-9	702-707	KCNJ6	_	
3-10	708-711	SNP	_	
3-11	712-713	(	_	
3-12	713-721	rs702859	_	
3-13	721-722	)	_	
3-14	722-723	,	_	
3-15	724-734	previously	_	
3-16	735-745	associated	_	
3-17	746-750	with	_	
3-18	751-756	theta	_	
3-19	757-760	ERO	_	
3-20	761-763	to	_	
3-21	764-771	targets	_	
3-22	772-774	in	_	
3-23	775-776	a	_	
3-24	777-783	visual	_	
3-25	784-791	oddball	_	
3-26	792-796	task	_	
3-27	796-797	,	_	
3-28	798-800	on	_	
3-29	801-806	theta	_	
3-30	807-811	EROs	_	
3-31	812-818	during	_	
3-32	819-825	reward	_	
3-33	826-836	processing	_	
3-34	837-839	in	_	
3-35	840-841	a	_	
3-36	842-850	monetary	_	
3-37	851-859	gambling	_	
3-38	860-864	task	_	
3-39	864-865	.	_	

#Text=The participants were 1,601 adolescent and young adult offspring within the age-range of 17–25 years (800 males and 801 females) from high-dense alcoholism families as well as control families of the COGA prospective study.
4-1	866-869	The	_	
4-2	870-882	participants	_	
4-3	883-887	were	_	
4-4	888-893	1,601	_	
4-5	894-904	adolescent	_	
4-6	905-908	and	_	
4-7	909-914	young	_	
4-8	915-920	adult	_	
4-9	921-930	offspring	_	
4-10	931-937	within	_	
4-11	938-941	the	_	
4-12	942-951	age-range	_	
4-13	952-954	of	_	
4-14	955-957	17	_	
4-15	957-958	–	_	
4-16	958-960	25	_	
4-17	961-966	years	_	
4-18	967-968	(	_	
4-19	968-971	800	_	
4-20	972-977	males	_	
4-21	978-981	and	_	
4-22	982-985	801	_	
4-23	986-993	females	_	
4-24	993-994	)	_	
4-25	995-999	from	_	
4-26	1000-1010	high-dense	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]	
4-27	1011-1021	alcoholism	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]	
4-28	1022-1030	families	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]	
4-29	1031-1033	as	_	
4-30	1034-1038	well	_	
4-31	1039-1041	as	_	
4-32	1042-1049	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
4-33	1050-1058	families	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
4-34	1059-1061	of	_	
4-35	1062-1065	the	_	
4-36	1066-1070	COGA	_	
4-37	1071-1082	prospective	_	
4-38	1083-1088	study	_	
4-39	1088-1089	.	_	

#Text=Theta ERO power (3.5–7.5 Hz, 200–500 ms post-stimulus) was compared across genotype groups.
5-1	1090-1095	Theta	_	
5-2	1096-1099	ERO	_	
5-3	1100-1105	power	_	
5-4	1106-1107	(	_	
5-5	1107-1110	3.5	_	
5-6	1110-1111	–	_	
5-7	1111-1114	7.5	_	
5-8	1115-1117	Hz	_	
5-9	1117-1118	,	_	
5-10	1119-1122	200	_	
5-11	1122-1123	–	_	
5-12	1123-1126	500	_	
5-13	1127-1129	ms	_	
5-14	1130-1143	post-stimulus	_	
5-15	1143-1144	)	_	
5-16	1145-1148	was	_	
5-17	1149-1157	compared	_	
5-18	1158-1164	across	_	
5-19	1165-1173	genotype	_	
5-20	1174-1180	groups	_	
5-21	1180-1181	.	_	

#Text=ERO theta power at central and parietal regions increased as a function of the minor allele (A) dose in the genotype (AA > AG > GG) in both loss and gain conditions.
6-1	1182-1185	ERO	_	
6-2	1186-1191	theta	_	
6-3	1192-1197	power	_	
6-4	1198-1200	at	_	
6-5	1201-1208	central	_	
6-6	1209-1212	and	_	
6-7	1213-1221	parietal	_	
6-8	1222-1229	regions	_	
6-9	1230-1239	increased	_	
6-10	1240-1242	as	_	
6-11	1243-1244	a	_	
6-12	1245-1253	function	_	
6-13	1254-1256	of	_	
6-14	1257-1260	the	_	
6-15	1261-1266	minor	_	
6-16	1267-1273	allele	_	
6-17	1274-1275	(	_	
6-18	1275-1276	A	_	
6-19	1276-1277	)	_	
6-20	1278-1282	dose	_	
6-21	1283-1285	in	_	
6-22	1286-1289	the	_	
6-23	1290-1298	genotype	_	
6-24	1299-1300	(	_	
6-25	1300-1302	AA	_	
6-26	1303-1304	>	_	
6-27	1305-1307	AG	_	
6-28	1308-1309	>	_	
6-29	1310-1312	GG	_	
6-30	1312-1313	)	_	
6-31	1314-1316	in	_	
6-32	1317-1321	both	_	
6-33	1322-1326	loss	_	
6-34	1327-1330	and	_	
6-35	1331-1335	gain	_	
6-36	1336-1346	conditions	_	
6-37	1346-1347	.	_	

#Text=These findings indicate that variations in the KCNJ6 SNP influence magnitude of theta oscillations at posterior loci during the evaluation of loss and gain, reflecting a genetic influence on neuronal circuits involved in reward-processing.
7-1	1348-1353	These	_	
7-2	1354-1362	findings	_	
7-3	1363-1371	indicate	_	
7-4	1372-1376	that	_	
7-5	1377-1387	variations	_	
7-6	1388-1390	in	_	
7-7	1391-1394	the	_	
7-8	1395-1400	KCNJ6	_	
7-9	1401-1404	SNP	_	
7-10	1405-1414	influence	_	
7-11	1415-1424	magnitude	_	
7-12	1425-1427	of	_	
7-13	1428-1433	theta	_	
7-14	1434-1446	oscillations	_	
7-15	1447-1449	at	_	
7-16	1450-1459	posterior	_	
7-17	1460-1464	loci	_	
7-18	1465-1471	during	_	
7-19	1472-1475	the	_	
7-20	1476-1486	evaluation	_	
7-21	1487-1489	of	_	
7-22	1490-1494	loss	_	
7-23	1495-1498	and	_	
7-24	1499-1503	gain	_	
7-25	1503-1504	,	_	
7-26	1505-1515	reflecting	_	
7-27	1516-1517	a	_	
7-28	1518-1525	genetic	_	
7-29	1526-1535	influence	_	
7-30	1536-1538	on	_	
7-31	1539-1547	neuronal	_	
7-32	1548-1556	circuits	_	
7-33	1557-1565	involved	_	
7-34	1566-1568	in	_	
7-35	1569-1586	reward-processing	_	
7-36	1586-1587	.	_	

#Text=Increased theta power as a function of minor allele dose suggests more efficient cognitive processing in those carrying the minor allele of the KCNJ6 SNPs.
8-1	1588-1597	Increased	_	
8-2	1598-1603	theta	_	
8-3	1604-1609	power	_	
8-4	1610-1612	as	_	
8-5	1613-1614	a	_	
8-6	1615-1623	function	_	
8-7	1624-1626	of	_	
8-8	1627-1632	minor	_	
8-9	1633-1639	allele	_	
8-10	1640-1644	dose	_	
8-11	1645-1653	suggests	_	
8-12	1654-1658	more	_	
8-13	1659-1668	efficient	_	
8-14	1669-1678	cognitive	_	
8-15	1679-1689	processing	_	
8-16	1690-1692	in	_	
8-17	1693-1698	those	_	
8-18	1699-1707	carrying	_	
8-19	1708-1711	the	_	
8-20	1712-1717	minor	_	
8-21	1718-1724	allele	_	
8-22	1725-1727	of	_	
8-23	1728-1731	the	_	
8-24	1732-1737	KCNJ6	_	
8-25	1738-1742	SNPs	_	
8-26	1742-1743	.	_	

#Text=Future studies are needed to determine the implications of these genetic effects on posterior theta EROs as possible “protective” factors, or as indices of delays in brain maturation (i.e., lack of frontalization).
#Text=1.
9-1	1744-1750	Future	_	
9-2	1751-1758	studies	_	
9-3	1759-1762	are	_	
9-4	1763-1769	needed	_	
9-5	1770-1772	to	_	
9-6	1773-1782	determine	_	
9-7	1783-1786	the	_	
9-8	1787-1799	implications	_	
9-9	1800-1802	of	_	
9-10	1803-1808	these	_	
9-11	1809-1816	genetic	_	
9-12	1817-1824	effects	_	
9-13	1825-1827	on	_	
9-14	1828-1837	posterior	_	
9-15	1838-1843	theta	_	
9-16	1844-1848	EROs	_	
9-17	1849-1851	as	_	
9-18	1852-1860	possible	_	
9-19	1861-1862	“	_	
9-20	1862-1872	protective	_	
9-21	1872-1873	”	_	
9-22	1874-1881	factors	_	
9-23	1881-1882	,	_	
9-24	1883-1885	or	_	
9-25	1886-1888	as	_	
9-26	1889-1896	indices	_	
9-27	1897-1899	of	_	
9-28	1900-1906	delays	_	
9-29	1907-1909	in	_	
9-30	1910-1915	brain	_	
9-31	1916-1926	maturation	_	
9-32	1927-1928	(	_	
9-33	1928-1931	i.e	_	
9-34	1931-1932	.	_	
9-35	1932-1933	,	_	
9-36	1934-1938	lack	_	
9-37	1939-1941	of	_	
9-38	1942-1956	frontalization	_	
9-39	1956-1957	)	_	
9-40	1957-1958	.	_	
9-41	1959-1960	1	_	
9-42	1960-1961	.	_	

#Text=Introduction
#Text=Over several decades, electrophysiological brain signals recorded from the human scalp have provided a set of heritable quantitative measures of resting state (electroencephalogram, EEG) and of neurocognitive function during cognitive tasks (event-related potentials, ERPs) and their time-frequency constituents (event-related oscillations, EROs).
10-1	1962-1974	Introduction	_	
10-2	1975-1979	Over	_	
10-3	1980-1987	several	_	
10-4	1988-1995	decades	_	
10-5	1995-1996	,	_	
10-6	1997-2017	electrophysiological	_	
10-7	2018-2023	brain	_	
10-8	2024-2031	signals	_	
10-9	2032-2040	recorded	_	
10-10	2041-2045	from	_	
10-11	2046-2049	the	_	
10-12	2050-2055	human	_	
10-13	2056-2061	scalp	_	
10-14	2062-2066	have	_	
10-15	2067-2075	provided	_	
10-16	2076-2077	a	_	
10-17	2078-2081	set	_	
10-18	2082-2084	of	_	
10-19	2085-2094	heritable	_	
10-20	2095-2107	quantitative	_	
10-21	2108-2116	measures	_	
10-22	2117-2119	of	_	
10-23	2120-2127	resting	_	
10-24	2128-2133	state	_	
10-25	2134-2135	(	_	
10-26	2135-2155	electroencephalogram	_	
10-27	2155-2156	,	_	
10-28	2157-2160	EEG	_	
10-29	2160-2161	)	_	
10-30	2162-2165	and	_	
10-31	2166-2168	of	_	
10-32	2169-2183	neurocognitive	_	
10-33	2184-2192	function	_	
10-34	2193-2199	during	_	
10-35	2200-2209	cognitive	_	
10-36	2210-2215	tasks	_	
10-37	2216-2217	(	_	
10-38	2217-2230	event-related	_	
10-39	2231-2241	potentials	_	
10-40	2241-2242	,	_	
10-41	2243-2247	ERPs	_	
10-42	2247-2248	)	_	
10-43	2249-2252	and	_	
10-44	2253-2258	their	_	
10-45	2259-2273	time-frequency	_	
10-46	2274-2286	constituents	_	
10-47	2287-2288	(	_	
10-48	2288-2301	event-related	_	
10-49	2302-2314	oscillations	_	
10-50	2314-2315	,	_	
10-51	2316-2320	EROs	_	
10-52	2320-2321	)	_	
10-53	2321-2322	.	_	

#Text=Electrophysiological measures have proven to be highly useful in studying neurocognitive functions that unfold at the millisecond range of the time scale (compared to other neuroimaging methods, such as fMRI, PET, etc.).
11-1	2323-2343	Electrophysiological	_	
11-2	2344-2352	measures	_	
11-3	2353-2357	have	_	
11-4	2358-2364	proven	_	
11-5	2365-2367	to	_	
11-6	2368-2370	be	_	
11-7	2371-2377	highly	_	
11-8	2378-2384	useful	_	
11-9	2385-2387	in	_	
11-10	2388-2396	studying	_	
11-11	2397-2411	neurocognitive	_	
11-12	2412-2421	functions	_	
11-13	2422-2426	that	_	
11-14	2427-2433	unfold	_	
11-15	2434-2436	at	_	
11-16	2437-2440	the	_	
11-17	2441-2452	millisecond	_	
11-18	2453-2458	range	_	
11-19	2459-2461	of	_	
11-20	2462-2465	the	_	
11-21	2466-2470	time	_	
11-22	2471-2476	scale	_	
11-23	2477-2478	(	_	
11-24	2478-2486	compared	_	
11-25	2487-2489	to	_	
11-26	2490-2495	other	_	
11-27	2496-2508	neuroimaging	_	
11-28	2509-2516	methods	_	
11-29	2516-2517	,	_	
11-30	2518-2522	such	_	
11-31	2523-2525	as	_	
11-32	2526-2530	fMRI	_	
11-33	2530-2531	,	_	
11-34	2532-2535	PET	_	
11-35	2535-2536	,	_	
11-36	2537-2540	etc	_	
11-37	2540-2541	.	_	
11-38	2541-2542	)	_	
11-39	2542-2543	.	_	

#Text=EROs represent the basic mechanisms of neural communication during cognitive tasks, and they provide links to associative and integrative brain functions that can be used to investigate neurocognitive processes in normal as well as clinical conditions.
12-1	2544-2548	EROs	_	
12-2	2549-2558	represent	_	
12-3	2559-2562	the	_	
12-4	2563-2568	basic	_	
12-5	2569-2579	mechanisms	_	
12-6	2580-2582	of	_	
12-7	2583-2589	neural	_	
12-8	2590-2603	communication	_	
12-9	2604-2610	during	_	
12-10	2611-2620	cognitive	_	
12-11	2621-2626	tasks	_	
12-12	2626-2627	,	_	
12-13	2628-2631	and	_	
12-14	2632-2636	they	_	
12-15	2637-2644	provide	_	
12-16	2645-2650	links	_	
12-17	2651-2653	to	_	
12-18	2654-2665	associative	_	
12-19	2666-2669	and	_	
12-20	2670-2681	integrative	_	
12-21	2682-2687	brain	_	
12-22	2688-2697	functions	_	
12-23	2698-2702	that	_	
12-24	2703-2706	can	_	
12-25	2707-2709	be	_	
12-26	2710-2714	used	_	
12-27	2715-2717	to	_	
12-28	2718-2729	investigate	_	
12-29	2730-2744	neurocognitive	_	
12-30	2745-2754	processes	_	
12-31	2755-2757	in	_	
12-32	2758-2764	normal	_	
12-33	2765-2767	as	_	
12-34	2768-2772	well	_	
12-35	2773-2775	as	_	
12-36	2776-2784	clinical	_	
12-37	2785-2795	conditions	_	
12-38	2795-2796	.	_	

#Text=Specific frequency bands within ERO responses are associated with particular cognitive processes based on the context and demand of the task.
13-1	2797-2805	Specific	_	
13-2	2806-2815	frequency	_	
13-3	2816-2821	bands	_	
13-4	2822-2828	within	_	
13-5	2829-2832	ERO	_	
13-6	2833-2842	responses	_	
13-7	2843-2846	are	_	
13-8	2847-2857	associated	_	
13-9	2858-2862	with	_	
13-10	2863-2873	particular	_	
13-11	2874-2883	cognitive	_	
13-12	2884-2893	processes	_	
13-13	2894-2899	based	_	
13-14	2900-2902	on	_	
13-15	2903-2906	the	_	
13-16	2907-2914	context	_	
13-17	2915-2918	and	_	
13-18	2919-2925	demand	_	
13-19	2926-2928	of	_	
13-20	2929-2932	the	_	
13-21	2933-2937	task	_	
13-22	2937-2938	.	_	

#Text=Recent studies have indicated that ERO theta activity in particular is related to a variety of behavioral, cognitive, and motivational or emotional aspects of human information processing, including reward processing.
14-1	2939-2945	Recent	_	
14-2	2946-2953	studies	_	
14-3	2954-2958	have	_	
14-4	2959-2968	indicated	_	
14-5	2969-2973	that	_	
14-6	2974-2977	ERO	_	
14-7	2978-2983	theta	_	
14-8	2984-2992	activity	_	
14-9	2993-2995	in	_	
14-10	2996-3006	particular	_	
14-11	3007-3009	is	_	
14-12	3010-3017	related	_	
14-13	3018-3020	to	_	
14-14	3021-3022	a	_	
14-15	3023-3030	variety	_	
14-16	3031-3033	of	_	
14-17	3034-3044	behavioral	_	
14-18	3044-3045	,	_	
14-19	3046-3055	cognitive	_	
14-20	3055-3056	,	_	
14-21	3057-3060	and	_	
14-22	3061-3073	motivational	_	
14-23	3074-3076	or	_	
14-24	3077-3086	emotional	_	
14-25	3087-3094	aspects	_	
14-26	3095-3097	of	_	
14-27	3098-3103	human	_	
14-28	3104-3115	information	_	
14-29	3116-3126	processing	_	
14-30	3126-3127	,	_	
14-31	3128-3137	including	_	
14-32	3138-3144	reward	_	
14-33	3145-3155	processing	_	
14-34	3155-3156	.	_	

#Text=Specifically, ERO theta activity underlying feedback/outcome processing of monetary loss and gain has been reported to be a highly useful measure to characterize reward circuitry dysfunction in psychiatric conditions, including alcoholism.
15-1	3157-3169	Specifically	_	
15-2	3169-3170	,	_	
15-3	3171-3174	ERO	_	
15-4	3175-3180	theta	_	
15-5	3181-3189	activity	_	
15-6	3190-3200	underlying	_	
15-7	3201-3209	feedback	_	
15-8	3209-3210	/	_	
15-9	3210-3217	outcome	_	
15-10	3218-3228	processing	_	
15-11	3229-3231	of	_	
15-12	3232-3240	monetary	_	
15-13	3241-3245	loss	_	
15-14	3246-3249	and	_	
15-15	3250-3254	gain	_	
15-16	3255-3258	has	_	
15-17	3259-3263	been	_	
15-18	3264-3272	reported	_	
15-19	3273-3275	to	_	
15-20	3276-3278	be	_	
15-21	3279-3280	a	_	
15-22	3281-3287	highly	_	
15-23	3288-3294	useful	_	
15-24	3295-3302	measure	_	
15-25	3303-3305	to	_	
15-26	3306-3318	characterize	_	
15-27	3319-3325	reward	_	
15-28	3326-3335	circuitry	_	
15-29	3336-3347	dysfunction	_	
15-30	3348-3350	in	_	
15-31	3351-3362	psychiatric	_	
15-32	3363-3373	conditions	_	
15-33	3373-3374	,	_	
15-34	3375-3384	including	_	
15-35	3385-3395	alcoholism	_	
15-36	3395-3396	.	_	

#Text=ERO measures have been used as effective tools to understand brain mechanisms underlying alcoholism and its predisposition (for reviews, see).
16-1	3397-3400	ERO	_	
16-2	3401-3409	measures	_	
16-3	3410-3414	have	_	
16-4	3415-3419	been	_	
16-5	3420-3424	used	_	
16-6	3425-3427	as	_	
16-7	3428-3437	effective	_	
16-8	3438-3443	tools	_	
16-9	3444-3446	to	_	
16-10	3447-3457	understand	_	
16-11	3458-3463	brain	_	
16-12	3464-3474	mechanisms	_	
16-13	3475-3485	underlying	_	
16-14	3486-3496	alcoholism	_	
16-15	3497-3500	and	_	
16-16	3501-3504	its	_	
16-17	3505-3519	predisposition	_	
16-18	3520-3521	(	_	
16-19	3521-3524	for	_	
16-20	3525-3532	reviews	_	
16-21	3532-3533	,	_	
16-22	3534-3537	see	_	
16-23	3537-3538	)	_	
16-24	3538-3539	.	_	

#Text=Further, as reported in the combined analyses of ERP and ERO data, ERO measures yielded additional information than the traditional ERP measures to discriminate alcoholics from controls (e.g.,) as well as high-risk from low-risk individuals (e.g.,).
17-1	3540-3547	Further	_	
17-2	3547-3548	,	_	
17-3	3549-3551	as	_	
17-4	3552-3560	reported	_	
17-5	3561-3563	in	_	
17-6	3564-3567	the	_	
17-7	3568-3576	combined	_	
17-8	3577-3585	analyses	_	
17-9	3586-3588	of	_	
17-10	3589-3592	ERP	_	
17-11	3593-3596	and	_	
17-12	3597-3600	ERO	_	
17-13	3601-3605	data	_	
17-14	3605-3606	,	_	
17-15	3607-3610	ERO	_	
17-16	3611-3619	measures	_	
17-17	3620-3627	yielded	_	
17-18	3628-3638	additional	_	
17-19	3639-3650	information	_	
17-20	3651-3655	than	_	
17-21	3656-3659	the	_	
17-22	3660-3671	traditional	_	
17-23	3672-3675	ERP	_	
17-24	3676-3684	measures	_	
17-25	3685-3687	to	_	
17-26	3688-3700	discriminate	_	
17-27	3701-3711	alcoholics	_	
17-28	3712-3716	from	_	
17-29	3717-3725	controls	_	
17-30	3726-3727	(	_	
17-31	3727-3730	e.g	_	
17-32	3730-3731	.	_	
17-33	3731-3732	,	_	
17-34	3732-3733	)	_	
17-35	3734-3736	as	_	
17-36	3737-3741	well	_	
17-37	3742-3744	as	_	
17-38	3745-3754	high-risk	_	
17-39	3755-3759	from	_	
17-40	3760-3768	low-risk	_	
17-41	3769-3780	individuals	_	
17-42	3781-3782	(	_	
17-43	3782-3785	e.g	_	
17-44	3785-3786	.	_	
17-45	3786-3787	,	_	
17-46	3787-3788	)	_	
17-47	3788-3789	.	_	

#Text=In the Collaborative Study on the Genetics of Alcoholism (COGA), we have successfully used EROs as endophenotypes in the search for genes involved in alcoholism and related disorders (for reviews, see).
18-1	3790-3792	In	_	
18-2	3793-3796	the	_	
18-3	3797-3810	Collaborative	_	
18-4	3811-3816	Study	_	
18-5	3817-3819	on	_	
18-6	3820-3823	the	_	
18-7	3824-3832	Genetics	_	
18-8	3833-3835	of	_	
18-9	3836-3846	Alcoholism	_	
18-10	3847-3848	(	_	
18-11	3848-3852	COGA	_	
18-12	3852-3853	)	_	
18-13	3853-3854	,	_	
18-14	3855-3857	we	_	
18-15	3858-3862	have	_	
18-16	3863-3875	successfully	_	
18-17	3876-3880	used	_	
18-18	3881-3885	EROs	_	
18-19	3886-3888	as	_	
18-20	3889-3903	endophenotypes	_	
18-21	3904-3906	in	_	
18-22	3907-3910	the	_	
18-23	3911-3917	search	_	
18-24	3918-3921	for	_	
18-25	3922-3927	genes	_	
18-26	3928-3936	involved	_	
18-27	3937-3939	in	_	
18-28	3940-3950	alcoholism	_	
18-29	3951-3954	and	_	
18-30	3955-3962	related	_	
18-31	3963-3972	disorders	_	
18-32	3973-3974	(	_	
18-33	3974-3977	for	_	
18-34	3978-3985	reviews	_	
18-35	3985-3986	,	_	
18-36	3987-3990	see	_	
18-37	3990-3991	)	_	
18-38	3991-3992	.	_	

#Text=Genetic studies of the theta ERO phenotype in a visual oddball task has been associated with several genes, including CHRM2, GRM8, and HTR7.
19-1	3993-4000	Genetic	_	
19-2	4001-4008	studies	_	
19-3	4009-4011	of	_	
19-4	4012-4015	the	_	
19-5	4016-4021	theta	_	
19-6	4022-4025	ERO	_	
19-7	4026-4035	phenotype	_	
19-8	4036-4038	in	_	
19-9	4039-4040	a	_	
19-10	4041-4047	visual	_	
19-11	4048-4055	oddball	_	
19-12	4056-4060	task	_	
19-13	4061-4064	has	_	
19-14	4065-4069	been	_	
19-15	4070-4080	associated	_	
19-16	4081-4085	with	_	
19-17	4086-4093	several	_	
19-18	4094-4099	genes	_	
19-19	4099-4100	,	_	
19-20	4101-4110	including	_	
19-21	4111-4116	CHRM2	_	
19-22	4116-4117	,	_	
19-23	4118-4122	GRM8	_	
19-24	4122-4123	,	_	
19-25	4124-4127	and	_	
19-26	4128-4132	HTR7	_	
19-27	4132-4133	.	_	

#Text=Recently, in the first family-based GWAS of the frontal theta ERO phenotype, found genome-wide significant association between the frontal theta ERO power to targets in a visual oddball task and several SNPs (including a synonymous SNP, rs702859) in KCNJ6 (KIR3.2/GIRK2, an inward rectifier potassium channel).
20-1	4134-4142	Recently	_	
20-2	4142-4143	,	_	
20-3	4144-4146	in	_	
20-4	4147-4150	the	_	
20-5	4151-4156	first	_	
20-6	4157-4169	family-based	_	
20-7	4170-4174	GWAS	_	
20-8	4175-4177	of	_	
20-9	4178-4181	the	_	
20-10	4182-4189	frontal	_	
20-11	4190-4195	theta	_	
20-12	4196-4199	ERO	_	
20-13	4200-4209	phenotype	_	
20-14	4209-4210	,	_	
20-15	4211-4216	found	_	
20-16	4217-4228	genome-wide	_	
20-17	4229-4240	significant	_	
20-18	4241-4252	association	_	
20-19	4253-4260	between	_	
20-20	4261-4264	the	_	
20-21	4265-4272	frontal	_	
20-22	4273-4278	theta	_	
20-23	4279-4282	ERO	_	
20-24	4283-4288	power	_	
20-25	4289-4291	to	_	
20-26	4292-4299	targets	_	
20-27	4300-4302	in	_	
20-28	4303-4304	a	_	
20-29	4305-4311	visual	_	
20-30	4312-4319	oddball	_	
20-31	4320-4324	task	_	
20-32	4325-4328	and	_	
20-33	4329-4336	several	_	
20-34	4337-4341	SNPs	_	
20-35	4342-4343	(	_	
20-36	4343-4352	including	_	
20-37	4353-4354	a	_	
20-38	4355-4365	synonymous	_	
20-39	4366-4369	SNP	_	
20-40	4369-4370	,	_	
20-41	4371-4379	rs702859	_	
20-42	4379-4380	)	_	
20-43	4381-4383	in	_	
20-44	4384-4389	KCNJ6	_	
20-45	4390-4391	(	_	
20-46	4391-4397	KIR3.2	_	
20-47	4397-4398	/	_	
20-48	4398-4403	GIRK2	_	
20-49	4403-4404	,	_	
20-50	4405-4407	an	_	
20-51	4408-4414	inward	_	
20-52	4415-4424	rectifier	_	
20-53	4425-4434	potassium	_	
20-54	4435-4442	channel	_	
20-55	4442-4443	)	_	
20-56	4443-4444	.	_	

#Text=GIRK2, the protein encoded by KCNJ6, is widely distributed in the brain and is an important functional element in dopaminergic, cholinergic, GABAergic and glutamatergic synapses, and hence the regulation of neuronal excitability.
21-1	4445-4450	GIRK2	_	
21-2	4450-4451	,	_	
21-3	4452-4455	the	_	
21-4	4456-4463	protein	_	
21-5	4464-4471	encoded	_	
21-6	4472-4474	by	_	
21-7	4475-4480	KCNJ6	_	
21-8	4480-4481	,	_	
21-9	4482-4484	is	_	
21-10	4485-4491	widely	_	
21-11	4492-4503	distributed	_	
21-12	4504-4506	in	_	
21-13	4507-4510	the	_	
21-14	4511-4516	brain	_	
21-15	4517-4520	and	_	
21-16	4521-4523	is	_	
21-17	4524-4526	an	_	
21-18	4527-4536	important	_	
21-19	4537-4547	functional	_	
21-20	4548-4555	element	_	
21-21	4556-4558	in	_	
21-22	4559-4571	dopaminergic	_	
21-23	4571-4572	,	_	
21-24	4573-4584	cholinergic	_	
21-25	4584-4585	,	_	
21-26	4586-4595	GABAergic	_	
21-27	4596-4599	and	_	
21-28	4600-4613	glutamatergic	_	
21-29	4614-4622	synapses	_	
21-30	4622-4623	,	_	
21-31	4624-4627	and	_	
21-32	4628-4633	hence	_	
21-33	4634-4637	the	_	
21-34	4638-4648	regulation	_	
21-35	4649-4651	of	_	
21-36	4652-4660	neuronal	_	
21-37	4661-4673	excitability	_	
21-38	4673-4674	.	_	

#Text=The advantage of a family-based study design is robustness against population substructure and the availability of the genotypes of both parents, which enables a more correct evaluation of genotype errors (cf.).
22-1	4675-4678	The	_	
22-2	4679-4688	advantage	_	
22-3	4689-4691	of	_	
22-4	4692-4693	a	_	
22-5	4694-4706	family-based	_	
22-6	4707-4712	study	_	
22-7	4713-4719	design	_	
22-8	4720-4722	is	_	
22-9	4723-4733	robustness	_	
22-10	4734-4741	against	_	
22-11	4742-4752	population	_	
22-12	4753-4765	substructure	_	
22-13	4766-4769	and	_	
22-14	4770-4773	the	_	
22-15	4774-4786	availability	_	
22-16	4787-4789	of	_	
22-17	4790-4793	the	_	
22-18	4794-4803	genotypes	_	
22-19	4804-4806	of	_	
22-20	4807-4811	both	_	
22-21	4812-4819	parents	_	
22-22	4819-4820	,	_	
22-23	4821-4826	which	_	
22-24	4827-4834	enables	_	
22-25	4835-4836	a	_	
22-26	4837-4841	more	_	
22-27	4842-4849	correct	_	
22-28	4850-4860	evaluation	_	
22-29	4861-4863	of	_	
22-30	4864-4872	genotype	_	
22-31	4873-4879	errors	_	
22-32	4880-4881	(	_	
22-33	4881-4883	cf	_	
22-34	4883-4884	.	_	
22-35	4884-4885	)	_	
22-36	4885-4886	.	_	

#Text=Following up this finding, a recent study from our group examined the effects of KCNJ6 SNPs on developmental trajectories of the same theta ERO phenotypes in auditory and visual oddball tasks in adolescent and young adults (12–25) from the COGA prospective study; significant age- and gender-specific effects were found, with some effects of scalp locality and task modality.
23-1	4887-4896	Following	_	
23-2	4897-4899	up	_	
23-3	4900-4904	this	_	
23-4	4905-4912	finding	_	
23-5	4912-4913	,	_	
23-6	4914-4915	a	_	
23-7	4916-4922	recent	_	
23-8	4923-4928	study	_	
23-9	4929-4933	from	_	
23-10	4934-4937	our	_	
23-11	4938-4943	group	_	
23-12	4944-4952	examined	_	
23-13	4953-4956	the	_	
23-14	4957-4964	effects	_	
23-15	4965-4967	of	_	
23-16	4968-4973	KCNJ6	_	
23-17	4974-4978	SNPs	_	
23-18	4979-4981	on	_	
23-19	4982-4995	developmental	_	
23-20	4996-5008	trajectories	_	
23-21	5009-5011	of	_	
23-22	5012-5015	the	_	
23-23	5016-5020	same	_	
23-24	5021-5026	theta	_	
23-25	5027-5030	ERO	_	
23-26	5031-5041	phenotypes	_	
23-27	5042-5044	in	_	
23-28	5045-5053	auditory	_	
23-29	5054-5057	and	_	
23-30	5058-5064	visual	_	
23-31	5065-5072	oddball	_	
23-32	5073-5078	tasks	_	
23-33	5079-5081	in	_	
23-34	5082-5092	adolescent	_	
23-35	5093-5096	and	_	
23-36	5097-5102	young	_	
23-37	5103-5109	adults	_	
23-38	5110-5111	(	_	
23-39	5111-5113	12	_	
23-40	5113-5114	–	_	
23-41	5114-5116	25	_	
23-42	5116-5117	)	_	
23-43	5118-5122	from	_	
23-44	5123-5126	the	_	
23-45	5127-5131	COGA	_	
23-46	5132-5143	prospective	_	
23-47	5144-5149	study	_	
23-48	5149-5150	;	_	
23-49	5151-5162	significant	_	
23-50	5163-5166	age	_	
23-51	5166-5167	-	_	
23-52	5168-5171	and	_	
23-53	5172-5187	gender-specific	_	
23-54	5188-5195	effects	_	
23-55	5196-5200	were	_	
23-56	5201-5206	found	_	
23-57	5206-5207	,	_	
23-58	5208-5212	with	_	
23-59	5213-5217	some	_	
23-60	5218-5225	effects	_	
23-61	5226-5228	of	_	
23-62	5229-5234	scalp	_	
23-63	5235-5243	locality	_	
23-64	5244-5247	and	_	
23-65	5248-5252	task	_	
23-66	5253-5261	modality	_	
23-67	5261-5262	.	_	

#Text=ERO theta power during a monetary gambling task has been reported to be reduced while processing monetary loss and gain in both alcoholics and their high risk offspring, and the findings were interpreted as reward processing deficits in these groups.
24-1	5263-5266	ERO	_	
24-2	5267-5272	theta	_	
24-3	5273-5278	power	_	
24-4	5279-5285	during	_	
24-5	5286-5287	a	_	
24-6	5288-5296	monetary	_	
24-7	5297-5305	gambling	_	
24-8	5306-5310	task	_	
24-9	5311-5314	has	_	
24-10	5315-5319	been	_	
24-11	5320-5328	reported	_	
24-12	5329-5331	to	_	
24-13	5332-5334	be	_	
24-14	5335-5342	reduced	_	
24-15	5343-5348	while	_	
24-16	5349-5359	processing	_	
24-17	5360-5368	monetary	_	
24-18	5369-5373	loss	_	
24-19	5374-5377	and	_	
24-20	5378-5382	gain	_	
24-21	5383-5385	in	_	
24-22	5386-5390	both	_	
24-23	5391-5401	alcoholics	_	
24-24	5402-5405	and	_	
24-25	5406-5411	their	_	
24-26	5412-5416	high	_	
24-27	5417-5421	risk	_	
24-28	5422-5431	offspring	_	
24-29	5431-5432	,	_	
24-30	5433-5436	and	_	
24-31	5437-5440	the	_	
24-32	5441-5449	findings	_	
24-33	5450-5454	were	_	
24-34	5455-5466	interpreted	_	
24-35	5467-5469	as	_	
24-36	5470-5476	reward	_	
24-37	5477-5487	processing	_	
24-38	5488-5496	deficits	_	
24-39	5497-5499	in	_	
24-40	5500-5505	these	_	
24-41	5506-5512	groups	_	
24-42	5512-5513	.	_	

#Text=There is evidence to show that neural oscillations during reward processing underlie brain reward regions and/or circuits.
25-1	5514-5519	There	_	
25-2	5520-5522	is	_	
25-3	5523-5531	evidence	_	
25-4	5532-5534	to	_	
25-5	5535-5539	show	_	
25-6	5540-5544	that	_	
25-7	5545-5551	neural	_	
25-8	5552-5564	oscillations	_	
25-9	5565-5571	during	_	
25-10	5572-5578	reward	_	
25-11	5579-5589	processing	_	
25-12	5590-5598	underlie	_	
25-13	5599-5604	brain	_	
25-14	5605-5611	reward	_	
25-15	5612-5619	regions	_	
25-16	5620-5623	and	_	
25-17	5623-5624	/	_	
25-18	5624-5626	or	_	
25-19	5627-5635	circuits	_	
25-20	5635-5636	.	_	

#Text=For example, in a combined study of time-frequency ERO measure and fMRI data in human participants, reported that oscillatory activity elicited by monetary gains was associated with fronto-striatal-hippocampal reward network identified by the fMRI activity.
26-1	5637-5640	For	_	
26-2	5641-5648	example	_	
26-3	5648-5649	,	_	
26-4	5650-5652	in	_	
26-5	5653-5654	a	_	
26-6	5655-5663	combined	_	
26-7	5664-5669	study	_	
26-8	5670-5672	of	_	
26-9	5673-5687	time-frequency	_	
26-10	5688-5691	ERO	_	
26-11	5692-5699	measure	_	
26-12	5700-5703	and	_	
26-13	5704-5708	fMRI	_	
26-14	5709-5713	data	_	
26-15	5714-5716	in	_	
26-16	5717-5722	human	_	
26-17	5723-5735	participants	_	
26-18	5735-5736	,	_	
26-19	5737-5745	reported	_	
26-20	5746-5750	that	_	
26-21	5751-5762	oscillatory	_	
26-22	5763-5771	activity	_	
26-23	5772-5780	elicited	_	
26-24	5781-5783	by	_	
26-25	5784-5792	monetary	_	
26-26	5793-5798	gains	_	
26-27	5799-5802	was	_	
26-28	5803-5813	associated	_	
26-29	5814-5818	with	_	
26-30	5819-5846	fronto-striatal-hippocampal	_	
26-31	5847-5853	reward	_	
26-32	5854-5861	network	_	
26-33	5862-5872	identified	_	
26-34	5873-5875	by	_	
26-35	5876-5879	the	_	
26-36	5880-5884	fMRI	_	
26-37	5885-5893	activity	_	
26-38	5893-5894	.	_	

#Text=Studies using implanted depth electrodes in rats have reported that neural oscillations were modulated by anticipation and delivery of reward.
27-1	5895-5902	Studies	_	
27-2	5903-5908	using	_	
27-3	5909-5918	implanted	_	
27-4	5919-5924	depth	_	
27-5	5925-5935	electrodes	_	
27-6	5936-5938	in	_	
27-7	5939-5943	rats	_	
27-8	5944-5948	have	_	
27-9	5949-5957	reported	_	
27-10	5958-5962	that	_	
27-11	5963-5969	neural	_	
27-12	5970-5982	oscillations	_	
27-13	5983-5987	were	_	
27-14	5988-5997	modulated	_	
27-15	5998-6000	by	_	
27-16	6001-6013	anticipation	_	
27-17	6014-6017	and	_	
27-18	6018-6026	delivery	_	
27-19	6027-6029	of	_	
27-20	6030-6036	reward	_	
27-21	6036-6037	.	_	

#Text=Animal studies have also reported that genetic ablation of G-protein-regulated inward-rectifier potassium channel 2 (GIRK2, a protein encoded by KCNJ6 gene), promotes adaptations in the mesolimbic dopaminergic system, a mechanism which is related to brain reward network and believed to promote chronic alcohol/drug intake leading to addiction.
28-1	6038-6044	Animal	_	
28-2	6045-6052	studies	_	
28-3	6053-6057	have	_	
28-4	6058-6062	also	_	
28-5	6063-6071	reported	_	
28-6	6072-6076	that	_	
28-7	6077-6084	genetic	_	
28-8	6085-6093	ablation	_	
28-9	6094-6096	of	_	
28-10	6097-6116	G-protein-regulated	_	
28-11	6117-6133	inward-rectifier	_	
28-12	6134-6143	potassium	_	
28-13	6144-6151	channel	_	
28-14	6152-6153	2	_	
28-15	6154-6155	(	_	
28-16	6155-6160	GIRK2	_	
28-17	6160-6161	,	_	
28-18	6162-6163	a	_	
28-19	6164-6171	protein	_	
28-20	6172-6179	encoded	_	
28-21	6180-6182	by	_	
28-22	6183-6188	KCNJ6	_	
28-23	6189-6193	gene	_	
28-24	6193-6194	)	_	
28-25	6194-6195	,	_	
28-26	6196-6204	promotes	_	
28-27	6205-6216	adaptations	_	
28-28	6217-6219	in	_	
28-29	6220-6223	the	_	
28-30	6224-6234	mesolimbic	_	
28-31	6235-6247	dopaminergic	_	
28-32	6248-6254	system	_	
28-33	6254-6255	,	_	
28-34	6256-6257	a	_	
28-35	6258-6267	mechanism	_	
28-36	6268-6273	which	_	
28-37	6274-6276	is	_	
28-38	6277-6284	related	_	
28-39	6285-6287	to	_	
28-40	6288-6293	brain	_	
28-41	6294-6300	reward	_	
28-42	6301-6308	network	_	
28-43	6309-6312	and	_	
28-44	6313-6321	believed	_	
28-45	6322-6324	to	_	
28-46	6325-6332	promote	_	
28-47	6333-6340	chronic	_	
28-48	6341-6348	alcohol	_	
28-49	6348-6349	/	_	
28-50	6349-6353	drug	_	
28-51	6354-6360	intake	_	
28-52	6361-6368	leading	_	
28-53	6369-6371	to	_	
28-54	6372-6381	addiction	_	
28-55	6381-6382	.	_	

#Text=Based on these findings, it was conceptualized that studying the effect of a KCNJ6 SNP on brain oscillations during reward processing would help elucidate its role underlying the brain reward system.
29-1	6383-6388	Based	_	
29-2	6389-6391	on	_	
29-3	6392-6397	these	_	
29-4	6398-6406	findings	_	
29-5	6406-6407	,	_	
29-6	6408-6410	it	_	
29-7	6411-6414	was	_	
29-8	6415-6429	conceptualized	_	
29-9	6430-6434	that	_	
29-10	6435-6443	studying	_	
29-11	6444-6447	the	_	
29-12	6448-6454	effect	_	
29-13	6455-6457	of	_	
29-14	6458-6459	a	_	
29-15	6460-6465	KCNJ6	_	
29-16	6466-6469	SNP	_	
29-17	6470-6472	on	_	
29-18	6473-6478	brain	_	
29-19	6479-6491	oscillations	_	
29-20	6492-6498	during	_	
29-21	6499-6505	reward	_	
29-22	6506-6516	processing	_	
29-23	6517-6522	would	_	
29-24	6523-6527	help	_	
29-25	6528-6537	elucidate	_	
29-26	6538-6541	its	_	
29-27	6542-6546	role	_	
29-28	6547-6557	underlying	_	
29-29	6558-6561	the	_	
29-30	6562-6567	brain	_	
29-31	6568-6574	reward	_	
29-32	6575-6581	system	_	
29-33	6581-6582	.	_	

#Text=There are studies implicating GIRK2/KCNJ6 in regulating neuronal excitability.
30-1	6583-6588	There	_	
30-2	6589-6592	are	_	
30-3	6593-6600	studies	_	
30-4	6601-6612	implicating	_	
30-5	6613-6618	GIRK2	_	
30-6	6618-6619	/	_	
30-7	6619-6624	KCNJ6	_	
30-8	6625-6627	in	_	
30-9	6628-6638	regulating	_	
30-10	6639-6647	neuronal	_	
30-11	6648-6660	excitability	_	
30-12	6660-6661	.	_	

#Text=Studies have shown that GIRK2 contributes to the slow inhibitory postsynaptic potentials due to GABAB action.
31-1	6662-6669	Studies	_	
31-2	6670-6674	have	_	
31-3	6675-6680	shown	_	
31-4	6681-6685	that	_	
31-5	6686-6691	GIRK2	_	
31-6	6692-6703	contributes	_	
31-7	6704-6706	to	_	
31-8	6707-6710	the	_	
31-9	6711-6715	slow	_	
31-10	6716-6726	inhibitory	_	
31-11	6727-6739	postsynaptic	_	
31-12	6740-6750	potentials	_	
31-13	6751-6754	due	_	
31-14	6755-6757	to	_	
31-15	6758-6763	GABAB	_	
31-16	6764-6770	action	_	
31-17	6770-6771	.	_	

#Text=Activity of GIRK receptors results in hyperpolarization that decreases neuronal excitability and this in turn directly influences neuronal activity (cf.).
32-1	6772-6780	Activity	_	
32-2	6781-6783	of	_	
32-3	6784-6788	GIRK	_	
32-4	6789-6798	receptors	_	
32-5	6799-6806	results	_	
32-6	6807-6809	in	_	
32-7	6810-6827	hyperpolarization	_	
32-8	6828-6832	that	_	
32-9	6833-6842	decreases	_	
32-10	6843-6851	neuronal	_	
32-11	6852-6864	excitability	_	
32-12	6865-6868	and	_	
32-13	6869-6873	this	_	
32-14	6874-6876	in	_	
32-15	6877-6881	turn	_	
32-16	6882-6890	directly	_	
32-17	6891-6901	influences	_	
32-18	6902-6910	neuronal	_	
32-19	6911-6919	activity	_	
32-20	6920-6921	(	_	
32-21	6921-6923	cf	_	
32-22	6923-6924	.	_	
32-23	6924-6925	)	_	
32-24	6925-6926	.	_	

#Text=There is also evidence that highlights the role of inhibition in pacing oscillations and establishing synchrony during cognitive processing in the brain.
33-1	6927-6932	There	_	
33-2	6933-6935	is	_	
33-3	6936-6940	also	_	
33-4	6941-6949	evidence	_	
33-5	6950-6954	that	_	
33-6	6955-6965	highlights	_	
33-7	6966-6969	the	_	
33-8	6970-6974	role	_	
33-9	6975-6977	of	_	
33-10	6978-6988	inhibition	_	
33-11	6989-6991	in	_	
33-12	6992-6998	pacing	_	
33-13	6999-7011	oscillations	_	
33-14	7012-7015	and	_	
33-15	7016-7028	establishing	_	
33-16	7029-7038	synchrony	_	
33-17	7039-7045	during	_	
33-18	7046-7055	cognitive	_	
33-19	7056-7066	processing	_	
33-20	7067-7069	in	_	
33-21	7070-7073	the	_	
33-22	7074-7079	brain	_	
33-23	7079-7080	.	_	

#Text=A simulation study examining decision time and theta rhythm suggests that a mixture of slow and fast inhibition can affect the power in the theta band and speed up the reaction times in a decision-making network.
34-1	7081-7082	A	_	
34-2	7083-7093	simulation	_	
34-3	7094-7099	study	_	
34-4	7100-7109	examining	_	
34-5	7110-7118	decision	_	
34-6	7119-7123	time	_	
34-7	7124-7127	and	_	
34-8	7128-7133	theta	_	
34-9	7134-7140	rhythm	_	
34-10	7141-7149	suggests	_	
34-11	7150-7154	that	_	
34-12	7155-7156	a	_	
34-13	7157-7164	mixture	_	
34-14	7165-7167	of	_	
34-15	7168-7172	slow	_	
34-16	7173-7176	and	_	
34-17	7177-7181	fast	_	
34-18	7182-7192	inhibition	_	
34-19	7193-7196	can	_	
34-20	7197-7203	affect	_	
34-21	7204-7207	the	_	
34-22	7208-7213	power	_	
34-23	7214-7216	in	_	
34-24	7217-7220	the	_	
34-25	7221-7226	theta	_	
34-26	7227-7231	band	_	
34-27	7232-7235	and	_	
34-28	7236-7241	speed	_	
34-29	7242-7244	up	_	
34-30	7245-7248	the	_	
34-31	7249-7257	reaction	_	
34-32	7258-7263	times	_	
34-33	7264-7266	in	_	
34-34	7267-7268	a	_	
34-35	7269-7284	decision-making	_	
34-36	7285-7292	network	_	
34-37	7292-7293	.	_	

#Text=The current study follows up the COGA genome-wide significant association of KCNJ6 SNPs with theta EROs to targets during a visual oddball paradigm to determine its association with theta EROs during reward processing in a monetary gambling task, a phenotype similar to the one used in the original study, but tapping different neural processes, in order to determine if there is an association with theta EROs during a different task.
35-1	7294-7297	The	_	
35-2	7298-7305	current	_	
35-3	7306-7311	study	_	
35-4	7312-7319	follows	_	
35-5	7320-7322	up	_	
35-6	7323-7326	the	_	
35-7	7327-7331	COGA	_	
35-8	7332-7343	genome-wide	_	
35-9	7344-7355	significant	_	
35-10	7356-7367	association	_	
35-11	7368-7370	of	_	
35-12	7371-7376	KCNJ6	_	
35-13	7377-7381	SNPs	_	
35-14	7382-7386	with	_	
35-15	7387-7392	theta	_	
35-16	7393-7397	EROs	_	
35-17	7398-7400	to	_	
35-18	7401-7408	targets	_	
35-19	7409-7415	during	_	
35-20	7416-7417	a	_	
35-21	7418-7424	visual	_	
35-22	7425-7432	oddball	_	
35-23	7433-7441	paradigm	_	
35-24	7442-7444	to	_	
35-25	7445-7454	determine	_	
35-26	7455-7458	its	_	
35-27	7459-7470	association	_	
35-28	7471-7475	with	_	
35-29	7476-7481	theta	_	
35-30	7482-7486	EROs	_	
35-31	7487-7493	during	_	
35-32	7494-7500	reward	_	
35-33	7501-7511	processing	_	
35-34	7512-7514	in	_	
35-35	7515-7516	a	_	
35-36	7517-7525	monetary	_	
35-37	7526-7534	gambling	_	
35-38	7535-7539	task	_	
35-39	7539-7540	,	_	
35-40	7541-7542	a	_	
35-41	7543-7552	phenotype	_	
35-42	7553-7560	similar	_	
35-43	7561-7563	to	_	
35-44	7564-7567	the	_	
35-45	7568-7571	one	_	
35-46	7572-7576	used	_	
35-47	7577-7579	in	_	
35-48	7580-7583	the	_	
35-49	7584-7592	original	_	
35-50	7593-7598	study	_	
35-51	7598-7599	,	_	
35-52	7600-7603	but	_	
35-53	7604-7611	tapping	_	
35-54	7612-7621	different	_	
35-55	7622-7628	neural	_	
35-56	7629-7638	processes	_	
35-57	7638-7639	,	_	
35-58	7640-7642	in	_	
35-59	7643-7648	order	_	
35-60	7649-7651	to	_	
35-61	7652-7661	determine	_	
35-62	7662-7664	if	_	
35-63	7665-7670	there	_	
35-64	7671-7673	is	_	
35-65	7674-7676	an	_	
35-66	7677-7688	association	_	
35-67	7689-7693	with	_	
35-68	7694-7699	theta	_	
35-69	7700-7704	EROs	_	
35-70	7705-7711	during	_	
35-71	7712-7713	a	_	
35-72	7714-7723	different	_	
35-73	7724-7728	task	_	
35-74	7728-7729	.	_	

#Text=The overall goal of the present study is to investigate the genotypic effects of a KCNJ6 SNP (rs702859) on theta EROs during reward processing in subjects (17–25 years old) in the COGA Prospective study.
36-1	7730-7733	The	_	
36-2	7734-7741	overall	_	
36-3	7742-7746	goal	_	
36-4	7747-7749	of	_	
36-5	7750-7753	the	_	
36-6	7754-7761	present	_	
36-7	7762-7767	study	_	
36-8	7768-7770	is	_	
36-9	7771-7773	to	_	
36-10	7774-7785	investigate	_	
36-11	7786-7789	the	_	
36-12	7790-7799	genotypic	_	
36-13	7800-7807	effects	_	
36-14	7808-7810	of	_	
36-15	7811-7812	a	_	
36-16	7813-7818	KCNJ6	_	
36-17	7819-7822	SNP	_	
36-18	7823-7824	(	_	
36-19	7824-7832	rs702859	_	
36-20	7832-7833	)	_	
36-21	7834-7836	on	_	
36-22	7837-7842	theta	_	
36-23	7843-7847	EROs	_	
36-24	7848-7854	during	_	
36-25	7855-7861	reward	_	
36-26	7862-7872	processing	_	
36-27	7873-7875	in	_	
36-28	7876-7884	subjects	_	
36-29	7885-7886	(	_	
36-30	7886-7888	17	_	
36-31	7888-7889	–	_	
36-32	7889-7891	25	_	
36-33	7892-7897	years	_	
36-34	7898-7901	old	_	
36-35	7901-7902	)	_	
36-36	7903-7905	in	_	
36-37	7906-7909	the	_	
36-38	7910-7914	COGA	_	
36-39	7915-7926	Prospective	_	
36-40	7927-7932	study	_	
36-41	7932-7933	.	_	

#Text=This age range was selected as the study by indicated that the effects of this SNP on theta EROs were strongest in this age range of the prospective study.
37-1	7934-7938	This	_	
37-2	7939-7942	age	_	
37-3	7943-7948	range	_	
37-4	7949-7952	was	_	
37-5	7953-7961	selected	_	
37-6	7962-7964	as	_	
37-7	7965-7968	the	_	
37-8	7969-7974	study	_	
37-9	7975-7977	by	_	
37-10	7978-7987	indicated	_	
37-11	7988-7992	that	_	
37-12	7993-7996	the	_	
37-13	7997-8004	effects	_	
37-14	8005-8007	of	_	
37-15	8008-8012	this	_	
37-16	8013-8016	SNP	_	
37-17	8017-8019	on	_	
37-18	8020-8025	theta	_	
37-19	8026-8030	EROs	_	
37-20	8031-8035	were	_	
37-21	8036-8045	strongest	_	
37-22	8046-8048	in	_	
37-23	8049-8053	this	_	
37-24	8054-8057	age	_	
37-25	8058-8063	range	_	
37-26	8064-8066	of	_	
37-27	8067-8070	the	_	
37-28	8071-8082	prospective	_	
37-29	8083-8088	study	_	
37-30	8088-8089	.	_	

#Text=The rationale for selecting rs702859 was three-fold: (i) this SNP had a genome-wide significant association with theta ERO in the previous GWAS study; (ii) this SNP was in high LD with the top genome-wide significant genotyped SNPs, and (iii) this was the only exonic genomewide significant SNP in the KCNJ6 gene.
38-1	8090-8093	The	_	
38-2	8094-8103	rationale	_	
38-3	8104-8107	for	_	
38-4	8108-8117	selecting	_	
38-5	8118-8126	rs702859	_	
38-6	8127-8130	was	_	
38-7	8131-8141	three-fold	_	
38-8	8141-8142	:	_	
38-9	8143-8144	(	_	
38-10	8144-8145	i	_	
38-11	8145-8146	)	_	
38-12	8147-8151	this	_	
38-13	8152-8155	SNP	_	
38-14	8156-8159	had	_	
38-15	8160-8161	a	_	
38-16	8162-8173	genome-wide	_	
38-17	8174-8185	significant	_	
38-18	8186-8197	association	_	
38-19	8198-8202	with	_	
38-20	8203-8208	theta	_	
38-21	8209-8212	ERO	_	
38-22	8213-8215	in	_	
38-23	8216-8219	the	_	
38-24	8220-8228	previous	_	
38-25	8229-8233	GWAS	_	
38-26	8234-8239	study	_	
38-27	8239-8240	;	_	
38-28	8241-8242	(	_	
38-29	8242-8244	ii	_	
38-30	8244-8245	)	_	
38-31	8246-8250	this	_	
38-32	8251-8254	SNP	_	
38-33	8255-8258	was	_	
38-34	8259-8261	in	_	
38-35	8262-8266	high	_	
38-36	8267-8269	LD	_	
38-37	8270-8274	with	_	
38-38	8275-8278	the	_	
38-39	8279-8282	top	_	
38-40	8283-8294	genome-wide	_	
38-41	8295-8306	significant	_	
38-42	8307-8316	genotyped	_	
38-43	8317-8321	SNPs	_	
38-44	8321-8322	,	_	
38-45	8323-8326	and	_	
38-46	8327-8328	(	_	
38-47	8328-8331	iii	_	
38-48	8331-8332	)	_	
38-49	8333-8337	this	_	
38-50	8338-8341	was	_	
38-51	8342-8345	the	_	
38-52	8346-8350	only	_	
38-53	8351-8357	exonic	_	
38-54	8358-8368	genomewide	_	
38-55	8369-8380	significant	_	
38-56	8381-8384	SNP	_	
38-57	8385-8387	in	_	
38-58	8388-8391	the	_	
38-59	8392-8397	KCNJ6	_	
38-60	8398-8402	gene	_	
38-61	8402-8403	.	_	

#Text=Given that there is empirical evidence showing relationships between (i) KCNJ6 and the reward system, (ii) theta EROs and the reward system, and (iii) KCNJ6 and brain oscillations, the primary hypothesis of the study is that variations in rs702859 genotypes will influence theta ERO power during loss and gain processing.
39-1	8404-8409	Given	_	
39-2	8410-8414	that	_	
39-3	8415-8420	there	_	
39-4	8421-8423	is	_	
39-5	8424-8433	empirical	_	
39-6	8434-8442	evidence	_	
39-7	8443-8450	showing	_	
39-8	8451-8464	relationships	_	
39-9	8465-8472	between	_	
39-10	8473-8474	(	_	
39-11	8474-8475	i	_	
39-12	8475-8476	)	_	
39-13	8477-8482	KCNJ6	_	
39-14	8483-8486	and	_	
39-15	8487-8490	the	_	
39-16	8491-8497	reward	_	
39-17	8498-8504	system	_	
39-18	8504-8505	,	_	
39-19	8506-8507	(	_	
39-20	8507-8509	ii	_	
39-21	8509-8510	)	_	
39-22	8511-8516	theta	_	
39-23	8517-8521	EROs	_	
39-24	8522-8525	and	_	
39-25	8526-8529	the	_	
39-26	8530-8536	reward	_	
39-27	8537-8543	system	_	
39-28	8543-8544	,	_	
39-29	8545-8548	and	_	
39-30	8549-8550	(	_	
39-31	8550-8553	iii	_	
39-32	8553-8554	)	_	
39-33	8555-8560	KCNJ6	_	
39-34	8561-8564	and	_	
39-35	8565-8570	brain	_	
39-36	8571-8583	oscillations	_	
39-37	8583-8584	,	_	
39-38	8585-8588	the	_	
39-39	8589-8596	primary	_	
39-40	8597-8607	hypothesis	_	
39-41	8608-8610	of	_	
39-42	8611-8614	the	_	
39-43	8615-8620	study	_	
39-44	8621-8623	is	_	
39-45	8624-8628	that	_	
39-46	8629-8639	variations	_	
39-47	8640-8642	in	_	
39-48	8643-8651	rs702859	_	
39-49	8652-8661	genotypes	_	
39-50	8662-8666	will	_	
39-51	8667-8676	influence	_	
39-52	8677-8682	theta	_	
39-53	8683-8686	ERO	_	
39-54	8687-8692	power	_	
39-55	8693-8699	during	_	
39-56	8700-8704	loss	_	
39-57	8705-8708	and	_	
39-58	8709-8713	gain	_	
39-59	8714-8724	processing	_	
39-60	8724-8725	.	_	

#Text=In the current study, the term ‘reward processing’ is being used to mean neurocognitive processing related to both loss and gain, and any effect/context specific to either loss or gain will be properly mentioned.
40-1	8726-8728	In	_	
40-2	8729-8732	the	_	
40-3	8733-8740	current	_	
40-4	8741-8746	study	_	
40-5	8746-8747	,	_	
40-6	8748-8751	the	_	
40-7	8752-8756	term	_	
40-8	8757-8758	‘	_	
40-9	8758-8764	reward	_	
40-10	8765-8775	processing	_	
40-11	8775-8776	’	_	
40-12	8777-8779	is	_	
40-13	8780-8785	being	_	
40-14	8786-8790	used	_	
40-15	8791-8793	to	_	
40-16	8794-8798	mean	_	
40-17	8799-8813	neurocognitive	_	
40-18	8814-8824	processing	_	
40-19	8825-8832	related	_	
40-20	8833-8835	to	_	
40-21	8836-8840	both	_	
40-22	8841-8845	loss	_	
40-23	8846-8849	and	_	
40-24	8850-8854	gain	_	
40-25	8854-8855	,	_	
40-26	8856-8859	and	_	
40-27	8860-8863	any	_	
40-28	8864-8870	effect	_	
40-29	8870-8871	/	_	
40-30	8871-8878	context	_	
40-31	8879-8887	specific	_	
40-32	8888-8890	to	_	
40-33	8891-8897	either	_	
40-34	8898-8902	loss	_	
40-35	8903-8905	or	_	
40-36	8906-8910	gain	_	
40-37	8911-8915	will	_	
40-38	8916-8918	be	_	
40-39	8919-8927	properly	_	
40-40	8928-8937	mentioned	_	
40-41	8937-8938	.	_	

#Text=We expect that the findings from this study of variations in the KCNJ6 gene on reward-related theta EROs may help to further our understanding of these genetic effects on reward processing and possible neurocognitive, behavioral and clinical implications.
#Text=2.
41-1	8939-8941	We	_	
41-2	8942-8948	expect	_	
41-3	8949-8953	that	_	
41-4	8954-8957	the	_	
41-5	8958-8966	findings	_	
41-6	8967-8971	from	_	
41-7	8972-8976	this	_	
41-8	8977-8982	study	_	
41-9	8983-8985	of	_	
41-10	8986-8996	variations	_	
41-11	8997-8999	in	_	
41-12	9000-9003	the	_	
41-13	9004-9009	KCNJ6	_	
41-14	9010-9014	gene	_	
41-15	9015-9017	on	_	
41-16	9018-9032	reward-related	_	
41-17	9033-9038	theta	_	
41-18	9039-9043	EROs	_	
41-19	9044-9047	may	_	
41-20	9048-9052	help	_	
41-21	9053-9055	to	_	
41-22	9056-9063	further	_	
41-23	9064-9067	our	_	
41-24	9068-9081	understanding	_	
41-25	9082-9084	of	_	
41-26	9085-9090	these	_	
41-27	9091-9098	genetic	_	
41-28	9099-9106	effects	_	
41-29	9107-9109	on	_	
41-30	9110-9116	reward	_	
41-31	9117-9127	processing	_	
41-32	9128-9131	and	_	
41-33	9132-9140	possible	_	
41-34	9141-9155	neurocognitive	_	
41-35	9155-9156	,	_	
41-36	9157-9167	behavioral	_	
41-37	9168-9171	and	_	
41-38	9172-9180	clinical	_	
41-39	9181-9193	implications	_	
41-40	9193-9194	.	_	
41-41	9195-9196	2	_	
41-42	9196-9197	.	_	

#Text=Methods
#Text=2.1.
42-1	9198-9205	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
42-2	9206-9209	2.1	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
42-3	9209-9210	.	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	

#Text=Sample
#Text=The sample consisted of 1,601 participants (800 males and 801 females) between 17 and 25 years of age from the prospective sample of the COGA study.
43-1	9211-9217	Sample	_	
43-2	9218-9221	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-3	9222-9228	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-4	9229-9238	consisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-5	9239-9241	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-6	9242-9247	1,601	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-7	9248-9260	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-8	9261-9262	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-9	9262-9265	800	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-10	9266-9271	males	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-11	9272-9275	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-12	9276-9279	801	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-13	9280-9287	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-14	9287-9288	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-15	9289-9296	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-16	9297-9299	17	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-17	9300-9303	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-18	9304-9306	25	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-19	9307-9312	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-20	9313-9315	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-21	9316-9319	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-22	9320-9324	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-23	9325-9328	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-24	9329-9340	prospective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-25	9341-9347	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-26	9348-9350	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-27	9351-9354	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-28	9355-9359	COGA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-29	9360-9365	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-30	9365-9366	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=The participants were offspring from families ascertained in previous phases of COGA: (1) multiplex alcohol dependent families (AD), many with multiple alcoholism-affected family members, and (2) community comparison families (CC) drawn from the general population.
44-1	9367-9370	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-2	9371-9383	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-3	9384-9388	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-4	9389-9398	offspring	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-5	9399-9403	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-6	9404-9412	families	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-7	9413-9424	ascertained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-8	9425-9427	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-9	9428-9436	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-10	9437-9443	phases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-11	9444-9446	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-12	9447-9451	COGA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-13	9451-9452	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-14	9453-9454	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-15	9454-9455	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-16	9455-9456	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-17	9457-9466	multiplex	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-18	9467-9474	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[5]	
44-19	9475-9484	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[5]	
44-20	9485-9493	families	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[5]	
44-21	9494-9495	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[5]	
44-22	9495-9497	AD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[5]	
44-23	9497-9498	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[5]	
44-24	9498-9499	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-25	9500-9504	many	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-26	9505-9509	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-27	9510-9518	multiple	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-28	9519-9538	alcoholism-affected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-29	9539-9545	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-30	9546-9553	members	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-31	9553-9554	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-32	9555-9558	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-33	9559-9560	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-34	9560-9561	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-35	9561-9562	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-36	9563-9572	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-37	9573-9583	comparison	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-38	9584-9592	families	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-39	9593-9594	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-40	9594-9596	CC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-41	9596-9597	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-42	9598-9603	drawn	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-43	9604-9608	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-44	9609-9612	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-45	9613-9620	general	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-46	9621-9631	population	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
44-47	9631-9632	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Participants enter the study when they are between the ages of 12–22 and are reassessed every two years with age-appropriate clinical, behavioral and neurophysiological assessments.
45-1	9633-9645	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-2	9646-9651	enter	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-3	9652-9655	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-4	9656-9661	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-5	9662-9666	when	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-6	9667-9671	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-7	9672-9675	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-8	9676-9683	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-9	9684-9687	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-10	9688-9692	ages	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-11	9693-9695	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-12	9696-9698	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-13	9698-9699	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-14	9699-9701	22	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-15	9702-9705	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-16	9706-9709	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-17	9710-9720	reassessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-18	9721-9726	every	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-19	9727-9730	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-20	9731-9736	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-21	9737-9741	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-22	9742-9757	age-appropriate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-23	9758-9766	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-24	9766-9767	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-25	9768-9778	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-26	9779-9782	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-27	9783-9801	neurophysiological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-28	9802-9813	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
45-29	9813-9814	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=For additional details of the sample characteristics, see.
46-1	9815-9818	For	_	
46-2	9819-9829	additional	_	
46-3	9830-9837	details	_	
46-4	9838-9840	of	_	
46-5	9841-9844	the	_	
46-6	9845-9851	sample	_	
46-7	9852-9867	characteristics	_	
46-8	9867-9868	,	_	
46-9	9869-9872	see	_	
46-10	9872-9873	.	_	

#Text=For this study, participants within the age range of 17–25 years were selected; each individual was represented only once in the sample, at their earliest assessment within this age range.
47-1	9874-9877	For	_	
47-2	9878-9882	this	_	
47-3	9883-9888	study	_	
47-4	9888-9889	,	_	
47-5	9890-9902	participants	_	
47-6	9903-9909	within	_	
47-7	9910-9913	the	_	
47-8	9914-9917	age	_	
47-9	9918-9923	range	_	
47-10	9924-9926	of	_	
47-11	9927-9929	17	_	
47-12	9929-9930	–	_	
47-13	9930-9932	25	_	
47-14	9933-9938	years	_	
47-15	9939-9943	were	_	
47-16	9944-9952	selected	_	
47-17	9952-9953	;	_	
47-18	9954-9958	each	_	
47-19	9959-9969	individual	_	
47-20	9970-9973	was	_	
47-21	9974-9985	represented	_	
47-22	9986-9990	only	_	
47-23	9991-9995	once	_	
47-24	9996-9998	in	_	
47-25	9999-10002	the	_	
47-26	10003-10009	sample	_	
47-27	10009-10010	,	_	
47-28	10011-10013	at	_	
47-29	10014-10019	their	_	
47-30	10020-10028	earliest	_	
47-31	10029-10039	assessment	_	
47-32	10040-10046	within	_	
47-33	10047-10051	this	_	
47-34	10052-10055	age	_	
47-35	10056-10061	range	_	
47-36	10061-10062	.	_	

#Text=The number of subjects in each subgroup is shown in Table 1.
48-1	10063-10066	The	_	
48-2	10067-10073	number	_	
48-3	10074-10076	of	_	
48-4	10077-10085	subjects	_	
48-5	10086-10088	in	_	
48-6	10089-10093	each	_	
48-7	10094-10102	subgroup	_	
48-8	10103-10105	is	_	
48-9	10106-10111	shown	_	
48-10	10112-10114	in	_	
48-11	10115-10120	Table	_	
48-12	10121-10122	1	_	
48-13	10122-10123	.	_	

#Text=The sample predominantly included participants with European ancestry (EA: 65.08%) and African ancestry (AA: 32.29), in addition to a small fraction with Hispanic ancestry (HA: 2.62%).
49-1	10124-10127	The	_	
49-2	10128-10134	sample	_	
49-3	10135-10148	predominantly	_	
49-4	10149-10157	included	_	
49-5	10158-10170	participants	_	
49-6	10171-10175	with	_	
49-7	10176-10184	European	_	
49-8	10185-10193	ancestry	_	
49-9	10194-10195	(	_	
49-10	10195-10197	EA	_	
49-11	10197-10198	:	_	
49-12	10199-10205	65.08%	_	
49-13	10205-10206	)	_	
49-14	10207-10210	and	_	
49-15	10211-10218	African	_	
49-16	10219-10227	ancestry	_	
49-17	10228-10229	(	_	
49-18	10229-10231	AA	_	
49-19	10231-10232	:	_	
49-20	10233-10238	32.29	_	
49-21	10238-10239	)	_	
49-22	10239-10240	,	_	
49-23	10241-10243	in	_	
49-24	10244-10252	addition	_	
49-25	10253-10255	to	_	
49-26	10256-10257	a	_	
49-27	10258-10263	small	_	
49-28	10264-10272	fraction	_	
49-29	10273-10277	with	_	
49-30	10278-10286	Hispanic	_	
49-31	10287-10295	ancestry	_	
49-32	10296-10297	(	_	
49-33	10297-10299	HA	_	
49-34	10299-10300	:	_	
49-35	10301-10306	2.62%	_	
49-36	10306-10307	)	_	
49-37	10307-10308	.	_	

#Text=Data from six collection centers have been included in this study: SUNY Downstate Medical Center at Brooklyn, New York; University of Connecticut Health Science Center; Washington University School of Medicine in St.
50-1	10309-10313	Data	_	
50-2	10314-10318	from	_	
50-3	10319-10322	six	_	
50-4	10323-10333	collection	_	
50-5	10334-10341	centers	_	
50-6	10342-10346	have	_	
50-7	10347-10351	been	_	
50-8	10352-10360	included	_	
50-9	10361-10363	in	_	
50-10	10364-10368	this	_	
50-11	10369-10374	study	_	
50-12	10374-10375	:	_	
50-13	10376-10380	SUNY	_	
50-14	10381-10390	Downstate	_	
50-15	10391-10398	Medical	_	
50-16	10399-10405	Center	_	
50-17	10406-10408	at	_	
50-18	10409-10417	Brooklyn	_	
50-19	10417-10418	,	_	
50-20	10419-10422	New	_	
50-21	10423-10427	York	_	
50-22	10427-10428	;	_	
50-23	10429-10439	University	_	
50-24	10440-10442	of	_	
50-25	10443-10454	Connecticut	_	
50-26	10455-10461	Health	_	
50-27	10462-10469	Science	_	
50-28	10470-10476	Center	_	
50-29	10476-10477	;	_	
50-30	10478-10488	Washington	_	
50-31	10489-10499	University	_	
50-32	10500-10506	School	_	
50-33	10507-10509	of	_	
50-34	10510-10518	Medicine	_	
50-35	10519-10521	in	_	
50-36	10522-10524	St	_	
50-37	10524-10525	.	_	

#Text=Louis; University of California at San Diego; University of Iowa, and Indiana University School of Medicine.
51-1	10526-10531	Louis	_	
51-2	10531-10532	;	_	
51-3	10533-10543	University	_	
51-4	10544-10546	of	_	
51-5	10547-10557	California	_	
51-6	10558-10560	at	_	
51-7	10561-10564	San	_	
51-8	10565-10570	Diego	_	
51-9	10570-10571	;	_	
51-10	10572-10582	University	_	
51-11	10583-10585	of	_	
51-12	10586-10590	Iowa	_	
51-13	10590-10591	,	_	
51-14	10592-10595	and	_	
51-15	10596-10603	Indiana	_	
51-16	10604-10614	University	_	
51-17	10615-10621	School	_	
51-18	10622-10624	of	_	
51-19	10625-10633	Medicine	_	
51-20	10633-10634	.	_	

#Text=Recruitment and assessment procedures have been described elsewhere and are also available at this website: https://zork5.wustl.edu/coganew/data/instruments.html.
52-1	10635-10646	Recruitment	_	
52-2	10647-10650	and	_	
52-3	10651-10661	assessment	_	
52-4	10662-10672	procedures	_	
52-5	10673-10677	have	_	
52-6	10678-10682	been	_	
52-7	10683-10692	described	_	
52-8	10693-10702	elsewhere	_	
52-9	10703-10706	and	_	
52-10	10707-10710	are	_	
52-11	10711-10715	also	_	
52-12	10716-10725	available	_	
52-13	10726-10728	at	_	
52-14	10729-10733	this	_	
52-15	10734-10741	website	_	
52-16	10741-10742	:	_	
52-17	10743-10748	https	_	
52-18	10748-10749	:	_	
52-19	10749-10750	/	_	
52-20	10750-10751	/	_	
52-21	10751-10756	zork5	_	
52-22	10756-10757	.	_	
52-23	10757-10766	wustl.edu	_	
52-24	10766-10767	/	_	
52-25	10767-10774	coganew	_	
52-26	10774-10775	/	_	
52-27	10775-10779	data	_	
52-28	10779-10780	/	_	
52-29	10780-10796	instruments.html	_	
52-30	10796-10797	.	_	

#Text=Subjects were instructed to refrain from using alcohol and substances for at least 5 days prior to EEG recording.
53-1	10798-10806	Subjects	_	
53-2	10807-10811	were	_	
53-3	10812-10822	instructed	_	
53-4	10823-10825	to	_	
53-5	10826-10833	refrain	_	
53-6	10834-10838	from	_	
53-7	10839-10844	using	_	
53-8	10845-10852	alcohol	_	
53-9	10853-10856	and	_	
53-10	10857-10867	substances	_	
53-11	10868-10871	for	_	
53-12	10872-10874	at	_	
53-13	10875-10880	least	_	
53-14	10881-10882	5	_	
53-15	10883-10887	days	_	
53-16	10888-10893	prior	_	
53-17	10894-10896	to	_	
53-18	10897-10900	EEG	http://www.case.edu/ProvCaRe/provcare#Electroencephalograph[6]	
53-19	10901-10910	recording	http://www.case.edu/ProvCaRe/provcare#Electroencephalograph[6]	
53-20	10910-10911	.	_	

#Text=Subjects were excluded from neurophysiological assessment if they had any of the following: (1) recent substance or alcohol use (i.e., positive breath-analyzer test), (2) hepatic encephalopathy/cirrhosis of the liver, (3) history of head injury, seizures or neurosurgery, (4) uncorrected sensory deficits, (5) use of medication known to influence brain functioning, and (6) other acute/chronic medical illnesses that affects brain function.
#Text=2.2.
54-1	10912-10920	Subjects	_	
54-2	10921-10925	were	_	
54-3	10926-10934	excluded	_	
54-4	10935-10939	from	_	
54-5	10940-10958	neurophysiological	_	
54-6	10959-10969	assessment	_	
54-7	10970-10972	if	_	
54-8	10973-10977	they	_	
54-9	10978-10981	had	_	
54-10	10982-10985	any	_	
54-11	10986-10988	of	_	
54-12	10989-10992	the	_	
54-13	10993-11002	following	_	
54-14	11002-11003	:	_	
54-15	11004-11005	(	_	
54-16	11005-11006	1	_	
54-17	11006-11007	)	_	
54-18	11008-11014	recent	_	
54-19	11015-11024	substance	_	
54-20	11025-11027	or	_	
54-21	11028-11035	alcohol	_	
54-22	11036-11039	use	_	
54-23	11040-11041	(	_	
54-24	11041-11044	i.e	_	
54-25	11044-11045	.	_	
54-26	11045-11046	,	_	
54-27	11047-11055	positive	_	
54-28	11056-11071	breath-analyzer	_	
54-29	11072-11076	test	_	
54-30	11076-11077	)	_	
54-31	11077-11078	,	_	
54-32	11079-11080	(	_	
54-33	11080-11081	2	_	
54-34	11081-11082	)	_	
54-35	11083-11090	hepatic	_	
54-36	11091-11105	encephalopathy	_	
54-37	11105-11106	/	_	
54-38	11106-11115	cirrhosis	_	
54-39	11116-11118	of	_	
54-40	11119-11122	the	_	
54-41	11123-11128	liver	_	
54-42	11128-11129	,	_	
54-43	11130-11131	(	_	
54-44	11131-11132	3	_	
54-45	11132-11133	)	_	
54-46	11134-11141	history	_	
54-47	11142-11144	of	_	
54-48	11145-11149	head	_	
54-49	11150-11156	injury	_	
54-50	11156-11157	,	_	
54-51	11158-11166	seizures	_	
54-52	11167-11169	or	_	
54-53	11170-11182	neurosurgery	_	
54-54	11182-11183	,	_	
54-55	11184-11185	(	_	
54-56	11185-11186	4	_	
54-57	11186-11187	)	_	
54-58	11188-11199	uncorrected	_	
54-59	11200-11207	sensory	_	
54-60	11208-11216	deficits	_	
54-61	11216-11217	,	_	
54-62	11218-11219	(	_	
54-63	11219-11220	5	_	
54-64	11220-11221	)	_	
54-65	11222-11225	use	_	
54-66	11226-11228	of	_	
54-67	11229-11239	medication	_	
54-68	11240-11245	known	_	
54-69	11246-11248	to	_	
54-70	11249-11258	influence	_	
54-71	11259-11264	brain	_	
54-72	11265-11276	functioning	_	
54-73	11276-11277	,	_	
54-74	11278-11281	and	_	
54-75	11282-11283	(	_	
54-76	11283-11284	6	_	
54-77	11284-11285	)	_	
54-78	11286-11291	other	_	
54-79	11292-11297	acute	_	
54-80	11297-11298	/	_	
54-81	11298-11305	chronic	_	
54-82	11306-11313	medical	_	
54-83	11314-11323	illnesses	_	
54-84	11324-11328	that	_	
54-85	11329-11336	affects	_	
54-86	11337-11342	brain	_	
54-87	11343-11351	function	_	
54-88	11351-11352	.	_	
54-89	11353-11356	2.2	_	
54-90	11356-11357	.	_	

#Text=Monetary Gambling Task
#Text=The monetary gambling task (MGT) used in this study is illustrated in Figure 1.
55-1	11358-11366	Monetary	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[7]	
55-2	11367-11375	Gambling	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[7]	
55-3	11376-11380	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[7]	
55-4	11381-11384	The	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
55-5	11385-11393	monetary	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
55-6	11394-11402	gambling	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
55-7	11403-11407	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
55-8	11408-11409	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
55-9	11409-11412	MGT	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
55-10	11412-11413	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
55-11	11414-11418	used	_	
55-12	11419-11421	in	_	
55-13	11422-11426	this	_	
55-14	11427-11432	study	_	
55-15	11433-11435	is	_	
55-16	11436-11447	illustrated	_	
55-17	11448-11450	in	_	
55-18	11451-11457	Figure	_	
55-19	11458-11459	1	_	
55-20	11459-11460	.	_	

#Text=Each trial begins with a choice stimulus (CS), with two numbers (representing monetary values in US cents) of 10 (left box) and 50 (right box), displayed for 800 ms.
56-1	11461-11465	Each	_	
56-2	11466-11471	trial	_	
56-3	11472-11478	begins	_	
56-4	11479-11483	with	_	
56-5	11484-11485	a	_	
56-6	11486-11492	choice	_	
56-7	11493-11501	stimulus	_	
56-8	11502-11503	(	_	
56-9	11503-11505	CS	_	
56-10	11505-11506	)	_	
56-11	11506-11507	,	_	
56-12	11508-11512	with	_	
56-13	11513-11516	two	_	
56-14	11517-11524	numbers	_	
56-15	11525-11526	(	_	
56-16	11526-11538	representing	_	
56-17	11539-11547	monetary	_	
56-18	11548-11554	values	_	
56-19	11555-11557	in	_	
56-20	11558-11560	US	_	
56-21	11561-11566	cents	_	
56-22	11566-11567	)	_	
56-23	11568-11570	of	_	
56-24	11571-11573	10	_	
56-25	11574-11575	(	_	
56-26	11575-11579	left	_	
56-27	11580-11583	box	_	
56-28	11583-11584	)	_	
56-29	11585-11588	and	_	
56-30	11589-11591	50	_	
56-31	11592-11593	(	_	
56-32	11593-11598	right	_	
56-33	11599-11602	box	_	
56-34	11602-11603	)	_	
56-35	11603-11604	,	_	
56-36	11605-11614	displayed	_	
56-37	11615-11618	for	_	
56-38	11619-11622	800	_	
56-39	11623-11625	ms	_	
56-40	11625-11626	.	_	

#Text=The participants select a bet of either 50¢ or 10¢, and receive feedback of either loss or gain for the selected amount (outcome stimulus, OS).
57-1	11627-11630	The	_	
57-2	11631-11643	participants	_	
57-3	11644-11650	select	_	
57-4	11651-11652	a	_	
57-5	11653-11656	bet	_	
57-6	11657-11659	of	_	
57-7	11660-11666	either	_	
57-8	11667-11670	50¢	_	
57-9	11671-11673	or	_	
57-10	11674-11677	10¢	_	
57-11	11677-11678	,	_	
57-12	11679-11682	and	_	
57-13	11683-11690	receive	_	
57-14	11691-11699	feedback	_	
57-15	11700-11702	of	_	
57-16	11703-11709	either	_	
57-17	11710-11714	loss	_	
57-18	11715-11717	or	_	
57-19	11718-11722	gain	_	
57-20	11723-11726	for	_	
57-21	11727-11730	the	_	
57-22	11731-11739	selected	_	
57-23	11740-11746	amount	_	
57-24	11747-11748	(	_	
57-25	11748-11755	outcome	_	
57-26	11756-11764	stimulus	_	
57-27	11764-11765	,	_	
57-28	11766-11768	OS	_	
57-29	11768-11769	)	_	
57-30	11769-11770	.	_	

#Text=The task details have been described in our previous publications.
58-1	11771-11774	The	_	
58-2	11775-11779	task	_	
58-3	11780-11787	details	_	
58-4	11788-11792	have	_	
58-5	11793-11797	been	_	
58-6	11798-11807	described	_	
58-7	11808-11810	in	_	
58-8	11811-11814	our	_	
58-9	11815-11823	previous	_	
58-10	11824-11836	publications	_	
58-11	11836-11837	.	_	

#Text=The inter-stimulus interval between a CS and OS, and between an OS and the next CS is 1500 ms.
59-1	11838-11841	The	_	
59-2	11842-11856	inter-stimulus	_	
59-3	11857-11865	interval	_	
59-4	11866-11873	between	_	
59-5	11874-11875	a	_	
59-6	11876-11878	CS	_	
59-7	11879-11882	and	_	
59-8	11883-11885	OS	_	
59-9	11885-11886	,	_	
59-10	11887-11890	and	_	
59-11	11891-11898	between	_	
59-12	11899-11901	an	_	
59-13	11902-11904	OS	_	
59-14	11905-11908	and	_	
59-15	11909-11912	the	_	
59-16	11913-11917	next	_	
59-17	11918-11920	CS	_	
59-18	11921-11923	is	_	
59-19	11924-11928	1500	_	
59-20	11929-11931	ms	_	
59-21	11931-11932	.	_	

#Text=The task involves a total of 172 trials, each with one of four possible outcomes: Loss 50, Loss 10, Gain 50, and Gain 10.
60-1	11933-11936	The	_	
60-2	11937-11941	task	_	
60-3	11942-11950	involves	_	
60-4	11951-11952	a	_	
60-5	11953-11958	total	_	
60-6	11959-11961	of	_	
60-7	11962-11965	172	_	
60-8	11966-11972	trials	_	
60-9	11972-11973	,	_	
60-10	11974-11978	each	_	
60-11	11979-11983	with	_	
60-12	11984-11987	one	_	
60-13	11988-11990	of	_	
60-14	11991-11995	four	_	
60-15	11996-12004	possible	_	
60-16	12005-12013	outcomes	_	
60-17	12013-12014	:	_	
60-18	12015-12019	Loss	_	
60-19	12020-12022	50	_	
60-20	12022-12023	,	_	
60-21	12024-12028	Loss	_	
60-22	12029-12031	10	_	
60-23	12031-12032	,	_	
60-24	12033-12037	Gain	_	
60-25	12038-12040	50	_	
60-26	12040-12041	,	_	
60-27	12042-12045	and	_	
60-28	12046-12050	Gain	_	
60-29	12051-12053	10	_	
60-30	12053-12054	.	_	

#Text=The number of outcome events for loss/red and gain/green trials (OS) are equal (i.e., 50% loss and 50% gain trials regardless of the amount within each outcome), and the order of trial sequence is predetermined, pseudo-randomized, and identical for all participants.
61-1	12055-12058	The	_	
61-2	12059-12065	number	_	
61-3	12066-12068	of	_	
61-4	12069-12076	outcome	_	
61-5	12077-12083	events	_	
61-6	12084-12087	for	_	
61-7	12088-12092	loss	_	
61-8	12092-12093	/	_	
61-9	12093-12096	red	_	
61-10	12097-12100	and	_	
61-11	12101-12105	gain	_	
61-12	12105-12106	/	_	
61-13	12106-12111	green	_	
61-14	12112-12118	trials	_	
61-15	12119-12120	(	_	
61-16	12120-12122	OS	_	
61-17	12122-12123	)	_	
61-18	12124-12127	are	_	
61-19	12128-12133	equal	_	
61-20	12134-12135	(	_	
61-21	12135-12138	i.e	_	
61-22	12138-12139	.	_	
61-23	12139-12140	,	_	
61-24	12141-12144	50%	_	
61-25	12145-12149	loss	_	
61-26	12150-12153	and	_	
61-27	12154-12157	50%	_	
61-28	12158-12162	gain	_	
61-29	12163-12169	trials	_	
61-30	12170-12180	regardless	_	
61-31	12181-12183	of	_	
61-32	12184-12187	the	_	
61-33	12188-12194	amount	_	
61-34	12195-12201	within	_	
61-35	12202-12206	each	_	
61-36	12207-12214	outcome	_	
61-37	12214-12215	)	_	
61-38	12215-12216	,	_	
61-39	12217-12220	and	_	
61-40	12221-12224	the	_	
61-41	12225-12230	order	_	
61-42	12231-12233	of	_	
61-43	12234-12239	trial	_	
61-44	12240-12248	sequence	_	
61-45	12249-12251	is	_	
61-46	12252-12265	predetermined	_	
61-47	12265-12266	,	_	
61-48	12267-12284	pseudo-randomized	_	
61-49	12284-12285	,	_	
61-50	12286-12289	and	_	
61-51	12290-12299	identical	_	
61-52	12300-12303	for	_	
61-53	12304-12307	all	_	
61-54	12308-12320	participants	_	
61-55	12320-12321	.	_	

#Text=However, the participants are not aware of the probability or sequence of the trials.
62-1	12322-12329	However	_	
62-2	12329-12330	,	_	
62-3	12331-12334	the	_	
62-4	12335-12347	participants	_	
62-5	12348-12351	are	_	
62-6	12352-12355	not	_	
62-7	12356-12361	aware	_	
62-8	12362-12364	of	_	
62-9	12365-12368	the	_	
62-10	12369-12380	probability	_	
62-11	12381-12383	or	_	
62-12	12384-12392	sequence	_	
62-13	12393-12395	of	_	
62-14	12396-12399	the	_	
62-15	12400-12406	trials	_	
62-16	12406-12407	.	_	

#Text=Although the loss and gain events are predetermined, the final outcome trials varied across the participants as they are free to choose either of the amounts in each trial.
#Text=2.3.
63-1	12408-12416	Although	_	
63-2	12417-12420	the	_	
63-3	12421-12425	loss	_	
63-4	12426-12429	and	_	
63-5	12430-12434	gain	_	
63-6	12435-12441	events	_	
63-7	12442-12445	are	_	
63-8	12446-12459	predetermined	_	
63-9	12459-12460	,	_	
63-10	12461-12464	the	_	
63-11	12465-12470	final	_	
63-12	12471-12478	outcome	_	
63-13	12479-12485	trials	_	
63-14	12486-12492	varied	_	
63-15	12493-12499	across	_	
63-16	12500-12503	the	_	
63-17	12504-12516	participants	_	
63-18	12517-12519	as	_	
63-19	12520-12524	they	_	
63-20	12525-12528	are	_	
63-21	12529-12533	free	_	
63-22	12534-12536	to	_	
63-23	12537-12543	choose	_	
63-24	12544-12550	either	_	
63-25	12551-12553	of	_	
63-26	12554-12557	the	_	
63-27	12558-12565	amounts	_	
63-28	12566-12568	in	_	
63-29	12569-12573	each	_	
63-30	12574-12579	trial	_	
63-31	12579-12580	.	_	
63-32	12581-12584	2.3	_	
63-33	12584-12585	.	_	

#Text=EEG Data Acquisition and Preprocessing
#Text=Identical experimental procedures and EEG acquisition systems were used at all neurophysiology collection sites with high inter-laboratory consistency in recordings.
64-1	12586-12589	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram[9]	
64-2	12590-12594	Data	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram[9]	
64-3	12595-12606	Acquisition	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram[9]	
64-4	12607-12610	and	_	
64-5	12611-12624	Preprocessing	_	
64-6	12625-12634	Identical	_	
64-7	12635-12647	experimental	_	
64-8	12648-12658	procedures	_	
64-9	12659-12662	and	_	
64-10	12663-12666	EEG	_	
64-11	12667-12678	acquisition	_	
64-12	12679-12686	systems	_	
64-13	12687-12691	were	_	
64-14	12692-12696	used	_	
64-15	12697-12699	at	_	
64-16	12700-12703	all	_	
64-17	12704-12719	neurophysiology	_	
64-18	12720-12730	collection	_	
64-19	12731-12736	sites	_	
64-20	12737-12741	with	_	
64-21	12742-12746	high	_	
64-22	12747-12763	inter-laboratory	_	
64-23	12764-12775	consistency	_	
64-24	12776-12778	in	_	
64-25	12779-12789	recordings	_	
64-26	12789-12790	.	_	

#Text=Subjects were seated comfortably 1 meter from a monitor in a dimly lit sound-attenuated RF-shielded booth (Industrial Acoustics, Inc., Bronx, NY, USA), and wore a 61-channel electrode cap (Electro-Cap International, Inc., Eaton, OH, USA) based on the Extended 10–20 System (Fig. 2), with a reference electrode at the tip of the nose and with a ground electrode at the forehead.
65-1	12791-12799	Subjects	_	
65-2	12800-12804	were	_	
65-3	12805-12811	seated	_	
65-4	12812-12823	comfortably	_	
65-5	12824-12825	1	_	
65-6	12826-12831	meter	_	
65-7	12832-12836	from	_	
65-8	12837-12838	a	_	
65-9	12839-12846	monitor	_	
65-10	12847-12849	in	_	
65-11	12850-12851	a	_	
65-12	12852-12857	dimly	_	
65-13	12858-12861	lit	_	
65-14	12862-12878	sound-attenuated	_	
65-15	12879-12890	RF-shielded	_	
65-16	12891-12896	booth	_	
65-17	12897-12898	(	_	
65-18	12898-12908	Industrial	_	
65-19	12909-12918	Acoustics	_	
65-20	12918-12919	,	_	
65-21	12920-12923	Inc	_	
65-22	12923-12924	.	_	
65-23	12924-12925	,	_	
65-24	12926-12931	Bronx	_	
65-25	12931-12932	,	_	
65-26	12933-12935	NY	_	
65-27	12935-12936	,	_	
65-28	12937-12940	USA	_	
65-29	12940-12941	)	_	
65-30	12941-12942	,	_	
65-31	12943-12946	and	_	
65-32	12947-12951	wore	_	
65-33	12952-12953	a	_	
65-34	12954-12956	61	_	
65-35	12956-12957	-	_	
65-36	12957-12964	channel	_	
65-37	12965-12974	electrode	_	
65-38	12975-12978	cap	_	
65-39	12979-12980	(	_	
65-40	12980-12991	Electro-Cap	_	
65-41	12992-13005	International	_	
65-42	13005-13006	,	_	
65-43	13007-13010	Inc	_	
65-44	13010-13011	.	_	
65-45	13011-13012	,	_	
65-46	13013-13018	Eaton	_	
65-47	13018-13019	,	_	
65-48	13020-13022	OH	_	
65-49	13022-13023	,	_	
65-50	13024-13027	USA	_	
65-51	13027-13028	)	_	
65-52	13029-13034	based	_	
65-53	13035-13037	on	_	
65-54	13038-13041	the	_	
65-55	13042-13050	Extended	_	
65-56	13051-13053	10	_	
65-57	13053-13054	–	_	
65-58	13054-13056	20	_	
65-59	13057-13063	System	_	
65-60	13064-13065	(	_	
65-61	13065-13068	Fig	_	
65-62	13068-13069	.	_	
65-63	13070-13071	2	_	
65-64	13071-13072	)	_	
65-65	13072-13073	,	_	
65-66	13074-13078	with	_	
65-67	13079-13080	a	_	
65-68	13081-13090	reference	_	
65-69	13091-13100	electrode	_	
65-70	13101-13103	at	_	
65-71	13104-13107	the	_	
65-72	13108-13111	tip	_	
65-73	13112-13114	of	_	
65-74	13115-13118	the	_	
65-75	13119-13123	nose	_	
65-76	13124-13127	and	_	
65-77	13128-13132	with	_	
65-78	13133-13134	a	_	
65-79	13135-13141	ground	_	
65-80	13142-13151	electrode	_	
65-81	13152-13154	at	_	
65-82	13155-13158	the	_	
65-83	13159-13167	forehead	_	
65-84	13167-13168	.	_	

#Text=The electrooculogram (EOG) was recorded by a supraorbital vertical electrode and by a horizontal electrode on the external canthus of the left eye.
66-1	13169-13172	The	_	
66-2	13173-13189	electrooculogram	http://www.case.edu/ProvCaRe/provcare#Electrooculogram[10]	
66-3	13190-13191	(	http://www.case.edu/ProvCaRe/provcare#Electrooculogram[10]	
66-4	13191-13194	EOG	http://www.case.edu/ProvCaRe/provcare#Electrooculogram[10]	
66-5	13194-13195	)	http://www.case.edu/ProvCaRe/provcare#Electrooculogram[10]	
66-6	13196-13199	was	_	
66-7	13200-13208	recorded	_	
66-8	13209-13211	by	_	
66-9	13212-13213	a	_	
66-10	13214-13226	supraorbital	_	
66-11	13227-13235	vertical	_	
66-12	13236-13245	electrode	_	
66-13	13246-13249	and	_	
66-14	13250-13252	by	_	
66-15	13253-13254	a	_	
66-16	13255-13265	horizontal	_	
66-17	13266-13275	electrode	_	
66-18	13276-13278	on	_	
66-19	13279-13282	the	_	
66-20	13283-13291	external	_	
66-21	13292-13299	canthus	_	
66-22	13300-13302	of	_	
66-23	13303-13306	the	_	
66-24	13307-13311	left	_	
66-25	13312-13315	eye	_	
66-26	13315-13316	.	_	

#Text=Electrode impedances were maintained below 5 kΩ.
67-1	13317-13326	Electrode	_	
67-2	13327-13337	impedances	_	
67-3	13338-13342	were	_	
67-4	13343-13353	maintained	_	
67-5	13354-13359	below	_	
67-6	13360-13361	5	_	
67-7	13362-13364	kΩ	_	
67-8	13364-13365	.	_	

#Text=Electrical activity was amplified 10,000 times using SynAmps2 amplifiers (Compumedics USA, Charlotte, NC) and was recorded continuously over a bandwidth between near-DC (0 Hz) and 100.0 Hz on a Neuroscan system (Versions 4.3–4.5; Compumedics USA, Charlotte, NC) at a sampling rate of 500 Hz.
68-1	13366-13376	Electrical	_	
68-2	13377-13385	activity	_	
68-3	13386-13389	was	_	
68-4	13390-13399	amplified	_	
68-5	13400-13406	10,000	_	
68-6	13407-13412	times	_	
68-7	13413-13418	using	_	
68-8	13419-13427	SynAmps2	_	
68-9	13428-13438	amplifiers	_	
68-10	13439-13440	(	_	
68-11	13440-13451	Compumedics	_	
68-12	13452-13455	USA	_	
68-13	13455-13456	,	_	
68-14	13457-13466	Charlotte	_	
68-15	13466-13467	,	_	
68-16	13468-13470	NC	_	
68-17	13470-13471	)	_	
68-18	13472-13475	and	_	
68-19	13476-13479	was	_	
68-20	13480-13488	recorded	_	
68-21	13489-13501	continuously	_	
68-22	13502-13506	over	_	
68-23	13507-13508	a	_	
68-24	13509-13518	bandwidth	_	
68-25	13519-13526	between	_	
68-26	13527-13534	near-DC	_	
68-27	13535-13536	(	_	
68-28	13536-13537	0	_	
68-29	13538-13540	Hz	_	
68-30	13540-13541	)	_	
68-31	13542-13545	and	_	
68-32	13546-13551	100.0	_	
68-33	13552-13554	Hz	_	
68-34	13555-13557	on	_	
68-35	13558-13559	a	_	
68-36	13560-13569	Neuroscan	_	
68-37	13570-13576	system	_	
68-38	13577-13578	(	_	
68-39	13578-13586	Versions	_	
68-40	13587-13590	4.3	_	
68-41	13590-13591	–	_	
68-42	13591-13594	4.5	_	
68-43	13594-13595	;	_	
68-44	13596-13607	Compumedics	_	
68-45	13608-13611	USA	_	
68-46	13611-13612	,	_	
68-47	13613-13622	Charlotte	_	
68-48	13622-13623	,	_	
68-49	13624-13626	NC	_	
68-50	13626-13627	)	_	
68-51	13628-13630	at	_	
68-52	13631-13632	a	_	
68-53	13633-13641	sampling	_	
68-54	13642-13646	rate	_	
68-55	13647-13649	of	_	
68-56	13650-13653	500	_	
68-57	13654-13656	Hz	_	
68-58	13656-13657	.	_	

#Text=The EEG data were resampled offline to 256 Hz for the analyses.
69-1	13658-13661	The	_	
69-2	13662-13665	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram[11]	
69-3	13666-13670	data	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram[11]	
69-4	13671-13675	were	_	
69-5	13676-13685	resampled	_	
69-6	13686-13693	offline	_	
69-7	13694-13696	to	_	
69-8	13697-13700	256	_	
69-9	13701-13703	Hz	_	
69-10	13704-13707	for	_	
69-11	13708-13711	the	_	
69-12	13712-13720	analyses	_	
69-13	13720-13721	.	_	

#Text=Then the waveforms were bandpass filtered offline with 0.05 Hz (low pass) and 55 Hz (high pass).
70-1	13722-13726	Then	_	
70-2	13727-13730	the	_	
70-3	13731-13740	waveforms	_	
70-4	13741-13745	were	_	
70-5	13746-13754	bandpass	_	
70-6	13755-13763	filtered	_	
70-7	13764-13771	offline	_	
70-8	13772-13776	with	_	
70-9	13777-13781	0.05	_	
70-10	13782-13784	Hz	_	
70-11	13785-13786	(	_	
70-12	13786-13789	low	_	
70-13	13790-13794	pass	_	
70-14	13794-13795	)	_	
70-15	13796-13799	and	_	
70-16	13800-13802	55	_	
70-17	13803-13805	Hz	_	
70-18	13806-13807	(	_	
70-19	13807-13811	high	_	
70-20	13812-13816	pass	_	
70-21	13816-13817	)	_	
70-22	13817-13818	.	_	

#Text=EOG correction procedures were not applied.
71-1	13819-13822	EOG	_	
71-2	13823-13833	correction	_	
71-3	13834-13844	procedures	_	
71-4	13845-13849	were	_	
71-5	13850-13853	not	_	
71-6	13854-13861	applied	_	
71-7	13861-13862	.	_	

#Text=However, the trials with waveforms exceeding ±100 µV (primarily due to eye movement artifacts) and other artifacts (e.g., low frequency (DC) drifts and shifts and high frequency noise above 50 Hz) were excluded from the analyses.
72-1	13863-13870	However	_	
72-2	13870-13871	,	_	
72-3	13872-13875	the	_	
72-4	13876-13882	trials	_	
72-5	13883-13887	with	_	
72-6	13888-13897	waveforms	_	
72-7	13898-13907	exceeding	_	
72-8	13908-13909	±	_	
72-9	13909-13912	100	_	
72-10	13913-13915	µV	_	
72-11	13916-13917	(	_	
72-12	13917-13926	primarily	_	
72-13	13927-13930	due	_	
72-14	13931-13933	to	_	
72-15	13934-13937	eye	_	
72-16	13938-13946	movement	_	
72-17	13947-13956	artifacts	_	
72-18	13956-13957	)	_	
72-19	13958-13961	and	_	
72-20	13962-13967	other	_	
72-21	13968-13977	artifacts	_	
72-22	13978-13979	(	_	
72-23	13979-13982	e.g	_	
72-24	13982-13983	.	_	
72-25	13983-13984	,	_	
72-26	13985-13988	low	_	
72-27	13989-13998	frequency	_	
72-28	13999-14000	(	_	
72-29	14000-14002	DC	_	
72-30	14002-14003	)	_	
72-31	14004-14010	drifts	_	
72-32	14011-14014	and	_	
72-33	14015-14021	shifts	_	
72-34	14022-14025	and	_	
72-35	14026-14030	high	_	
72-36	14031-14040	frequency	_	
72-37	14041-14046	noise	_	
72-38	14047-14052	above	_	
72-39	14053-14055	50	_	
72-40	14056-14058	Hz	_	
72-41	14058-14059	)	_	
72-42	14060-14064	were	_	
72-43	14065-14073	excluded	_	
72-44	14074-14078	from	_	
72-45	14079-14082	the	_	
72-46	14083-14091	analyses	_	
72-47	14091-14092	.	_	

#Text=EROs were extracted from the trial epochs of outcome stimuli (1000 ms post stimulus) which contained the feedback of either loss or gain condition (i.e., the epochs following colored frames in Figure 1).
73-1	14093-14097	EROs	_	
73-2	14098-14102	were	_	
73-3	14103-14112	extracted	_	
73-4	14113-14117	from	_	
73-5	14118-14121	the	_	
73-6	14122-14127	trial	_	
73-7	14128-14134	epochs	_	
73-8	14135-14137	of	_	
73-9	14138-14145	outcome	_	
73-10	14146-14153	stimuli	_	
73-11	14154-14155	(	_	
73-12	14155-14159	1000	_	
73-13	14160-14162	ms	_	
73-14	14163-14167	post	_	
73-15	14168-14176	stimulus	_	
73-16	14176-14177	)	_	
73-17	14178-14183	which	_	
73-18	14184-14193	contained	_	
73-19	14194-14197	the	_	
73-20	14198-14206	feedback	_	
73-21	14207-14209	of	_	
73-22	14210-14216	either	_	
73-23	14217-14221	loss	_	
73-24	14222-14224	or	_	
73-25	14225-14229	gain	_	
73-26	14230-14239	condition	_	
73-27	14240-14241	(	_	
73-28	14241-14244	i.e	_	
73-29	14244-14245	.	_	
73-30	14245-14246	,	_	
73-31	14247-14250	the	_	
73-32	14251-14257	epochs	_	
73-33	14258-14267	following	_	
73-34	14268-14275	colored	_	
73-35	14276-14282	frames	_	
73-36	14283-14285	in	_	
73-37	14286-14292	Figure	_	
73-38	14293-14294	1	_	
73-39	14294-14295	)	_	
73-40	14295-14296	.	_	

#Text=The ERO data for the subjects whose ERP waveforms were morphologically aberrant were also further removed from the analyses.
74-1	14297-14300	The	_	
74-2	14301-14304	ERO	_	
74-3	14305-14309	data	_	
74-4	14310-14313	for	_	
74-5	14314-14317	the	_	
74-6	14318-14326	subjects	_	
74-7	14327-14332	whose	_	
74-8	14333-14336	ERP	_	
74-9	14337-14346	waveforms	_	
74-10	14347-14351	were	_	
74-11	14352-14367	morphologically	_	
74-12	14368-14376	aberrant	_	
74-13	14377-14381	were	_	
74-14	14382-14386	also	_	
74-15	14387-14394	further	_	
74-16	14395-14402	removed	_	
74-17	14403-14407	from	_	
74-18	14408-14411	the	_	
74-19	14412-14420	analyses	_	
74-20	14420-14421	.	_	

#Text=Only the trials containing loss and gain conditions for the bigger amount (50¢) were analyzed in the current study, as our previous work showed topographic similarity of theta power for both amounts within loss and gain conditions and more trials for the 50¢ conditions.
75-1	14422-14426	Only	_	
75-2	14427-14430	the	_	
75-3	14431-14437	trials	_	
75-4	14438-14448	containing	_	
75-5	14449-14453	loss	_	
75-6	14454-14457	and	_	
75-7	14458-14462	gain	_	
75-8	14463-14473	conditions	_	
75-9	14474-14477	for	_	
75-10	14478-14481	the	_	
75-11	14482-14488	bigger	_	
75-12	14489-14495	amount	_	
75-13	14496-14497	(	_	
75-14	14497-14500	50¢	_	
75-15	14500-14501	)	_	
75-16	14502-14506	were	_	
75-17	14507-14515	analyzed	_	
75-18	14516-14518	in	_	
75-19	14519-14522	the	_	
75-20	14523-14530	current	_	
75-21	14531-14536	study	_	
75-22	14536-14537	,	_	
75-23	14538-14540	as	_	
75-24	14541-14544	our	_	
75-25	14545-14553	previous	_	
75-26	14554-14558	work	_	
75-27	14559-14565	showed	_	
75-28	14566-14577	topographic	_	
75-29	14578-14588	similarity	_	
75-30	14589-14591	of	_	
75-31	14592-14597	theta	_	
75-32	14598-14603	power	_	
75-33	14604-14607	for	_	
75-34	14608-14612	both	_	
75-35	14613-14620	amounts	_	
75-36	14621-14627	within	_	
75-37	14628-14632	loss	_	
75-38	14633-14636	and	_	
75-39	14637-14641	gain	_	
75-40	14642-14652	conditions	_	
75-41	14653-14656	and	_	
75-42	14657-14661	more	_	
75-43	14662-14668	trials	_	
75-44	14669-14672	for	_	
75-45	14673-14676	the	_	
75-46	14677-14680	50¢	_	
75-47	14681-14691	conditions	_	
75-48	14691-14692	.	_	

#Text=Each subject had a minimum of 15 artifact free trials for the ERO analyses.
#Text=2.4.
76-1	14693-14697	Each	_	
76-2	14698-14705	subject	_	
76-3	14706-14709	had	_	
76-4	14710-14711	a	_	
76-5	14712-14719	minimum	_	
76-6	14720-14722	of	_	
76-7	14723-14725	15	_	
76-8	14726-14734	artifact	_	
76-9	14735-14739	free	_	
76-10	14740-14746	trials	_	
76-11	14747-14750	for	_	
76-12	14751-14754	the	_	
76-13	14755-14758	ERO	_	
76-14	14759-14767	analyses	_	
76-15	14767-14768	.	_	
76-16	14769-14772	2.4	_	
76-17	14772-14773	.	_	

#Text=ERO Signal Processing using S-Transform
#Text=Time-frequency (TF) data were derived using the S-transform signal processing method, introduced by.
77-1	14774-14777	ERO	_	
77-2	14778-14784	Signal	_	
77-3	14785-14795	Processing	_	
77-4	14796-14801	using	_	
77-5	14802-14813	S-Transform	_	
77-6	14814-14828	Time-frequency	_	
77-7	14829-14830	(	_	
77-8	14830-14832	TF	_	
77-9	14832-14833	)	_	
77-10	14834-14838	data	_	
77-11	14839-14843	were	_	
77-12	14844-14851	derived	_	
77-13	14852-14857	using	_	
77-14	14858-14861	the	_	
77-15	14862-14873	S-transform	_	
77-16	14874-14880	signal	_	
77-17	14881-14891	processing	_	
77-18	14892-14898	method	_	
77-19	14898-14899	,	_	
77-20	14900-14910	introduced	_	
77-21	14911-14913	by	_	
77-22	14913-14914	.	_	

#Text=The S-transform has been explained in our previous papers.
78-1	14915-14918	The	_	
78-2	14919-14930	S-transform	_	
78-3	14931-14934	has	_	
78-4	14935-14939	been	_	
78-5	14940-14949	explained	_	
78-6	14950-14952	in	_	
78-7	14953-14956	our	_	
78-8	14957-14965	previous	_	
78-9	14966-14972	papers	_	
78-10	14972-14973	.	_	

#Text=The S-transform is derived from short-time Fourier transform and continuous wavelet transform, and has a greater flexibility, anti-noise performance, and utility in the processing of non-stationary and complex signals compared to other traditional methods, such as short-time Fourier transform and Wigner-Ville distribution.
79-1	14974-14977	The	_	
79-2	14978-14989	S-transform	_	
79-3	14990-14992	is	_	
79-4	14993-15000	derived	_	
79-5	15001-15005	from	_	
79-6	15006-15016	short-time	_	
79-7	15017-15024	Fourier	_	
79-8	15025-15034	transform	_	
79-9	15035-15038	and	_	
79-10	15039-15049	continuous	_	
79-11	15050-15057	wavelet	_	
79-12	15058-15067	transform	_	
79-13	15067-15068	,	_	
79-14	15069-15072	and	_	
79-15	15073-15076	has	_	
79-16	15077-15078	a	_	
79-17	15079-15086	greater	_	
79-18	15087-15098	flexibility	_	
79-19	15098-15099	,	_	
79-20	15100-15110	anti-noise	_	
79-21	15111-15122	performance	_	
79-22	15122-15123	,	_	
79-23	15124-15127	and	_	
79-24	15128-15135	utility	_	
79-25	15136-15138	in	_	
79-26	15139-15142	the	_	
79-27	15143-15153	processing	_	
79-28	15154-15156	of	_	
79-29	15157-15171	non-stationary	_	
79-30	15172-15175	and	_	
79-31	15176-15183	complex	_	
79-32	15184-15191	signals	_	
79-33	15192-15200	compared	_	
79-34	15201-15203	to	_	
79-35	15204-15209	other	_	
79-36	15210-15221	traditional	_	
79-37	15222-15229	methods	_	
79-38	15229-15230	,	_	
79-39	15231-15235	such	_	
79-40	15236-15238	as	_	
79-41	15239-15249	short-time	_	
79-42	15250-15257	Fourier	_	
79-43	15258-15267	transform	_	
79-44	15268-15271	and	_	
79-45	15272-15284	Wigner-Ville	_	
79-46	15285-15297	distribution	_	
79-47	15297-15298	.	_	

#Text=This method has been applied in several recent studies to analyze time-frequency signals of event-related oscillation.
80-1	15299-15303	This	_	
80-2	15304-15310	method	_	
80-3	15311-15314	has	_	
80-4	15315-15319	been	_	
80-5	15320-15327	applied	_	
80-6	15328-15330	in	_	
80-7	15331-15338	several	_	
80-8	15339-15345	recent	_	
80-9	15346-15353	studies	_	
80-10	15354-15356	to	_	
80-11	15357-15364	analyze	_	
80-12	15365-15379	time-frequency	_	
80-13	15380-15387	signals	_	
80-14	15388-15390	of	_	
80-15	15391-15404	event-related	_	
80-16	15405-15416	oscillation	_	
80-17	15416-15417	.	_	

#Text=In the current study, total ERO theta power (which is a combination of both phase-locked and non-phase-locked activity) was computed from the outcome trials of the larger loss and gain conditions (50¢).
81-1	15418-15420	In	_	
81-2	15421-15424	the	_	
81-3	15425-15432	current	_	
81-4	15433-15438	study	_	
81-5	15438-15439	,	_	
81-6	15440-15445	total	_	
81-7	15446-15449	ERO	_	
81-8	15450-15455	theta	_	
81-9	15456-15461	power	_	
81-10	15462-15463	(	_	
81-11	15463-15468	which	_	
81-12	15469-15471	is	_	
81-13	15472-15473	a	_	
81-14	15474-15485	combination	_	
81-15	15486-15488	of	_	
81-16	15489-15493	both	_	
81-17	15494-15506	phase-locked	_	
81-18	15507-15510	and	_	
81-19	15511-15527	non-phase-locked	_	
81-20	15528-15536	activity	_	
81-21	15536-15537	)	_	
81-22	15538-15541	was	_	
81-23	15542-15550	computed	_	
81-24	15551-15555	from	_	
81-25	15556-15559	the	_	
81-26	15560-15567	outcome	_	
81-27	15568-15574	trials	_	
81-28	15575-15577	of	_	
81-29	15578-15581	the	_	
81-30	15582-15588	larger	_	
81-31	15589-15593	loss	_	
81-32	15594-15597	and	_	
81-33	15598-15602	gain	_	
81-34	15603-15613	conditions	_	
81-35	15614-15615	(	_	
81-36	15615-15618	50¢	_	
81-37	15618-15619	)	_	
81-38	15619-15620	.	_	

#Text=Specifically, theta power (3.5–7.5 Hz) within the TFR corresponding to the 200–500 ms post-stimulus time window underlying both N2 and P3 components during ‘loss 50’ and ‘gain 50’ conditions was extracted at frontal (F3, FZ, F4), central (C3, CZ, C4), and parietal (P3, PZ, P4) regions.
82-1	15621-15633	Specifically	_	
82-2	15633-15634	,	_	
82-3	15635-15640	theta	_	
82-4	15641-15646	power	_	
82-5	15647-15648	(	_	
82-6	15648-15651	3.5	_	
82-7	15651-15652	–	_	
82-8	15652-15655	7.5	_	
82-9	15656-15658	Hz	_	
82-10	15658-15659	)	_	
82-11	15660-15666	within	_	
82-12	15667-15670	the	_	
82-13	15671-15674	TFR	_	
82-14	15675-15688	corresponding	_	
82-15	15689-15691	to	_	
82-16	15692-15695	the	_	
82-17	15696-15699	200	_	
82-18	15699-15700	–	_	
82-19	15700-15703	500	_	
82-20	15704-15706	ms	_	
82-21	15707-15720	post-stimulus	_	
82-22	15721-15725	time	_	
82-23	15726-15732	window	_	
82-24	15733-15743	underlying	_	
82-25	15744-15748	both	_	
82-26	15749-15751	N2	_	
82-27	15752-15755	and	_	
82-28	15756-15758	P3	_	
82-29	15759-15769	components	_	
82-30	15770-15776	during	_	
82-31	15777-15778	‘	_	
82-32	15778-15782	loss	_	
82-33	15783-15785	50	_	
82-34	15785-15786	’	_	
82-35	15787-15790	and	_	
82-36	15791-15792	‘	_	
82-37	15792-15796	gain	_	
82-38	15797-15799	50	_	
82-39	15799-15800	’	_	
82-40	15801-15811	conditions	_	
82-41	15812-15815	was	_	
82-42	15816-15825	extracted	_	
82-43	15826-15828	at	_	
82-44	15829-15836	frontal	_	
82-45	15837-15838	(	_	
82-46	15838-15840	F3	_	
82-47	15840-15841	,	_	
82-48	15842-15844	FZ	_	
82-49	15844-15845	,	_	
82-50	15846-15848	F4	_	
82-51	15848-15849	)	_	
82-52	15849-15850	,	_	
82-53	15851-15858	central	_	
82-54	15859-15860	(	_	
82-55	15860-15862	C3	_	
82-56	15862-15863	,	_	
82-57	15864-15866	CZ	_	
82-58	15866-15867	,	_	
82-59	15868-15870	C4	_	
82-60	15870-15871	)	_	
82-61	15871-15872	,	_	
82-62	15873-15876	and	_	
82-63	15877-15885	parietal	_	
82-64	15886-15887	(	_	
82-65	15887-15889	P3	_	
82-66	15889-15890	,	_	
82-67	15891-15893	PZ	_	
82-68	15893-15894	,	_	
82-69	15895-15897	P4	_	
82-70	15897-15898	)	_	
82-71	15899-15906	regions	_	
82-72	15906-15907	.	_	

#Text=The average number of trials were 26.21 and 28.43 for the loss and gain condition, respectively.
#Text=2.5.
83-1	15908-15911	The	_	
83-2	15912-15919	average	_	
83-3	15920-15926	number	_	
83-4	15927-15929	of	_	
83-5	15930-15936	trials	_	
83-6	15937-15941	were	_	
83-7	15942-15947	26.21	_	
83-8	15948-15951	and	_	
83-9	15952-15957	28.43	_	
83-10	15958-15961	for	_	
83-11	15962-15965	the	_	
83-12	15966-15970	loss	_	
83-13	15971-15974	and	_	
83-14	15975-15979	gain	_	
83-15	15980-15989	condition	_	
83-16	15989-15990	,	_	
83-17	15991-16003	respectively	_	
83-18	16003-16004	.	_	
83-19	16005-16008	2.5	_	
83-20	16008-16009	.	_	

#Text=Genotyping
#Text=Genotyping was performed at Washington University School of Medicine in St.
84-1	16010-16020	Genotyping	_	
84-2	16021-16031	Genotyping	_	
84-3	16032-16035	was	_	
84-4	16036-16045	performed	_	
84-5	16046-16048	at	_	
84-6	16049-16059	Washington	_	
84-7	16060-16070	University	_	
84-8	16071-16077	School	_	
84-9	16078-16080	of	_	
84-10	16081-16089	Medicine	_	
84-11	16090-16092	in	_	
84-12	16093-16095	St	_	
84-13	16095-16096	.	_	

#Text=Louis on an OpenArray platform, and at Indiana University School of Medicine in Indianapolis on the Sequenom MassArray system on a larger group of COGA subjects of which the sample described here is a subset.
85-1	16097-16102	Louis	_	
85-2	16103-16105	on	_	
85-3	16106-16108	an	_	
85-4	16109-16118	OpenArray	_	
85-5	16119-16127	platform	_	
85-6	16127-16128	,	_	
85-7	16129-16132	and	_	
85-8	16133-16135	at	_	
85-9	16136-16143	Indiana	_	
85-10	16144-16154	University	_	
85-11	16155-16161	School	_	
85-12	16162-16164	of	_	
85-13	16165-16173	Medicine	_	
85-14	16174-16176	in	_	
85-15	16177-16189	Indianapolis	_	
85-16	16190-16192	on	_	
85-17	16193-16196	the	_	
85-18	16197-16205	Sequenom	_	
85-19	16206-16215	MassArray	_	
85-20	16216-16222	system	_	
85-21	16223-16225	on	_	
85-22	16226-16227	a	_	
85-23	16228-16234	larger	_	
85-24	16235-16240	group	_	
85-25	16241-16243	of	_	
85-26	16244-16248	COGA	_	
85-27	16249-16257	subjects	_	
85-28	16258-16260	of	_	
85-29	16261-16266	which	_	
85-30	16267-16270	the	_	
85-31	16271-16277	sample	_	
85-32	16278-16287	described	_	
85-33	16288-16292	here	_	
85-34	16293-16295	is	_	
85-35	16296-16297	a	_	
85-36	16298-16304	subset	_	
85-37	16304-16305	.	_	

#Text=OpenArray genotyping is a multiplex TaqMan assay platform.
86-1	16306-16315	OpenArray	_	
86-2	16316-16326	genotyping	_	
86-3	16327-16329	is	_	
86-4	16330-16331	a	_	
86-5	16332-16341	multiplex	_	
86-6	16342-16348	TaqMan	_	
86-7	16349-16354	assay	_	
86-8	16355-16363	platform	_	
86-9	16363-16364	.	_	

#Text=The OpenArray Genotyping Plate Configurator was used to design assays.
87-1	16365-16368	The	_	
87-2	16369-16378	OpenArray	_	
87-3	16379-16389	Genotyping	_	
87-4	16390-16395	Plate	_	
87-5	16396-16408	Configurator	_	
87-6	16409-16412	was	_	
87-7	16413-16417	used	_	
87-8	16418-16420	to	_	
87-9	16421-16427	design	_	
87-10	16428-16434	assays	_	
87-11	16434-16435	.	_	

#Text=Arrays were scanned on the OpenArray NT imager and genotypes were called using the OpenArray SNP Genotyping analysis software.
88-1	16436-16442	Arrays	_	
88-2	16443-16447	were	_	
88-3	16448-16455	scanned	_	
88-4	16456-16458	on	_	
88-5	16459-16462	the	_	
88-6	16463-16472	OpenArray	_	
88-7	16473-16475	NT	_	
88-8	16476-16482	imager	_	
88-9	16483-16486	and	_	
88-10	16487-16496	genotypes	_	
88-11	16497-16501	were	_	
88-12	16502-16508	called	_	
88-13	16509-16514	using	_	
88-14	16515-16518	the	_	
88-15	16519-16528	OpenArray	_	
88-16	16529-16532	SNP	_	
88-17	16533-16543	Genotyping	_	
88-18	16544-16552	analysis	_	
88-19	16553-16561	software	_	
88-20	16561-16562	.	_	

#Text=Sequenom Assays (iPLEX Gold) were designed using MassArray Assay Design Software (Sequenom, San Diego, CA).
89-1	16563-16571	Sequenom	_	
89-2	16572-16578	Assays	_	
89-3	16579-16580	(	_	
89-4	16580-16585	iPLEX	_	
89-5	16586-16590	Gold	_	
89-6	16590-16591	)	_	
89-7	16592-16596	were	_	
89-8	16597-16605	designed	_	
89-9	16606-16611	using	_	
89-10	16612-16621	MassArray	_	
89-11	16622-16627	Assay	_	
89-12	16628-16634	Design	_	
89-13	16635-16643	Software	_	
89-14	16644-16645	(	_	
89-15	16645-16653	Sequenom	_	
89-16	16653-16654	,	_	
89-17	16655-16658	San	_	
89-18	16659-16664	Diego	_	
89-19	16664-16665	,	_	
89-20	16666-16668	CA	_	
89-21	16668-16669	)	_	
89-22	16669-16670	.	_	

#Text=Hardy-Weinberg equilibrium (HWE) was computed separately in European Americans and African Americans, and cluster data were re-evaluated if HWE was significant at p < 0.05.
90-1	16671-16685	Hardy-Weinberg	_	
90-2	16686-16697	equilibrium	_	
90-3	16698-16699	(	_	
90-4	16699-16702	HWE	_	
90-5	16702-16703	)	_	
90-6	16704-16707	was	_	
90-7	16708-16716	computed	_	
90-8	16717-16727	separately	_	
90-9	16728-16730	in	_	
90-10	16731-16739	European	_	
90-11	16740-16749	Americans	_	
90-12	16750-16753	and	_	
90-13	16754-16761	African	_	
90-14	16762-16771	Americans	_	
90-15	16771-16772	,	_	
90-16	16773-16776	and	_	
90-17	16777-16784	cluster	_	
90-18	16785-16789	data	_	
90-19	16790-16794	were	_	
90-20	16795-16807	re-evaluated	_	
90-21	16808-16810	if	_	
90-22	16811-16814	HWE	_	
90-23	16815-16818	was	_	
90-24	16819-16830	significant	_	
90-25	16831-16833	at	_	
90-26	16834-16835	p	_	
90-27	16836-16837	<	_	
90-28	16838-16842	0.05	_	
90-29	16842-16843	.	_	

#Text=All SNPs were cleaned for Mendelian inheritance using PEDCHECK.
91-1	16844-16847	All	_	
91-2	16848-16852	SNPs	_	
91-3	16853-16857	were	_	
91-4	16858-16865	cleaned	_	
91-5	16866-16869	for	_	
91-6	16870-16879	Mendelian	_	
91-7	16880-16891	inheritance	_	
91-8	16892-16897	using	_	
91-9	16898-16906	PEDCHECK	_	
91-10	16906-16907	.	_	

#Text=SNP allele frequencies and heterozygosities were computed in PLINK using data on founders only included in the larger group.
92-1	16908-16911	SNP	_	
92-2	16912-16918	allele	_	
92-3	16919-16930	frequencies	_	
92-4	16931-16934	and	_	
92-5	16935-16951	heterozygosities	_	
92-6	16952-16956	were	_	
92-7	16957-16965	computed	_	
92-8	16966-16968	in	_	
92-9	16969-16974	PLINK	_	
92-10	16975-16980	using	_	
92-11	16981-16985	data	_	
92-12	16986-16988	on	_	
92-13	16989-16997	founders	_	
92-14	16998-17002	only	_	
92-15	17003-17011	included	_	
92-16	17012-17014	in	_	
92-17	17015-17018	the	_	
92-18	17019-17025	larger	_	
92-19	17026-17031	group	_	
92-20	17031-17032	.	_	

#Text=Ethnic stratification was assessed with SNPrelate using 64 ancestry-informative SNPs, as part of a larger 96 SNP panel developed at the Rutgers University DNA and Cell Repository (RUID™).
93-1	17033-17039	Ethnic	_	
93-2	17040-17054	stratification	_	
93-3	17055-17058	was	_	
93-4	17059-17067	assessed	_	
93-5	17068-17072	with	_	
93-6	17073-17082	SNPrelate	_	
93-7	17083-17088	using	_	
93-8	17089-17091	64	_	
93-9	17092-17112	ancestry-informative	_	
93-10	17113-17117	SNPs	_	
93-11	17117-17118	,	_	
93-12	17119-17121	as	_	
93-13	17122-17126	part	_	
93-14	17127-17129	of	_	
93-15	17130-17131	a	_	
93-16	17132-17138	larger	_	
93-17	17139-17141	96	_	
93-18	17142-17145	SNP	_	
93-19	17146-17151	panel	_	
93-20	17152-17161	developed	_	
93-21	17162-17164	at	_	
93-22	17165-17168	the	_	
93-23	17169-17176	Rutgers	_	
93-24	17177-17187	University	_	
93-25	17188-17191	DNA	_	
93-26	17192-17195	and	_	
93-27	17196-17200	Cell	_	
93-28	17201-17211	Repository	_	
93-29	17212-17213	(	_	
93-30	17213-17217	RUID	_	
93-31	17217-17218	™	_	
93-32	17218-17219	)	_	
93-33	17219-17220	.	_	

#Text=Further details on the genotyping data is available elsewhere.
94-1	17221-17228	Further	_	
94-2	17229-17236	details	_	
94-3	17237-17239	on	_	
94-4	17240-17243	the	_	
94-5	17244-17254	genotyping	_	
94-6	17255-17259	data	_	
94-7	17260-17262	is	_	
94-8	17263-17272	available	_	
94-9	17273-17282	elsewhere	_	
94-10	17282-17283	.	_	

#Text=The KCNJ6 SNP assayed and used in this study, rs702859, is a synonymous SNP in exon 4 found to be associated with theta EROs to target stimuli in a visual oddball task in our previous GWAS at a genome-wide level of significance.
95-1	17284-17287	The	_	
95-2	17288-17293	KCNJ6	_	
95-3	17294-17297	SNP	_	
95-4	17298-17305	assayed	_	
95-5	17306-17309	and	_	
95-6	17310-17314	used	_	
95-7	17315-17317	in	_	
95-8	17318-17322	this	_	
95-9	17323-17328	study	_	
95-10	17328-17329	,	_	
95-11	17330-17338	rs702859	_	
95-12	17338-17339	,	_	
95-13	17340-17342	is	_	
95-14	17343-17344	a	_	
95-15	17345-17355	synonymous	_	
95-16	17356-17359	SNP	_	
95-17	17360-17362	in	_	
95-18	17363-17367	exon	_	
95-19	17368-17369	4	_	
95-20	17370-17375	found	_	
95-21	17376-17378	to	_	
95-22	17379-17381	be	_	
95-23	17382-17392	associated	_	
95-24	17393-17397	with	_	
95-25	17398-17403	theta	_	
95-26	17404-17408	EROs	_	
95-27	17409-17411	to	_	
95-28	17412-17418	target	_	
95-29	17419-17426	stimuli	_	
95-30	17427-17429	in	_	
95-31	17430-17431	a	_	
95-32	17432-17438	visual	_	
95-33	17439-17446	oddball	_	
95-34	17447-17451	task	_	
95-35	17452-17454	in	_	
95-36	17455-17458	our	_	
95-37	17459-17467	previous	_	
95-38	17468-17472	GWAS	_	
95-39	17473-17475	at	_	
95-40	17476-17477	a	_	
95-41	17478-17489	genome-wide	_	
95-42	17490-17495	level	_	
95-43	17496-17498	of	_	
95-44	17499-17511	significance	_	
95-45	17511-17512	.	_	

#Text=This SNP had the nucleotides ‘A’ (adenine) as the major allele and ‘G’ (guanine) as the minor allele, and the participants were classified into one of three genotype groups based on the number of minor allele(s): 0 (AA), 1 (AG/GA), and 2 (GG).
#Text=2.6.
96-1	17513-17517	This	_	
96-2	17518-17521	SNP	_	
96-3	17522-17525	had	_	
96-4	17526-17529	the	_	
96-5	17530-17541	nucleotides	_	
96-6	17542-17543	‘	_	
96-7	17543-17544	A	_	
96-8	17544-17545	’	_	
96-9	17546-17547	(	_	
96-10	17547-17554	adenine	_	
96-11	17554-17555	)	_	
96-12	17556-17558	as	_	
96-13	17559-17562	the	_	
96-14	17563-17568	major	_	
96-15	17569-17575	allele	_	
96-16	17576-17579	and	_	
96-17	17580-17581	‘	_	
96-18	17581-17582	G	_	
96-19	17582-17583	’	_	
96-20	17584-17585	(	_	
96-21	17585-17592	guanine	_	
96-22	17592-17593	)	_	
96-23	17594-17596	as	_	
96-24	17597-17600	the	_	
96-25	17601-17606	minor	_	
96-26	17607-17613	allele	_	
96-27	17613-17614	,	_	
96-28	17615-17618	and	_	
96-29	17619-17622	the	_	
96-30	17623-17635	participants	_	
96-31	17636-17640	were	_	
96-32	17641-17651	classified	_	
96-33	17652-17656	into	_	
96-34	17657-17660	one	_	
96-35	17661-17663	of	_	
96-36	17664-17669	three	_	
96-37	17670-17678	genotype	_	
96-38	17679-17685	groups	_	
96-39	17686-17691	based	_	
96-40	17692-17694	on	_	
96-41	17695-17698	the	_	
96-42	17699-17705	number	_	
96-43	17706-17708	of	_	
96-44	17709-17714	minor	_	
96-45	17715-17721	allele	_	
96-46	17721-17722	(	_	
96-47	17722-17723	s	_	
96-48	17723-17724	)	_	
96-49	17724-17725	:	_	
96-50	17726-17727	0	_	
96-51	17728-17729	(	_	
96-52	17729-17731	AA	_	
96-53	17731-17732	)	_	
96-54	17732-17733	,	_	
96-55	17734-17735	1	_	
96-56	17736-17737	(	_	
96-57	17737-17739	AG	_	
96-58	17739-17740	/	_	
96-59	17740-17742	GA	_	
96-60	17742-17743	)	_	
96-61	17743-17744	,	_	
96-62	17745-17748	and	_	
96-63	17749-17750	2	_	
96-64	17751-17752	(	_	
96-65	17752-17754	GG	_	
96-66	17754-17755	)	_	
96-67	17755-17756	.	_	
96-68	17757-17760	2.6	_	
96-69	17760-17761	.	_	

#Text=Statistical Analyses
#Text=Log-transformed ERO theta power, representing frontal (F3, FZ, F4), central (C3, CZ, C4), and parietal (P3, PZ, P4) electrodes, was compared across genotypes using repeated measures analysis of variance (RM-ANOVA) of the general linear model (GLM) by using (i) the genotype (0, 1, 2) as between subjects factor, (ii) task condition (loss, gain) and region (frontal, central, parietal) as within-subjects factors, and (iii) ethnic stratification (PC1, PC2), age, gender, and family type as covariates in the model (see Table 2).
97-1	17762-17773	Statistical	_	
97-2	17774-17782	Analyses	_	
97-3	17783-17798	Log-transformed	_	
97-4	17799-17802	ERO	_	
97-5	17803-17808	theta	_	
97-6	17809-17814	power	_	
97-7	17814-17815	,	_	
97-8	17816-17828	representing	_	
97-9	17829-17836	frontal	_	
97-10	17837-17838	(	_	
97-11	17838-17840	F3	_	
97-12	17840-17841	,	_	
97-13	17842-17844	FZ	_	
97-14	17844-17845	,	_	
97-15	17846-17848	F4	_	
97-16	17848-17849	)	_	
97-17	17849-17850	,	_	
97-18	17851-17858	central	_	
97-19	17859-17860	(	_	
97-20	17860-17862	C3	_	
97-21	17862-17863	,	_	
97-22	17864-17866	CZ	_	
97-23	17866-17867	,	_	
97-24	17868-17870	C4	_	
97-25	17870-17871	)	_	
97-26	17871-17872	,	_	
97-27	17873-17876	and	_	
97-28	17877-17885	parietal	_	
97-29	17886-17887	(	_	
97-30	17887-17889	P3	_	
97-31	17889-17890	,	_	
97-32	17891-17893	PZ	_	
97-33	17893-17894	,	_	
97-34	17895-17897	P4	_	
97-35	17897-17898	)	_	
97-36	17899-17909	electrodes	_	
97-37	17909-17910	,	_	
97-38	17911-17914	was	_	
97-39	17915-17923	compared	_	
97-40	17924-17930	across	_	
97-41	17931-17940	genotypes	_	
97-42	17941-17946	using	_	
97-43	17947-17955	repeated	_	
97-44	17956-17964	measures	_	
97-45	17965-17973	analysis	_	
97-46	17974-17976	of	_	
97-47	17977-17985	variance	_	
97-48	17986-17987	(	_	
97-49	17987-17995	RM-ANOVA	_	
97-50	17995-17996	)	_	
97-51	17997-17999	of	_	
97-52	18000-18003	the	_	
97-53	18004-18011	general	_	
97-54	18012-18018	linear	_	
97-55	18019-18024	model	_	
97-56	18025-18026	(	_	
97-57	18026-18029	GLM	_	
97-58	18029-18030	)	_	
97-59	18031-18033	by	_	
97-60	18034-18039	using	_	
97-61	18040-18041	(	_	
97-62	18041-18042	i	_	
97-63	18042-18043	)	_	
97-64	18044-18047	the	_	
97-65	18048-18056	genotype	_	
97-66	18057-18058	(	_	
97-67	18058-18059	0	_	
97-68	18059-18060	,	_	
97-69	18061-18062	1	_	
97-70	18062-18063	,	_	
97-71	18064-18065	2	_	
97-72	18065-18066	)	_	
97-73	18067-18069	as	_	
97-74	18070-18077	between	_	
97-75	18078-18086	subjects	_	
97-76	18087-18093	factor	_	
97-77	18093-18094	,	_	
97-78	18095-18096	(	_	
97-79	18096-18098	ii	_	
97-80	18098-18099	)	_	
97-81	18100-18104	task	_	
97-82	18105-18114	condition	_	
97-83	18115-18116	(	_	
97-84	18116-18120	loss	_	
97-85	18120-18121	,	_	
97-86	18122-18126	gain	_	
97-87	18126-18127	)	_	
97-88	18128-18131	and	_	
97-89	18132-18138	region	_	
97-90	18139-18140	(	_	
97-91	18140-18147	frontal	_	
97-92	18147-18148	,	_	
97-93	18149-18156	central	_	
97-94	18156-18157	,	_	
97-95	18158-18166	parietal	_	
97-96	18166-18167	)	_	
97-97	18168-18170	as	_	
97-98	18171-18186	within-subjects	_	
97-99	18187-18194	factors	_	
97-100	18194-18195	,	_	
97-101	18196-18199	and	_	
97-102	18200-18201	(	_	
97-103	18201-18204	iii	_	
97-104	18204-18205	)	_	
97-105	18206-18212	ethnic	_	
97-106	18213-18227	stratification	_	
97-107	18228-18229	(	_	
97-108	18229-18232	PC1	_	
97-109	18232-18233	,	_	
97-110	18234-18237	PC2	_	
97-111	18237-18238	)	_	
97-112	18238-18239	,	_	
97-113	18240-18243	age	_	
97-114	18243-18244	,	_	
97-115	18245-18251	gender	_	
97-116	18251-18252	,	_	
97-117	18253-18256	and	_	
97-118	18257-18263	family	_	
97-119	18264-18268	type	_	
97-120	18269-18271	as	_	
97-121	18272-18282	covariates	_	
97-122	18283-18285	in	_	
97-123	18286-18289	the	_	
97-124	18290-18295	model	_	
97-125	18296-18297	(	_	
97-126	18297-18300	see	_	
97-127	18301-18306	Table	_	
97-128	18307-18308	2	_	
97-129	18308-18309	)	_	
97-130	18309-18310	.	_	

#Text=RM-ANOVA results were extracted from the multivariate test statistics as the ERO data for the within-subjects factors did not adhere to sphericity assumptions (i.e., the equality of the variances of the differences between levels of the repeated measures factor such as region).
98-1	18311-18319	RM-ANOVA	_	
98-2	18320-18327	results	_	
98-3	18328-18332	were	_	
98-4	18333-18342	extracted	_	
98-5	18343-18347	from	_	
98-6	18348-18351	the	_	
98-7	18352-18364	multivariate	_	
98-8	18365-18369	test	_	
98-9	18370-18380	statistics	_	
98-10	18381-18383	as	_	
98-11	18384-18387	the	_	
98-12	18388-18391	ERO	_	
98-13	18392-18396	data	_	
98-14	18397-18400	for	_	
98-15	18401-18404	the	_	
98-16	18405-18420	within-subjects	_	
98-17	18421-18428	factors	_	
98-18	18429-18432	did	_	
98-19	18433-18436	not	_	
98-20	18437-18443	adhere	_	
98-21	18444-18446	to	_	
98-22	18447-18457	sphericity	_	
98-23	18458-18469	assumptions	_	
98-24	18470-18471	(	_	
98-25	18471-18474	i.e	_	
98-26	18474-18475	.	_	
98-27	18475-18476	,	_	
98-28	18477-18480	the	_	
98-29	18481-18489	equality	_	
98-30	18490-18492	of	_	
98-31	18493-18496	the	_	
98-32	18497-18506	variances	_	
98-33	18507-18509	of	_	
98-34	18510-18513	the	_	
98-35	18514-18525	differences	_	
98-36	18526-18533	between	_	
98-37	18534-18540	levels	_	
98-38	18541-18543	of	_	
98-39	18544-18547	the	_	
98-40	18548-18556	repeated	_	
98-41	18557-18565	measures	_	
98-42	18566-18572	factor	_	
98-43	18573-18577	such	_	
98-44	18578-18580	as	_	
98-45	18581-18587	region	_	
98-46	18587-18588	)	_	
98-47	18588-18589	.	_	

#Text=In other words, an appropriate alternative for the sphericity assumption while analyzing the EEG data is to use multivariate tests within a repeated-measures design, as used in the current study.
99-1	18590-18592	In	_	
99-2	18593-18598	other	_	
99-3	18599-18604	words	_	
99-4	18604-18605	,	_	
99-5	18606-18608	an	_	
99-6	18609-18620	appropriate	_	
99-7	18621-18632	alternative	_	
99-8	18633-18636	for	_	
99-9	18637-18640	the	_	
99-10	18641-18651	sphericity	_	
99-11	18652-18662	assumption	_	
99-12	18663-18668	while	_	
99-13	18669-18678	analyzing	_	
99-14	18679-18682	the	_	
99-15	18683-18686	EEG	_	
99-16	18687-18691	data	_	
99-17	18692-18694	is	_	
99-18	18695-18697	to	_	
99-19	18698-18701	use	_	
99-20	18702-18714	multivariate	_	
99-21	18715-18720	tests	_	
99-22	18721-18727	within	_	
99-23	18728-18729	a	_	
99-24	18730-18747	repeated-measures	_	
99-25	18748-18754	design	_	
99-26	18754-18755	,	_	
99-27	18756-18758	as	_	
99-28	18759-18763	used	_	
99-29	18764-18766	in	_	
99-30	18767-18770	the	_	
99-31	18771-18778	current	_	
99-32	18779-18784	study	_	
99-33	18784-18785	.	_	

#Text=F-values and p-values of Pillai’s Trace were used.
100-1	18786-18794	F-values	_	
100-2	18795-18798	and	_	
100-3	18799-18807	p-values	_	
100-4	18808-18810	of	_	
100-5	18811-18817	Pillai	_	
100-6	18817-18818	’	_	
100-7	18818-18819	s	_	
100-8	18820-18825	Trace	_	
100-9	18826-18830	were	_	
100-10	18831-18835	used	_	
100-11	18835-18836	.	_	

#Text=Further, on the figure illustrating the means of the EROs separated by genotype, region, and condition, the Bonferroni adjusted p-values of significant pairwise multiple comparisons have been provided [see Fig. 3].
#Text=3.
101-1	18837-18844	Further	_	
101-2	18844-18845	,	_	
101-3	18846-18848	on	_	
101-4	18849-18852	the	_	
101-5	18853-18859	figure	_	
101-6	18860-18872	illustrating	_	
101-7	18873-18876	the	_	
101-8	18877-18882	means	_	
101-9	18883-18885	of	_	
101-10	18886-18889	the	_	
101-11	18890-18894	EROs	_	
101-12	18895-18904	separated	_	
101-13	18905-18907	by	_	
101-14	18908-18916	genotype	_	
101-15	18916-18917	,	_	
101-16	18918-18924	region	_	
101-17	18924-18925	,	_	
101-18	18926-18929	and	_	
101-19	18930-18939	condition	_	
101-20	18939-18940	,	_	
101-21	18941-18944	the	_	
101-22	18945-18955	Bonferroni	_	
101-23	18956-18964	adjusted	_	
101-24	18965-18973	p-values	_	
101-25	18974-18976	of	_	
101-26	18977-18988	significant	_	
101-27	18989-18997	pairwise	_	
101-28	18998-19006	multiple	_	
101-29	19007-19018	comparisons	_	
101-30	19019-19023	have	_	
101-31	19024-19028	been	_	
101-32	19029-19037	provided	_	
101-33	19038-19039	[	_	
101-34	19039-19042	see	_	
101-35	19043-19046	Fig	_	
101-36	19046-19047	.	_	
101-37	19048-19049	3	_	
101-38	19049-19050	]	_	
101-39	19050-19051	.	_	
101-40	19052-19053	3	_	
101-41	19053-19054	.	_	

#Text=Results
#Text=3.1.
102-1	19055-19062	Results	_	
102-2	19063-19066	3.1	_	
102-3	19066-19067	.	_	

#Text=Theta EROs across genotypes
#Text=Mean age across genotype groups [AA = 19.29; AG = 19.25; GG = 19.41] was not significantly different.
103-1	19068-19073	Theta	_	
103-2	19074-19078	EROs	_	
103-3	19079-19085	across	_	
103-4	19086-19095	genotypes	_	
103-5	19096-19100	Mean	_	
103-6	19101-19104	age	_	
103-7	19105-19111	across	_	
103-8	19112-19120	genotype	_	
103-9	19121-19127	groups	_	
103-10	19128-19129	[	_	
103-11	19129-19131	AA	_	
103-12	19132-19133	=	_	
103-13	19134-19139	19.29	_	
103-14	19139-19140	;	_	
103-15	19141-19143	AG	_	
103-16	19144-19145	=	_	
103-17	19146-19151	19.25	_	
103-18	19151-19152	;	_	
103-19	19153-19155	GG	_	
103-20	19156-19157	=	_	
103-21	19158-19163	19.41	_	
103-22	19163-19164	]	_	
103-23	19165-19168	was	_	
103-24	19169-19172	not	_	
103-25	19173-19186	significantly	_	
103-26	19187-19196	different	_	
103-27	19196-19197	.	_	

#Text=Significant main and interaction effects extracted from the ANOVA results have been presented in Table 2 and Fig. 3.
104-1	19198-19209	Significant	_	
104-2	19210-19214	main	_	
104-3	19215-19218	and	_	
104-4	19219-19230	interaction	_	
104-5	19231-19238	effects	_	
104-6	19239-19248	extracted	_	
104-7	19249-19253	from	_	
104-8	19254-19257	the	_	
104-9	19258-19263	ANOVA	_	
104-10	19264-19271	results	_	
104-11	19272-19276	have	_	
104-12	19277-19281	been	_	
104-13	19282-19291	presented	_	
104-14	19292-19294	in	_	
104-15	19295-19300	Table	_	
104-16	19301-19302	2	_	
104-17	19303-19306	and	_	
104-18	19307-19310	Fig	_	
104-19	19310-19311	.	_	
104-20	19312-19313	3	_	
104-21	19313-19314	.	_	

#Text=There was a significant main effect of genotype showing an additive effect with increase in theta power corresponding to the number of minor alleles (GG > AG > AA <=> 2.82 > 2.74 > 2.70) [see Table 2].
105-1	19315-19320	There	_	
105-2	19321-19324	was	_	
105-3	19325-19326	a	_	
105-4	19327-19338	significant	_	
105-5	19339-19343	main	_	
105-6	19344-19350	effect	_	
105-7	19351-19353	of	_	
105-8	19354-19362	genotype	_	
105-9	19363-19370	showing	_	
105-10	19371-19373	an	_	
105-11	19374-19382	additive	_	
105-12	19383-19389	effect	_	
105-13	19390-19394	with	_	
105-14	19395-19403	increase	_	
105-15	19404-19406	in	_	
105-16	19407-19412	theta	_	
105-17	19413-19418	power	_	
105-18	19419-19432	corresponding	_	
105-19	19433-19435	to	_	
105-20	19436-19439	the	_	
105-21	19440-19446	number	_	
105-22	19447-19449	of	_	
105-23	19450-19455	minor	_	
105-24	19456-19463	alleles	_	
105-25	19464-19465	(	_	
105-26	19465-19467	GG	_	
105-27	19468-19469	>	_	
105-28	19470-19472	AG	_	
105-29	19473-19474	>	_	
105-30	19475-19477	AA	_	
105-31	19478-19479	<	_	
105-32	19479-19480	=	_	
105-33	19480-19481	>	_	
105-34	19482-19486	2.82	_	
105-35	19487-19488	>	_	
105-36	19489-19493	2.74	_	
105-37	19494-19495	>	_	
105-38	19496-19500	2.70	_	
105-39	19500-19501	)	_	
105-40	19502-19503	[	_	
105-41	19503-19506	see	_	
105-42	19507-19512	Table	_	
105-43	19513-19514	2	_	
105-44	19514-19515	]	_	
105-45	19515-19516	.	_	

#Text=The significant main effect of condition revealed that the gain condition (M = 2.79; SE = 0.02) displayed higher theta power than the loss condition (M = 2.71; SE = 0.02).
106-1	19517-19520	The	_	
106-2	19521-19532	significant	_	
106-3	19533-19537	main	_	
106-4	19538-19544	effect	_	
106-5	19545-19547	of	_	
106-6	19548-19557	condition	_	
106-7	19558-19566	revealed	_	
106-8	19567-19571	that	_	
106-9	19572-19575	the	_	
106-10	19576-19580	gain	_	
106-11	19581-19590	condition	_	
106-12	19591-19592	(	_	
106-13	19592-19593	M	_	
106-14	19594-19595	=	_	
106-15	19596-19600	2.79	_	
106-16	19600-19601	;	_	
106-17	19602-19604	SE	_	
106-18	19605-19606	=	_	
106-19	19607-19611	0.02	_	
106-20	19611-19612	)	_	
106-21	19613-19622	displayed	_	
106-22	19623-19629	higher	_	
106-23	19630-19635	theta	_	
106-24	19636-19641	power	_	
106-25	19642-19646	than	_	
106-26	19647-19650	the	_	
106-27	19651-19655	loss	_	
106-28	19656-19665	condition	_	
106-29	19666-19667	(	_	
106-30	19667-19668	M	_	
106-31	19669-19670	=	_	
106-32	19671-19675	2.71	_	
106-33	19675-19676	;	_	
106-34	19677-19679	SE	_	
106-35	19680-19681	=	_	
106-36	19682-19686	0.02	_	
106-37	19686-19687	)	_	
106-38	19687-19688	.	_	

#Text=The region main effect indicated that the parietal region had the highest theta power (M = 2.79; SE = 0.02) followed by central (M = 2.77; SE = 0.02) and frontal regions (M = 2.70; SE = 0.02).
107-1	19689-19692	The	_	
107-2	19693-19699	region	_	
107-3	19700-19704	main	_	
107-4	19705-19711	effect	_	
107-5	19712-19721	indicated	_	
107-6	19722-19726	that	_	
107-7	19727-19730	the	_	
107-8	19731-19739	parietal	_	
107-9	19740-19746	region	_	
107-10	19747-19750	had	_	
107-11	19751-19754	the	_	
107-12	19755-19762	highest	_	
107-13	19763-19768	theta	_	
107-14	19769-19774	power	_	
107-15	19775-19776	(	_	
107-16	19776-19777	M	_	
107-17	19778-19779	=	_	
107-18	19780-19784	2.79	_	
107-19	19784-19785	;	_	
107-20	19786-19788	SE	_	
107-21	19789-19790	=	_	
107-22	19791-19795	0.02	_	
107-23	19795-19796	)	_	
107-24	19797-19805	followed	_	
107-25	19806-19808	by	_	
107-26	19809-19816	central	_	
107-27	19817-19818	(	_	
107-28	19818-19819	M	_	
107-29	19820-19821	=	_	
107-30	19822-19826	2.77	_	
107-31	19826-19827	;	_	
107-32	19828-19830	SE	_	
107-33	19831-19832	=	_	
107-34	19833-19837	0.02	_	
107-35	19837-19838	)	_	
107-36	19839-19842	and	_	
107-37	19843-19850	frontal	_	
107-38	19851-19858	regions	_	
107-39	19859-19860	(	_	
107-40	19860-19861	M	_	
107-41	19862-19863	=	_	
107-42	19864-19868	2.70	_	
107-43	19868-19869	;	_	
107-44	19870-19872	SE	_	
107-45	19873-19874	=	_	
107-46	19875-19879	0.02	_	
107-47	19879-19880	)	_	
107-48	19880-19881	.	_	

#Text=Genotype × region interaction effect indicated that theta differences between genotypes (GG > AA) were significant in central (2.84 > 2.71) and parietal (2.88 > 2.72) but not in frontal region (2.73 vs 2.68).
108-1	19882-19890	Genotype	_	
108-2	19891-19892	×	_	
108-3	19893-19899	region	_	
108-4	19900-19911	interaction	_	
108-5	19912-19918	effect	_	
108-6	19919-19928	indicated	_	
108-7	19929-19933	that	_	
108-8	19934-19939	theta	_	
108-9	19940-19951	differences	_	
108-10	19952-19959	between	_	
108-11	19960-19969	genotypes	_	
108-12	19970-19971	(	_	
108-13	19971-19973	GG	_	
108-14	19974-19975	>	_	
108-15	19976-19978	AA	_	
108-16	19978-19979	)	_	
108-17	19980-19984	were	_	
108-18	19985-19996	significant	_	
108-19	19997-19999	in	_	
108-20	20000-20007	central	_	
108-21	20008-20009	(	_	
108-22	20009-20013	2.84	_	
108-23	20014-20015	>	_	
108-24	20016-20020	2.71	_	
108-25	20020-20021	)	_	
108-26	20022-20025	and	_	
108-27	20026-20034	parietal	_	
108-28	20035-20036	(	_	
108-29	20036-20040	2.88	_	
108-30	20041-20042	>	_	
108-31	20043-20047	2.72	_	
108-32	20047-20048	)	_	
108-33	20049-20052	but	_	
108-34	20053-20056	not	_	
108-35	20057-20059	in	_	
108-36	20060-20067	frontal	_	
108-37	20068-20074	region	_	
108-38	20075-20076	(	_	
108-39	20076-20080	2.73	_	
108-40	20081-20083	vs	_	
108-41	20084-20088	2.68	_	
108-42	20088-20089	)	_	
108-43	20089-20090	.	_	

#Text=Genotype × region interaction effect also revealed that theta power significantly varied between the regions (frontal vs. parietal) in each genotype group.
109-1	20091-20099	Genotype	_	
109-2	20100-20101	×	_	
109-3	20102-20108	region	_	
109-4	20109-20120	interaction	_	
109-5	20121-20127	effect	_	
109-6	20128-20132	also	_	
109-7	20133-20141	revealed	_	
109-8	20142-20146	that	_	
109-9	20147-20152	theta	_	
109-10	20153-20158	power	_	
109-11	20159-20172	significantly	_	
109-12	20173-20179	varied	_	
109-13	20180-20187	between	_	
109-14	20188-20191	the	_	
109-15	20192-20199	regions	_	
109-16	20200-20201	(	_	
109-17	20201-20208	frontal	_	
109-18	20209-20211	vs	_	
109-19	20211-20212	.	_	
109-20	20213-20221	parietal	_	
109-21	20221-20222	)	_	
109-22	20223-20225	in	_	
109-23	20226-20230	each	_	
109-24	20231-20239	genotype	_	
109-25	20240-20245	group	_	
109-26	20245-20246	.	_	

#Text=Condition × region effect for theta power had a posterior maximum (parietal > central > frontal <=> 2.87 > 2.82 > 2.69) for gain (p < 0.001) and a topographic pattern that was not significant during loss (2.71 vs 2.71 vs 2.72).
110-1	20247-20256	Condition	_	
110-2	20257-20258	×	_	
110-3	20259-20265	region	_	
110-4	20266-20272	effect	_	
110-5	20273-20276	for	_	
110-6	20277-20282	theta	_	
110-7	20283-20288	power	_	
110-8	20289-20292	had	_	
110-9	20293-20294	a	_	
110-10	20295-20304	posterior	_	
110-11	20305-20312	maximum	_	
110-12	20313-20314	(	_	
110-13	20314-20322	parietal	_	
110-14	20323-20324	>	_	
110-15	20325-20332	central	_	
110-16	20333-20334	>	_	
110-17	20335-20342	frontal	_	
110-18	20343-20344	<	_	
110-19	20344-20345	=	_	
110-20	20345-20346	>	_	
110-21	20347-20351	2.87	_	
110-22	20352-20353	>	_	
110-23	20354-20358	2.82	_	
110-24	20359-20360	>	_	
110-25	20361-20365	2.69	_	
110-26	20365-20366	)	_	
110-27	20367-20370	for	_	
110-28	20371-20375	gain	_	
110-29	20376-20377	(	_	
110-30	20377-20378	p	_	
110-31	20379-20380	<	_	
110-32	20381-20386	0.001	_	
110-33	20386-20387	)	_	
110-34	20388-20391	and	_	
110-35	20392-20393	a	_	
110-36	20394-20405	topographic	_	
110-37	20406-20413	pattern	_	
110-38	20414-20418	that	_	
110-39	20419-20422	was	_	
110-40	20423-20426	not	_	
110-41	20427-20438	significant	_	
110-42	20439-20445	during	_	
110-43	20446-20450	loss	_	
110-44	20451-20452	(	_	
110-45	20452-20456	2.71	_	
110-46	20457-20459	vs	_	
110-47	20460-20464	2.71	_	
110-48	20465-20467	vs	_	
110-49	20468-20472	2.72	_	
110-50	20472-20473	)	_	
110-51	20473-20474	.	_	

#Text=However, genotype × condition and genotype × condition × region interaction effects were not significant.
111-1	20475-20482	However	_	
111-2	20482-20483	,	_	
111-3	20484-20492	genotype	_	
111-4	20493-20494	×	_	
111-5	20495-20504	condition	_	
111-6	20505-20508	and	_	
111-7	20509-20517	genotype	_	
111-8	20518-20519	×	_	
111-9	20520-20529	condition	_	
111-10	20530-20531	×	_	
111-11	20532-20538	region	_	
111-12	20539-20550	interaction	_	
111-13	20551-20558	effects	_	
111-14	20559-20563	were	_	
111-15	20564-20567	not	_	
111-16	20568-20579	significant	_	
111-17	20579-20580	.	_	

#Text=Bonferroni adjusted pairwise comparisons across genotypes, as derived from the estimated marginal means of the ANOVA model, have been illustrated in Fig. 3.
112-1	20581-20591	Bonferroni	_	
112-2	20592-20600	adjusted	_	
112-3	20601-20609	pairwise	_	
112-4	20610-20621	comparisons	_	
112-5	20622-20628	across	_	
112-6	20629-20638	genotypes	_	
112-7	20638-20639	,	_	
112-8	20640-20642	as	_	
112-9	20643-20650	derived	_	
112-10	20651-20655	from	_	
112-11	20656-20659	the	_	
112-12	20660-20669	estimated	_	
112-13	20670-20678	marginal	_	
112-14	20679-20684	means	_	
112-15	20685-20687	of	_	
112-16	20688-20691	the	_	
112-17	20692-20697	ANOVA	_	
112-18	20698-20703	model	_	
112-19	20703-20704	,	_	
112-20	20705-20709	have	_	
112-21	20710-20714	been	_	
112-22	20715-20726	illustrated	_	
112-23	20727-20729	in	_	
112-24	20730-20733	Fig	_	
112-25	20733-20734	.	_	
112-26	20735-20736	3	_	
112-27	20736-20737	.	_	

#Text=Significant differences between AA and GG [GG > AA] at central (p < 0.05) and parietal (p < 0.01) regions during both loss and gain condition were found, while significant differences between AG and GG [GG > AG] were found only during gain condition at the parietal region (p < 0.05).
#Text=3.2.
113-1	20738-20749	Significant	_	
113-2	20750-20761	differences	_	
113-3	20762-20769	between	_	
113-4	20770-20772	AA	_	
113-5	20773-20776	and	_	
113-6	20777-20779	GG	_	
113-7	20780-20781	[	_	
113-8	20781-20783	GG	_	
113-9	20784-20785	>	_	
113-10	20786-20788	AA	_	
113-11	20788-20789	]	_	
113-12	20790-20792	at	_	
113-13	20793-20800	central	_	
113-14	20801-20802	(	_	
113-15	20802-20803	p	_	
113-16	20804-20805	<	_	
113-17	20806-20810	0.05	_	
113-18	20810-20811	)	_	
113-19	20812-20815	and	_	
113-20	20816-20824	parietal	_	
113-21	20825-20826	(	_	
113-22	20826-20827	p	_	
113-23	20828-20829	<	_	
113-24	20830-20834	0.01	_	
113-25	20834-20835	)	_	
113-26	20836-20843	regions	_	
113-27	20844-20850	during	_	
113-28	20851-20855	both	_	
113-29	20856-20860	loss	_	
113-30	20861-20864	and	_	
113-31	20865-20869	gain	_	
113-32	20870-20879	condition	_	
113-33	20880-20884	were	_	
113-34	20885-20890	found	_	
113-35	20890-20891	,	_	
113-36	20892-20897	while	_	
113-37	20898-20909	significant	_	
113-38	20910-20921	differences	_	
113-39	20922-20929	between	_	
113-40	20930-20932	AG	_	
113-41	20933-20936	and	_	
113-42	20937-20939	GG	_	
113-43	20940-20941	[	_	
113-44	20941-20943	GG	_	
113-45	20944-20945	>	_	
113-46	20946-20948	AG	_	
113-47	20948-20949	]	_	
113-48	20950-20954	were	_	
113-49	20955-20960	found	_	
113-50	20961-20965	only	_	
113-51	20966-20972	during	_	
113-52	20973-20977	gain	_	
113-53	20978-20987	condition	_	
113-54	20988-20990	at	_	
113-55	20991-20994	the	_	
113-56	20995-21003	parietal	_	
113-57	21004-21010	region	_	
113-58	21011-21012	(	_	
113-59	21012-21013	p	_	
113-60	21014-21015	<	_	
113-61	21016-21020	0.05	_	
113-62	21020-21021	)	_	
113-63	21021-21022	.	_	
113-64	21023-21026	3.2	_	
113-65	21026-21027	.	_	

#Text=Topography of theta power across genotypes
#Text=Time-frequency (TF) plots and head maps of theta power across the genotypes during loss and gain conditions are shown in Fig. 4.
114-1	21028-21038	Topography	_	
114-2	21039-21041	of	_	
114-3	21042-21047	theta	_	
114-4	21048-21053	power	_	
114-5	21054-21060	across	_	
114-6	21061-21070	genotypes	_	
114-7	21071-21085	Time-frequency	_	
114-8	21086-21087	(	_	
114-9	21087-21089	TF	_	
114-10	21089-21090	)	_	
114-11	21091-21096	plots	_	
114-12	21097-21100	and	_	
114-13	21101-21105	head	_	
114-14	21106-21110	maps	_	
114-15	21111-21113	of	_	
114-16	21114-21119	theta	_	
114-17	21120-21125	power	_	
114-18	21126-21132	across	_	
114-19	21133-21136	the	_	
114-20	21137-21146	genotypes	_	
114-21	21147-21153	during	_	
114-22	21154-21158	loss	_	
114-23	21159-21162	and	_	
114-24	21163-21167	gain	_	
114-25	21168-21178	conditions	_	
114-26	21179-21182	are	_	
114-27	21183-21188	shown	_	
114-28	21189-21191	in	_	
114-29	21192-21195	Fig	_	
114-30	21195-21196	.	_	
114-31	21197-21198	4	_	
114-32	21198-21199	.	_	

#Text=There is an additive effect of genotypes [GG > AG > AA] with increasing theta power corresponding to the number of minor allele(s) during evaluation of loss as well as gain in central and parietal regions illustrating the effects shown in Fig. 3.
115-1	21200-21205	There	_	
115-2	21206-21208	is	_	
115-3	21209-21211	an	_	
115-4	21212-21220	additive	_	
115-5	21221-21227	effect	_	
115-6	21228-21230	of	_	
115-7	21231-21240	genotypes	_	
115-8	21241-21242	[	_	
115-9	21242-21244	GG	_	
115-10	21245-21246	>	_	
115-11	21247-21249	AG	_	
115-12	21250-21251	>	_	
115-13	21252-21254	AA	_	
115-14	21254-21255	]	_	
115-15	21256-21260	with	_	
115-16	21261-21271	increasing	_	
115-17	21272-21277	theta	_	
115-18	21278-21283	power	_	
115-19	21284-21297	corresponding	_	
115-20	21298-21300	to	_	
115-21	21301-21304	the	_	
115-22	21305-21311	number	_	
115-23	21312-21314	of	_	
115-24	21315-21320	minor	_	
115-25	21321-21327	allele	_	
115-26	21327-21328	(	_	
115-27	21328-21329	s	_	
115-28	21329-21330	)	_	
115-29	21331-21337	during	_	
115-30	21338-21348	evaluation	_	
115-31	21349-21351	of	_	
115-32	21352-21356	loss	_	
115-33	21357-21359	as	_	
115-34	21360-21364	well	_	
115-35	21365-21367	as	_	
115-36	21368-21372	gain	_	
115-37	21373-21375	in	_	
115-38	21376-21383	central	_	
115-39	21384-21387	and	_	
115-40	21388-21396	parietal	_	
115-41	21397-21404	regions	_	
115-42	21405-21417	illustrating	_	
115-43	21418-21421	the	_	
115-44	21422-21429	effects	_	
115-45	21430-21435	shown	_	
115-46	21436-21438	in	_	
115-47	21439-21442	Fig	_	
115-48	21442-21443	.	_	
115-49	21444-21445	3	_	
115-50	21445-21446	.	_	

#Text=Subtle topographic differences across genotypes manifested as gradual and relative increases of posterior theta power (i.e., minor allele(s) contributing to posteriorization of theta power).
116-1	21447-21453	Subtle	_	
116-2	21454-21465	topographic	_	
116-3	21466-21477	differences	_	
116-4	21478-21484	across	_	
116-5	21485-21494	genotypes	_	
116-6	21495-21505	manifested	_	
116-7	21506-21508	as	_	
116-8	21509-21516	gradual	_	
116-9	21517-21520	and	_	
116-10	21521-21529	relative	_	
116-11	21530-21539	increases	_	
116-12	21540-21542	of	_	
116-13	21543-21552	posterior	_	
116-14	21553-21558	theta	_	
116-15	21559-21564	power	_	
116-16	21565-21566	(	_	
116-17	21566-21569	i.e	_	
116-18	21569-21570	.	_	
116-19	21570-21571	,	_	
116-20	21572-21577	minor	_	
116-21	21578-21584	allele	_	
116-22	21584-21585	(	_	
116-23	21585-21586	s	_	
116-24	21586-21587	)	_	
116-25	21588-21600	contributing	_	
116-26	21601-21603	to	_	
116-27	21604-21620	posteriorization	_	
116-28	21621-21623	of	_	
116-29	21624-21629	theta	_	
116-30	21630-21635	power	_	
116-31	21635-21636	)	_	
116-32	21636-21637	.	_	

#Text=The ERP waveforms and P3 topography revealed a similar (but less robust) finding that the group with minor allele(s) displayed higher P3 amplitude compared to the group homozygous for the major allele [GG/AG > AA], prominently at the posterior region, during the evaluation of loss as well as gain (see Fig.
117-1	21638-21641	The	_	
117-2	21642-21645	ERP	_	
117-3	21646-21655	waveforms	_	
117-4	21656-21659	and	_	
117-5	21660-21662	P3	_	
117-6	21663-21673	topography	_	
117-7	21674-21682	revealed	_	
117-8	21683-21684	a	_	
117-9	21685-21692	similar	_	
117-10	21693-21694	(	_	
117-11	21694-21697	but	_	
117-12	21698-21702	less	_	
117-13	21703-21709	robust	_	
117-14	21709-21710	)	_	
117-15	21711-21718	finding	_	
117-16	21719-21723	that	_	
117-17	21724-21727	the	_	
117-18	21728-21733	group	_	
117-19	21734-21738	with	_	
117-20	21739-21744	minor	_	
117-21	21745-21751	allele	_	
117-22	21751-21752	(	_	
117-23	21752-21753	s	_	
117-24	21753-21754	)	_	
117-25	21755-21764	displayed	_	
117-26	21765-21771	higher	_	
117-27	21772-21774	P3	_	
117-28	21775-21784	amplitude	_	
117-29	21785-21793	compared	_	
117-30	21794-21796	to	_	
117-31	21797-21800	the	_	
117-32	21801-21806	group	_	
117-33	21807-21817	homozygous	_	
117-34	21818-21821	for	_	
117-35	21822-21825	the	_	
117-36	21826-21831	major	_	
117-37	21832-21838	allele	_	
117-38	21839-21840	[	_	
117-39	21840-21842	GG	_	
117-40	21842-21843	/	_	
117-41	21843-21845	AG	_	
117-42	21846-21847	>	_	
117-43	21848-21850	AA	_	
117-44	21850-21851	]	_	
117-45	21851-21852	,	_	
117-46	21853-21864	prominently	_	
117-47	21865-21867	at	_	
117-48	21868-21871	the	_	
117-49	21872-21881	posterior	_	
117-50	21882-21888	region	_	
117-51	21888-21889	,	_	
117-52	21890-21896	during	_	
117-53	21897-21900	the	_	
117-54	21901-21911	evaluation	_	
117-55	21912-21914	of	_	
117-56	21915-21919	loss	_	
117-57	21920-21922	as	_	
117-58	21923-21927	well	_	
117-59	21928-21930	as	_	
117-60	21931-21935	gain	_	
117-61	21936-21937	(	_	
117-62	21937-21940	see	_	
117-63	21941-21944	Fig	_	
117-64	21944-21945	.	_	

#Text=A1 in Appendix).
#Text=4.
118-1	21946-21948	A1	_	
118-2	21949-21951	in	_	
118-3	21952-21960	Appendix	_	
118-4	21960-21961	)	_	
118-5	21961-21962	.	_	
118-6	21963-21964	4	_	
118-7	21964-21965	.	_	

#Text=Discussion
#Text=The major findings of the current study are 1) an additive genotypic effect of the KCNJ6 SNP on the ERO theta power phenotype during reward processing, increasing significantly across genotypes (GG > AG > AA) in central and parietal regions in both loss and gain conditions, and 2) genotypic effect on scalp topography of theta ERO phenotype during reward processing, with an anterior topography in those with the dominant AA genotype during loss evaluation not present in the AG and GG genotypes, while the ‘anterior – posterior’ effect was strongest in GG followed by AG and AA genotypes during gain processing.
119-1	21966-21976	Discussion	_	
119-2	21977-21980	The	_	
119-3	21981-21986	major	_	
119-4	21987-21995	findings	_	
119-5	21996-21998	of	_	
119-6	21999-22002	the	_	
119-7	22003-22010	current	_	
119-8	22011-22016	study	_	
119-9	22017-22020	are	_	
119-10	22021-22022	1	_	
119-11	22022-22023	)	_	
119-12	22024-22026	an	_	
119-13	22027-22035	additive	_	
119-14	22036-22045	genotypic	_	
119-15	22046-22052	effect	_	
119-16	22053-22055	of	_	
119-17	22056-22059	the	_	
119-18	22060-22065	KCNJ6	_	
119-19	22066-22069	SNP	_	
119-20	22070-22072	on	_	
119-21	22073-22076	the	_	
119-22	22077-22080	ERO	_	
119-23	22081-22086	theta	_	
119-24	22087-22092	power	_	
119-25	22093-22102	phenotype	_	
119-26	22103-22109	during	_	
119-27	22110-22116	reward	_	
119-28	22117-22127	processing	_	
119-29	22127-22128	,	_	
119-30	22129-22139	increasing	_	
119-31	22140-22153	significantly	_	
119-32	22154-22160	across	_	
119-33	22161-22170	genotypes	_	
119-34	22171-22172	(	_	
119-35	22172-22174	GG	_	
119-36	22175-22176	>	_	
119-37	22177-22179	AG	_	
119-38	22180-22181	>	_	
119-39	22182-22184	AA	_	
119-40	22184-22185	)	_	
119-41	22186-22188	in	_	
119-42	22189-22196	central	_	
119-43	22197-22200	and	_	
119-44	22201-22209	parietal	_	
119-45	22210-22217	regions	_	
119-46	22218-22220	in	_	
119-47	22221-22225	both	_	
119-48	22226-22230	loss	_	
119-49	22231-22234	and	_	
119-50	22235-22239	gain	_	
119-51	22240-22250	conditions	_	
119-52	22250-22251	,	_	
119-53	22252-22255	and	_	
119-54	22256-22257	2	_	
119-55	22257-22258	)	_	
119-56	22259-22268	genotypic	_	
119-57	22269-22275	effect	_	
119-58	22276-22278	on	_	
119-59	22279-22284	scalp	_	
119-60	22285-22295	topography	_	
119-61	22296-22298	of	_	
119-62	22299-22304	theta	_	
119-63	22305-22308	ERO	_	
119-64	22309-22318	phenotype	_	
119-65	22319-22325	during	_	
119-66	22326-22332	reward	_	
119-67	22333-22343	processing	_	
119-68	22343-22344	,	_	
119-69	22345-22349	with	_	
119-70	22350-22352	an	_	
119-71	22353-22361	anterior	_	
119-72	22362-22372	topography	_	
119-73	22373-22375	in	_	
119-74	22376-22381	those	_	
119-75	22382-22386	with	_	
119-76	22387-22390	the	_	
119-77	22391-22399	dominant	_	
119-78	22400-22402	AA	_	
119-79	22403-22411	genotype	_	
119-80	22412-22418	during	_	
119-81	22419-22423	loss	_	
119-82	22424-22434	evaluation	_	
119-83	22435-22438	not	_	
119-84	22439-22446	present	_	
119-85	22447-22449	in	_	
119-86	22450-22453	the	_	
119-87	22454-22456	AG	_	
119-88	22457-22460	and	_	
119-89	22461-22463	GG	_	
119-90	22464-22473	genotypes	_	
119-91	22473-22474	,	_	
119-92	22475-22480	while	_	
119-93	22481-22484	the	_	
119-94	22485-22486	‘	_	
119-95	22486-22494	anterior	_	
119-96	22495-22496	–	_	
119-97	22497-22506	posterior	_	
119-98	22506-22507	’	_	
119-99	22508-22514	effect	_	
119-100	22515-22518	was	_	
119-101	22519-22528	strongest	_	
119-102	22529-22531	in	_	
119-103	22532-22534	GG	_	
119-104	22535-22543	followed	_	
119-105	22544-22546	by	_	
119-106	22547-22549	AG	_	
119-107	22550-22553	and	_	
119-108	22554-22556	AA	_	
119-109	22557-22566	genotypes	_	
119-110	22567-22573	during	_	
119-111	22574-22578	gain	_	
119-112	22579-22589	processing	_	
119-113	22589-22590	.	_	

#Text=Our current study extends the previous findings showing an association between KCNJ6 gene polymorphisms and theta ERO phenotypes to targets in an oddball task to an association with theta EROs during reward processing.
#Text=4.1.
120-1	22591-22594	Our	_	
120-2	22595-22602	current	_	
120-3	22603-22608	study	_	
120-4	22609-22616	extends	_	
120-5	22617-22620	the	_	
120-6	22621-22629	previous	_	
120-7	22630-22638	findings	_	
120-8	22639-22646	showing	_	
120-9	22647-22649	an	_	
120-10	22650-22661	association	_	
120-11	22662-22669	between	_	
120-12	22670-22675	KCNJ6	_	
120-13	22676-22680	gene	_	
120-14	22681-22694	polymorphisms	_	
120-15	22695-22698	and	_	
120-16	22699-22704	theta	_	
120-17	22705-22708	ERO	_	
120-18	22709-22719	phenotypes	_	
120-19	22720-22722	to	_	
120-20	22723-22730	targets	_	
120-21	22731-22733	in	_	
120-22	22734-22736	an	_	
120-23	22737-22744	oddball	_	
120-24	22745-22749	task	_	
120-25	22750-22752	to	_	
120-26	22753-22755	an	_	
120-27	22756-22767	association	_	
120-28	22768-22772	with	_	
120-29	22773-22778	theta	_	
120-30	22779-22783	EROs	_	
120-31	22784-22790	during	_	
120-32	22791-22797	reward	_	
120-33	22798-22808	processing	_	
120-34	22808-22809	.	_	
120-35	22810-22813	4.1	_	
120-36	22813-22814	.	_	

#Text=Genotypic Effects on Theta EROs
#Text=The major finding of the current study is that genotypic variations in the KCNJ6 SNP (rs702859) influenced both magnitude and topography of ERO theta power with the minor allele (G) contributing to higher theta power (GG > AG > AA) at central and parietal regions (see Figs. 3 and 4).
121-1	22815-22824	Genotypic	_	
121-2	22825-22832	Effects	_	
121-3	22833-22835	on	_	
121-4	22836-22841	Theta	_	
121-5	22842-22846	EROs	_	
121-6	22847-22850	The	_	
121-7	22851-22856	major	_	
121-8	22857-22864	finding	_	
121-9	22865-22867	of	_	
121-10	22868-22871	the	_	
121-11	22872-22879	current	_	
121-12	22880-22885	study	_	
121-13	22886-22888	is	_	
121-14	22889-22893	that	_	
121-15	22894-22903	genotypic	_	
121-16	22904-22914	variations	_	
121-17	22915-22917	in	_	
121-18	22918-22921	the	_	
121-19	22922-22927	KCNJ6	_	
121-20	22928-22931	SNP	_	
121-21	22932-22933	(	_	
121-22	22933-22941	rs702859	_	
121-23	22941-22942	)	_	
121-24	22943-22953	influenced	_	
121-25	22954-22958	both	_	
121-26	22959-22968	magnitude	_	
121-27	22969-22972	and	_	
121-28	22973-22983	topography	_	
121-29	22984-22986	of	_	
121-30	22987-22990	ERO	_	
121-31	22991-22996	theta	_	
121-32	22997-23002	power	_	
121-33	23003-23007	with	_	
121-34	23008-23011	the	_	
121-35	23012-23017	minor	_	
121-36	23018-23024	allele	_	
121-37	23025-23026	(	_	
121-38	23026-23027	G	_	
121-39	23027-23028	)	_	
121-40	23029-23041	contributing	_	
121-41	23042-23044	to	_	
121-42	23045-23051	higher	_	
121-43	23052-23057	theta	_	
121-44	23058-23063	power	_	
121-45	23064-23065	(	_	
121-46	23065-23067	GG	_	
121-47	23068-23069	>	_	
121-48	23070-23072	AG	_	
121-49	23073-23074	>	_	
121-50	23075-23077	AA	_	
121-51	23077-23078	)	_	
121-52	23079-23081	at	_	
121-53	23082-23089	central	_	
121-54	23090-23093	and	_	
121-55	23094-23102	parietal	_	
121-56	23103-23110	regions	_	
121-57	23111-23112	(	_	
121-58	23112-23115	see	_	
121-59	23116-23120	Figs	_	
121-60	23120-23121	.	_	
121-61	23122-23123	3	_	
121-62	23124-23127	and	_	
121-63	23128-23129	4	_	
121-64	23129-23130	)	_	
121-65	23130-23131	.	_	

#Text=Previous studies have suggested that higher theta power during task conditions indicate efficient cognitive processing.
122-1	23132-23140	Previous	_	
122-2	23141-23148	studies	_	
122-3	23149-23153	have	_	
122-4	23154-23163	suggested	_	
122-5	23164-23168	that	_	
122-6	23169-23175	higher	_	
122-7	23176-23181	theta	_	
122-8	23182-23187	power	_	
122-9	23188-23194	during	_	
122-10	23195-23199	task	_	
122-11	23200-23210	conditions	_	
122-12	23211-23219	indicate	_	
122-13	23220-23229	efficient	_	
122-14	23230-23239	cognitive	_	
122-15	23240-23250	processing	_	
122-16	23250-23251	.	_	

#Text=For example, individuals with and/or at risk for AUD have been shown to have lower theta power in several cognitive paradigms, reflecting deficient neurocognitive functioning in these individuals.
123-1	23252-23255	For	_	
123-2	23256-23263	example	_	
123-3	23263-23264	,	_	
123-4	23265-23276	individuals	_	
123-5	23277-23281	with	_	
123-6	23282-23285	and	_	
123-7	23285-23286	/	_	
123-8	23286-23288	or	_	
123-9	23289-23291	at	_	
123-10	23292-23296	risk	_	
123-11	23297-23300	for	_	
123-12	23301-23304	AUD	_	
123-13	23305-23309	have	_	
123-14	23310-23314	been	_	
123-15	23315-23320	shown	_	
123-16	23321-23323	to	_	
123-17	23324-23328	have	_	
123-18	23329-23334	lower	_	
123-19	23335-23340	theta	_	
123-20	23341-23346	power	_	
123-21	23347-23349	in	_	
123-22	23350-23357	several	_	
123-23	23358-23367	cognitive	_	
123-24	23368-23377	paradigms	_	
123-25	23377-23378	,	_	
123-26	23379-23389	reflecting	_	
123-27	23390-23399	deficient	_	
123-28	23400-23414	neurocognitive	_	
123-29	23415-23426	functioning	_	
123-30	23427-23429	in	_	
123-31	23430-23435	these	_	
123-32	23436-23447	individuals	_	
123-33	23447-23448	.	_	

#Text=Therefore, the current findings of higher theta power during reward processing in the carriers of minor alleles may indicate that they have more efficient cognitive processing.
124-1	23449-23458	Therefore	_	
124-2	23458-23459	,	_	
124-3	23460-23463	the	_	
124-4	23464-23471	current	_	
124-5	23472-23480	findings	_	
124-6	23481-23483	of	_	
124-7	23484-23490	higher	_	
124-8	23491-23496	theta	_	
124-9	23497-23502	power	_	
124-10	23503-23509	during	_	
124-11	23510-23516	reward	_	
124-12	23517-23527	processing	_	
124-13	23528-23530	in	_	
124-14	23531-23534	the	_	
124-15	23535-23543	carriers	_	
124-16	23544-23546	of	_	
124-17	23547-23552	minor	_	
124-18	23553-23560	alleles	_	
124-19	23561-23564	may	_	
124-20	23565-23573	indicate	_	
124-21	23574-23578	that	_	
124-22	23579-23583	they	_	
124-23	23584-23588	have	_	
124-24	23589-23593	more	_	
124-25	23594-23603	efficient	_	
124-26	23604-23613	cognitive	_	
124-27	23614-23624	processing	_	
124-28	23624-23625	.	_	

#Text=Future studies will be needed to determine whether carrying the minor allele perhaps confers a ‘protective’ factor.
125-1	23626-23632	Future	_	
125-2	23633-23640	studies	_	
125-3	23641-23645	will	_	
125-4	23646-23648	be	_	
125-5	23649-23655	needed	_	
125-6	23656-23658	to	_	
125-7	23659-23668	determine	_	
125-8	23669-23676	whether	_	
125-9	23677-23685	carrying	_	
125-10	23686-23689	the	_	
125-11	23690-23695	minor	_	
125-12	23696-23702	allele	_	
125-13	23703-23710	perhaps	_	
125-14	23711-23718	confers	_	
125-15	23719-23720	a	_	
125-16	23721-23722	‘	_	
125-17	23722-23732	protective	_	
125-18	23732-23733	’	_	
125-19	23734-23740	factor	_	
125-20	23740-23741	.	_	

#Text=Our results also showed topographic differences of theta power across genotype during the loss condition (Fig. 4, panel A), with a gradual shift from a highly anteriorized topography of the AA genotype through a less anteriorized topography of the AG genotype to a weakly posteriorized topography of the GG phenotype.
126-1	23742-23745	Our	_	
126-2	23746-23753	results	_	
126-3	23754-23758	also	_	
126-4	23759-23765	showed	_	
126-5	23766-23777	topographic	_	
126-6	23778-23789	differences	_	
126-7	23790-23792	of	_	
126-8	23793-23798	theta	_	
126-9	23799-23804	power	_	
126-10	23805-23811	across	_	
126-11	23812-23820	genotype	_	
126-12	23821-23827	during	_	
126-13	23828-23831	the	_	
126-14	23832-23836	loss	_	
126-15	23837-23846	condition	_	
126-16	23847-23848	(	_	
126-17	23848-23851	Fig	_	
126-18	23851-23852	.	_	
126-19	23853-23854	4	_	
126-20	23854-23855	,	_	
126-21	23856-23861	panel	_	
126-22	23862-23863	A	_	
126-23	23863-23864	)	_	
126-24	23864-23865	,	_	
126-25	23866-23870	with	_	
126-26	23871-23872	a	_	
126-27	23873-23880	gradual	_	
126-28	23881-23886	shift	_	
126-29	23887-23891	from	_	
126-30	23892-23893	a	_	
126-31	23894-23900	highly	_	
126-32	23901-23913	anteriorized	_	
126-33	23914-23924	topography	_	
126-34	23925-23927	of	_	
126-35	23928-23931	the	_	
126-36	23932-23934	AA	_	
126-37	23935-23943	genotype	_	
126-38	23944-23951	through	_	
126-39	23952-23953	a	_	
126-40	23954-23958	less	_	
126-41	23959-23971	anteriorized	_	
126-42	23972-23982	topography	_	
126-43	23983-23985	of	_	
126-44	23986-23989	the	_	
126-45	23990-23992	AG	_	
126-46	23993-24001	genotype	_	
126-47	24002-24004	to	_	
126-48	24005-24006	a	_	
126-49	24007-24013	weakly	_	
126-50	24014-24027	posteriorized	_	
126-51	24028-24038	topography	_	
126-52	24039-24041	of	_	
126-53	24042-24045	the	_	
126-54	24046-24048	GG	_	
126-55	24049-24058	phenotype	_	
126-56	24058-24059	.	_	

#Text=Similar results were seen in the ERP waveforms and topography across the genotype groups (see Fig.
127-1	24060-24067	Similar	_	
127-2	24068-24075	results	_	
127-3	24076-24080	were	_	
127-4	24081-24085	seen	_	
127-5	24086-24088	in	_	
127-6	24089-24092	the	_	
127-7	24093-24096	ERP	_	
127-8	24097-24106	waveforms	_	
127-9	24107-24110	and	_	
127-10	24111-24121	topography	_	
127-11	24122-24128	across	_	
127-12	24129-24132	the	_	
127-13	24133-24141	genotype	_	
127-14	24142-24148	groups	_	
127-15	24149-24150	(	_	
127-16	24150-24153	see	_	
127-17	24154-24157	Fig	_	
127-18	24157-24158	.	_	

#Text=A1 in Appendix) but were less robust compared to the theta ERO findings, suggesting that time-frequency measures may be more useful to identify group differences.
128-1	24159-24161	A1	_	
128-2	24162-24164	in	_	
128-3	24165-24173	Appendix	_	
128-4	24173-24174	)	_	
128-5	24175-24178	but	_	
128-6	24179-24183	were	_	
128-7	24184-24188	less	_	
128-8	24189-24195	robust	_	
128-9	24196-24204	compared	_	
128-10	24205-24207	to	_	
128-11	24208-24211	the	_	
128-12	24212-24217	theta	_	
128-13	24218-24221	ERO	_	
128-14	24222-24230	findings	_	
128-15	24230-24231	,	_	
128-16	24232-24242	suggesting	_	
128-17	24243-24247	that	_	
128-18	24248-24262	time-frequency	_	
128-19	24263-24271	measures	_	
128-20	24272-24275	may	_	
128-21	24276-24278	be	_	
128-22	24279-24283	more	_	
128-23	24284-24290	useful	_	
128-24	24291-24293	to	_	
128-25	24294-24302	identify	_	
128-26	24303-24308	group	_	
128-27	24309-24320	differences	_	
128-28	24320-24321	.	_	

#Text=Previous studies have reported that ERO measures were better able to discriminate between alcoholics and controls and between high-risk offspring of alcoholics and low-risk offspring of controls.
129-1	24322-24330	Previous	_	
129-2	24331-24338	studies	_	
129-3	24339-24343	have	_	
129-4	24344-24352	reported	_	
129-5	24353-24357	that	_	
129-6	24358-24361	ERO	_	
129-7	24362-24370	measures	_	
129-8	24371-24375	were	_	
129-9	24376-24382	better	_	
129-10	24383-24387	able	_	
129-11	24388-24390	to	_	
129-12	24391-24403	discriminate	_	
129-13	24404-24411	between	_	
129-14	24412-24422	alcoholics	_	
129-15	24423-24426	and	_	
129-16	24427-24435	controls	_	
129-17	24436-24439	and	_	
129-18	24440-24447	between	_	
129-19	24448-24457	high-risk	_	
129-20	24458-24467	offspring	_	
129-21	24468-24470	of	_	
129-22	24471-24481	alcoholics	_	
129-23	24482-24485	and	_	
129-24	24486-24494	low-risk	_	
129-25	24495-24504	offspring	_	
129-26	24505-24507	of	_	
129-27	24508-24516	controls	_	
129-28	24516-24517	.	_	

#Text=In a previous study of theta EROs during loss and gain in the same monetary gambling task, we reported topographic differences between the younger (12–15) and older (16–25) subsamples of the COGA prospective study in the same baseline condition.
130-1	24518-24520	In	_	
130-2	24521-24522	a	_	
130-3	24523-24531	previous	_	
130-4	24532-24537	study	_	
130-5	24538-24540	of	_	
130-6	24541-24546	theta	_	
130-7	24547-24551	EROs	_	
130-8	24552-24558	during	_	
130-9	24559-24563	loss	_	
130-10	24564-24567	and	_	
130-11	24568-24572	gain	_	
130-12	24573-24575	in	_	
130-13	24576-24579	the	_	
130-14	24580-24584	same	_	
130-15	24585-24593	monetary	_	
130-16	24594-24602	gambling	_	
130-17	24603-24607	task	_	
130-18	24607-24608	,	_	
130-19	24609-24611	we	_	
130-20	24612-24620	reported	_	
130-21	24621-24632	topographic	_	
130-22	24633-24644	differences	_	
130-23	24645-24652	between	_	
130-24	24653-24656	the	_	
130-25	24657-24664	younger	_	
130-26	24665-24666	(	_	
130-27	24666-24668	12	_	
130-28	24668-24669	–	_	
130-29	24669-24671	15	_	
130-30	24671-24672	)	_	
130-31	24673-24676	and	_	
130-32	24677-24682	older	_	
130-33	24683-24684	(	_	
130-34	24684-24686	16	_	
130-35	24686-24687	–	_	
130-36	24687-24689	25	_	
130-37	24689-24690	)	_	
130-38	24691-24701	subsamples	_	
130-39	24702-24704	of	_	
130-40	24705-24708	the	_	
130-41	24709-24713	COGA	_	
130-42	24714-24725	prospective	_	
130-43	24726-24731	study	_	
130-44	24732-24734	in	_	
130-45	24735-24738	the	_	
130-46	24739-24743	same	_	
130-47	24744-24752	baseline	_	
130-48	24753-24762	condition	_	
130-49	24762-24763	.	_	

#Text=In that study, we found that the younger subsample (12–15) showed more theta power and less frontalization, particularly for the loss condition, than the older subsample (16–25) (see Figs. 3 and 4 in).
131-1	24764-24766	In	_	
131-2	24767-24771	that	_	
131-3	24772-24777	study	_	
131-4	24777-24778	,	_	
131-5	24779-24781	we	_	
131-6	24782-24787	found	_	
131-7	24788-24792	that	_	
131-8	24793-24796	the	_	
131-9	24797-24804	younger	_	
131-10	24805-24814	subsample	_	
131-11	24815-24816	(	_	
131-12	24816-24818	12	_	
131-13	24818-24819	–	_	
131-14	24819-24821	15	_	
131-15	24821-24822	)	_	
131-16	24823-24829	showed	_	
131-17	24830-24834	more	_	
131-18	24835-24840	theta	_	
131-19	24841-24846	power	_	
131-20	24847-24850	and	_	
131-21	24851-24855	less	_	
131-22	24856-24870	frontalization	_	
131-23	24870-24871	,	_	
131-24	24872-24884	particularly	_	
131-25	24885-24888	for	_	
131-26	24889-24892	the	_	
131-27	24893-24897	loss	_	
131-28	24898-24907	condition	_	
131-29	24907-24908	,	_	
131-30	24909-24913	than	_	
131-31	24914-24917	the	_	
131-32	24918-24923	older	_	
131-33	24924-24933	subsample	_	
131-34	24934-24935	(	_	
131-35	24935-24937	16	_	
131-36	24937-24938	–	_	
131-37	24938-24940	25	_	
131-38	24940-24941	)	_	
131-39	24942-24943	(	_	
131-40	24943-24946	see	_	
131-41	24947-24951	Figs	_	
131-42	24951-24952	.	_	
131-43	24953-24954	3	_	
131-44	24955-24958	and	_	
131-45	24959-24960	4	_	
131-46	24961-24963	in	_	
131-47	24963-24964	)	_	
131-48	24964-24965	.	_	

#Text=Although the age range in the current study is not ‘ideal’ to examine these developmental changes in brain oscillations, when the topographic maps of late adolescents (17–18 years) and young adults (19–25 years were compared (see Fig.
132-1	24966-24974	Although	_	
132-2	24975-24978	the	_	
132-3	24979-24982	age	_	
132-4	24983-24988	range	_	
132-5	24989-24991	in	_	
132-6	24992-24995	the	_	
132-7	24996-25003	current	_	
132-8	25004-25009	study	_	
132-9	25010-25012	is	_	
132-10	25013-25016	not	_	
132-11	25017-25018	‘	_	
132-12	25018-25023	ideal	_	
132-13	25023-25024	’	_	
132-14	25025-25027	to	_	
132-15	25028-25035	examine	_	
132-16	25036-25041	these	_	
132-17	25042-25055	developmental	_	
132-18	25056-25063	changes	_	
132-19	25064-25066	in	_	
132-20	25067-25072	brain	_	
132-21	25073-25085	oscillations	_	
132-22	25085-25086	,	_	
132-23	25087-25091	when	_	
132-24	25092-25095	the	_	
132-25	25096-25107	topographic	_	
132-26	25108-25112	maps	_	
132-27	25113-25115	of	_	
132-28	25116-25120	late	_	
132-29	25121-25132	adolescents	_	
132-30	25133-25134	(	_	
132-31	25134-25136	17	_	
132-32	25136-25137	–	_	
132-33	25137-25139	18	_	
132-34	25140-25145	years	_	
132-35	25145-25146	)	_	
132-36	25147-25150	and	_	
132-37	25151-25156	young	_	
132-38	25157-25163	adults	_	
132-39	25164-25165	(	_	
132-40	25165-25167	19	_	
132-41	25167-25168	–	_	
132-42	25168-25170	25	_	
132-43	25171-25176	years	_	
132-44	25177-25181	were	_	
132-45	25182-25190	compared	_	
132-46	25191-25192	(	_	
132-47	25192-25195	see	_	
132-48	25196-25199	Fig	_	
132-49	25199-25200	.	_	

#Text=A2 in Appendix), it was found that overall, the adolescent group showed more theta power and more diffuse posterior topography than the adult group, regardless of genotype.
133-1	25201-25203	A2	_	
133-2	25204-25206	in	_	
133-3	25207-25215	Appendix	_	
133-4	25215-25216	)	_	
133-5	25216-25217	,	_	
133-6	25218-25220	it	_	
133-7	25221-25224	was	_	
133-8	25225-25230	found	_	
133-9	25231-25235	that	_	
133-10	25236-25243	overall	_	
133-11	25243-25244	,	_	
133-12	25245-25248	the	_	
133-13	25249-25259	adolescent	_	
133-14	25260-25265	group	_	
133-15	25266-25272	showed	_	
133-16	25273-25277	more	_	
133-17	25278-25283	theta	_	
133-18	25284-25289	power	_	
133-19	25290-25293	and	_	
133-20	25294-25298	more	_	
133-21	25299-25306	diffuse	_	
133-22	25307-25316	posterior	_	
133-23	25317-25327	topography	_	
133-24	25328-25332	than	_	
133-25	25333-25336	the	_	
133-26	25337-25342	adult	_	
133-27	25343-25348	group	_	
133-28	25348-25349	,	_	
133-29	25350-25360	regardless	_	
133-30	25361-25363	of	_	
133-31	25364-25372	genotype	_	
133-32	25372-25373	.	_	

#Text=Furthermore, the subgroups with minor allele(s) (AG and GG) showed a more diffuse topography with less frontalization than those with the AA genotype, perhaps suggesting a delay in brain maturation.
134-1	25374-25385	Furthermore	_	
134-2	25385-25386	,	_	
134-3	25387-25390	the	_	
134-4	25391-25400	subgroups	_	
134-5	25401-25405	with	_	
134-6	25406-25411	minor	_	
134-7	25412-25418	allele	_	
134-8	25418-25419	(	_	
134-9	25419-25420	s	_	
134-10	25420-25421	)	_	
134-11	25422-25423	(	_	
134-12	25423-25425	AG	_	
134-13	25426-25429	and	_	
134-14	25430-25432	GG	_	
134-15	25432-25433	)	_	
134-16	25434-25440	showed	_	
134-17	25441-25442	a	_	
134-18	25443-25447	more	_	
134-19	25448-25455	diffuse	_	
134-20	25456-25466	topography	_	
134-21	25467-25471	with	_	
134-22	25472-25476	less	_	
134-23	25477-25491	frontalization	_	
134-24	25492-25496	than	_	
134-25	25497-25502	those	_	
134-26	25503-25507	with	_	
134-27	25508-25511	the	_	
134-28	25512-25514	AA	_	
134-29	25515-25523	genotype	_	
134-30	25523-25524	,	_	
134-31	25525-25532	perhaps	_	
134-32	25533-25543	suggesting	_	
134-33	25544-25545	a	_	
134-34	25546-25551	delay	_	
134-35	25552-25554	in	_	
134-36	25555-25560	brain	_	
134-37	25561-25571	maturation	_	
134-38	25571-25572	.	_	

#Text=Electrophysiological and neuroimaging studies of brain development indicate a reduction and focusing of activity, with a shift toward more frontal activity as pruning occurs in the brain (i.e., frontalization).
135-1	25573-25593	Electrophysiological	_	
135-2	25594-25597	and	_	
135-3	25598-25610	neuroimaging	_	
135-4	25611-25618	studies	_	
135-5	25619-25621	of	_	
135-6	25622-25627	brain	_	
135-7	25628-25639	development	_	
135-8	25640-25648	indicate	_	
135-9	25649-25650	a	_	
135-10	25651-25660	reduction	_	
135-11	25661-25664	and	_	
135-12	25665-25673	focusing	_	
135-13	25674-25676	of	_	
135-14	25677-25685	activity	_	
135-15	25685-25686	,	_	
135-16	25687-25691	with	_	
135-17	25692-25693	a	_	
135-18	25694-25699	shift	_	
135-19	25700-25706	toward	_	
135-20	25707-25711	more	_	
135-21	25712-25719	frontal	_	
135-22	25720-25728	activity	_	
135-23	25729-25731	as	_	
135-24	25732-25739	pruning	_	
135-25	25740-25746	occurs	_	
135-26	25747-25749	in	_	
135-27	25750-25753	the	_	
135-28	25754-25759	brain	_	
135-29	25760-25761	(	_	
135-30	25761-25764	i.e	_	
135-31	25764-25765	.	_	
135-32	25765-25766	,	_	
135-33	25767-25781	frontalization	_	
135-34	25781-25782	)	_	
135-35	25782-25783	.	_	

#Text=Specifically, ERO theta power gradually decreases as children mature, becoming less in early adolescents, and even less in young adults, as efficiency of cognitive functioning improves with increased phase locking of the theta system and hence neural communication in the course of development.
136-1	25784-25796	Specifically	_	
136-2	25796-25797	,	_	
136-3	25798-25801	ERO	_	
136-4	25802-25807	theta	_	
136-5	25808-25813	power	_	
136-6	25814-25823	gradually	_	
136-7	25824-25833	decreases	_	
136-8	25834-25836	as	_	
136-9	25837-25845	children	_	
136-10	25846-25852	mature	_	
136-11	25852-25853	,	_	
136-12	25854-25862	becoming	_	
136-13	25863-25867	less	_	
136-14	25868-25870	in	_	
136-15	25871-25876	early	_	
136-16	25877-25888	adolescents	_	
136-17	25888-25889	,	_	
136-18	25890-25893	and	_	
136-19	25894-25898	even	_	
136-20	25899-25903	less	_	
136-21	25904-25906	in	_	
136-22	25907-25912	young	_	
136-23	25913-25919	adults	_	
136-24	25919-25920	,	_	
136-25	25921-25923	as	_	
136-26	25924-25934	efficiency	_	
136-27	25935-25937	of	_	
136-28	25938-25947	cognitive	_	
136-29	25948-25959	functioning	_	
136-30	25960-25968	improves	_	
136-31	25969-25973	with	_	
136-32	25974-25983	increased	_	
136-33	25984-25989	phase	_	
136-34	25990-25997	locking	_	
136-35	25998-26000	of	_	
136-36	26001-26004	the	_	
136-37	26005-26010	theta	_	
136-38	26011-26017	system	_	
136-39	26018-26021	and	_	
136-40	26022-26027	hence	_	
136-41	26028-26034	neural	_	
136-42	26035-26048	communication	_	
136-43	26049-26051	in	_	
136-44	26052-26055	the	_	
136-45	26056-26062	course	_	
136-46	26063-26065	of	_	
136-47	26066-26077	development	_	
136-48	26077-26078	.	_	

#Text=Therefore, given these suggested findings in the current study, it is possible that the minor alleles of KCNJ6 could be associated with lack of frontalization and/or delayed brain maturation.
137-1	26079-26088	Therefore	_	
137-2	26088-26089	,	_	
137-3	26090-26095	given	_	
137-4	26096-26101	these	_	
137-5	26102-26111	suggested	_	
137-6	26112-26120	findings	_	
137-7	26121-26123	in	_	
137-8	26124-26127	the	_	
137-9	26128-26135	current	_	
137-10	26136-26141	study	_	
137-11	26141-26142	,	_	
137-12	26143-26145	it	_	
137-13	26146-26148	is	_	
137-14	26149-26157	possible	_	
137-15	26158-26162	that	_	
137-16	26163-26166	the	_	
137-17	26167-26172	minor	_	
137-18	26173-26180	alleles	_	
137-19	26181-26183	of	_	
137-20	26184-26189	KCNJ6	_	
137-21	26190-26195	could	_	
137-22	26196-26198	be	_	
137-23	26199-26209	associated	_	
137-24	26210-26214	with	_	
137-25	26215-26219	lack	_	
137-26	26220-26222	of	_	
137-27	26223-26237	frontalization	_	
137-28	26238-26241	and	_	
137-29	26241-26242	/	_	
137-30	26242-26244	or	_	
137-31	26245-26252	delayed	_	
137-32	26253-26258	brain	_	
137-33	26259-26269	maturation	_	
137-34	26269-26270	.	_	

#Text=It is also important to mention that the genotype × condition interaction was not significant, indicating that the main effect of genotype may be non-specific and pertain to the feedback evaluation process in general, rather than to loss or gain specifically.
138-1	26271-26273	It	_	
138-2	26274-26276	is	_	
138-3	26277-26281	also	_	
138-4	26282-26291	important	_	
138-5	26292-26294	to	_	
138-6	26295-26302	mention	_	
138-7	26303-26307	that	_	
138-8	26308-26311	the	_	
138-9	26312-26320	genotype	_	
138-10	26321-26322	×	_	
138-11	26323-26332	condition	_	
138-12	26333-26344	interaction	_	
138-13	26345-26348	was	_	
138-14	26349-26352	not	_	
138-15	26353-26364	significant	_	
138-16	26364-26365	,	_	
138-17	26366-26376	indicating	_	
138-18	26377-26381	that	_	
138-19	26382-26385	the	_	
138-20	26386-26390	main	_	
138-21	26391-26397	effect	_	
138-22	26398-26400	of	_	
138-23	26401-26409	genotype	_	
138-24	26410-26413	may	_	
138-25	26414-26416	be	_	
138-26	26417-26429	non-specific	_	
138-27	26430-26433	and	_	
138-28	26434-26441	pertain	_	
138-29	26442-26444	to	_	
138-30	26445-26448	the	_	
138-31	26449-26457	feedback	_	
138-32	26458-26468	evaluation	_	
138-33	26469-26476	process	_	
138-34	26477-26479	in	_	
138-35	26480-26487	general	_	
138-36	26487-26488	,	_	
138-37	26489-26495	rather	_	
138-38	26496-26500	than	_	
138-39	26501-26503	to	_	
138-40	26504-26508	loss	_	
138-41	26509-26511	or	_	
138-42	26512-26516	gain	_	
138-43	26517-26529	specifically	_	
138-44	26529-26530	.	_	

#Text=Since theta-band responses can be elicited by a variety of task-relevant stimuli, the effect observed could be non-specific.
139-1	26531-26536	Since	_	
139-2	26537-26547	theta-band	_	
139-3	26548-26557	responses	_	
139-4	26558-26561	can	_	
139-5	26562-26564	be	_	
139-6	26565-26573	elicited	_	
139-7	26574-26576	by	_	
139-8	26577-26578	a	_	
139-9	26579-26586	variety	_	
139-10	26587-26589	of	_	
139-11	26590-26603	task-relevant	_	
139-12	26604-26611	stimuli	_	
139-13	26611-26612	,	_	
139-14	26613-26616	the	_	
139-15	26617-26623	effect	_	
139-16	26624-26632	observed	_	
139-17	26633-26638	could	_	
139-18	26639-26641	be	_	
139-19	26642-26654	non-specific	_	
139-20	26654-26655	.	_	

#Text=On the other hand, significant condition × region effect suggested outcome-specific theta activity, in which gain manifested posteriorly focused (parietal) theta power while the loss condition showed relatively anterior (fronto-central) focus.
140-1	26656-26658	On	_	
140-2	26659-26662	the	_	
140-3	26663-26668	other	_	
140-4	26669-26673	hand	_	
140-5	26673-26674	,	_	
140-6	26675-26686	significant	_	
140-7	26687-26696	condition	_	
140-8	26697-26698	×	_	
140-9	26699-26705	region	_	
140-10	26706-26712	effect	_	
140-11	26713-26722	suggested	_	
140-12	26723-26739	outcome-specific	_	
140-13	26740-26745	theta	_	
140-14	26746-26754	activity	_	
140-15	26754-26755	,	_	
140-16	26756-26758	in	_	
140-17	26759-26764	which	_	
140-18	26765-26769	gain	_	
140-19	26770-26780	manifested	_	
140-20	26781-26792	posteriorly	_	
140-21	26793-26800	focused	_	
140-22	26801-26802	(	_	
140-23	26802-26810	parietal	_	
140-24	26810-26811	)	_	
140-25	26812-26817	theta	_	
140-26	26818-26823	power	_	
140-27	26824-26829	while	_	
140-28	26830-26833	the	_	
140-29	26834-26838	loss	_	
140-30	26839-26848	condition	_	
140-31	26849-26855	showed	_	
140-32	26856-26866	relatively	_	
140-33	26867-26875	anterior	_	
140-34	26876-26877	(	_	
140-35	26877-26891	fronto-central	_	
140-36	26891-26892	)	_	
140-37	26893-26898	focus	_	
140-38	26898-26899	.	_	

#Text=With regard to visual oddball paradigm, reported that theta power related to target processing was frontally focused, and the genome wide association was strongest for the frontal region, followed by central and parietal regions.
141-1	26900-26904	With	_	
141-2	26905-26911	regard	_	
141-3	26912-26914	to	_	
141-4	26915-26921	visual	_	
141-5	26922-26929	oddball	_	
141-6	26930-26938	paradigm	_	
141-7	26938-26939	,	_	
141-8	26940-26948	reported	_	
141-9	26949-26953	that	_	
141-10	26954-26959	theta	_	
141-11	26960-26965	power	_	
141-12	26966-26973	related	_	
141-13	26974-26976	to	_	
141-14	26977-26983	target	_	
141-15	26984-26994	processing	_	
141-16	26995-26998	was	_	
141-17	26999-27008	frontally	_	
141-18	27009-27016	focused	_	
141-19	27016-27017	,	_	
141-20	27018-27021	and	_	
141-21	27022-27025	the	_	
141-22	27026-27032	genome	_	
141-23	27033-27037	wide	_	
141-24	27038-27049	association	_	
141-25	27050-27053	was	_	
141-26	27054-27063	strongest	_	
141-27	27064-27067	for	_	
141-28	27068-27071	the	_	
141-29	27072-27079	frontal	_	
141-30	27080-27086	region	_	
141-31	27086-27087	,	_	
141-32	27088-27096	followed	_	
141-33	27097-27099	by	_	
141-34	27100-27107	central	_	
141-35	27108-27111	and	_	
141-36	27112-27120	parietal	_	
141-37	27121-27128	regions	_	
141-38	27128-27129	.	_	

#Text=Further studies are needed to ascertain the effects of task-specific theta activity on the genotypes of KCNJ6 polymorphisms.
142-1	27130-27137	Further	_	
142-2	27138-27145	studies	_	
142-3	27146-27149	are	_	
142-4	27150-27156	needed	_	
142-5	27157-27159	to	_	
142-6	27160-27169	ascertain	_	
142-7	27170-27173	the	_	
142-8	27174-27181	effects	_	
142-9	27182-27184	of	_	
142-10	27185-27198	task-specific	_	
142-11	27199-27204	theta	_	
142-12	27205-27213	activity	_	
142-13	27214-27216	on	_	
142-14	27217-27220	the	_	
142-15	27221-27230	genotypes	_	
142-16	27231-27233	of	_	
142-17	27234-27239	KCNJ6	_	
142-18	27240-27253	polymorphisms	_	
142-19	27253-27254	.	_	

#Text=Additional studies are also required to elucidate the exact role of variations in KCNJ6 in modulating cognitive functioning and brain maturation.
#Text=4.2.
143-1	27255-27265	Additional	_	
143-2	27266-27273	studies	_	
143-3	27274-27277	are	_	
143-4	27278-27282	also	_	
143-5	27283-27291	required	_	
143-6	27292-27294	to	_	
143-7	27295-27304	elucidate	_	
143-8	27305-27308	the	_	
143-9	27309-27314	exact	_	
143-10	27315-27319	role	_	
143-11	27320-27322	of	_	
143-12	27323-27333	variations	_	
143-13	27334-27336	in	_	
143-14	27337-27342	KCNJ6	_	
143-15	27343-27345	in	_	
143-16	27346-27356	modulating	_	
143-17	27357-27366	cognitive	_	
143-18	27367-27378	functioning	_	
143-19	27379-27382	and	_	
143-20	27383-27388	brain	_	
143-21	27389-27399	maturation	_	
143-22	27399-27400	.	_	
143-23	27401-27404	4.2	_	
143-24	27404-27405	.	_	

#Text=Role of KCNJ6 / GIRK2 in neurocognitive (dys)function and disorders
#Text=KCNJ6 gene encodes G-protein-coupled inwardly rectifying potassium channel 2 (GIRK2) which is one of four primary neuronal GIRK subunits, GIRK1-GIRK4.
144-1	27406-27410	Role	_	
144-2	27411-27413	of	_	
144-3	27414-27419	KCNJ6	_	
144-4	27420-27421	/	_	
144-5	27422-27427	GIRK2	_	
144-6	27428-27430	in	_	
144-7	27431-27445	neurocognitive	_	
144-8	27446-27447	(	_	
144-9	27447-27450	dys	_	
144-10	27450-27451	)	_	
144-11	27451-27459	function	_	
144-12	27460-27463	and	_	
144-13	27464-27473	disorders	_	
144-14	27474-27479	KCNJ6	_	
144-15	27480-27484	gene	_	
144-16	27485-27492	encodes	_	
144-17	27493-27510	G-protein-coupled	_	
144-18	27511-27519	inwardly	_	
144-19	27520-27530	rectifying	_	
144-20	27531-27540	potassium	_	
144-21	27541-27548	channel	_	
144-22	27549-27550	2	_	
144-23	27551-27552	(	_	
144-24	27552-27557	GIRK2	_	
144-25	27557-27558	)	_	
144-26	27559-27564	which	_	
144-27	27565-27567	is	_	
144-28	27568-27571	one	_	
144-29	27572-27574	of	_	
144-30	27575-27579	four	_	
144-31	27580-27587	primary	_	
144-32	27588-27596	neuronal	_	
144-33	27597-27601	GIRK	_	
144-34	27602-27610	subunits	_	
144-35	27610-27611	,	_	
144-36	27612-27617	GIRK1	_	
144-37	27617-27618	-	_	
144-38	27618-27623	GIRK4	_	
144-39	27623-27624	.	_	

#Text=GIRK channels allow potassium ions to flow into the cell rather than out of the cell, a property referred to as “inward rectification”.
145-1	27625-27629	GIRK	_	
145-2	27630-27638	channels	_	
145-3	27639-27644	allow	_	
145-4	27645-27654	potassium	_	
145-5	27655-27659	ions	_	
145-6	27660-27662	to	_	
145-7	27663-27667	flow	_	
145-8	27668-27672	into	_	
145-9	27673-27676	the	_	
145-10	27677-27681	cell	_	
145-11	27682-27688	rather	_	
145-12	27689-27693	than	_	
145-13	27694-27697	out	_	
145-14	27698-27700	of	_	
145-15	27701-27704	the	_	
145-16	27705-27709	cell	_	
145-17	27709-27710	,	_	
145-18	27711-27712	a	_	
145-19	27713-27721	property	_	
145-20	27722-27730	referred	_	
145-21	27731-27733	to	_	
145-22	27734-27736	as	_	
145-23	27737-27738	“	_	
145-24	27738-27744	inward	_	
145-25	27745-27758	rectification	_	
145-26	27758-27759	”	_	
145-27	27759-27760	.	_	

#Text=GIRK channels have been shown to be critical for excitatory synaptic plasticity that underlies learning and memory, as GIRK2 null mutation or GIRK channel blockade has been found to abolish depotentiation of long-term potentiation in cultured hippocampal neurons.
146-1	27761-27765	GIRK	_	
146-2	27766-27774	channels	_	
146-3	27775-27779	have	_	
146-4	27780-27784	been	_	
146-5	27785-27790	shown	_	
146-6	27791-27793	to	_	
146-7	27794-27796	be	_	
146-8	27797-27805	critical	_	
146-9	27806-27809	for	_	
146-10	27810-27820	excitatory	_	
146-11	27821-27829	synaptic	_	
146-12	27830-27840	plasticity	_	
146-13	27841-27845	that	_	
146-14	27846-27855	underlies	_	
146-15	27856-27864	learning	_	
146-16	27865-27868	and	_	
146-17	27869-27875	memory	_	
146-18	27875-27876	,	_	
146-19	27877-27879	as	_	
146-20	27880-27885	GIRK2	_	
146-21	27886-27890	null	_	
146-22	27891-27899	mutation	_	
146-23	27900-27902	or	_	
146-24	27903-27907	GIRK	_	
146-25	27908-27915	channel	_	
146-26	27916-27924	blockade	_	
146-27	27925-27928	has	_	
146-28	27929-27933	been	_	
146-29	27934-27939	found	_	
146-30	27940-27942	to	_	
146-31	27943-27950	abolish	_	
146-32	27951-27965	depotentiation	_	
146-33	27966-27968	of	_	
146-34	27969-27978	long-term	_	
146-35	27979-27991	potentiation	_	
146-36	27992-27994	in	_	
146-37	27995-28003	cultured	_	
146-38	28004-28015	hippocampal	_	
146-39	28016-28023	neurons	_	
146-40	28023-28024	.	_	

#Text=GIRK2 is also associated with opioid transmission in the brain and analgesic properties.
147-1	28025-28030	GIRK2	_	
147-2	28031-28033	is	_	
147-3	28034-28038	also	_	
147-4	28039-28049	associated	_	
147-5	28050-28054	with	_	
147-6	28055-28061	opioid	_	
147-7	28062-28074	transmission	_	
147-8	28075-28077	in	_	
147-9	28078-28081	the	_	
147-10	28082-28087	brain	_	
147-11	28088-28091	and	_	
147-12	28092-28101	analgesic	_	
147-13	28102-28112	properties	_	
147-14	28112-28113	.	_	

#Text=Further, GIRK2 is widely expressed in cerebellum, and an elevated expression of these channels may be involved in neuropathology, and contribute to a range of mental and functional disabilities in Down syndrome.
148-1	28114-28121	Further	_	
148-2	28121-28122	,	_	
148-3	28123-28128	GIRK2	_	
148-4	28129-28131	is	_	
148-5	28132-28138	widely	_	
148-6	28139-28148	expressed	_	
148-7	28149-28151	in	_	
148-8	28152-28162	cerebellum	_	
148-9	28162-28163	,	_	
148-10	28164-28167	and	_	
148-11	28168-28170	an	_	
148-12	28171-28179	elevated	_	
148-13	28180-28190	expression	_	
148-14	28191-28193	of	_	
148-15	28194-28199	these	_	
148-16	28200-28208	channels	_	
148-17	28209-28212	may	_	
148-18	28213-28215	be	_	
148-19	28216-28224	involved	_	
148-20	28225-28227	in	_	
148-21	28228-28242	neuropathology	_	
148-22	28242-28243	,	_	
148-23	28244-28247	and	_	
148-24	28248-28258	contribute	_	
148-25	28259-28261	to	_	
148-26	28262-28263	a	_	
148-27	28264-28269	range	_	
148-28	28270-28272	of	_	
148-29	28273-28279	mental	_	
148-30	28280-28283	and	_	
148-31	28284-28294	functional	_	
148-32	28295-28307	disabilities	_	
148-33	28308-28310	in	_	
148-34	28311-28315	Down	_	
148-35	28316-28324	syndrome	_	
148-36	28324-28325	.	_	

#Text=Alterations in GIRK channel function have been associated with pathophysiology of severe neurological disorders (cf.), such as epilepsy, Parkinson’s disease and ataxia and Down’s syndrome.
149-1	28326-28337	Alterations	_	
149-2	28338-28340	in	_	
149-3	28341-28345	GIRK	_	
149-4	28346-28353	channel	_	
149-5	28354-28362	function	_	
149-6	28363-28367	have	_	
149-7	28368-28372	been	_	
149-8	28373-28383	associated	_	
149-9	28384-28388	with	_	
149-10	28389-28404	pathophysiology	_	
149-11	28405-28407	of	_	
149-12	28408-28414	severe	_	
149-13	28415-28427	neurological	_	
149-14	28428-28437	disorders	_	
149-15	28438-28439	(	_	
149-16	28439-28441	cf	_	
149-17	28441-28442	.	_	
149-18	28442-28443	)	_	
149-19	28443-28444	,	_	
149-20	28445-28449	such	_	
149-21	28450-28452	as	_	
149-22	28453-28461	epilepsy	_	
149-23	28461-28462	,	_	
149-24	28463-28472	Parkinson	_	
149-25	28472-28473	’	_	
149-26	28473-28474	s	_	
149-27	28475-28482	disease	_	
149-28	28483-28486	and	_	
149-29	28487-28493	ataxia	_	
149-30	28494-28497	and	_	
149-31	28498-28502	Down	_	
149-32	28502-28503	’	_	
149-33	28503-28504	s	_	
149-34	28505-28513	syndrome	_	
149-35	28513-28514	.	_	

#Text=GIRK channels are implicated in motor activity, anxiety, reward and movement disorder (ataxia).
150-1	28515-28519	GIRK	_	
150-2	28520-28528	channels	_	
150-3	28529-28532	are	_	
150-4	28533-28543	implicated	_	
150-5	28544-28546	in	_	
150-6	28547-28552	motor	_	
150-7	28553-28561	activity	_	
150-8	28561-28562	,	_	
150-9	28563-28570	anxiety	_	
150-10	28570-28571	,	_	
150-11	28572-28578	reward	_	
150-12	28579-28582	and	_	
150-13	28583-28591	movement	_	
150-14	28592-28600	disorder	_	
150-15	28601-28602	(	_	
150-16	28602-28608	ataxia	_	
150-17	28608-28609	)	_	
150-18	28609-28610	.	_	

#Text=Recent studies have suggested possible role of KCNJ6/GIRK2 in bipolar disorder and depression.
151-1	28611-28617	Recent	_	
151-2	28618-28625	studies	_	
151-3	28626-28630	have	_	
151-4	28631-28640	suggested	_	
151-5	28641-28649	possible	_	
151-6	28650-28654	role	_	
151-7	28655-28657	of	_	
151-8	28658-28663	KCNJ6	_	
151-9	28663-28664	/	_	
151-10	28664-28669	GIRK2	_	
151-11	28670-28672	in	_	
151-12	28673-28680	bipolar	_	
151-13	28681-28689	disorder	_	
151-14	28690-28693	and	_	
151-15	28694-28704	depression	_	
151-16	28704-28705	.	_	

#Text=Further, there is also evidence to show that GIRK2/KCNJ6 function directly influences neuroelectric activity (EEG).
152-1	28706-28713	Further	_	
152-2	28713-28714	,	_	
152-3	28715-28720	there	_	
152-4	28721-28723	is	_	
152-5	28724-28728	also	_	
152-6	28729-28737	evidence	_	
152-7	28738-28740	to	_	
152-8	28741-28745	show	_	
152-9	28746-28750	that	_	
152-10	28751-28756	GIRK2	_	
152-11	28756-28757	/	_	
152-12	28757-28762	KCNJ6	_	
152-13	28763-28771	function	_	
152-14	28772-28780	directly	_	
152-15	28781-28791	influences	_	
152-16	28792-28805	neuroelectric	_	
152-17	28806-28814	activity	_	
152-18	28815-28816	(	_	
152-19	28816-28819	EEG	_	
152-20	28819-28820	)	_	
152-21	28820-28821	.	_	

#Text=For example, there are animal studies showing relationship between KCNJ6 and neuroelectric/seizure activity of the brain.
153-1	28822-28825	For	_	
153-2	28826-28833	example	_	
153-3	28833-28834	,	_	
153-4	28835-28840	there	_	
153-5	28841-28844	are	_	
153-6	28845-28851	animal	_	
153-7	28852-28859	studies	_	
153-8	28860-28867	showing	_	
153-9	28868-28880	relationship	_	
153-10	28881-28888	between	_	
153-11	28889-28894	KCNJ6	_	
153-12	28895-28898	and	_	
153-13	28899-28912	neuroelectric	_	
153-14	28912-28913	/	_	
153-15	28913-28920	seizure	_	
153-16	28921-28929	activity	_	
153-17	28930-28932	of	_	
153-18	28933-28936	the	_	
153-19	28937-28942	brain	_	
153-20	28942-28943	.	_	

#Text=A knockout mouse model found that animals deprived of functional KCNJ6 protein were susceptible to spontaneous and provoked seizures (cf.).
154-1	28944-28945	A	_	
154-2	28946-28954	knockout	_	
154-3	28955-28960	mouse	_	
154-4	28961-28966	model	_	
154-5	28967-28972	found	_	
154-6	28973-28977	that	_	
154-7	28978-28985	animals	_	
154-8	28986-28994	deprived	_	
154-9	28995-28997	of	_	
154-10	28998-29008	functional	_	
154-11	29009-29014	KCNJ6	_	
154-12	29015-29022	protein	_	
154-13	29023-29027	were	_	
154-14	29028-29039	susceptible	_	
154-15	29040-29042	to	_	
154-16	29043-29054	spontaneous	_	
154-17	29055-29058	and	_	
154-18	29059-29067	provoked	_	
154-19	29068-29076	seizures	_	
154-20	29077-29078	(	_	
154-21	29078-29080	cf	_	
154-22	29080-29081	.	_	
154-23	29081-29082	)	_	
154-24	29082-29083	.	_	

#Text=A recent study with a mouse model of seizure activity reported that GIRK2 channel (KCNJ6) may play a major role in the genesis of childhood epilepsy (infantile spasms) as measured by the changes in EEG activity and behavior.
155-1	29084-29085	A	_	
155-2	29086-29092	recent	_	
155-3	29093-29098	study	_	
155-4	29099-29103	with	_	
155-5	29104-29105	a	_	
155-6	29106-29111	mouse	_	
155-7	29112-29117	model	_	
155-8	29118-29120	of	_	
155-9	29121-29128	seizure	_	
155-10	29129-29137	activity	_	
155-11	29138-29146	reported	_	
155-12	29147-29151	that	_	
155-13	29152-29157	GIRK2	_	
155-14	29158-29165	channel	_	
155-15	29166-29167	(	_	
155-16	29167-29172	KCNJ6	_	
155-17	29172-29173	)	_	
155-18	29174-29177	may	_	
155-19	29178-29182	play	_	
155-20	29183-29184	a	_	
155-21	29185-29190	major	_	
155-22	29191-29195	role	_	
155-23	29196-29198	in	_	
155-24	29199-29202	the	_	
155-25	29203-29210	genesis	_	
155-26	29211-29213	of	_	
155-27	29214-29223	childhood	_	
155-28	29224-29232	epilepsy	_	
155-29	29233-29234	(	_	
155-30	29234-29243	infantile	_	
155-31	29244-29250	spasms	_	
155-32	29250-29251	)	_	
155-33	29252-29254	as	_	
155-34	29255-29263	measured	_	
155-35	29264-29266	by	_	
155-36	29267-29270	the	_	
155-37	29271-29278	changes	_	
155-38	29279-29281	in	_	
155-39	29282-29285	EEG	_	
155-40	29286-29294	activity	_	
155-41	29295-29298	and	_	
155-42	29299-29307	behavior	_	
155-43	29307-29308	.	_	

#Text=Importantly, animal studies have reported that GIRK2 channels influence reward network by promoting adaptations in the mesolimbic dopaminergic system, and thus could influence reward-related behaviors and actions including alcohol and drug addiction.
156-1	29309-29320	Importantly	_	
156-2	29320-29321	,	_	
156-3	29322-29328	animal	_	
156-4	29329-29336	studies	_	
156-5	29337-29341	have	_	
156-6	29342-29350	reported	_	
156-7	29351-29355	that	_	
156-8	29356-29361	GIRK2	_	
156-9	29362-29370	channels	_	
156-10	29371-29380	influence	_	
156-11	29381-29387	reward	_	
156-12	29388-29395	network	_	
156-13	29396-29398	by	_	
156-14	29399-29408	promoting	_	
156-15	29409-29420	adaptations	_	
156-16	29421-29423	in	_	
156-17	29424-29427	the	_	
156-18	29428-29438	mesolimbic	_	
156-19	29439-29451	dopaminergic	_	
156-20	29452-29458	system	_	
156-21	29458-29459	,	_	
156-22	29460-29463	and	_	
156-23	29464-29468	thus	_	
156-24	29469-29474	could	_	
156-25	29475-29484	influence	_	
156-26	29485-29499	reward-related	_	
156-27	29500-29509	behaviors	_	
156-28	29510-29513	and	_	
156-29	29514-29521	actions	_	
156-30	29522-29531	including	_	
156-31	29532-29539	alcohol	_	
156-32	29540-29543	and	_	
156-33	29544-29548	drug	_	
156-34	29549-29558	addiction	_	
156-35	29558-29559	.	_	

#Text=Taken together, these findings suggest that GIRK2 (or the KCNJ6 gene) may play a vital role in modulating neurocognitive function/dysfunction.
#Text=4.3.
157-1	29560-29565	Taken	_	
157-2	29566-29574	together	_	
157-3	29574-29575	,	_	
157-4	29576-29581	these	_	
157-5	29582-29590	findings	_	
157-6	29591-29598	suggest	_	
157-7	29599-29603	that	_	
157-8	29604-29609	GIRK2	_	
157-9	29610-29611	(	_	
157-10	29611-29613	or	_	
157-11	29614-29617	the	_	
157-12	29618-29623	KCNJ6	_	
157-13	29624-29628	gene	_	
157-14	29628-29629	)	_	
157-15	29630-29633	may	_	
157-16	29634-29638	play	_	
157-17	29639-29640	a	_	
157-18	29641-29646	vital	_	
157-19	29647-29651	role	_	
157-20	29652-29654	in	_	
157-21	29655-29665	modulating	_	
157-22	29666-29680	neurocognitive	_	
157-23	29681-29689	function	_	
157-24	29689-29690	/	_	
157-25	29690-29701	dysfunction	_	
157-26	29701-29702	.	_	
157-27	29703-29706	4.3	_	
157-28	29706-29707	.	_	

#Text=Role of KCNJ6 / GIRK2 in modulating alcohol actions and addiction
#Text=Studies reporting alcohol modulation of GIRK channels have been well-documented (for a recent review, see).
158-1	29708-29712	Role	_	
158-2	29713-29715	of	_	
158-3	29716-29721	KCNJ6	_	
158-4	29722-29723	/	_	
158-5	29724-29729	GIRK2	_	
158-6	29730-29732	in	_	
158-7	29733-29743	modulating	_	
158-8	29744-29751	alcohol	_	
158-9	29752-29759	actions	_	
158-10	29760-29763	and	_	
158-11	29764-29773	addiction	_	
158-12	29774-29781	Studies	_	
158-13	29782-29791	reporting	_	
158-14	29792-29799	alcohol	_	
158-15	29800-29810	modulation	_	
158-16	29811-29813	of	_	
158-17	29814-29818	GIRK	_	
158-18	29819-29827	channels	_	
158-19	29828-29832	have	_	
158-20	29833-29837	been	_	
158-21	29838-29853	well-documented	_	
158-22	29854-29855	(	_	
158-23	29855-29858	for	_	
158-24	29859-29860	a	_	
158-25	29861-29867	recent	_	
158-26	29868-29874	review	_	
158-27	29874-29875	,	_	
158-28	29876-29879	see	_	
158-29	29879-29880	)	_	
158-30	29880-29881	.	_	

#Text=KCNJ6/GIRK2 has also been found to be involved in addictions to several drugs, such as opioid/opiate, nicotine, morphine, and cocaine.
159-1	29882-29887	KCNJ6	_	
159-2	29887-29888	/	_	
159-3	29888-29893	GIRK2	_	
159-4	29894-29897	has	_	
159-5	29898-29902	also	_	
159-6	29903-29907	been	_	
159-7	29908-29913	found	_	
159-8	29914-29916	to	_	
159-9	29917-29919	be	_	
159-10	29920-29928	involved	_	
159-11	29929-29931	in	_	
159-12	29932-29942	addictions	_	
159-13	29943-29945	to	_	
159-14	29946-29953	several	_	
159-15	29954-29959	drugs	_	
159-16	29959-29960	,	_	
159-17	29961-29965	such	_	
159-18	29966-29968	as	_	
159-19	29969-29975	opioid	_	
159-20	29975-29976	/	_	
159-21	29976-29982	opiate	_	
159-22	29982-29983	,	_	
159-23	29984-29992	nicotine	_	
159-24	29992-29993	,	_	
159-25	29994-30002	morphine	_	
159-26	30002-30003	,	_	
159-27	30004-30007	and	_	
159-28	30008-30015	cocaine	_	
159-29	30015-30016	.	_	

#Text=It is proposed that the regulator of G-protein signaling (RGS) proteins in the reward pathway might underlie adaptation to alcohol and other addictive drugs.
160-1	30017-30019	It	_	
160-2	30020-30022	is	_	
160-3	30023-30031	proposed	_	
160-4	30032-30036	that	_	
160-5	30037-30040	the	_	
160-6	30041-30050	regulator	_	
160-7	30051-30053	of	_	
160-8	30054-30063	G-protein	_	
160-9	30064-30073	signaling	_	
160-10	30074-30075	(	_	
160-11	30075-30078	RGS	_	
160-12	30078-30079	)	_	
160-13	30080-30088	proteins	_	
160-14	30089-30091	in	_	
160-15	30092-30095	the	_	
160-16	30096-30102	reward	_	
160-17	30103-30110	pathway	_	
160-18	30111-30116	might	_	
160-19	30117-30125	underlie	_	
160-20	30126-30136	adaptation	_	
160-21	30137-30139	to	_	
160-22	30140-30147	alcohol	_	
160-23	30148-30151	and	_	
160-24	30152-30157	other	_	
160-25	30158-30167	addictive	_	
160-26	30168-30173	drugs	_	
160-27	30173-30174	.	_	

#Text=Neurochemical mechanisms underlying ethanol activation of GIRK channels have also been extensively studied (for reviews, see).
161-1	30175-30188	Neurochemical	_	
161-2	30189-30199	mechanisms	_	
161-3	30200-30210	underlying	_	
161-4	30211-30218	ethanol	_	
161-5	30219-30229	activation	_	
161-6	30230-30232	of	_	
161-7	30233-30237	GIRK	_	
161-8	30238-30246	channels	_	
161-9	30247-30251	have	_	
161-10	30252-30256	also	_	
161-11	30257-30261	been	_	
161-12	30262-30273	extensively	_	
161-13	30274-30281	studied	_	
161-14	30282-30283	(	_	
161-15	30283-30286	for	_	
161-16	30287-30294	reviews	_	
161-17	30294-30295	,	_	
161-18	30296-30299	see	_	
161-19	30299-30300	)	_	
161-20	30300-30301	.	_	

#Text=It has been shown that mice lacking GIRK2 channels consumed more ethanol and failed to develop conditioned place preference for ethanol when compared to their controls, suggesting that GIRK2 may be mediating the reinforcing and/or aversive motivational aspects of ethanol action.
162-1	30302-30304	It	_	
162-2	30305-30308	has	_	
162-3	30309-30313	been	_	
162-4	30314-30319	shown	_	
162-5	30320-30324	that	_	
162-6	30325-30329	mice	_	
162-7	30330-30337	lacking	_	
162-8	30338-30343	GIRK2	_	
162-9	30344-30352	channels	_	
162-10	30353-30361	consumed	_	
162-11	30362-30366	more	_	
162-12	30367-30374	ethanol	_	
162-13	30375-30378	and	_	
162-14	30379-30385	failed	_	
162-15	30386-30388	to	_	
162-16	30389-30396	develop	_	
162-17	30397-30408	conditioned	_	
162-18	30409-30414	place	_	
162-19	30415-30425	preference	_	
162-20	30426-30429	for	_	
162-21	30430-30437	ethanol	_	
162-22	30438-30442	when	_	
162-23	30443-30451	compared	_	
162-24	30452-30454	to	_	
162-25	30455-30460	their	_	
162-26	30461-30469	controls	_	
162-27	30469-30470	,	_	
162-28	30471-30481	suggesting	_	
162-29	30482-30486	that	_	
162-30	30487-30492	GIRK2	_	
162-31	30493-30496	may	_	
162-32	30497-30499	be	_	
162-33	30500-30509	mediating	_	
162-34	30510-30513	the	_	
162-35	30514-30525	reinforcing	_	
162-36	30526-30529	and	_	
162-37	30529-30530	/	_	
162-38	30530-30532	or	_	
162-39	30533-30541	aversive	_	
162-40	30542-30554	motivational	_	
162-41	30555-30562	aspects	_	
162-42	30563-30565	of	_	
162-43	30566-30573	ethanol	_	
162-44	30574-30580	action	_	
162-45	30580-30581	.	_	

#Text=In a GWAS in the COGA sample with a neurophysiological phenotype (ERO theta power to targets in an oddball task) we have reported genome wide significant associations of KCNJ6 SNPs; however, the association of these SNPs with alcoholism (or other addictions phenotypes) in COGA were not examined.
163-1	30582-30584	In	_	
163-2	30585-30586	a	_	
163-3	30587-30591	GWAS	_	
163-4	30592-30594	in	_	
163-5	30595-30598	the	_	
163-6	30599-30603	COGA	_	
163-7	30604-30610	sample	_	
163-8	30611-30615	with	_	
163-9	30616-30617	a	_	
163-10	30618-30636	neurophysiological	_	
163-11	30637-30646	phenotype	_	
163-12	30647-30648	(	_	
163-13	30648-30651	ERO	_	
163-14	30652-30657	theta	_	
163-15	30658-30663	power	_	
163-16	30664-30666	to	_	
163-17	30667-30674	targets	_	
163-18	30675-30677	in	_	
163-19	30678-30680	an	_	
163-20	30681-30688	oddball	_	
163-21	30689-30693	task	_	
163-22	30693-30694	)	_	
163-23	30695-30697	we	_	
163-24	30698-30702	have	_	
163-25	30703-30711	reported	_	
163-26	30712-30718	genome	_	
163-27	30719-30723	wide	_	
163-28	30724-30735	significant	_	
163-29	30736-30748	associations	_	
163-30	30749-30751	of	_	
163-31	30752-30757	KCNJ6	_	
163-32	30758-30762	SNPs	_	
163-33	30762-30763	;	_	
163-34	30764-30771	however	_	
163-35	30771-30772	,	_	
163-36	30773-30776	the	_	
163-37	30777-30788	association	_	
163-38	30789-30791	of	_	
163-39	30792-30797	these	_	
163-40	30798-30802	SNPs	_	
163-41	30803-30807	with	_	
163-42	30808-30818	alcoholism	_	
163-43	30819-30820	(	_	
163-44	30820-30822	or	_	
163-45	30823-30828	other	_	
163-46	30829-30839	addictions	_	
163-47	30840-30850	phenotypes	_	
163-48	30850-30851	)	_	
163-49	30852-30854	in	_	
163-50	30855-30859	COGA	_	
163-51	30860-30864	were	_	
163-52	30865-30868	not	_	
163-53	30869-30877	examined	_	
163-54	30877-30878	.	_	

#Text=On the other hand, using a candidate gene approach, reported a significant association of a KCNJ6 polymorphism (rs2836016) with alcohol dependence, hazardous drinking and early life stress, and suggested that individuals consumed more alcohol to experience its rewarding effects possibly mediated by the role of GIRK2 in dopaminergic signaling.
164-1	30879-30881	On	_	
164-2	30882-30885	the	_	
164-3	30886-30891	other	_	
164-4	30892-30896	hand	_	
164-5	30896-30897	,	_	
164-6	30898-30903	using	_	
164-7	30904-30905	a	_	
164-8	30906-30915	candidate	_	
164-9	30916-30920	gene	_	
164-10	30921-30929	approach	_	
164-11	30929-30930	,	_	
164-12	30931-30939	reported	_	
164-13	30940-30941	a	_	
164-14	30942-30953	significant	_	
164-15	30954-30965	association	_	
164-16	30966-30968	of	_	
164-17	30969-30970	a	_	
164-18	30971-30976	KCNJ6	_	
164-19	30977-30989	polymorphism	_	
164-20	30990-30991	(	_	
164-21	30991-31000	rs2836016	_	
164-22	31000-31001	)	_	
164-23	31002-31006	with	_	
164-24	31007-31014	alcohol	_	
164-25	31015-31025	dependence	_	
164-26	31025-31026	,	_	
164-27	31027-31036	hazardous	_	
164-28	31037-31045	drinking	_	
164-29	31046-31049	and	_	
164-30	31050-31055	early	_	
164-31	31056-31060	life	_	
164-32	31061-31067	stress	_	
164-33	31067-31068	,	_	
164-34	31069-31072	and	_	
164-35	31073-31082	suggested	_	
164-36	31083-31087	that	_	
164-37	31088-31099	individuals	_	
164-38	31100-31108	consumed	_	
164-39	31109-31113	more	_	
164-40	31114-31121	alcohol	_	
164-41	31122-31124	to	_	
164-42	31125-31135	experience	_	
164-43	31136-31139	its	_	
164-44	31140-31149	rewarding	_	
164-45	31150-31157	effects	_	
164-46	31158-31166	possibly	_	
164-47	31167-31175	mediated	_	
164-48	31176-31178	by	_	
164-49	31179-31182	the	_	
164-50	31183-31187	role	_	
164-51	31188-31190	of	_	
164-52	31191-31196	GIRK2	_	
164-53	31197-31199	in	_	
164-54	31200-31212	dopaminergic	_	
164-55	31213-31222	signaling	_	
164-56	31222-31223	.	_	

#Text=However, this SNP is located in a different region of the KCNJ6 gene compared to the SNP explored in the current study.
165-1	31224-31231	However	_	
165-2	31231-31232	,	_	
165-3	31233-31237	this	_	
165-4	31238-31241	SNP	_	
165-5	31242-31244	is	_	
165-6	31245-31252	located	_	
165-7	31253-31255	in	_	
165-8	31256-31257	a	_	
165-9	31258-31267	different	_	
165-10	31268-31274	region	_	
165-11	31275-31277	of	_	
165-12	31278-31281	the	_	
165-13	31282-31287	KCNJ6	_	
165-14	31288-31292	gene	_	
165-15	31293-31301	compared	_	
165-16	31302-31304	to	_	
165-17	31305-31308	the	_	
165-18	31309-31312	SNP	_	
165-19	31313-31321	explored	_	
165-20	31322-31324	in	_	
165-21	31325-31328	the	_	
165-22	31329-31336	current	_	
165-23	31337-31342	study	_	
165-24	31342-31343	.	_	

#Text=Since GIRK2/3 channels are exclusively expressed in VTA dopaminergic neurons, these channel properties may have important implications for addiction in general and AUD in particular.
166-1	31344-31349	Since	_	
166-2	31350-31355	GIRK2	_	
166-3	31355-31356	/	_	
166-4	31356-31357	3	_	
166-5	31358-31366	channels	_	
166-6	31367-31370	are	_	
166-7	31371-31382	exclusively	_	
166-8	31383-31392	expressed	_	
166-9	31393-31395	in	_	
166-10	31396-31399	VTA	_	
166-11	31400-31412	dopaminergic	_	
166-12	31413-31420	neurons	_	
166-13	31420-31421	,	_	
166-14	31422-31427	these	_	
166-15	31428-31435	channel	_	
166-16	31436-31446	properties	_	
166-17	31447-31450	may	_	
166-18	31451-31455	have	_	
166-19	31456-31465	important	_	
166-20	31466-31478	implications	_	
166-21	31479-31482	for	_	
166-22	31483-31492	addiction	_	
166-23	31493-31495	in	_	
166-24	31496-31503	general	_	
166-25	31504-31507	and	_	
166-26	31508-31511	AUD	_	
166-27	31512-31514	in	_	
166-28	31515-31525	particular	_	
166-29	31525-31526	.	_	

#Text=Taken together, these findings may lead to uncovering new therapeutic targets as well as drug development for prevention and/or management of alcohol dependence by providing an opportunity to discover possible antagonists for ethanol-dependent activation.
#Text=4.4.
167-1	31527-31532	Taken	_	
167-2	31533-31541	together	_	
167-3	31541-31542	,	_	
167-4	31543-31548	these	_	
167-5	31549-31557	findings	_	
167-6	31558-31561	may	_	
167-7	31562-31566	lead	_	
167-8	31567-31569	to	_	
167-9	31570-31580	uncovering	_	
167-10	31581-31584	new	_	
167-11	31585-31596	therapeutic	_	
167-12	31597-31604	targets	_	
167-13	31605-31607	as	_	
167-14	31608-31612	well	_	
167-15	31613-31615	as	_	
167-16	31616-31620	drug	_	
167-17	31621-31632	development	_	
167-18	31633-31636	for	_	
167-19	31637-31647	prevention	_	
167-20	31648-31651	and	_	
167-21	31651-31652	/	_	
167-22	31652-31654	or	_	
167-23	31655-31665	management	_	
167-24	31666-31668	of	_	
167-25	31669-31676	alcohol	_	
167-26	31677-31687	dependence	_	
167-27	31688-31690	by	_	
167-28	31691-31700	providing	_	
167-29	31701-31703	an	_	
167-30	31704-31715	opportunity	_	
167-31	31716-31718	to	_	
167-32	31719-31727	discover	_	
167-33	31728-31736	possible	_	
167-34	31737-31748	antagonists	_	
167-35	31749-31752	for	_	
167-36	31753-31770	ethanol-dependent	_	
167-37	31771-31781	activation	_	
167-38	31781-31782	.	_	
167-39	31783-31786	4.4	_	
167-40	31786-31787	.	_	

#Text=Summary and Implications
#Text=It is well-established that neuroelectrophysiological phenotypes, such as EEG, ERPs, and EROs are highly heritable (for reviews, see).
168-1	31788-31795	Summary	_	
168-2	31796-31799	and	_	
168-3	31800-31812	Implications	_	
168-4	31813-31815	It	_	
168-5	31816-31818	is	_	
168-6	31819-31835	well-established	_	
168-7	31836-31840	that	_	
168-8	31841-31866	neuroelectrophysiological	_	
168-9	31867-31877	phenotypes	_	
168-10	31877-31878	,	_	
168-11	31879-31883	such	_	
168-12	31884-31886	as	_	
168-13	31887-31890	EEG	_	
168-14	31890-31891	,	_	
168-15	31892-31896	ERPs	_	
168-16	31896-31897	,	_	
168-17	31898-31901	and	_	
168-18	31902-31906	EROs	_	
168-19	31907-31910	are	_	
168-20	31911-31917	highly	_	
168-21	31918-31927	heritable	_	
168-22	31928-31929	(	_	
168-23	31929-31932	for	_	
168-24	31933-31940	reviews	_	
168-25	31940-31941	,	_	
168-26	31942-31945	see	_	
168-27	31945-31946	)	_	
168-28	31946-31947	.	_	

#Text=It is suggested that genetic underpinnings of EROs likely stem from regulatory genes that control the neurochemical processes of the brain, thereby influencing neural function (cf.).
169-1	31948-31950	It	_	
169-2	31951-31953	is	_	
169-3	31954-31963	suggested	_	
169-4	31964-31968	that	_	
169-5	31969-31976	genetic	_	
169-6	31977-31990	underpinnings	_	
169-7	31991-31993	of	_	
169-8	31994-31998	EROs	_	
169-9	31999-32005	likely	_	
169-10	32006-32010	stem	_	
169-11	32011-32015	from	_	
169-12	32016-32026	regulatory	_	
169-13	32027-32032	genes	_	
169-14	32033-32037	that	_	
169-15	32038-32045	control	_	
169-16	32046-32049	the	_	
169-17	32050-32063	neurochemical	_	
169-18	32064-32073	processes	_	
169-19	32074-32076	of	_	
169-20	32077-32080	the	_	
169-21	32081-32086	brain	_	
169-22	32086-32087	,	_	
169-23	32088-32095	thereby	_	
169-24	32096-32107	influencing	_	
169-25	32108-32114	neural	_	
169-26	32115-32123	function	_	
169-27	32124-32125	(	_	
169-28	32125-32127	cf	_	
169-29	32127-32128	.	_	
169-30	32128-32129	)	_	
169-31	32129-32130	.	_	

#Text=Recent genetic studies and the current study have demonstrated associations of KCNJ6 with theta EROs.
170-1	32131-32137	Recent	_	
170-2	32138-32145	genetic	_	
170-3	32146-32153	studies	_	
170-4	32154-32157	and	_	
170-5	32158-32161	the	_	
170-6	32162-32169	current	_	
170-7	32170-32175	study	_	
170-8	32176-32180	have	_	
170-9	32181-32193	demonstrated	_	
170-10	32194-32206	associations	_	
170-11	32207-32209	of	_	
170-12	32210-32215	KCNJ6	_	
170-13	32216-32220	with	_	
170-14	32221-32226	theta	_	
170-15	32227-32231	EROs	_	
170-16	32231-32232	.	_	

#Text=The current study has indicated that variations in the KCNJ6 SNP (rs702859) influence magnitude of theta ERO power at posterior leads during during the evaluation of loss and gain, reflecting a genetic influence on neuronal circuits involved in reward processing.
171-1	32233-32236	The	_	
171-2	32237-32244	current	_	
171-3	32245-32250	study	_	
171-4	32251-32254	has	_	
171-5	32255-32264	indicated	_	
171-6	32265-32269	that	_	
171-7	32270-32280	variations	_	
171-8	32281-32283	in	_	
171-9	32284-32287	the	_	
171-10	32288-32293	KCNJ6	_	
171-11	32294-32297	SNP	_	
171-12	32298-32299	(	_	
171-13	32299-32307	rs702859	_	
171-14	32307-32308	)	_	
171-15	32309-32318	influence	_	
171-16	32319-32328	magnitude	_	
171-17	32329-32331	of	_	
171-18	32332-32337	theta	_	
171-19	32338-32341	ERO	_	
171-20	32342-32347	power	_	
171-21	32348-32350	at	_	
171-22	32351-32360	posterior	_	
171-23	32361-32366	leads	_	
171-24	32367-32373	during	_	
171-25	32374-32380	during	_	
171-26	32381-32384	the	_	
171-27	32385-32395	evaluation	_	
171-28	32396-32398	of	_	
171-29	32399-32403	loss	_	
171-30	32404-32407	and	_	
171-31	32408-32412	gain	_	
171-32	32412-32413	,	_	
171-33	32414-32424	reflecting	_	
171-34	32425-32426	a	_	
171-35	32427-32434	genetic	_	
171-36	32435-32444	influence	_	
171-37	32445-32447	on	_	
171-38	32448-32456	neuronal	_	
171-39	32457-32465	circuits	_	
171-40	32466-32474	involved	_	
171-41	32475-32477	in	_	
171-42	32478-32484	reward	_	
171-43	32485-32495	processing	_	
171-44	32495-32496	.	_	

#Text=Higher theta power as a function of minor allele dose suggests more efficient cognitive processing in those carrying the minor allele of the KCNJ6 SNPs, as increased theta activity during cognitive tasks is indicative of efficient processing.
172-1	32497-32503	Higher	_	
172-2	32504-32509	theta	_	
172-3	32510-32515	power	_	
172-4	32516-32518	as	_	
172-5	32519-32520	a	_	
172-6	32521-32529	function	_	
172-7	32530-32532	of	_	
172-8	32533-32538	minor	_	
172-9	32539-32545	allele	_	
172-10	32546-32550	dose	_	
172-11	32551-32559	suggests	_	
172-12	32560-32564	more	_	
172-13	32565-32574	efficient	_	
172-14	32575-32584	cognitive	_	
172-15	32585-32595	processing	_	
172-16	32596-32598	in	_	
172-17	32599-32604	those	_	
172-18	32605-32613	carrying	_	
172-19	32614-32617	the	_	
172-20	32618-32623	minor	_	
172-21	32624-32630	allele	_	
172-22	32631-32633	of	_	
172-23	32634-32637	the	_	
172-24	32638-32643	KCNJ6	_	
172-25	32644-32648	SNPs	_	
172-26	32648-32649	,	_	
172-27	32650-32652	as	_	
172-28	32653-32662	increased	_	
172-29	32663-32668	theta	_	
172-30	32669-32677	activity	_	
172-31	32678-32684	during	_	
172-32	32685-32694	cognitive	_	
172-33	32695-32700	tasks	_	
172-34	32701-32703	is	_	
172-35	32704-32714	indicative	_	
172-36	32715-32717	of	_	
172-37	32718-32727	efficient	_	
172-38	32728-32738	processing	_	
172-39	32738-32739	.	_	

#Text=On the other hand, lack of frontalization in theta EROs observed in those carrying minor alleles may be suggestive of delayed brain maturation in these individuals.
173-1	32740-32742	On	_	
173-2	32743-32746	the	_	
173-3	32747-32752	other	_	
173-4	32753-32757	hand	_	
173-5	32757-32758	,	_	
173-6	32759-32763	lack	_	
173-7	32764-32766	of	_	
173-8	32767-32781	frontalization	_	
173-9	32782-32784	in	_	
173-10	32785-32790	theta	_	
173-11	32791-32795	EROs	_	
173-12	32796-32804	observed	_	
173-13	32805-32807	in	_	
173-14	32808-32813	those	_	
173-15	32814-32822	carrying	_	
173-16	32823-32828	minor	_	
173-17	32829-32836	alleles	_	
173-18	32837-32840	may	_	
173-19	32841-32843	be	_	
173-20	32844-32854	suggestive	_	
173-21	32855-32857	of	_	
173-22	32858-32865	delayed	_	
173-23	32866-32871	brain	_	
173-24	32872-32882	maturation	_	
173-25	32883-32885	in	_	
173-26	32886-32891	these	_	
173-27	32892-32903	individuals	_	
173-28	32903-32904	.	_	

#Text=Future studies are needed to determine the specific effects of KCNJ6 on cognitive (dys)functions.
174-1	32905-32911	Future	_	
174-2	32912-32919	studies	_	
174-3	32920-32923	are	_	
174-4	32924-32930	needed	_	
174-5	32931-32933	to	_	
174-6	32934-32943	determine	_	
174-7	32944-32947	the	_	
174-8	32948-32956	specific	_	
174-9	32957-32964	effects	_	
174-10	32965-32967	of	_	
174-11	32968-32973	KCNJ6	_	
174-12	32974-32976	on	_	
174-13	32977-32986	cognitive	_	
174-14	32987-32988	(	_	
174-15	32988-32991	dys	_	
174-16	32991-32992	)	_	
174-17	32992-33001	functions	_	
174-18	33001-33002	.	_	

#Text=Further, since KCNJ6 / GIRK2 has been shown to be linked with the brain reward system though its modulation of dopaminergic signaling, these genetic findings with reward related brain oscillations may have behavioral and clinical implications.
175-1	33003-33010	Further	_	
175-2	33010-33011	,	_	
175-3	33012-33017	since	_	
175-4	33018-33023	KCNJ6	_	
175-5	33024-33025	/	_	
175-6	33026-33031	GIRK2	_	
175-7	33032-33035	has	_	
175-8	33036-33040	been	_	
175-9	33041-33046	shown	_	
175-10	33047-33049	to	_	
175-11	33050-33052	be	_	
175-12	33053-33059	linked	_	
175-13	33060-33064	with	_	
175-14	33065-33068	the	_	
175-15	33069-33074	brain	_	
175-16	33075-33081	reward	_	
175-17	33082-33088	system	_	
175-18	33089-33095	though	_	
175-19	33096-33099	its	_	
175-20	33100-33110	modulation	_	
175-21	33111-33113	of	_	
175-22	33114-33126	dopaminergic	_	
175-23	33127-33136	signaling	_	
175-24	33136-33137	,	_	
175-25	33138-33143	these	_	
175-26	33144-33151	genetic	_	
175-27	33152-33160	findings	_	
175-28	33161-33165	with	_	
175-29	33166-33172	reward	_	
175-30	33173-33180	related	_	
175-31	33181-33186	brain	_	
175-32	33187-33199	oscillations	_	
175-33	33200-33203	may	_	
175-34	33204-33208	have	_	
175-35	33209-33219	behavioral	_	
175-36	33220-33223	and	_	
175-37	33224-33232	clinical	_	
175-38	33233-33245	implications	_	
175-39	33245-33246	.	_	

#Text=Since KCNJ6/GIRK2 is related to alcohol action and addiction, it is possible that the finding has some relevance to alcoholism, although further studies linking KCNJ6 and human alcoholism are needed.
176-1	33247-33252	Since	_	
176-2	33253-33258	KCNJ6	_	
176-3	33258-33259	/	_	
176-4	33259-33264	GIRK2	_	
176-5	33265-33267	is	_	
176-6	33268-33275	related	_	
176-7	33276-33278	to	_	
176-8	33279-33286	alcohol	_	
176-9	33287-33293	action	_	
176-10	33294-33297	and	_	
176-11	33298-33307	addiction	_	
176-12	33307-33308	,	_	
176-13	33309-33311	it	_	
176-14	33312-33314	is	_	
176-15	33315-33323	possible	_	
176-16	33324-33328	that	_	
176-17	33329-33332	the	_	
176-18	33333-33340	finding	_	
176-19	33341-33344	has	_	
176-20	33345-33349	some	_	
176-21	33350-33359	relevance	_	
176-22	33360-33362	to	_	
176-23	33363-33373	alcoholism	_	
176-24	33373-33374	,	_	
176-25	33375-33383	although	_	
176-26	33384-33391	further	_	
176-27	33392-33399	studies	_	
176-28	33400-33407	linking	_	
176-29	33408-33413	KCNJ6	_	
176-30	33414-33417	and	_	
176-31	33418-33423	human	_	
176-32	33424-33434	alcoholism	_	
176-33	33435-33438	are	_	
176-34	33439-33445	needed	_	
176-35	33445-33446	.	_	

#Text=As the KCNJ6 / GIRK2 system modulates neuronal excitability and inhibition at a cellular and network level and/or epilepsy, it may be involved in the neuronal hyperexcitabity (CNS disinhibition) indexed by high resting EEG beta and low P3 amplitude, theta and delta EROs that we have observed in our studies of alcoholics and those at risk, including during reward processing (for reviews, see).
177-1	33447-33449	As	_	
177-2	33450-33453	the	_	
177-3	33454-33459	KCNJ6	_	
177-4	33460-33461	/	_	
177-5	33462-33467	GIRK2	_	
177-6	33468-33474	system	_	
177-7	33475-33484	modulates	_	
177-8	33485-33493	neuronal	_	
177-9	33494-33506	excitability	_	
177-10	33507-33510	and	_	
177-11	33511-33521	inhibition	_	
177-12	33522-33524	at	_	
177-13	33525-33526	a	_	
177-14	33527-33535	cellular	_	
177-15	33536-33539	and	_	
177-16	33540-33547	network	_	
177-17	33548-33553	level	_	
177-18	33554-33557	and	_	
177-19	33557-33558	/	_	
177-20	33558-33560	or	_	
177-21	33561-33569	epilepsy	_	
177-22	33569-33570	,	_	
177-23	33571-33573	it	_	
177-24	33574-33577	may	_	
177-25	33578-33580	be	_	
177-26	33581-33589	involved	_	
177-27	33590-33592	in	_	
177-28	33593-33596	the	_	
177-29	33597-33605	neuronal	_	
177-30	33606-33621	hyperexcitabity	_	
177-31	33622-33623	(	_	
177-32	33623-33626	CNS	_	
177-33	33627-33640	disinhibition	_	
177-34	33640-33641	)	_	
177-35	33642-33649	indexed	_	
177-36	33650-33652	by	_	
177-37	33653-33657	high	_	
177-38	33658-33665	resting	_	
177-39	33666-33669	EEG	_	
177-40	33670-33674	beta	_	
177-41	33675-33678	and	_	
177-42	33679-33682	low	_	
177-43	33683-33685	P3	_	
177-44	33686-33695	amplitude	_	
177-45	33695-33696	,	_	
177-46	33697-33702	theta	_	
177-47	33703-33706	and	_	
177-48	33707-33712	delta	_	
177-49	33713-33717	EROs	_	
177-50	33718-33722	that	_	
177-51	33723-33725	we	_	
177-52	33726-33730	have	_	
177-53	33731-33739	observed	_	
177-54	33740-33742	in	_	
177-55	33743-33746	our	_	
177-56	33747-33754	studies	_	
177-57	33755-33757	of	_	
177-58	33758-33768	alcoholics	_	
177-59	33769-33772	and	_	
177-60	33773-33778	those	_	
177-61	33779-33781	at	_	
177-62	33782-33786	risk	_	
177-63	33786-33787	,	_	
177-64	33788-33797	including	_	
177-65	33798-33804	during	_	
177-66	33805-33811	reward	_	
177-67	33812-33822	processing	_	
177-68	33823-33824	(	_	
177-69	33824-33827	for	_	
177-70	33828-33835	reviews	_	
177-71	33835-33836	,	_	
177-72	33837-33840	see	_	
177-73	33840-33841	)	_	
177-74	33841-33842	.	_	

#Text=According to the ‘CNS disinhibition’ model of alcoholism proposed by, a heritable hyperexcitability of the CNS caused by homeostatic imbalance is involved in a genetic predisposition to develop alcoholism and related externalizing disorders.
178-1	33843-33852	According	_	
178-2	33853-33855	to	_	
178-3	33856-33859	the	_	
178-4	33860-33861	‘	_	
178-5	33861-33864	CNS	_	
178-6	33865-33878	disinhibition	_	
178-7	33878-33879	’	_	
178-8	33880-33885	model	_	
178-9	33886-33888	of	_	
178-10	33889-33899	alcoholism	_	
178-11	33900-33908	proposed	_	
178-12	33909-33911	by	_	
178-13	33911-33912	,	_	
178-14	33913-33914	a	_	
178-15	33915-33924	heritable	_	
178-16	33925-33942	hyperexcitability	_	
178-17	33943-33945	of	_	
178-18	33946-33949	the	_	
178-19	33950-33953	CNS	_	
178-20	33954-33960	caused	_	
178-21	33961-33963	by	_	
178-22	33964-33975	homeostatic	_	
178-23	33976-33985	imbalance	_	
178-24	33986-33988	is	_	
178-25	33989-33997	involved	_	
178-26	33998-34000	in	_	
178-27	34001-34002	a	_	
178-28	34003-34010	genetic	_	
178-29	34011-34025	predisposition	_	
178-30	34026-34028	to	_	
178-31	34029-34036	develop	_	
178-32	34037-34047	alcoholism	_	
178-33	34048-34051	and	_	
178-34	34052-34059	related	_	
178-35	34060-34073	externalizing	_	
178-36	34074-34083	disorders	_	
178-37	34083-34084	.	_	

#Text=This model seems more relevant now than ever before, and the KCNJ6 system could very well be one of the factors involved in ‘CNS hyperexcitability’ that may be related to clinical manifestations of neurobehavioral disinhibition associated with risk for AUDs and other substance use disorders (e.g.,).
179-1	34085-34089	This	_	
179-2	34090-34095	model	_	
179-3	34096-34101	seems	_	
179-4	34102-34106	more	_	
179-5	34107-34115	relevant	_	
179-6	34116-34119	now	_	
179-7	34120-34124	than	_	
179-8	34125-34129	ever	_	
179-9	34130-34136	before	_	
179-10	34136-34137	,	_	
179-11	34138-34141	and	_	
179-12	34142-34145	the	_	
179-13	34146-34151	KCNJ6	_	
179-14	34152-34158	system	_	
179-15	34159-34164	could	_	
179-16	34165-34169	very	_	
179-17	34170-34174	well	_	
179-18	34175-34177	be	_	
179-19	34178-34181	one	_	
179-20	34182-34184	of	_	
179-21	34185-34188	the	_	
179-22	34189-34196	factors	_	
179-23	34197-34205	involved	_	
179-24	34206-34208	in	_	
179-25	34209-34210	‘	_	
179-26	34210-34213	CNS	_	
179-27	34214-34231	hyperexcitability	_	
179-28	34231-34232	’	_	
179-29	34233-34237	that	_	
179-30	34238-34241	may	_	
179-31	34242-34244	be	_	
179-32	34245-34252	related	_	
179-33	34253-34255	to	_	
179-34	34256-34264	clinical	_	
179-35	34265-34279	manifestations	_	
179-36	34280-34282	of	_	
179-37	34283-34298	neurobehavioral	_	
179-38	34299-34312	disinhibition	_	
179-39	34313-34323	associated	_	
179-40	34324-34328	with	_	
179-41	34329-34333	risk	_	
179-42	34334-34337	for	_	
179-43	34338-34342	AUDs	_	
179-44	34343-34346	and	_	
179-45	34347-34352	other	_	
179-46	34353-34362	substance	_	
179-47	34363-34366	use	_	
179-48	34367-34376	disorders	_	
179-49	34377-34378	(	_	
179-50	34378-34381	e.g	_	
179-51	34381-34382	.	_	
179-52	34382-34383	,	_	
179-53	34383-34384	)	_	
179-54	34384-34385	.	_	

#Text=As KCNJ6 / GIRK2 has been found to be related to neural excitability, reward processing, alcohol modulation and addiction, future studies are needed to investigate potential behavioral and clinical implications.
#Text=4.5.
180-1	34386-34388	As	_	
180-2	34389-34394	KCNJ6	_	
180-3	34395-34396	/	_	
180-4	34397-34402	GIRK2	_	
180-5	34403-34406	has	_	
180-6	34407-34411	been	_	
180-7	34412-34417	found	_	
180-8	34418-34420	to	_	
180-9	34421-34423	be	_	
180-10	34424-34431	related	_	
180-11	34432-34434	to	_	
180-12	34435-34441	neural	_	
180-13	34442-34454	excitability	_	
180-14	34454-34455	,	_	
180-15	34456-34462	reward	_	
180-16	34463-34473	processing	_	
180-17	34473-34474	,	_	
180-18	34475-34482	alcohol	_	
180-19	34483-34493	modulation	_	
180-20	34494-34497	and	_	
180-21	34498-34507	addiction	_	
180-22	34507-34508	,	_	
180-23	34509-34515	future	_	
180-24	34516-34523	studies	_	
180-25	34524-34527	are	_	
180-26	34528-34534	needed	_	
180-27	34535-34537	to	_	
180-28	34538-34549	investigate	_	
180-29	34550-34559	potential	_	
180-30	34560-34570	behavioral	_	
180-31	34571-34574	and	_	
180-32	34575-34583	clinical	_	
180-33	34584-34596	implications	_	
180-34	34596-34597	.	_	
180-35	34598-34601	4.5	_	
180-36	34601-34602	.	_	

#Text=Limitations of the current study and suggestion for future studies
#Text=Although the current study has found that the KCNJ6 SNP (rs702859) is associated with reward related theta EROs, it has a few limitations.
181-1	34603-34614	Limitations	_	
181-2	34615-34617	of	_	
181-3	34618-34621	the	_	
181-4	34622-34629	current	_	
181-5	34630-34635	study	_	
181-6	34636-34639	and	_	
181-7	34640-34650	suggestion	_	
181-8	34651-34654	for	_	
181-9	34655-34661	future	_	
181-10	34662-34669	studies	_	
181-11	34670-34678	Although	_	
181-12	34679-34682	the	_	
181-13	34683-34690	current	_	
181-14	34691-34696	study	_	
181-15	34697-34700	has	_	
181-16	34701-34706	found	_	
181-17	34707-34711	that	_	
181-18	34712-34715	the	_	
181-19	34716-34721	KCNJ6	_	
181-20	34722-34725	SNP	_	
181-21	34726-34727	(	_	
181-22	34727-34735	rs702859	_	
181-23	34735-34736	)	_	
181-24	34737-34739	is	_	
181-25	34740-34750	associated	_	
181-26	34751-34755	with	_	
181-27	34756-34762	reward	_	
181-28	34763-34770	related	_	
181-29	34771-34776	theta	_	
181-30	34777-34781	EROs	_	
181-31	34781-34782	,	_	
181-32	34783-34785	it	_	
181-33	34786-34789	has	_	
181-34	34790-34791	a	_	
181-35	34792-34795	few	_	
181-36	34796-34807	limitations	_	
181-37	34807-34808	.	_	

#Text=While the sample size of the current study appears large, it may not be sufficiently large for a genetic study to test multiple hypotheses involving several factors.
182-1	34809-34814	While	_	
182-2	34815-34818	the	_	
182-3	34819-34825	sample	_	
182-4	34826-34830	size	_	
182-5	34831-34833	of	_	
182-6	34834-34837	the	_	
182-7	34838-34845	current	_	
182-8	34846-34851	study	_	
182-9	34852-34859	appears	_	
182-10	34860-34865	large	_	
182-11	34865-34866	,	_	
182-12	34867-34869	it	_	
182-13	34870-34873	may	_	
182-14	34874-34877	not	_	
182-15	34878-34880	be	_	
182-16	34881-34893	sufficiently	_	
182-17	34894-34899	large	_	
182-18	34900-34903	for	_	
182-19	34904-34905	a	_	
182-20	34906-34913	genetic	_	
182-21	34914-34919	study	_	
182-22	34920-34922	to	_	
182-23	34923-34927	test	_	
182-24	34928-34936	multiple	_	
182-25	34937-34947	hypotheses	_	
182-26	34948-34957	involving	_	
182-27	34958-34965	several	_	
182-28	34966-34973	factors	_	
182-29	34973-34974	.	_	

#Text=Only a single KCNJ6 SNP has been explored in this study.
183-1	34975-34979	Only	_	
183-2	34980-34981	a	_	
183-3	34982-34988	single	_	
183-4	34989-34994	KCNJ6	_	
183-5	34995-34998	SNP	_	
183-6	34999-35002	has	_	
183-7	35003-35007	been	_	
183-8	35008-35016	explored	_	
183-9	35017-35019	in	_	
183-10	35020-35024	this	_	
183-11	35025-35030	study	_	
183-12	35030-35031	.	_	

#Text=Further studies exploring genetic effects on developmental trajectories of EROs from multiple task paradigms, including the monetary gambling task, are underway, and may offer important clues to better understand these factors.
184-1	35032-35039	Further	_	
184-2	35040-35047	studies	_	
184-3	35048-35057	exploring	_	
184-4	35058-35065	genetic	_	
184-5	35066-35073	effects	_	
184-6	35074-35076	on	_	
184-7	35077-35090	developmental	_	
184-8	35091-35103	trajectories	_	
184-9	35104-35106	of	_	
184-10	35107-35111	EROs	_	
184-11	35112-35116	from	_	
184-12	35117-35125	multiple	_	
184-13	35126-35130	task	_	
184-14	35131-35140	paradigms	_	
184-15	35140-35141	,	_	
184-16	35142-35151	including	_	
184-17	35152-35155	the	_	
184-18	35156-35164	monetary	_	
184-19	35165-35173	gambling	_	
184-20	35174-35178	task	_	
184-21	35178-35179	,	_	
184-22	35180-35183	are	_	
184-23	35184-35192	underway	_	
184-24	35192-35193	,	_	
184-25	35194-35197	and	_	
184-26	35198-35201	may	_	
184-27	35202-35207	offer	_	
184-28	35208-35217	important	_	
184-29	35218-35223	clues	_	
184-30	35224-35226	to	_	
184-31	35227-35233	better	_	
184-32	35234-35244	understand	_	
184-33	35245-35250	these	_	
184-34	35251-35258	factors	_	
184-35	35258-35259	.	_	

#Text=Future studies including the behavioral aspects associated with reward processing (e.g., risk-taking, decision making, reaction time, etc.) and clinical features (e.g., externalizing and internalizing) may offer valuable clues underlying connections between KCNJ6, risk propensity, brain oscillations, and potential clinical outcomes.
185-1	35260-35266	Future	_	
185-2	35267-35274	studies	_	
185-3	35275-35284	including	_	
185-4	35285-35288	the	_	
185-5	35289-35299	behavioral	_	
185-6	35300-35307	aspects	_	
185-7	35308-35318	associated	_	
185-8	35319-35323	with	_	
185-9	35324-35330	reward	_	
185-10	35331-35341	processing	_	
185-11	35342-35343	(	_	
185-12	35343-35346	e.g	_	
185-13	35346-35347	.	_	
185-14	35347-35348	,	_	
185-15	35349-35360	risk-taking	_	
185-16	35360-35361	,	_	
185-17	35362-35370	decision	_	
185-18	35371-35377	making	_	
185-19	35377-35378	,	_	
185-20	35379-35387	reaction	_	
185-21	35388-35392	time	_	
185-22	35392-35393	,	_	
185-23	35394-35397	etc	_	
185-24	35397-35398	.	_	
185-25	35398-35399	)	_	
185-26	35400-35403	and	_	
185-27	35404-35412	clinical	_	
185-28	35413-35421	features	_	
185-29	35422-35423	(	_	
185-30	35423-35426	e.g	_	
185-31	35426-35427	.	_	
185-32	35427-35428	,	_	
185-33	35429-35442	externalizing	_	
185-34	35443-35446	and	_	
185-35	35447-35460	internalizing	_	
185-36	35460-35461	)	_	
185-37	35462-35465	may	_	
185-38	35466-35471	offer	_	
185-39	35472-35480	valuable	_	
185-40	35481-35486	clues	_	
185-41	35487-35497	underlying	_	
185-42	35498-35509	connections	_	
185-43	35510-35517	between	_	
185-44	35518-35523	KCNJ6	_	
185-45	35523-35524	,	_	
185-46	35525-35529	risk	_	
185-47	35530-35540	propensity	_	
185-48	35540-35541	,	_	
185-49	35542-35547	brain	_	
185-50	35548-35560	oscillations	_	
185-51	35560-35561	,	_	
185-52	35562-35565	and	_	
185-53	35566-35575	potential	_	
185-54	35576-35584	clinical	_	
185-55	35585-35593	outcomes	_	
185-56	35593-35594	.	_	

#Text=Future studies are also needed to determine the implications of the genetic effects of variants in KCNJ6 on posterior theta EROs as possible “protective” or “risk” factors and the behavioral and clinical implications, and as indices of delays in brain maturation (i.e., lack of frontalization).
186-1	35595-35601	Future	_	
186-2	35602-35609	studies	_	
186-3	35610-35613	are	_	
186-4	35614-35618	also	_	
186-5	35619-35625	needed	_	
186-6	35626-35628	to	_	
186-7	35629-35638	determine	_	
186-8	35639-35642	the	_	
186-9	35643-35655	implications	_	
186-10	35656-35658	of	_	
186-11	35659-35662	the	_	
186-12	35663-35670	genetic	_	
186-13	35671-35678	effects	_	
186-14	35679-35681	of	_	
186-15	35682-35690	variants	_	
186-16	35691-35693	in	_	
186-17	35694-35699	KCNJ6	_	
186-18	35700-35702	on	_	
186-19	35703-35712	posterior	_	
186-20	35713-35718	theta	_	
186-21	35719-35723	EROs	_	
186-22	35724-35726	as	_	
186-23	35727-35735	possible	_	
186-24	35736-35737	“	_	
186-25	35737-35747	protective	_	
186-26	35747-35748	”	_	
186-27	35749-35751	or	_	
186-28	35752-35753	“	_	
186-29	35753-35757	risk	_	
186-30	35757-35758	”	_	
186-31	35759-35766	factors	_	
186-32	35767-35770	and	_	
186-33	35771-35774	the	_	
186-34	35775-35785	behavioral	_	
186-35	35786-35789	and	_	
186-36	35790-35798	clinical	_	
186-37	35799-35811	implications	_	
186-38	35811-35812	,	_	
186-39	35813-35816	and	_	
186-40	35817-35819	as	_	
186-41	35820-35827	indices	_	
186-42	35828-35830	of	_	
186-43	35831-35837	delays	_	
186-44	35838-35840	in	_	
186-45	35841-35846	brain	_	
186-46	35847-35857	maturation	_	
186-47	35858-35859	(	_	
186-48	35859-35862	i.e	_	
186-49	35862-35863	.	_	
186-50	35863-35864	,	_	
186-51	35865-35869	lack	_	
186-52	35870-35872	of	_	
186-53	35873-35887	frontalization	_	
186-54	35887-35888	)	_	
186-55	35888-35889	.	_	

#Text=Furthermore, functional studies are underway in COGA with KCNJ6 variants and 1) single cell electrophysiology, as well as 2) induced pluripotent stem cells (iPSC) derived neurons generated from the human participants of COGA with several KCNJ6 variants to examine acute and chronic effects of alcohol.
#Text=5.
187-1	35890-35901	Furthermore	_	
187-2	35901-35902	,	_	
187-3	35903-35913	functional	_	
187-4	35914-35921	studies	_	
187-5	35922-35925	are	_	
187-6	35926-35934	underway	_	
187-7	35935-35937	in	_	
187-8	35938-35942	COGA	_	
187-9	35943-35947	with	_	
187-10	35948-35953	KCNJ6	_	
187-11	35954-35962	variants	_	
187-12	35963-35966	and	_	
187-13	35967-35968	1	_	
187-14	35968-35969	)	_	
187-15	35970-35976	single	_	
187-16	35977-35981	cell	_	
187-17	35982-35999	electrophysiology	_	
187-18	35999-36000	,	_	
187-19	36001-36003	as	_	
187-20	36004-36008	well	_	
187-21	36009-36011	as	_	
187-22	36012-36013	2	_	
187-23	36013-36014	)	_	
187-24	36015-36022	induced	_	
187-25	36023-36034	pluripotent	_	
187-26	36035-36039	stem	_	
187-27	36040-36045	cells	_	
187-28	36046-36047	(	_	
187-29	36047-36051	iPSC	_	
187-30	36051-36052	)	_	
187-31	36053-36060	derived	_	
187-32	36061-36068	neurons	_	
187-33	36069-36078	generated	_	
187-34	36079-36083	from	_	
187-35	36084-36087	the	_	
187-36	36088-36093	human	_	
187-37	36094-36106	participants	_	
187-38	36107-36109	of	_	
187-39	36110-36114	COGA	_	
187-40	36115-36119	with	_	
187-41	36120-36127	several	_	
187-42	36128-36133	KCNJ6	_	
187-43	36134-36142	variants	_	
187-44	36143-36145	to	_	
187-45	36146-36153	examine	_	
187-46	36154-36159	acute	_	
187-47	36160-36163	and	_	
187-48	36164-36171	chronic	_	
187-49	36172-36179	effects	_	
187-50	36180-36182	of	_	
187-51	36183-36190	alcohol	_	
187-52	36190-36191	.	_	
187-53	36192-36193	5	_	
187-54	36193-36194	.	_	

#Text=Conclusions
#Text=The present study has found that a KCNJ6 polymorphism (rs702859) was associated with reward related theta EROs in a large sample of young adult subjects.
188-1	36195-36206	Conclusions	_	
188-2	36207-36210	The	_	
188-3	36211-36218	present	_	
188-4	36219-36224	study	_	
188-5	36225-36228	has	_	
188-6	36229-36234	found	_	
188-7	36235-36239	that	_	
188-8	36240-36241	a	_	
188-9	36242-36247	KCNJ6	_	
188-10	36248-36260	polymorphism	_	
188-11	36261-36262	(	_	
188-12	36262-36270	rs702859	_	
188-13	36270-36271	)	_	
188-14	36272-36275	was	_	
188-15	36276-36286	associated	_	
188-16	36287-36291	with	_	
188-17	36292-36298	reward	_	
188-18	36299-36306	related	_	
188-19	36307-36312	theta	_	
188-20	36313-36317	EROs	_	
188-21	36318-36320	in	_	
188-22	36321-36322	a	_	
188-23	36323-36328	large	_	
188-24	36329-36335	sample	_	
188-25	36336-36338	of	_	
188-26	36339-36344	young	_	
188-27	36345-36350	adult	_	
188-28	36351-36359	subjects	_	
188-29	36359-36360	.	_	

#Text=The results of the present study suggest that KCNJ6, through its protein GIRK2, exerts strong moderating effects on theta EROs.
189-1	36361-36364	The	_	
189-2	36365-36372	results	_	
189-3	36373-36375	of	_	
189-4	36376-36379	the	_	
189-5	36380-36387	present	_	
189-6	36388-36393	study	_	
189-7	36394-36401	suggest	_	
189-8	36402-36406	that	_	
189-9	36407-36412	KCNJ6	_	
189-10	36412-36413	,	_	
189-11	36414-36421	through	_	
189-12	36422-36425	its	_	
189-13	36426-36433	protein	_	
189-14	36434-36439	GIRK2	_	
189-15	36439-36440	,	_	
189-16	36441-36447	exerts	_	
189-17	36448-36454	strong	_	
189-18	36455-36465	moderating	_	
189-19	36466-36473	effects	_	
189-20	36474-36476	on	_	
189-21	36477-36482	theta	_	
189-22	36483-36487	EROs	_	
189-23	36487-36488	.	_	

#Text=Growing evidence from the literature suggests that KCNJ6 / GIRK2 may be a promising therapeutic target for alcoholism and related disorders.
190-1	36489-36496	Growing	_	
190-2	36497-36505	evidence	_	
190-3	36506-36510	from	_	
190-4	36511-36514	the	_	
190-5	36515-36525	literature	_	
190-6	36526-36534	suggests	_	
190-7	36535-36539	that	_	
190-8	36540-36545	KCNJ6	_	
190-9	36546-36547	/	_	
190-10	36548-36553	GIRK2	_	
190-11	36554-36557	may	_	
190-12	36558-36560	be	_	
190-13	36561-36562	a	_	
190-14	36563-36572	promising	_	
190-15	36573-36584	therapeutic	_	
190-16	36585-36591	target	_	
190-17	36592-36595	for	_	
190-18	36596-36606	alcoholism	_	
190-19	36607-36610	and	_	
190-20	36611-36618	related	_	
190-21	36619-36628	disorders	_	
190-22	36628-36629	.	_	

#Text=Functional studies on the KCNJ6 system, which are underway in COGA, may shed further light on neurogenetic mechanisms underlying cognitive processes and alcoholism.
191-1	36630-36640	Functional	_	
191-2	36641-36648	studies	_	
191-3	36649-36651	on	_	
191-4	36652-36655	the	_	
191-5	36656-36661	KCNJ6	_	
191-6	36662-36668	system	_	
191-7	36668-36669	,	_	
191-8	36670-36675	which	_	
191-9	36676-36679	are	_	
191-10	36680-36688	underway	_	
191-11	36689-36691	in	_	
191-12	36692-36696	COGA	_	
191-13	36696-36697	,	_	
191-14	36698-36701	may	_	
191-15	36702-36706	shed	_	
191-16	36707-36714	further	_	
191-17	36715-36720	light	_	
191-18	36721-36723	on	_	
191-19	36724-36736	neurogenetic	_	
191-20	36737-36747	mechanisms	_	
191-21	36748-36758	underlying	_	
191-22	36759-36768	cognitive	_	
191-23	36769-36778	processes	_	
191-24	36779-36782	and	_	
191-25	36783-36793	alcoholism	_	
191-26	36793-36794	.	_	

#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
192-1	36795-36799	This	_	
192-2	36800-36802	is	_	
192-3	36803-36804	a	_	
192-4	36805-36808	PDF	_	
192-5	36809-36813	file	_	
192-6	36814-36816	of	_	
192-7	36817-36819	an	_	
192-8	36820-36828	unedited	_	
192-9	36829-36839	manuscript	_	
192-10	36840-36844	that	_	
192-11	36845-36848	has	_	
192-12	36849-36853	been	_	
192-13	36854-36862	accepted	_	
192-14	36863-36866	for	_	
192-15	36867-36878	publication	_	
192-16	36878-36879	.	_	

#Text=As a service to our customers we are providing this early version of the manuscript.
193-1	36880-36882	As	_	
193-2	36883-36884	a	_	
193-3	36885-36892	service	_	
193-4	36893-36895	to	_	
193-5	36896-36899	our	_	
193-6	36900-36909	customers	_	
193-7	36910-36912	we	_	
193-8	36913-36916	are	_	
193-9	36917-36926	providing	_	
193-10	36927-36931	this	_	
193-11	36932-36937	early	_	
193-12	36938-36945	version	_	
193-13	36946-36948	of	_	
193-14	36949-36952	the	_	
193-15	36953-36963	manuscript	_	
193-16	36963-36964	.	_	

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.
194-1	36965-36968	The	_	
194-2	36969-36979	manuscript	_	
194-3	36980-36984	will	_	
194-4	36985-36992	undergo	_	
194-5	36993-37004	copyediting	_	
194-6	37004-37005	,	_	
194-7	37006-37017	typesetting	_	
194-8	37017-37018	,	_	
194-9	37019-37022	and	_	
194-10	37023-37029	review	_	
194-11	37030-37032	of	_	
194-12	37033-37036	the	_	
194-13	37037-37046	resulting	_	
194-14	37047-37052	proof	_	
194-15	37053-37059	before	_	
194-16	37060-37062	it	_	
194-17	37063-37065	is	_	
194-18	37066-37075	published	_	
194-19	37076-37078	in	_	
194-20	37079-37082	its	_	
194-21	37083-37088	final	_	
194-22	37089-37096	citable	_	
194-23	37097-37101	form	_	
194-24	37101-37102	.	_	

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
195-1	37103-37109	Please	_	
195-2	37110-37114	note	_	
195-3	37115-37119	that	_	
195-4	37120-37126	during	_	
195-5	37127-37130	the	_	
195-6	37131-37141	production	_	
195-7	37142-37149	process	_	
195-8	37150-37156	errors	_	
195-9	37157-37160	may	_	
195-10	37161-37163	be	_	
195-11	37164-37174	discovered	_	
195-12	37175-37180	which	_	
195-13	37181-37186	could	_	
195-14	37187-37193	affect	_	
195-15	37194-37197	the	_	
195-16	37198-37205	content	_	
195-17	37205-37206	,	_	
195-18	37207-37210	and	_	
195-19	37211-37214	all	_	
195-20	37215-37220	legal	_	
195-21	37221-37232	disclaimers	_	
195-22	37233-37237	that	_	
195-23	37238-37243	apply	_	
195-24	37244-37246	to	_	
195-25	37247-37250	the	_	
195-26	37251-37258	journal	_	
195-27	37259-37266	pertain	_	
195-28	37266-37267	.	_	

#Text=References
#Text=P300 from an auditory oddball task: inter-laboratory consistency
#Text=Oscillatory responses to reward processing in borderline personality disorder
#Text=Event-related oscillations versus event-related potentials in a P300 task as biomarkers for alcoholism
#Text=Genetic psychophysiology: advances, problems, and future directions
#Text=Altered neurotransmission in the mesolimbic reward system of Girk mice
#Text=Brain Function and Oscillations
#Text=Brain Function and Oscillations
#Text=Brain oscillations in neuropsychiatric disease
#Text=Gamma, alpha, delta, and theta oscillations govern cognitive processes
#Text=The selectively distributed theta system: functions
#Text=What is inherited in the predisposition toward alcoholism?
196-1	37268-37278	References	_	
196-2	37279-37283	P300	_	
196-3	37284-37288	from	_	
196-4	37289-37291	an	_	
196-5	37292-37300	auditory	_	
196-6	37301-37308	oddball	_	
196-7	37309-37313	task	_	
196-8	37313-37314	:	_	
196-9	37315-37331	inter-laboratory	_	
196-10	37332-37343	consistency	_	
196-11	37344-37355	Oscillatory	_	
196-12	37356-37365	responses	_	
196-13	37366-37368	to	_	
196-14	37369-37375	reward	_	
196-15	37376-37386	processing	_	
196-16	37387-37389	in	_	
196-17	37390-37400	borderline	_	
196-18	37401-37412	personality	_	
196-19	37413-37421	disorder	_	
196-20	37422-37435	Event-related	_	
196-21	37436-37448	oscillations	_	
196-22	37449-37455	versus	_	
196-23	37456-37469	event-related	_	
196-24	37470-37480	potentials	_	
196-25	37481-37483	in	_	
196-26	37484-37485	a	_	
196-27	37486-37490	P300	_	
196-28	37491-37495	task	_	
196-29	37496-37498	as	_	
196-30	37499-37509	biomarkers	_	
196-31	37510-37513	for	_	
196-32	37514-37524	alcoholism	_	
196-33	37525-37532	Genetic	_	
196-34	37533-37549	psychophysiology	_	
196-35	37549-37550	:	_	
196-36	37551-37559	advances	_	
196-37	37559-37560	,	_	
196-38	37561-37569	problems	_	
196-39	37569-37570	,	_	
196-40	37571-37574	and	_	
196-41	37575-37581	future	_	
196-42	37582-37592	directions	_	
196-43	37593-37600	Altered	_	
196-44	37601-37618	neurotransmission	_	
196-45	37619-37621	in	_	
196-46	37622-37625	the	_	
196-47	37626-37636	mesolimbic	_	
196-48	37637-37643	reward	_	
196-49	37644-37650	system	_	
196-50	37651-37653	of	_	
196-51	37654-37658	Girk	_	
196-52	37659-37663	mice	_	
196-53	37664-37669	Brain	_	
196-54	37670-37678	Function	_	
196-55	37679-37682	and	_	
196-56	37683-37695	Oscillations	_	
196-57	37696-37701	Brain	_	
196-58	37702-37710	Function	_	
196-59	37711-37714	and	_	
196-60	37715-37727	Oscillations	_	
196-61	37728-37733	Brain	_	
196-62	37734-37746	oscillations	_	
196-63	37747-37749	in	_	
196-64	37750-37766	neuropsychiatric	_	
196-65	37767-37774	disease	_	
196-66	37775-37780	Gamma	_	
196-67	37780-37781	,	_	
196-68	37782-37787	alpha	_	
196-69	37787-37788	,	_	
196-70	37789-37794	delta	_	
196-71	37794-37795	,	_	
196-72	37796-37799	and	_	
196-73	37800-37805	theta	_	
196-74	37806-37818	oscillations	_	
196-75	37819-37825	govern	_	
196-76	37826-37835	cognitive	_	
196-77	37836-37845	processes	_	
196-78	37846-37849	The	_	
196-79	37850-37861	selectively	_	
196-80	37862-37873	distributed	_	
196-81	37874-37879	theta	_	
196-82	37880-37886	system	_	
196-83	37886-37887	:	_	
196-84	37888-37897	functions	_	
196-85	37898-37902	What	_	
196-86	37903-37905	is	_	
196-87	37906-37915	inherited	_	
196-88	37916-37918	in	_	
196-89	37919-37922	the	_	
196-90	37923-37937	predisposition	_	
196-91	37938-37944	toward	_	
196-92	37945-37955	alcoholism	_	
196-93	37955-37956	?	_	

#Text=Genetics of human brain oscillations
#Text=The Collaborative Study on the Genetics of Alcoholism
#Text=Using EEG to Study Cognitive Development: Issues and Practices
#Text=Potassium channels as targets for ethanol: studies of G-protein-coupled inwardly rectifying potassium channel 2 (GIRK2) null mutant mice
#Text=The GIRK2 subunit is involved in IS-like seizures induced by GABA(B) receptor agonists
#Text=Alcohol modulation of G-protein-gated inwardly rectifying potassium channels: from binding to therapeutics
#Text=Ten percent electrode system for topographic studies of spontaneous and evoked EEG activities
#Text=Modified nomenclature for the “10%” electrode system
#Text=Association of single nucleotide polymorphisms in a glutamate receptor gene (GRM8) with theta power of event-related oscillations and alcohol dependence
#Text=Gender modulates the development of theta event related oscillations in adolescents and young adults
#Text=Genetic correlates of the development of theta event related oscillations in adolescents and young adults
#Text=G protein-activated inwardly rectifying potassium channels mediate depotentiation of long-term potentiation
#Text=KCNJ6 is associated with adult alcohol dependence and involved in gene x early life stress interactions in adolescent alcohol drinking
#Text=Visual P300: an interlaboratory consistency study
#Text=Reward expectation modulates feedback-related negativity and EEG spectra
#Text=Trisomy of the G protein-coupled K+ channel gene, Kcnj6, affects reward mechanisms, cognitive functions, and synaptic plasticity in mice
#Text=GABAB-GIRK2-mediated signaling in Down syndrome
#Text=Reward feedback processing in children and adolescents: medial frontal theta oscillations
#Text=Absence and rescue of morphine withdrawal in GIRK/Kir3 knock-out mice
#Text=Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system
#Text=How phenotype and developmental stage affect the genes we find: GABRA2 and impulsivity
#Text=Life-span changes in EEG spectral amplitude, amplitude variability and mean frequency
#Text=Description of the data from the Collaborative Study on the Genetics of Alcoholism (COGA) and single-nucleotide polymorphism genotyping for Genetic Analysis Workshop 14
#Text=A bluffer’s guide to sphericity
#Text=Development of the EEG of school-age children and adolescents.
197-1	37957-37965	Genetics	_	
197-2	37966-37968	of	_	
197-3	37969-37974	human	_	
197-4	37975-37980	brain	_	
197-5	37981-37993	oscillations	_	
197-6	37994-37997	The	_	
197-7	37998-38011	Collaborative	_	
197-8	38012-38017	Study	_	
197-9	38018-38020	on	_	
197-10	38021-38024	the	_	
197-11	38025-38033	Genetics	_	
197-12	38034-38036	of	_	
197-13	38037-38047	Alcoholism	_	
197-14	38048-38053	Using	_	
197-15	38054-38057	EEG	_	
197-16	38058-38060	to	_	
197-17	38061-38066	Study	_	
197-18	38067-38076	Cognitive	_	
197-19	38077-38088	Development	_	
197-20	38088-38089	:	_	
197-21	38090-38096	Issues	_	
197-22	38097-38100	and	_	
197-23	38101-38110	Practices	_	
197-24	38111-38120	Potassium	_	
197-25	38121-38129	channels	_	
197-26	38130-38132	as	_	
197-27	38133-38140	targets	_	
197-28	38141-38144	for	_	
197-29	38145-38152	ethanol	_	
197-30	38152-38153	:	_	
197-31	38154-38161	studies	_	
197-32	38162-38164	of	_	
197-33	38165-38182	G-protein-coupled	_	
197-34	38183-38191	inwardly	_	
197-35	38192-38202	rectifying	_	
197-36	38203-38212	potassium	_	
197-37	38213-38220	channel	_	
197-38	38221-38222	2	_	
197-39	38223-38224	(	_	
197-40	38224-38229	GIRK2	_	
197-41	38229-38230	)	_	
197-42	38231-38235	null	_	
197-43	38236-38242	mutant	_	
197-44	38243-38247	mice	_	
197-45	38248-38251	The	_	
197-46	38252-38257	GIRK2	_	
197-47	38258-38265	subunit	_	
197-48	38266-38268	is	_	
197-49	38269-38277	involved	_	
197-50	38278-38280	in	_	
197-51	38281-38288	IS-like	_	
197-52	38289-38297	seizures	_	
197-53	38298-38305	induced	_	
197-54	38306-38308	by	_	
197-55	38309-38313	GABA	_	
197-56	38313-38314	(	_	
197-57	38314-38315	B	_	
197-58	38315-38316	)	_	
197-59	38317-38325	receptor	_	
197-60	38326-38334	agonists	_	
197-61	38335-38342	Alcohol	_	
197-62	38343-38353	modulation	_	
197-63	38354-38356	of	_	
197-64	38357-38372	G-protein-gated	_	
197-65	38373-38381	inwardly	_	
197-66	38382-38392	rectifying	_	
197-67	38393-38402	potassium	_	
197-68	38403-38411	channels	_	
197-69	38411-38412	:	_	
197-70	38413-38417	from	_	
197-71	38418-38425	binding	_	
197-72	38426-38428	to	_	
197-73	38429-38441	therapeutics	_	
197-74	38442-38445	Ten	_	
197-75	38446-38453	percent	_	
197-76	38454-38463	electrode	_	
197-77	38464-38470	system	_	
197-78	38471-38474	for	_	
197-79	38475-38486	topographic	_	
197-80	38487-38494	studies	_	
197-81	38495-38497	of	_	
197-82	38498-38509	spontaneous	_	
197-83	38510-38513	and	_	
197-84	38514-38520	evoked	_	
197-85	38521-38524	EEG	_	
197-86	38525-38535	activities	_	
197-87	38536-38544	Modified	_	
197-88	38545-38557	nomenclature	_	
197-89	38558-38561	for	_	
197-90	38562-38565	the	_	
197-91	38566-38567	“	_	
197-92	38567-38570	10%	_	
197-93	38570-38571	”	_	
197-94	38572-38581	electrode	_	
197-95	38582-38588	system	_	
197-96	38589-38600	Association	_	
197-97	38601-38603	of	_	
197-98	38604-38610	single	_	
197-99	38611-38621	nucleotide	_	
197-100	38622-38635	polymorphisms	_	
197-101	38636-38638	in	_	
197-102	38639-38640	a	_	
197-103	38641-38650	glutamate	_	
197-104	38651-38659	receptor	_	
197-105	38660-38664	gene	_	
197-106	38665-38666	(	_	
197-107	38666-38670	GRM8	_	
197-108	38670-38671	)	_	
197-109	38672-38676	with	_	
197-110	38677-38682	theta	_	
197-111	38683-38688	power	_	
197-112	38689-38691	of	_	
197-113	38692-38705	event-related	_	
197-114	38706-38718	oscillations	_	
197-115	38719-38722	and	_	
197-116	38723-38730	alcohol	_	
197-117	38731-38741	dependence	_	
197-118	38742-38748	Gender	_	
197-119	38749-38758	modulates	_	
197-120	38759-38762	the	_	
197-121	38763-38774	development	_	
197-122	38775-38777	of	_	
197-123	38778-38783	theta	_	
197-124	38784-38789	event	_	
197-125	38790-38797	related	_	
197-126	38798-38810	oscillations	_	
197-127	38811-38813	in	_	
197-128	38814-38825	adolescents	_	
197-129	38826-38829	and	_	
197-130	38830-38835	young	_	
197-131	38836-38842	adults	_	
197-132	38843-38850	Genetic	_	
197-133	38851-38861	correlates	_	
197-134	38862-38864	of	_	
197-135	38865-38868	the	_	
197-136	38869-38880	development	_	
197-137	38881-38883	of	_	
197-138	38884-38889	theta	_	
197-139	38890-38895	event	_	
197-140	38896-38903	related	_	
197-141	38904-38916	oscillations	_	
197-142	38917-38919	in	_	
197-143	38920-38931	adolescents	_	
197-144	38932-38935	and	_	
197-145	38936-38941	young	_	
197-146	38942-38948	adults	_	
197-147	38949-38950	G	_	
197-148	38951-38968	protein-activated	_	
197-149	38969-38977	inwardly	_	
197-150	38978-38988	rectifying	_	
197-151	38989-38998	potassium	_	
197-152	38999-39007	channels	_	
197-153	39008-39015	mediate	_	
197-154	39016-39030	depotentiation	_	
197-155	39031-39033	of	_	
197-156	39034-39043	long-term	_	
197-157	39044-39056	potentiation	_	
197-158	39057-39062	KCNJ6	_	
197-159	39063-39065	is	_	
197-160	39066-39076	associated	_	
197-161	39077-39081	with	_	
197-162	39082-39087	adult	_	
197-163	39088-39095	alcohol	_	
197-164	39096-39106	dependence	_	
197-165	39107-39110	and	_	
197-166	39111-39119	involved	_	
197-167	39120-39122	in	_	
197-168	39123-39127	gene	_	
197-169	39128-39129	x	_	
197-170	39130-39135	early	_	
197-171	39136-39140	life	_	
197-172	39141-39147	stress	_	
197-173	39148-39160	interactions	_	
197-174	39161-39163	in	_	
197-175	39164-39174	adolescent	_	
197-176	39175-39182	alcohol	_	
197-177	39183-39191	drinking	_	
197-178	39192-39198	Visual	_	
197-179	39199-39203	P300	_	
197-180	39203-39204	:	_	
197-181	39205-39207	an	_	
197-182	39208-39223	interlaboratory	_	
197-183	39224-39235	consistency	_	
197-184	39236-39241	study	_	
197-185	39242-39248	Reward	_	
197-186	39249-39260	expectation	_	
197-187	39261-39270	modulates	_	
197-188	39271-39287	feedback-related	_	
197-189	39288-39298	negativity	_	
197-190	39299-39302	and	_	
197-191	39303-39306	EEG	_	
197-192	39307-39314	spectra	_	
197-193	39315-39322	Trisomy	_	
197-194	39323-39325	of	_	
197-195	39326-39329	the	_	
197-196	39330-39331	G	_	
197-197	39332-39347	protein-coupled	_	
197-198	39348-39349	K	_	
197-199	39349-39350	+	_	
197-200	39351-39358	channel	_	
197-201	39359-39363	gene	_	
197-202	39363-39364	,	_	
197-203	39365-39370	Kcnj6	_	
197-204	39370-39371	,	_	
197-205	39372-39379	affects	_	
197-206	39380-39386	reward	_	
197-207	39387-39397	mechanisms	_	
197-208	39397-39398	,	_	
197-209	39399-39408	cognitive	_	
197-210	39409-39418	functions	_	
197-211	39418-39419	,	_	
197-212	39420-39423	and	_	
197-213	39424-39432	synaptic	_	
197-214	39433-39443	plasticity	_	
197-215	39444-39446	in	_	
197-216	39447-39451	mice	_	
197-217	39452-39463	GABAB-GIRK2	_	
197-218	39463-39464	-	_	
197-219	39464-39472	mediated	_	
197-220	39473-39482	signaling	_	
197-221	39483-39485	in	_	
197-222	39486-39490	Down	_	
197-223	39491-39499	syndrome	_	
197-224	39500-39506	Reward	_	
197-225	39507-39515	feedback	_	
197-226	39516-39526	processing	_	
197-227	39527-39529	in	_	
197-228	39530-39538	children	_	
197-229	39539-39542	and	_	
197-230	39543-39554	adolescents	_	
197-231	39554-39555	:	_	
197-232	39556-39562	medial	_	
197-233	39563-39570	frontal	_	
197-234	39571-39576	theta	_	
197-235	39577-39589	oscillations	_	
197-236	39590-39597	Absence	_	
197-237	39598-39601	and	_	
197-238	39602-39608	rescue	_	
197-239	39609-39611	of	_	
197-240	39612-39620	morphine	_	
197-241	39621-39631	withdrawal	_	
197-242	39632-39634	in	_	
197-243	39635-39639	GIRK	_	
197-244	39639-39640	/	_	
197-245	39640-39644	Kir3	_	
197-246	39645-39654	knock-out	_	
197-247	39655-39659	mice	_	
197-248	39660-39674	Bi-directional	_	
197-249	39675-39682	effects	_	
197-250	39683-39685	of	_	
197-251	39686-39690	GABA	_	
197-252	39690-39691	(	_	
197-253	39691-39692	B	_	
197-254	39692-39693	)	_	
197-255	39694-39702	receptor	_	
197-256	39703-39711	agonists	_	
197-257	39712-39714	on	_	
197-258	39715-39718	the	_	
197-259	39719-39729	mesolimbic	_	
197-260	39730-39738	dopamine	_	
197-261	39739-39745	system	_	
197-262	39746-39749	How	_	
197-263	39750-39759	phenotype	_	
197-264	39760-39763	and	_	
197-265	39764-39777	developmental	_	
197-266	39778-39783	stage	_	
197-267	39784-39790	affect	_	
197-268	39791-39794	the	_	
197-269	39795-39800	genes	_	
197-270	39801-39803	we	_	
197-271	39804-39808	find	_	
197-272	39808-39809	:	_	
197-273	39810-39816	GABRA2	_	
197-274	39817-39820	and	_	
197-275	39821-39832	impulsivity	_	
197-276	39833-39842	Life-span	_	
197-277	39843-39850	changes	_	
197-278	39851-39853	in	_	
197-279	39854-39857	EEG	_	
197-280	39858-39866	spectral	_	
197-281	39867-39876	amplitude	_	
197-282	39876-39877	,	_	
197-283	39878-39887	amplitude	_	
197-284	39888-39899	variability	_	
197-285	39900-39903	and	_	
197-286	39904-39908	mean	_	
197-287	39909-39918	frequency	_	
197-288	39919-39930	Description	_	
197-289	39931-39933	of	_	
197-290	39934-39937	the	_	
197-291	39938-39942	data	_	
197-292	39943-39947	from	_	
197-293	39948-39951	the	_	
197-294	39952-39965	Collaborative	_	
197-295	39966-39971	Study	_	
197-296	39972-39974	on	_	
197-297	39975-39978	the	_	
197-298	39979-39987	Genetics	_	
197-299	39988-39990	of	_	
197-300	39991-40001	Alcoholism	_	
197-301	40002-40003	(	_	
197-302	40003-40007	COGA	_	
197-303	40007-40008	)	_	
197-304	40009-40012	and	_	
197-305	40013-40030	single-nucleotide	_	
197-306	40031-40043	polymorphism	_	
197-307	40044-40054	genotyping	_	
197-308	40055-40058	for	_	
197-309	40059-40066	Genetic	_	
197-310	40067-40075	Analysis	_	
197-311	40076-40084	Workshop	_	
197-312	40085-40087	14	_	
197-313	40088-40089	A	_	
197-314	40090-40097	bluffer	_	
197-315	40097-40098	’	_	
197-316	40098-40099	s	_	
197-317	40100-40105	guide	_	
197-318	40106-40108	to	_	
197-319	40109-40119	sphericity	_	
197-320	40120-40131	Development	_	
197-321	40132-40134	of	_	
197-322	40135-40138	the	_	
197-323	40139-40142	EEG	_	
197-324	40143-40145	of	_	
197-325	40146-40156	school-age	_	
197-326	40157-40165	children	_	
197-327	40166-40169	and	_	
197-328	40170-40181	adolescents	_	
197-329	40181-40182	.	_	

#Text=II.
198-1	40183-40185	II	_	
198-2	40185-40186	.	_	

#Text=Topography.
199-1	40187-40197	Topography	_	
199-2	40197-40198	.	_	

#Text=Electroencephalogr
#Text=Development of the EEG of school-age children and adolescents.
200-1	40199-40217	Electroencephalogr	_	
200-2	40218-40229	Development	_	
200-3	40230-40232	of	_	
200-4	40233-40236	the	_	
200-5	40237-40240	EEG	_	
200-6	40241-40243	of	_	
200-7	40244-40254	school-age	_	
200-8	40255-40263	children	_	
200-9	40264-40267	and	_	
200-10	40268-40279	adolescents	_	
200-11	40279-40280	.	_	

#Text=I.
201-1	40281-40282	I	_	
201-2	40282-40283	.	_	

#Text=Analysis of band power.
202-1	40284-40292	Analysis	_	
202-2	40293-40295	of	_	
202-3	40296-40300	band	_	
202-4	40301-40306	power	_	
202-5	40306-40307	.	_	

#Text=Electroencephalogr
#Text=Are all medial frontal negativities created equal?
203-1	40308-40326	Electroencephalogr	_	
203-2	40327-40330	Are	_	
203-3	40331-40334	all	_	
203-4	40335-40341	medial	_	
203-5	40342-40349	frontal	_	
203-6	40350-40362	negativities	_	
203-7	40363-40370	created	_	
203-8	40371-40376	equal	_	
203-9	40376-40377	?	_	

#Text=Toward a richer empirical basis for theories of action monitoring
#Text=Dynamic mapping of human cortical development during childhood through early adulthood
#Text=Mapping gray matter development: implications for typical development and vulnerability to psychopathology
#Text=Mutation analysis of the inwardly rectifying K(+) channels KCNJ6 (GIRK2) and KCNJ3 (GIRK1) in juvenile myoclonic epilepsy
#Text=Genetic utility of broadly defined bipolar schizoaffective disorder as a diagnostic concept
#Text=Elevated expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in cerebellar unipolar brush cells of a Down syndrome mouse model
#Text=Theta and delta band activity explain N2 and P3 ERP component activity in a go/no-go task
#Text=Reduced ethanol-induced conditioned taste aversion and conditioned place preference in GIRK2 null mutant mice
#Text=How inhibition shapes cortical activity
#Text=The ten-twenty electrode system of the International Federation
#Text=A cholinergic receptor gene (CHRM2) affects event-related oscillations
#Text=Linkage and linkage disequilibrium of evoked EEG oscillations with CHRM2 receptor gene polymorphisms: implications for human brain dynamics and cognition
#Text=S-transform time-frequency analysis of P300 reveals deficits in individuals diagnosed with alcoholism
#Text=The cognitive correlates of human brain oscillations
#Text=Theta returns
#Text=Reward-associated gamma oscillations in ventral striatum are regionally differentiated and modulate local firing activity
#Text=Deficient Event-Related Theta Oscillations in Individuals at Risk for Alcoholism: A Study of Reward Processing and Impulsivity Features
#Text=Reward processing deficits and impulsivity in high-risk offspring of alcoholics: A study of event-related potentials during a monetary gambling task
#Text=Advances in Electrophysiological Research
#Text=Event-related oscillations in offspring of alcoholics: neurocognitive disinhibition as a risk for alcoholism
#Text=The role of brain oscillations as functional correlates of cognitive systems: a study of frontal inhibitory control in alcoholism
#Text=Theta oscillations during the processing of monetary loss and gain: a perspective on gender and impulsivity
#Text=Topography, power, and current source density of theta oscillations during reward processing as markers for alcohol dependence
#Text=Family-based genome-wide association study of frontal theta oscillations identifies potassium channel gene KCNJ6
#Text=The genesis of human event-related responses explained through the theory of oscillatory neural assemblies
#Text=EEG alpha and theta oscillations reflect cognitive and memory performance: a review and analysis
#Text=The functional significance of theta and upper alpha oscillations
#Text=Modulators of G protein-activated inwardly rectifying K+ channels: potentially therapeutic agents for addictive drug users
#Text=
#Text=Multi-center N400 ERP consistency using a primed and unprimed word paradigm.
204-1	40378-40384	Toward	_	
204-2	40385-40386	a	_	
204-3	40387-40393	richer	_	
204-4	40394-40403	empirical	_	
204-5	40404-40409	basis	_	
204-6	40410-40413	for	_	
204-7	40414-40422	theories	_	
204-8	40423-40425	of	_	
204-9	40426-40432	action	_	
204-10	40433-40443	monitoring	_	
204-11	40444-40451	Dynamic	_	
204-12	40452-40459	mapping	_	
204-13	40460-40462	of	_	
204-14	40463-40468	human	_	
204-15	40469-40477	cortical	_	
204-16	40478-40489	development	_	
204-17	40490-40496	during	_	
204-18	40497-40506	childhood	_	
204-19	40507-40514	through	_	
204-20	40515-40520	early	_	
204-21	40521-40530	adulthood	_	
204-22	40531-40538	Mapping	_	
204-23	40539-40543	gray	_	
204-24	40544-40550	matter	_	
204-25	40551-40562	development	_	
204-26	40562-40563	:	_	
204-27	40564-40576	implications	_	
204-28	40577-40580	for	_	
204-29	40581-40588	typical	_	
204-30	40589-40600	development	_	
204-31	40601-40604	and	_	
204-32	40605-40618	vulnerability	_	
204-33	40619-40621	to	_	
204-34	40622-40637	psychopathology	_	
204-35	40638-40646	Mutation	_	
204-36	40647-40655	analysis	_	
204-37	40656-40658	of	_	
204-38	40659-40662	the	_	
204-39	40663-40671	inwardly	_	
204-40	40672-40682	rectifying	_	
204-41	40683-40684	K	_	
204-42	40684-40685	(	_	
204-43	40685-40686	+	_	
204-44	40686-40687	)	_	
204-45	40688-40696	channels	_	
204-46	40697-40702	KCNJ6	_	
204-47	40703-40704	(	_	
204-48	40704-40709	GIRK2	_	
204-49	40709-40710	)	_	
204-50	40711-40714	and	_	
204-51	40715-40720	KCNJ3	_	
204-52	40721-40722	(	_	
204-53	40722-40727	GIRK1	_	
204-54	40727-40728	)	_	
204-55	40729-40731	in	_	
204-56	40732-40740	juvenile	_	
204-57	40741-40750	myoclonic	_	
204-58	40751-40759	epilepsy	_	
204-59	40760-40767	Genetic	_	
204-60	40768-40775	utility	_	
204-61	40776-40778	of	_	
204-62	40779-40786	broadly	_	
204-63	40787-40794	defined	_	
204-64	40795-40802	bipolar	_	
204-65	40803-40818	schizoaffective	_	
204-66	40819-40827	disorder	_	
204-67	40828-40830	as	_	
204-68	40831-40832	a	_	
204-69	40833-40843	diagnostic	_	
204-70	40844-40851	concept	_	
204-71	40852-40860	Elevated	_	
204-72	40861-40871	expression	_	
204-73	40872-40874	of	_	
204-74	40875-40878	the	_	
204-75	40879-40898	G-protein-activated	_	
204-76	40899-40907	inwardly	_	
204-77	40908-40918	rectifying	_	
204-78	40919-40928	potassium	_	
204-79	40929-40936	channel	_	
204-80	40937-40938	2	_	
204-81	40939-40940	(	_	
204-82	40940-40945	GIRK2	_	
204-83	40945-40946	)	_	
204-84	40947-40949	in	_	
204-85	40950-40960	cerebellar	_	
204-86	40961-40969	unipolar	_	
204-87	40970-40975	brush	_	
204-88	40976-40981	cells	_	
204-89	40982-40984	of	_	
204-90	40985-40986	a	_	
204-91	40987-40991	Down	_	
204-92	40992-41000	syndrome	_	
204-93	41001-41006	mouse	_	
204-94	41007-41012	model	_	
204-95	41013-41018	Theta	_	
204-96	41019-41022	and	_	
204-97	41023-41028	delta	_	
204-98	41029-41033	band	_	
204-99	41034-41042	activity	_	
204-100	41043-41050	explain	_	
204-101	41051-41053	N2	_	
204-102	41054-41057	and	_	
204-103	41058-41060	P3	_	
204-104	41061-41064	ERP	_	
204-105	41065-41074	component	_	
204-106	41075-41083	activity	_	
204-107	41084-41086	in	_	
204-108	41087-41088	a	_	
204-109	41089-41091	go	_	
204-110	41091-41092	/	_	
204-111	41092-41097	no-go	_	
204-112	41098-41102	task	_	
204-113	41103-41110	Reduced	_	
204-114	41111-41126	ethanol-induced	_	
204-115	41127-41138	conditioned	_	
204-116	41139-41144	taste	_	
204-117	41145-41153	aversion	_	
204-118	41154-41157	and	_	
204-119	41158-41169	conditioned	_	
204-120	41170-41175	place	_	
204-121	41176-41186	preference	_	
204-122	41187-41189	in	_	
204-123	41190-41195	GIRK2	_	
204-124	41196-41200	null	_	
204-125	41201-41207	mutant	_	
204-126	41208-41212	mice	_	
204-127	41213-41216	How	_	
204-128	41217-41227	inhibition	_	
204-129	41228-41234	shapes	_	
204-130	41235-41243	cortical	_	
204-131	41244-41252	activity	_	
204-132	41253-41256	The	_	
204-133	41257-41267	ten-twenty	_	
204-134	41268-41277	electrode	_	
204-135	41278-41284	system	_	
204-136	41285-41287	of	_	
204-137	41288-41291	the	_	
204-138	41292-41305	International	_	
204-139	41306-41316	Federation	_	
204-140	41317-41318	A	_	
204-141	41319-41330	cholinergic	_	
204-142	41331-41339	receptor	_	
204-143	41340-41344	gene	_	
204-144	41345-41346	(	_	
204-145	41346-41351	CHRM2	_	
204-146	41351-41352	)	_	
204-147	41353-41360	affects	_	
204-148	41361-41374	event-related	_	
204-149	41375-41387	oscillations	_	
204-150	41388-41395	Linkage	_	
204-151	41396-41399	and	_	
204-152	41400-41407	linkage	_	
204-153	41408-41422	disequilibrium	_	
204-154	41423-41425	of	_	
204-155	41426-41432	evoked	_	
204-156	41433-41436	EEG	_	
204-157	41437-41449	oscillations	_	
204-158	41450-41454	with	_	
204-159	41455-41460	CHRM2	_	
204-160	41461-41469	receptor	_	
204-161	41470-41474	gene	_	
204-162	41475-41488	polymorphisms	_	
204-163	41488-41489	:	_	
204-164	41490-41502	implications	_	
204-165	41503-41506	for	_	
204-166	41507-41512	human	_	
204-167	41513-41518	brain	_	
204-168	41519-41527	dynamics	_	
204-169	41528-41531	and	_	
204-170	41532-41541	cognition	_	
204-171	41542-41553	S-transform	_	
204-172	41554-41568	time-frequency	_	
204-173	41569-41577	analysis	_	
204-174	41578-41580	of	_	
204-175	41581-41585	P300	_	
204-176	41586-41593	reveals	_	
204-177	41594-41602	deficits	_	
204-178	41603-41605	in	_	
204-179	41606-41617	individuals	_	
204-180	41618-41627	diagnosed	_	
204-181	41628-41632	with	_	
204-182	41633-41643	alcoholism	_	
204-183	41644-41647	The	_	
204-184	41648-41657	cognitive	_	
204-185	41658-41668	correlates	_	
204-186	41669-41671	of	_	
204-187	41672-41677	human	_	
204-188	41678-41683	brain	_	
204-189	41684-41696	oscillations	_	
204-190	41697-41702	Theta	_	
204-191	41703-41710	returns	_	
204-192	41711-41728	Reward-associated	_	
204-193	41729-41734	gamma	_	
204-194	41735-41747	oscillations	_	
204-195	41748-41750	in	_	
204-196	41751-41758	ventral	_	
204-197	41759-41767	striatum	_	
204-198	41768-41771	are	_	
204-199	41772-41782	regionally	_	
204-200	41783-41797	differentiated	_	
204-201	41798-41801	and	_	
204-202	41802-41810	modulate	_	
204-203	41811-41816	local	_	
204-204	41817-41823	firing	_	
204-205	41824-41832	activity	_	
204-206	41833-41842	Deficient	_	
204-207	41843-41856	Event-Related	_	
204-208	41857-41862	Theta	_	
204-209	41863-41875	Oscillations	_	
204-210	41876-41878	in	_	
204-211	41879-41890	Individuals	_	
204-212	41891-41893	at	_	
204-213	41894-41898	Risk	_	
204-214	41899-41902	for	_	
204-215	41903-41913	Alcoholism	_	
204-216	41913-41914	:	_	
204-217	41915-41916	A	_	
204-218	41917-41922	Study	_	
204-219	41923-41925	of	_	
204-220	41926-41932	Reward	_	
204-221	41933-41943	Processing	_	
204-222	41944-41947	and	_	
204-223	41948-41959	Impulsivity	_	
204-224	41960-41968	Features	_	
204-225	41969-41975	Reward	_	
204-226	41976-41986	processing	_	
204-227	41987-41995	deficits	_	
204-228	41996-41999	and	_	
204-229	42000-42011	impulsivity	_	
204-230	42012-42014	in	_	
204-231	42015-42024	high-risk	_	
204-232	42025-42034	offspring	_	
204-233	42035-42037	of	_	
204-234	42038-42048	alcoholics	_	
204-235	42048-42049	:	_	
204-236	42050-42051	A	_	
204-237	42052-42057	study	_	
204-238	42058-42060	of	_	
204-239	42061-42074	event-related	_	
204-240	42075-42085	potentials	_	
204-241	42086-42092	during	_	
204-242	42093-42094	a	_	
204-243	42095-42103	monetary	_	
204-244	42104-42112	gambling	_	
204-245	42113-42117	task	_	
204-246	42118-42126	Advances	_	
204-247	42127-42129	in	_	
204-248	42130-42150	Electrophysiological	_	
204-249	42151-42159	Research	_	
204-250	42160-42173	Event-related	_	
204-251	42174-42186	oscillations	_	
204-252	42187-42189	in	_	
204-253	42190-42199	offspring	_	
204-254	42200-42202	of	_	
204-255	42203-42213	alcoholics	_	
204-256	42213-42214	:	_	
204-257	42215-42229	neurocognitive	_	
204-258	42230-42243	disinhibition	_	
204-259	42244-42246	as	_	
204-260	42247-42248	a	_	
204-261	42249-42253	risk	_	
204-262	42254-42257	for	_	
204-263	42258-42268	alcoholism	_	
204-264	42269-42272	The	_	
204-265	42273-42277	role	_	
204-266	42278-42280	of	_	
204-267	42281-42286	brain	_	
204-268	42287-42299	oscillations	_	
204-269	42300-42302	as	_	
204-270	42303-42313	functional	_	
204-271	42314-42324	correlates	_	
204-272	42325-42327	of	_	
204-273	42328-42337	cognitive	_	
204-274	42338-42345	systems	_	
204-275	42345-42346	:	_	
204-276	42347-42348	a	_	
204-277	42349-42354	study	_	
204-278	42355-42357	of	_	
204-279	42358-42365	frontal	_	
204-280	42366-42376	inhibitory	_	
204-281	42377-42384	control	_	
204-282	42385-42387	in	_	
204-283	42388-42398	alcoholism	_	
204-284	42399-42404	Theta	_	
204-285	42405-42417	oscillations	_	
204-286	42418-42424	during	_	
204-287	42425-42428	the	_	
204-288	42429-42439	processing	_	
204-289	42440-42442	of	_	
204-290	42443-42451	monetary	_	
204-291	42452-42456	loss	_	
204-292	42457-42460	and	_	
204-293	42461-42465	gain	_	
204-294	42465-42466	:	_	
204-295	42467-42468	a	_	
204-296	42469-42480	perspective	_	
204-297	42481-42483	on	_	
204-298	42484-42490	gender	_	
204-299	42491-42494	and	_	
204-300	42495-42506	impulsivity	_	
204-301	42507-42517	Topography	_	
204-302	42517-42518	,	_	
204-303	42519-42524	power	_	
204-304	42524-42525	,	_	
204-305	42526-42529	and	_	
204-306	42530-42537	current	_	
204-307	42538-42544	source	_	
204-308	42545-42552	density	_	
204-309	42553-42555	of	_	
204-310	42556-42561	theta	_	
204-311	42562-42574	oscillations	_	
204-312	42575-42581	during	_	
204-313	42582-42588	reward	_	
204-314	42589-42599	processing	_	
204-315	42600-42602	as	_	
204-316	42603-42610	markers	_	
204-317	42611-42614	for	_	
204-318	42615-42622	alcohol	_	
204-319	42623-42633	dependence	_	
204-320	42634-42646	Family-based	_	
204-321	42647-42658	genome-wide	_	
204-322	42659-42670	association	_	
204-323	42671-42676	study	_	
204-324	42677-42679	of	_	
204-325	42680-42687	frontal	_	
204-326	42688-42693	theta	_	
204-327	42694-42706	oscillations	_	
204-328	42707-42717	identifies	_	
204-329	42718-42727	potassium	_	
204-330	42728-42735	channel	_	
204-331	42736-42740	gene	_	
204-332	42741-42746	KCNJ6	_	
204-333	42747-42750	The	_	
204-334	42751-42758	genesis	_	
204-335	42759-42761	of	_	
204-336	42762-42767	human	_	
204-337	42768-42781	event-related	_	
204-338	42782-42791	responses	_	
204-339	42792-42801	explained	_	
204-340	42802-42809	through	_	
204-341	42810-42813	the	_	
204-342	42814-42820	theory	_	
204-343	42821-42823	of	_	
204-344	42824-42835	oscillatory	_	
204-345	42836-42842	neural	_	
204-346	42843-42853	assemblies	_	
204-347	42854-42857	EEG	_	
204-348	42858-42863	alpha	_	
204-349	42864-42867	and	_	
204-350	42868-42873	theta	_	
204-351	42874-42886	oscillations	_	
204-352	42887-42894	reflect	_	
204-353	42895-42904	cognitive	_	
204-354	42905-42908	and	_	
204-355	42909-42915	memory	_	
204-356	42916-42927	performance	_	
204-357	42927-42928	:	_	
204-358	42929-42930	a	_	
204-359	42931-42937	review	_	
204-360	42938-42941	and	_	
204-361	42942-42950	analysis	_	
204-362	42951-42954	The	_	
204-363	42955-42965	functional	_	
204-364	42966-42978	significance	_	
204-365	42979-42981	of	_	
204-366	42982-42987	theta	_	
204-367	42988-42991	and	_	
204-368	42992-42997	upper	_	
204-369	42998-43003	alpha	_	
204-370	43004-43016	oscillations	_	
204-371	43017-43027	Modulators	_	
204-372	43028-43030	of	_	
204-373	43031-43032	G	_	
204-374	43033-43050	protein-activated	_	
204-375	43051-43059	inwardly	_	
204-376	43060-43070	rectifying	_	
204-377	43071-43072	K	_	
204-378	43072-43073	+	_	
204-379	43074-43082	channels	_	
204-380	43082-43083	:	_	
204-381	43084-43095	potentially	_	
204-382	43096-43107	therapeutic	_	
204-383	43108-43114	agents	_	
204-384	43115-43118	for	_	
204-385	43119-43128	addictive	_	
204-386	43129-43133	drug	_	
204-387	43134-43139	users	_	
204-388	43141-43153	Multi-center	_	
204-389	43154-43158	N400	_	
204-390	43159-43162	ERP	_	
204-391	43163-43174	consistency	_	
204-392	43175-43180	using	_	
204-393	43181-43182	a	_	
204-394	43183-43189	primed	_	
204-395	43190-43193	and	_	
204-396	43194-43202	unprimed	_	
204-397	43203-43207	word	_	
204-398	43208-43216	paradigm	_	
204-399	43216-43217	.	_	

#Text=Electroencephalogr
#Text=Epistatic interaction of CREB1 and KCNJ6 on rumination and negative emotionality
#Text=Addictive drugs modulate GIRK-channel signaling by regulating RGS proteins
#Text=A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size
#Text=G protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons
#Text=Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease
#Text=Electrophysiological responses to errors and feedback in the process of action regulation
#Text=Frontal midline theta and the error-related negativity: neurophysiological mechanisms of action regulation
#Text=
#Text=Beta oscillations and reward processing: Coupling oscillatory activity and hemodynamic responses
#Text=Frequency analysis of the EEG in normal children and adolescents
#Text=Regulation of kindling epileptogenesis by hippocampal galanin type 1 and type 2 receptors: The effects of subtype-selective agonists and the role of G-protein-mediated signaling
#Text=Decreased cocaine self-administration in Kir3 potassium channel subunit knockout mice
#Text=Sorting nexin 27 regulation of G protein-gated inwardly rectifying K(+) channels attenuates in vivo cocaine response
#Text=My close encounter with GABA(B) receptors
#Text=Association between KCNJ6 (GIRK2) gene polymorphism rs2835859 and post-operative analgesia, pain sensitivity, and nicotine dependence
#Text=Association between KCNJ6 (GIRK2) gene polymorphisms and postoperative analgesic requirements after major abdominal surgery
#Text=MANOVA method for analyzing repeated measures designs: an extensive primer
#Text=PedCheck: a program for identification of genotype incompatibilities in linkage analysis
#Text=Problem gamblers exhibit reward hypersensitivity in medial frontal cortex during gambling
#Text=An ADH1B variant and peer drinking in progression to adolescent drinking milestones: evidence of a gene-by-environment interaction
#Text=The five percent electrode system for high-resolution EEG and ERP measurements
#Text=Neurophysiological differences in reward processing in anhedonics
#Text=Delta, theta, and alpha event-related oscillations in alcoholics during Go/NoGo task: Neurocognitive deficits in execution, inhibition, and attention processing
#Text=Event-Related Oscillations in Alcoholism Research: A Review
#Text=A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation
#Text=Alteration in expression of G-protein-activated inward rectifier K+-channel subunits GIRK1 and GIRK2 in the rat brain following electroconvulsive shock
#Text=Some New Test Criteria in Multivariate Analysis
#Text=The utility of neurophysiological markers in the study of alcoholism
#Text=Behavioral characterization of mice lacking GIRK/Kir3 channel subunits
#Text=PLINK: a tool set for whole-genome association and population-based linkage analyses
#Text=Theta oscillations in human cortex during a working-memory task: evidence for local generators
#Text=Delta and theta oscillations as risk markers in adolescent offspring of alcoholics
#Text=
#Text=A genomic survey of alcohol dependence and related phenotypes: results from the Collaborative Study on the Genetics of Alcoholism (COGA)
#Text=Slow brain potentials in a visual-spatial memory task: topographic distribution and inter-laboratory consistency
#Text=Functional brain imaging across development
#Text=Functional frontalisation with age: mapping neurodevelopmental trajectories with fMRI
#Text=Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs
#Text=Distribution and neurochemical characterization of neurons expressing GIRK channels in the rat brain
#Text=The effect of GIRK2(wv) on neurite growth, protein expression, and viability in the CNS-derived neuronal cell line, CATH.A-differentiated
#Text=Electrophysiological changes during adolescence: a review
#Text=Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome
#Text=Normal cerebellar development but susceptibility to seizures in mice lacking G protein-coupled, inwardly rectifying K+ channel GIRK2
#Text=Functional effects of the mouse weaver mutation on G protein-gated inwardly rectifying K+ channels
#Text=Decision time, slow inhibition, and theta rhythm
#Text=Mapping changes in the human cortex throughout the span of life
#Text=Localization of the complex spectrum: The S transform
#Text=Neurobehavioral disinhibition in childhood predicts early age at onset of substance use disorder
#Text=Neural circuitry associated with risk for alcohol use disorders
#Text=Chromosome 21 KIR channels in brain development
#Text=Low and High Gamma Oscillations in Rat Ventral Striatum have Distinct Relationships to Behavior, Reward, and Spiking Activity on a Learned Spatial Decision Task
#Text=Developmental changes in the theta response system: a single sweep analysis
#Text=Event-Related Brain Oscillations Developmental Effects on Power and Synchronization
#Text=Time-frequency Analysis Based on the S-transform
#Text=Fear-related activity in the prefrontal cortex increases with age during adolescence: a preliminary fMRI study
#Text=A high-performance computing toolset for relatedness and principal component analysis of SNP data
#Text=Genome-wide association study of theta band event-related oscillations identifies serotonin receptor gene HTR7 influencing risk of alcohol dependence
#Text=Schematic illustration of the monetary gambling task.
205-1	43218-43236	Electroencephalogr	_	
205-2	43237-43246	Epistatic	_	
205-3	43247-43258	interaction	_	
205-4	43259-43261	of	_	
205-5	43262-43267	CREB1	_	
205-6	43268-43271	and	_	
205-7	43272-43277	KCNJ6	_	
205-8	43278-43280	on	_	
205-9	43281-43291	rumination	_	
205-10	43292-43295	and	_	
205-11	43296-43304	negative	_	
205-12	43305-43317	emotionality	_	
205-13	43318-43327	Addictive	_	
205-14	43328-43333	drugs	_	
205-15	43334-43342	modulate	_	
205-16	43343-43355	GIRK-channel	_	
205-17	43356-43365	signaling	_	
205-18	43366-43368	by	_	
205-19	43369-43379	regulating	_	
205-20	43380-43383	RGS	_	
205-21	43384-43392	proteins	_	
205-22	43393-43394	A	_	
205-23	43395-43400	KCNJ6	_	
205-24	43401-43402	(	_	
205-25	43402-43408	Kir3.2	_	
205-26	43408-43409	,	_	
205-27	43410-43415	GIRK2	_	
205-28	43415-43416	)	_	
205-29	43417-43421	gene	_	
205-30	43422-43434	polymorphism	_	
205-31	43435-43444	modulates	_	
205-32	43445-43451	opioid	_	
205-33	43452-43459	effects	_	
205-34	43460-43462	on	_	
205-35	43463-43472	analgesia	_	
205-36	43473-43476	and	_	
205-37	43477-43486	addiction	_	
205-38	43487-43490	but	_	
205-39	43491-43494	not	_	
205-40	43495-43497	on	_	
205-41	43498-43503	pupil	_	
205-42	43504-43508	size	_	
205-43	43509-43510	G	_	
205-44	43511-43526	protein-coupled	_	
205-45	43527-43535	inwardly	_	
205-46	43536-43546	rectifying	_	
205-47	43547-43548	K	_	
205-48	43548-43549	+	_	
205-49	43550-43558	channels	_	
205-50	43559-43560	(	_	
205-51	43560-43565	GIRKs	_	
205-52	43565-43566	)	_	
205-53	43567-43574	mediate	_	
205-54	43575-43587	postsynaptic	_	
205-55	43588-43591	but	_	
205-56	43592-43595	not	_	
205-57	43596-43607	presynaptic	_	
205-58	43608-43619	transmitter	_	
205-59	43620-43627	actions	_	
205-60	43628-43630	in	_	
205-61	43631-43642	hippocampal	_	
205-62	43643-43650	neurons	_	
205-63	43651-43659	Emerging	_	
205-64	43660-43665	roles	_	
205-65	43666-43669	for	_	
205-66	43670-43671	G	_	
205-67	43672-43685	protein-gated	_	
205-68	43686-43694	inwardly	_	
205-69	43695-43705	rectifying	_	
205-70	43706-43715	potassium	_	
205-71	43716-43717	(	_	
205-72	43717-43721	GIRK	_	
205-73	43721-43722	)	_	
205-74	43723-43731	channels	_	
205-75	43732-43734	in	_	
205-76	43735-43741	health	_	
205-77	43742-43745	and	_	
205-78	43746-43753	disease	_	
205-79	43754-43774	Electrophysiological	_	
205-80	43775-43784	responses	_	
205-81	43785-43787	to	_	
205-82	43788-43794	errors	_	
205-83	43795-43798	and	_	
205-84	43799-43807	feedback	_	
205-85	43808-43810	in	_	
205-86	43811-43814	the	_	
205-87	43815-43822	process	_	
205-88	43823-43825	of	_	
205-89	43826-43832	action	_	
205-90	43833-43843	regulation	_	
205-91	43844-43851	Frontal	_	
205-92	43852-43859	midline	_	
205-93	43860-43865	theta	_	
205-94	43866-43869	and	_	
205-95	43870-43873	the	_	
205-96	43874-43887	error-related	_	
205-97	43888-43898	negativity	_	
205-98	43898-43899	:	_	
205-99	43900-43918	neurophysiological	_	
205-100	43919-43929	mechanisms	_	
205-101	43930-43932	of	_	
205-102	43933-43939	action	_	
205-103	43940-43950	regulation	_	
205-104	43952-43956	Beta	_	
205-105	43957-43969	oscillations	_	
205-106	43970-43973	and	_	
205-107	43974-43980	reward	_	
205-108	43981-43991	processing	_	
205-109	43991-43992	:	_	
205-110	43993-44001	Coupling	_	
205-111	44002-44013	oscillatory	_	
205-112	44014-44022	activity	_	
205-113	44023-44026	and	_	
205-114	44027-44038	hemodynamic	_	
205-115	44039-44048	responses	_	
205-116	44049-44058	Frequency	_	
205-117	44059-44067	analysis	_	
205-118	44068-44070	of	_	
205-119	44071-44074	the	_	
205-120	44075-44078	EEG	_	
205-121	44079-44081	in	_	
205-122	44082-44088	normal	_	
205-123	44089-44097	children	_	
205-124	44098-44101	and	_	
205-125	44102-44113	adolescents	_	
205-126	44114-44124	Regulation	_	
205-127	44125-44127	of	_	
205-128	44128-44136	kindling	_	
205-129	44137-44152	epileptogenesis	_	
205-130	44153-44155	by	_	
205-131	44156-44167	hippocampal	_	
205-132	44168-44175	galanin	_	
205-133	44176-44180	type	_	
205-134	44181-44182	1	_	
205-135	44183-44186	and	_	
205-136	44187-44191	type	_	
205-137	44192-44193	2	_	
205-138	44194-44203	receptors	_	
205-139	44203-44204	:	_	
205-140	44205-44208	The	_	
205-141	44209-44216	effects	_	
205-142	44217-44219	of	_	
205-143	44220-44237	subtype-selective	_	
205-144	44238-44246	agonists	_	
205-145	44247-44250	and	_	
205-146	44251-44254	the	_	
205-147	44255-44259	role	_	
205-148	44260-44262	of	_	
205-149	44263-44281	G-protein-mediated	_	
205-150	44282-44291	signaling	_	
205-151	44292-44301	Decreased	_	
205-152	44302-44309	cocaine	_	
205-153	44310-44329	self-administration	_	
205-154	44330-44332	in	_	
205-155	44333-44337	Kir3	_	
205-156	44338-44347	potassium	_	
205-157	44348-44355	channel	_	
205-158	44356-44363	subunit	_	
205-159	44364-44372	knockout	_	
205-160	44373-44377	mice	_	
205-161	44378-44385	Sorting	_	
205-162	44386-44391	nexin	_	
205-163	44392-44394	27	_	
205-164	44395-44405	regulation	_	
205-165	44406-44408	of	_	
205-166	44409-44410	G	_	
205-167	44411-44424	protein-gated	_	
205-168	44425-44433	inwardly	_	
205-169	44434-44444	rectifying	_	
205-170	44445-44446	K	_	
205-171	44446-44447	(	_	
205-172	44447-44448	+	_	
205-173	44448-44449	)	_	
205-174	44450-44458	channels	_	
205-175	44459-44469	attenuates	_	
205-176	44470-44472	in	_	
205-177	44473-44477	vivo	_	
205-178	44478-44485	cocaine	_	
205-179	44486-44494	response	_	
205-180	44495-44497	My	_	
205-181	44498-44503	close	_	
205-182	44504-44513	encounter	_	
205-183	44514-44518	with	_	
205-184	44519-44523	GABA	_	
205-185	44523-44524	(	_	
205-186	44524-44525	B	_	
205-187	44525-44526	)	_	
205-188	44527-44536	receptors	_	
205-189	44537-44548	Association	_	
205-190	44549-44556	between	_	
205-191	44557-44562	KCNJ6	_	
205-192	44563-44564	(	_	
205-193	44564-44569	GIRK2	_	
205-194	44569-44570	)	_	
205-195	44571-44575	gene	_	
205-196	44576-44588	polymorphism	_	
205-197	44589-44598	rs2835859	_	
205-198	44599-44602	and	_	
205-199	44603-44617	post-operative	_	
205-200	44618-44627	analgesia	_	
205-201	44627-44628	,	_	
205-202	44629-44633	pain	_	
205-203	44634-44645	sensitivity	_	
205-204	44645-44646	,	_	
205-205	44647-44650	and	_	
205-206	44651-44659	nicotine	_	
205-207	44660-44670	dependence	_	
205-208	44671-44682	Association	_	
205-209	44683-44690	between	_	
205-210	44691-44696	KCNJ6	_	
205-211	44697-44698	(	_	
205-212	44698-44703	GIRK2	_	
205-213	44703-44704	)	_	
205-214	44705-44709	gene	_	
205-215	44710-44723	polymorphisms	_	
205-216	44724-44727	and	_	
205-217	44728-44741	postoperative	_	
205-218	44742-44751	analgesic	_	
205-219	44752-44764	requirements	_	
205-220	44765-44770	after	_	
205-221	44771-44776	major	_	
205-222	44777-44786	abdominal	_	
205-223	44787-44794	surgery	_	
205-224	44795-44801	MANOVA	_	
205-225	44802-44808	method	_	
205-226	44809-44812	for	_	
205-227	44813-44822	analyzing	_	
205-228	44823-44831	repeated	_	
205-229	44832-44840	measures	_	
205-230	44841-44848	designs	_	
205-231	44848-44849	:	_	
205-232	44850-44852	an	_	
205-233	44853-44862	extensive	_	
205-234	44863-44869	primer	_	
205-235	44870-44878	PedCheck	_	
205-236	44878-44879	:	_	
205-237	44880-44881	a	_	
205-238	44882-44889	program	_	
205-239	44890-44893	for	_	
205-240	44894-44908	identification	_	
205-241	44909-44911	of	_	
205-242	44912-44920	genotype	_	
205-243	44921-44938	incompatibilities	_	
205-244	44939-44941	in	_	
205-245	44942-44949	linkage	_	
205-246	44950-44958	analysis	_	
205-247	44959-44966	Problem	_	
205-248	44967-44975	gamblers	_	
205-249	44976-44983	exhibit	_	
205-250	44984-44990	reward	_	
205-251	44991-45007	hypersensitivity	_	
205-252	45008-45010	in	_	
205-253	45011-45017	medial	_	
205-254	45018-45025	frontal	_	
205-255	45026-45032	cortex	_	
205-256	45033-45039	during	_	
205-257	45040-45048	gambling	_	
205-258	45049-45051	An	_	
205-259	45052-45057	ADH1B	_	
205-260	45058-45065	variant	_	
205-261	45066-45069	and	_	
205-262	45070-45074	peer	_	
205-263	45075-45083	drinking	_	
205-264	45084-45086	in	_	
205-265	45087-45098	progression	_	
205-266	45099-45101	to	_	
205-267	45102-45112	adolescent	_	
205-268	45113-45121	drinking	_	
205-269	45122-45132	milestones	_	
205-270	45132-45133	:	_	
205-271	45134-45142	evidence	_	
205-272	45143-45145	of	_	
205-273	45146-45147	a	_	
205-274	45148-45167	gene-by-environment	_	
205-275	45168-45179	interaction	_	
205-276	45180-45183	The	_	
205-277	45184-45188	five	_	
205-278	45189-45196	percent	_	
205-279	45197-45206	electrode	_	
205-280	45207-45213	system	_	
205-281	45214-45217	for	_	
205-282	45218-45233	high-resolution	_	
205-283	45234-45237	EEG	_	
205-284	45238-45241	and	_	
205-285	45242-45245	ERP	_	
205-286	45246-45258	measurements	_	
205-287	45259-45277	Neurophysiological	_	
205-288	45278-45289	differences	_	
205-289	45290-45292	in	_	
205-290	45293-45299	reward	_	
205-291	45300-45310	processing	_	
205-292	45311-45313	in	_	
205-293	45314-45324	anhedonics	_	
205-294	45325-45330	Delta	_	
205-295	45330-45331	,	_	
205-296	45332-45337	theta	_	
205-297	45337-45338	,	_	
205-298	45339-45342	and	_	
205-299	45343-45348	alpha	_	
205-300	45349-45362	event-related	_	
205-301	45363-45375	oscillations	_	
205-302	45376-45378	in	_	
205-303	45379-45389	alcoholics	_	
205-304	45390-45396	during	_	
205-305	45397-45399	Go	_	
205-306	45399-45400	/	_	
205-307	45400-45404	NoGo	_	
205-308	45405-45409	task	_	
205-309	45409-45410	:	_	
205-310	45411-45425	Neurocognitive	_	
205-311	45426-45434	deficits	_	
205-312	45435-45437	in	_	
205-313	45438-45447	execution	_	
205-314	45447-45448	,	_	
205-315	45449-45459	inhibition	_	
205-316	45459-45460	,	_	
205-317	45461-45464	and	_	
205-318	45465-45474	attention	_	
205-319	45475-45485	processing	_	
205-320	45486-45499	Event-Related	_	
205-321	45500-45512	Oscillations	_	
205-322	45513-45515	in	_	
205-323	45516-45526	Alcoholism	_	
205-324	45527-45535	Research	_	
205-325	45535-45536	:	_	
205-326	45537-45538	A	_	
205-327	45539-45545	Review	_	
205-328	45546-45547	A	_	
205-329	45548-45557	potassium	_	
205-330	45558-45565	channel	_	
205-331	45566-45574	mutation	_	
205-332	45575-45577	in	_	
205-333	45578-45584	weaver	_	
205-334	45585-45589	mice	_	
205-335	45590-45600	implicates	_	
205-336	45601-45609	membrane	_	
205-337	45610-45622	excitability	_	
205-338	45623-45625	in	_	
205-339	45626-45633	granule	_	
205-340	45634-45638	cell	_	
205-341	45639-45654	differentiation	_	
205-342	45655-45665	Alteration	_	
205-343	45666-45668	in	_	
205-344	45669-45679	expression	_	
205-345	45680-45682	of	_	
205-346	45683-45702	G-protein-activated	_	
205-347	45703-45709	inward	_	
205-348	45710-45719	rectifier	_	
205-349	45720-45721	K	_	
205-350	45721-45722	+	_	
205-351	45722-45723	-	_	
205-352	45723-45730	channel	_	
205-353	45731-45739	subunits	_	
205-354	45740-45745	GIRK1	_	
205-355	45746-45749	and	_	
205-356	45750-45755	GIRK2	_	
205-357	45756-45758	in	_	
205-358	45759-45762	the	_	
205-359	45763-45766	rat	_	
205-360	45767-45772	brain	_	
205-361	45773-45782	following	_	
205-362	45783-45800	electroconvulsive	_	
205-363	45801-45806	shock	_	
205-364	45807-45811	Some	_	
205-365	45812-45815	New	_	
205-366	45816-45820	Test	_	
205-367	45821-45829	Criteria	_	
205-368	45830-45832	in	_	
205-369	45833-45845	Multivariate	_	
205-370	45846-45854	Analysis	_	
205-371	45855-45858	The	_	
205-372	45859-45866	utility	_	
205-373	45867-45869	of	_	
205-374	45870-45888	neurophysiological	_	
205-375	45889-45896	markers	_	
205-376	45897-45899	in	_	
205-377	45900-45903	the	_	
205-378	45904-45909	study	_	
205-379	45910-45912	of	_	
205-380	45913-45923	alcoholism	_	
205-381	45924-45934	Behavioral	_	
205-382	45935-45951	characterization	_	
205-383	45952-45954	of	_	
205-384	45955-45959	mice	_	
205-385	45960-45967	lacking	_	
205-386	45968-45972	GIRK	_	
205-387	45972-45973	/	_	
205-388	45973-45977	Kir3	_	
205-389	45978-45985	channel	_	
205-390	45986-45994	subunits	_	
205-391	45995-46000	PLINK	_	
205-392	46000-46001	:	_	
205-393	46002-46003	a	_	
205-394	46004-46008	tool	_	
205-395	46009-46012	set	_	
205-396	46013-46016	for	_	
205-397	46017-46029	whole-genome	_	
205-398	46030-46041	association	_	
205-399	46042-46045	and	_	
205-400	46046-46062	population-based	_	
205-401	46063-46070	linkage	_	
205-402	46071-46079	analyses	_	
205-403	46080-46085	Theta	_	
205-404	46086-46098	oscillations	_	
205-405	46099-46101	in	_	
205-406	46102-46107	human	_	
205-407	46108-46114	cortex	_	
205-408	46115-46121	during	_	
205-409	46122-46123	a	_	
205-410	46124-46138	working-memory	_	
205-411	46139-46143	task	_	
205-412	46143-46144	:	_	
205-413	46145-46153	evidence	_	
205-414	46154-46157	for	_	
205-415	46158-46163	local	_	
205-416	46164-46174	generators	_	
205-417	46175-46180	Delta	_	
205-418	46181-46184	and	_	
205-419	46185-46190	theta	_	
205-420	46191-46203	oscillations	_	
205-421	46204-46206	as	_	
205-422	46207-46211	risk	_	
205-423	46212-46219	markers	_	
205-424	46220-46222	in	_	
205-425	46223-46233	adolescent	_	
205-426	46234-46243	offspring	_	
205-427	46244-46246	of	_	
205-428	46247-46257	alcoholics	_	
205-429	46259-46260	A	_	
205-430	46261-46268	genomic	_	
205-431	46269-46275	survey	_	
205-432	46276-46278	of	_	
205-433	46279-46286	alcohol	_	
205-434	46287-46297	dependence	_	
205-435	46298-46301	and	_	
205-436	46302-46309	related	_	
205-437	46310-46320	phenotypes	_	
205-438	46320-46321	:	_	
205-439	46322-46329	results	_	
205-440	46330-46334	from	_	
205-441	46335-46338	the	_	
205-442	46339-46352	Collaborative	_	
205-443	46353-46358	Study	_	
205-444	46359-46361	on	_	
205-445	46362-46365	the	_	
205-446	46366-46374	Genetics	_	
205-447	46375-46377	of	_	
205-448	46378-46388	Alcoholism	_	
205-449	46389-46390	(	_	
205-450	46390-46394	COGA	_	
205-451	46394-46395	)	_	
205-452	46396-46400	Slow	_	
205-453	46401-46406	brain	_	
205-454	46407-46417	potentials	_	
205-455	46418-46420	in	_	
205-456	46421-46422	a	_	
205-457	46423-46437	visual-spatial	_	
205-458	46438-46444	memory	_	
205-459	46445-46449	task	_	
205-460	46449-46450	:	_	
205-461	46451-46462	topographic	_	
205-462	46463-46475	distribution	_	
205-463	46476-46479	and	_	
205-464	46480-46496	inter-laboratory	_	
205-465	46497-46508	consistency	_	
205-466	46509-46519	Functional	_	
205-467	46520-46525	brain	_	
205-468	46526-46533	imaging	_	
205-469	46534-46540	across	_	
205-470	46541-46552	development	_	
205-471	46553-46563	Functional	_	
205-472	46564-46578	frontalisation	_	
205-473	46579-46583	with	_	
205-474	46584-46587	age	_	
205-475	46587-46588	:	_	
205-476	46589-46596	mapping	_	
205-477	46597-46615	neurodevelopmental	_	
205-478	46616-46628	trajectories	_	
205-479	46629-46633	with	_	
205-480	46634-46638	fMRI	_	
205-481	46639-46650	Cholinergic	_	
205-482	46651-46660	nicotinic	_	
205-483	46661-46669	receptor	_	
205-484	46670-46675	genes	_	
205-485	46676-46686	implicated	_	
205-486	46687-46689	in	_	
205-487	46690-46691	a	_	
205-488	46692-46700	nicotine	_	
205-489	46701-46711	dependence	_	
205-490	46712-46723	association	_	
205-491	46724-46729	study	_	
205-492	46730-46739	targeting	_	
205-493	46740-46743	348	_	
205-494	46744-46753	candidate	_	
205-495	46754-46759	genes	_	
205-496	46760-46764	with	_	
205-497	46765-46769	3713	_	
205-498	46770-46774	SNPs	_	
205-499	46775-46787	Distribution	_	
205-500	46788-46791	and	_	
205-501	46792-46805	neurochemical	_	
205-502	46806-46822	characterization	_	
205-503	46823-46825	of	_	
205-504	46826-46833	neurons	_	
205-505	46834-46844	expressing	_	
205-506	46845-46849	GIRK	_	
205-507	46850-46858	channels	_	
205-508	46859-46861	in	_	
205-509	46862-46865	the	_	
205-510	46866-46869	rat	_	
205-511	46870-46875	brain	_	
205-512	46876-46879	The	_	
205-513	46880-46886	effect	_	
205-514	46887-46889	of	_	
205-515	46890-46895	GIRK2	_	
205-516	46895-46896	(	_	
205-517	46896-46898	wv	_	
205-518	46898-46899	)	_	
205-519	46900-46902	on	_	
205-520	46903-46910	neurite	_	
205-521	46911-46917	growth	_	
205-522	46917-46918	,	_	
205-523	46919-46926	protein	_	
205-524	46927-46937	expression	_	
205-525	46937-46938	,	_	
205-526	46939-46942	and	_	
205-527	46943-46952	viability	_	
205-528	46953-46955	in	_	
205-529	46956-46959	the	_	
205-530	46960-46971	CNS-derived	_	
205-531	46972-46980	neuronal	_	
205-532	46981-46985	cell	_	
205-533	46986-46990	line	_	
205-534	46990-46991	,	_	
205-535	46992-47013	CATH.A-differentiated	_	
205-536	47014-47034	Electrophysiological	_	
205-537	47035-47042	changes	_	
205-538	47043-47049	during	_	
205-539	47050-47061	adolescence	_	
205-540	47061-47062	:	_	
205-541	47063-47064	a	_	
205-542	47065-47071	review	_	
205-543	47072-47081	Increased	_	
205-544	47082-47090	synaptic	_	
205-545	47091-47101	depression	_	
205-546	47102-47104	in	_	
205-547	47105-47108	the	_	
205-548	47109-47115	Ts65Dn	_	
205-549	47116-47121	mouse	_	
205-550	47121-47122	,	_	
205-551	47123-47124	a	_	
205-552	47125-47130	model	_	
205-553	47131-47134	for	_	
205-554	47135-47141	mental	_	
205-555	47142-47153	retardation	_	
205-556	47154-47156	in	_	
205-557	47157-47161	Down	_	
205-558	47162-47170	syndrome	_	
205-559	47171-47177	Normal	_	
205-560	47178-47188	cerebellar	_	
205-561	47189-47200	development	_	
205-562	47201-47204	but	_	
205-563	47205-47219	susceptibility	_	
205-564	47220-47222	to	_	
205-565	47223-47231	seizures	_	
205-566	47232-47234	in	_	
205-567	47235-47239	mice	_	
205-568	47240-47247	lacking	_	
205-569	47248-47249	G	_	
205-570	47250-47265	protein-coupled	_	
205-571	47265-47266	,	_	
205-572	47267-47275	inwardly	_	
205-573	47276-47286	rectifying	_	
205-574	47287-47288	K	_	
205-575	47288-47289	+	_	
205-576	47290-47297	channel	_	
205-577	47298-47303	GIRK2	_	
205-578	47304-47314	Functional	_	
205-579	47315-47322	effects	_	
205-580	47323-47325	of	_	
205-581	47326-47329	the	_	
205-582	47330-47335	mouse	_	
205-583	47336-47342	weaver	_	
205-584	47343-47351	mutation	_	
205-585	47352-47354	on	_	
205-586	47355-47356	G	_	
205-587	47357-47370	protein-gated	_	
205-588	47371-47379	inwardly	_	
205-589	47380-47390	rectifying	_	
205-590	47391-47392	K	_	
205-591	47392-47393	+	_	
205-592	47394-47402	channels	_	
205-593	47403-47411	Decision	_	
205-594	47412-47416	time	_	
205-595	47416-47417	,	_	
205-596	47418-47422	slow	_	
205-597	47423-47433	inhibition	_	
205-598	47433-47434	,	_	
205-599	47435-47438	and	_	
205-600	47439-47444	theta	_	
205-601	47445-47451	rhythm	_	
205-602	47452-47459	Mapping	_	
205-603	47460-47467	changes	_	
205-604	47468-47470	in	_	
205-605	47471-47474	the	_	
205-606	47475-47480	human	_	
205-607	47481-47487	cortex	_	
205-608	47488-47498	throughout	_	
205-609	47499-47502	the	_	
205-610	47503-47507	span	_	
205-611	47508-47510	of	_	
205-612	47511-47515	life	_	
205-613	47516-47528	Localization	_	
205-614	47529-47531	of	_	
205-615	47532-47535	the	_	
205-616	47536-47543	complex	_	
205-617	47544-47552	spectrum	_	
205-618	47552-47553	:	_	
205-619	47554-47557	The	_	
205-620	47558-47559	S	_	
205-621	47560-47569	transform	_	
205-622	47570-47585	Neurobehavioral	_	
205-623	47586-47599	disinhibition	_	
205-624	47600-47602	in	_	
205-625	47603-47612	childhood	_	
205-626	47613-47621	predicts	_	
205-627	47622-47627	early	_	
205-628	47628-47631	age	_	
205-629	47632-47634	at	_	
205-630	47635-47640	onset	_	
205-631	47641-47643	of	_	
205-632	47644-47653	substance	_	
205-633	47654-47657	use	_	
205-634	47658-47666	disorder	_	
205-635	47667-47673	Neural	_	
205-636	47674-47683	circuitry	_	
205-637	47684-47694	associated	_	
205-638	47695-47699	with	_	
205-639	47700-47704	risk	_	
205-640	47705-47708	for	_	
205-641	47709-47716	alcohol	_	
205-642	47717-47720	use	_	
205-643	47721-47730	disorders	_	
205-644	47731-47741	Chromosome	_	
205-645	47742-47744	21	_	
205-646	47745-47748	KIR	_	
205-647	47749-47757	channels	_	
205-648	47758-47760	in	_	
205-649	47761-47766	brain	_	
205-650	47767-47778	development	_	
205-651	47779-47782	Low	_	
205-652	47783-47786	and	_	
205-653	47787-47791	High	_	
205-654	47792-47797	Gamma	_	
205-655	47798-47810	Oscillations	_	
205-656	47811-47813	in	_	
205-657	47814-47817	Rat	_	
205-658	47818-47825	Ventral	_	
205-659	47826-47834	Striatum	_	
205-660	47835-47839	have	_	
205-661	47840-47848	Distinct	_	
205-662	47849-47862	Relationships	_	
205-663	47863-47865	to	_	
205-664	47866-47874	Behavior	_	
205-665	47874-47875	,	_	
205-666	47876-47882	Reward	_	
205-667	47882-47883	,	_	
205-668	47884-47887	and	_	
205-669	47888-47895	Spiking	_	
205-670	47896-47904	Activity	_	
205-671	47905-47907	on	_	
205-672	47908-47909	a	_	
205-673	47910-47917	Learned	_	
205-674	47918-47925	Spatial	_	
205-675	47926-47934	Decision	_	
205-676	47935-47939	Task	_	
205-677	47940-47953	Developmental	_	
205-678	47954-47961	changes	_	
205-679	47962-47964	in	_	
205-680	47965-47968	the	_	
205-681	47969-47974	theta	_	
205-682	47975-47983	response	_	
205-683	47984-47990	system	_	
205-684	47990-47991	:	_	
205-685	47992-47993	a	_	
205-686	47994-48000	single	_	
205-687	48001-48006	sweep	_	
205-688	48007-48015	analysis	_	
205-689	48016-48029	Event-Related	_	
205-690	48030-48035	Brain	_	
205-691	48036-48048	Oscillations	_	
205-692	48049-48062	Developmental	_	
205-693	48063-48070	Effects	_	
205-694	48071-48073	on	_	
205-695	48074-48079	Power	_	
205-696	48080-48083	and	_	
205-697	48084-48099	Synchronization	_	
205-698	48100-48114	Time-frequency	_	
205-699	48115-48123	Analysis	_	
205-700	48124-48129	Based	_	
205-701	48130-48132	on	_	
205-702	48133-48136	the	_	
205-703	48137-48148	S-transform	_	
205-704	48149-48161	Fear-related	_	
205-705	48162-48170	activity	_	
205-706	48171-48173	in	_	
205-707	48174-48177	the	_	
205-708	48178-48188	prefrontal	_	
205-709	48189-48195	cortex	_	
205-710	48196-48205	increases	_	
205-711	48206-48210	with	_	
205-712	48211-48214	age	_	
205-713	48215-48221	during	_	
205-714	48222-48233	adolescence	_	
205-715	48233-48234	:	_	
205-716	48235-48236	a	_	
205-717	48237-48248	preliminary	_	
205-718	48249-48253	fMRI	_	
205-719	48254-48259	study	_	
205-720	48260-48261	A	_	
205-721	48262-48278	high-performance	_	
205-722	48279-48288	computing	_	
205-723	48289-48296	toolset	_	
205-724	48297-48300	for	_	
205-725	48301-48312	relatedness	_	
205-726	48313-48316	and	_	
205-727	48317-48326	principal	_	
205-728	48327-48336	component	_	
205-729	48337-48345	analysis	_	
205-730	48346-48348	of	_	
205-731	48349-48352	SNP	_	
205-732	48353-48357	data	_	
205-733	48358-48369	Genome-wide	_	
205-734	48370-48381	association	_	
205-735	48382-48387	study	_	
205-736	48388-48390	of	_	
205-737	48391-48396	theta	_	
205-738	48397-48401	band	_	
205-739	48402-48415	event-related	_	
205-740	48416-48428	oscillations	_	
205-741	48429-48439	identifies	_	
205-742	48440-48449	serotonin	_	
205-743	48450-48458	receptor	_	
205-744	48459-48463	gene	_	
205-745	48464-48468	HTR7	_	
205-746	48469-48480	influencing	_	
205-747	48481-48485	risk	_	
205-748	48486-48488	of	_	
205-749	48489-48496	alcohol	_	
205-750	48497-48507	dependence	_	
205-751	48508-48517	Schematic	_	
205-752	48518-48530	illustration	_	
205-753	48531-48533	of	_	
205-754	48534-48537	the	_	
205-755	48538-48546	monetary	_	
205-756	48547-48555	gambling	_	
205-757	48556-48560	task	_	
205-758	48560-48561	.	_	

#Text=Each trial starts with a choice stimulus (CS) which lasts for 800 ms and displays two amounts (10¢ or 50¢) to bet with.
206-1	48562-48566	Each	_	
206-2	48567-48572	trial	_	
206-3	48573-48579	starts	_	
206-4	48580-48584	with	_	
206-5	48585-48586	a	_	
206-6	48587-48593	choice	_	
206-7	48594-48602	stimulus	_	
206-8	48603-48604	(	_	
206-9	48604-48606	CS	_	
206-10	48606-48607	)	_	
206-11	48608-48613	which	_	
206-12	48614-48619	lasts	_	
206-13	48620-48623	for	_	
206-14	48624-48627	800	_	
206-15	48628-48630	ms	_	
206-16	48631-48634	and	_	
206-17	48635-48643	displays	_	
206-18	48644-48647	two	_	
206-19	48648-48655	amounts	_	
206-20	48656-48657	(	_	
206-21	48657-48660	10¢	_	
206-22	48661-48663	or	_	
206-23	48664-48667	50¢	_	
206-24	48667-48668	)	_	
206-25	48669-48671	to	_	
206-26	48672-48675	bet	_	
206-27	48676-48680	with	_	
206-28	48680-48681	.	_	

#Text=The participant selects one of the amounts and receives an outcome of either gain (green box) or loss (red box) for the selected amount as shown by the outcome stimulus (OS).
207-1	48682-48685	The	_	
207-2	48686-48697	participant	_	
207-3	48698-48705	selects	_	
207-4	48706-48709	one	_	
207-5	48710-48712	of	_	
207-6	48713-48716	the	_	
207-7	48717-48724	amounts	_	
207-8	48725-48728	and	_	
207-9	48729-48737	receives	_	
207-10	48738-48740	an	_	
207-11	48741-48748	outcome	_	
207-12	48749-48751	of	_	
207-13	48752-48758	either	_	
207-14	48759-48763	gain	_	
207-15	48764-48765	(	_	
207-16	48765-48770	green	_	
207-17	48771-48774	box	_	
207-18	48774-48775	)	_	
207-19	48776-48778	or	_	
207-20	48779-48783	loss	_	
207-21	48784-48785	(	_	
207-22	48785-48788	red	_	
207-23	48789-48792	box	_	
207-24	48792-48793	)	_	
207-25	48794-48797	for	_	
207-26	48798-48801	the	_	
207-27	48802-48810	selected	_	
207-28	48811-48817	amount	_	
207-29	48818-48820	as	_	
207-30	48821-48826	shown	_	
207-31	48827-48829	by	_	
207-32	48830-48833	the	_	
207-33	48834-48841	outcome	_	
207-34	48842-48850	stimulus	_	
207-35	48851-48852	(	_	
207-36	48852-48854	OS	_	
207-37	48854-48855	)	_	
207-38	48855-48856	.	_	

#Text=A trial with a gain of 50¢ and the next trial with a loss of 10¢ are illustrated.
208-1	48857-48858	A	_	
208-2	48859-48864	trial	_	
208-3	48865-48869	with	_	
208-4	48870-48871	a	_	
208-5	48872-48876	gain	_	
208-6	48877-48879	of	_	
208-7	48880-48883	50¢	_	
208-8	48884-48887	and	_	
208-9	48888-48891	the	_	
208-10	48892-48896	next	_	
208-11	48897-48902	trial	_	
208-12	48903-48907	with	_	
208-13	48908-48909	a	_	
208-14	48910-48914	loss	_	
208-15	48915-48917	of	_	
208-16	48918-48921	10¢	_	
208-17	48922-48925	are	_	
208-18	48926-48937	illustrated	_	
208-19	48937-48938	.	_	

#Text=The ISI between the CS and the OS is 1500 ms.
209-1	48939-48942	The	_	
209-2	48943-48946	ISI	_	
209-3	48947-48954	between	_	
209-4	48955-48958	the	_	
209-5	48959-48961	CS	_	
209-6	48962-48965	and	_	
209-7	48966-48969	the	_	
209-8	48970-48972	OS	_	
209-9	48973-48975	is	_	
209-10	48976-48980	1500	_	
209-11	48981-48983	ms	_	
209-12	48983-48984	.	_	

#Text=Participants were required to respond to the OS within 1000 ms (i.e., response window) by selecting one of the two amounts.
210-1	48985-48997	Participants	_	
210-2	48998-49002	were	_	
210-3	49003-49011	required	_	
210-4	49012-49014	to	_	
210-5	49015-49022	respond	_	
210-6	49023-49025	to	_	
210-7	49026-49029	the	_	
210-8	49030-49032	OS	_	
210-9	49033-49039	within	_	
210-10	49040-49044	1000	_	
210-11	49045-49047	ms	_	
210-12	49048-49049	(	_	
210-13	49049-49052	i.e	_	
210-14	49052-49053	.	_	
210-15	49053-49054	,	_	
210-16	49055-49063	response	_	
210-17	49064-49070	window	_	
210-18	49070-49071	)	_	
210-19	49072-49074	by	_	
210-20	49075-49084	selecting	_	
210-21	49085-49088	one	_	
210-22	49089-49091	of	_	
210-23	49092-49095	the	_	
210-24	49096-49099	two	_	
210-25	49100-49107	amounts	_	
210-26	49107-49108	.	_	

#Text=ERO analysis was performed on trial epochs of 1000 ms post-stimulus period after the onset of the OS (i.e., analysis window).
211-1	49109-49112	ERO	_	
211-2	49113-49121	analysis	_	
211-3	49122-49125	was	_	
211-4	49126-49135	performed	_	
211-5	49136-49138	on	_	
211-6	49139-49144	trial	_	
211-7	49145-49151	epochs	_	
211-8	49152-49154	of	_	
211-9	49155-49159	1000	_	
211-10	49160-49162	ms	_	
211-11	49163-49176	post-stimulus	_	
211-12	49177-49183	period	_	
211-13	49184-49189	after	_	
211-14	49190-49193	the	_	
211-15	49194-49199	onset	_	
211-16	49200-49202	of	_	
211-17	49203-49206	the	_	
211-18	49207-49209	OS	_	
211-19	49210-49211	(	_	
211-20	49211-49214	i.e	_	
211-21	49214-49215	.	_	
211-22	49215-49216	,	_	
211-23	49217-49225	analysis	_	
211-24	49226-49232	window	_	
211-25	49232-49233	)	_	
211-26	49233-49234	.	_	

#Text=Sixty-one electrodes were recorded in the current study from the surface of the scalp.
212-1	49235-49244	Sixty-one	_	
212-2	49245-49255	electrodes	_	
212-3	49256-49260	were	_	
212-4	49261-49269	recorded	_	
212-5	49270-49272	in	_	
212-6	49273-49276	the	_	
212-7	49277-49284	current	_	
212-8	49285-49290	study	_	
212-9	49291-49295	from	_	
212-10	49296-49299	the	_	
212-11	49300-49307	surface	_	
212-12	49308-49310	of	_	
212-13	49311-49314	the	_	
212-14	49315-49320	scalp	_	
212-15	49320-49321	.	_	

#Text=Three regions, representing frontal (F3, FZ, F4), central (C3, CZ, C4), and parietal (P3, PZ, P4) electrodes were selected for statistical analyses (see shaded electrodes contributing to each of these regions).
213-1	49322-49327	Three	_	
213-2	49328-49335	regions	_	
213-3	49335-49336	,	_	
213-4	49337-49349	representing	_	
213-5	49350-49357	frontal	_	
213-6	49358-49359	(	_	
213-7	49359-49361	F3	_	
213-8	49361-49362	,	_	
213-9	49363-49365	FZ	_	
213-10	49365-49366	,	_	
213-11	49367-49369	F4	_	
213-12	49369-49370	)	_	
213-13	49370-49371	,	_	
213-14	49372-49379	central	_	
213-15	49380-49381	(	_	
213-16	49381-49383	C3	_	
213-17	49383-49384	,	_	
213-18	49385-49387	CZ	_	
213-19	49387-49388	,	_	
213-20	49389-49391	C4	_	
213-21	49391-49392	)	_	
213-22	49392-49393	,	_	
213-23	49394-49397	and	_	
213-24	49398-49406	parietal	_	
213-25	49407-49408	(	_	
213-26	49408-49410	P3	_	
213-27	49410-49411	,	_	
213-28	49412-49414	PZ	_	
213-29	49414-49415	,	_	
213-30	49416-49418	P4	_	
213-31	49418-49419	)	_	
213-32	49420-49430	electrodes	_	
213-33	49431-49435	were	_	
213-34	49436-49444	selected	_	
213-35	49445-49448	for	_	
213-36	49449-49460	statistical	_	
213-37	49461-49469	analyses	_	
213-38	49470-49471	(	_	
213-39	49471-49474	see	_	
213-40	49475-49481	shaded	_	
213-41	49482-49492	electrodes	_	
213-42	49493-49505	contributing	_	
213-43	49506-49508	to	_	
213-44	49509-49513	each	_	
213-45	49514-49516	of	_	
213-46	49517-49522	these	_	
213-47	49523-49530	regions	_	
213-48	49530-49531	)	_	
213-49	49531-49532	.	_	

#Text=Theta-band response elicited by loss (A) and gain (B) feedback in the gambling task.
214-1	49533-49543	Theta-band	_	
214-2	49544-49552	response	_	
214-3	49553-49561	elicited	_	
214-4	49562-49564	by	_	
214-5	49565-49569	loss	_	
214-6	49570-49571	(	_	
214-7	49571-49572	A	_	
214-8	49572-49573	)	_	
214-9	49574-49577	and	_	
214-10	49578-49582	gain	_	
214-11	49583-49584	(	_	
214-12	49584-49585	B	_	
214-13	49585-49586	)	_	
214-14	49587-49595	feedback	_	
214-15	49596-49598	in	_	
214-16	49599-49602	the	_	
214-17	49603-49611	gambling	_	
214-18	49612-49616	task	_	
214-19	49616-49617	.	_	

#Text=Log-transformed theta power (estimated marginal means) is plotted as a function of scalp region and rs702859 genotype.
215-1	49618-49633	Log-transformed	_	
215-2	49634-49639	theta	_	
215-3	49640-49645	power	_	
215-4	49646-49647	(	_	
215-5	49647-49656	estimated	_	
215-6	49657-49665	marginal	_	
215-7	49666-49671	means	_	
215-8	49671-49672	)	_	
215-9	49673-49675	is	_	
215-10	49676-49683	plotted	_	
215-11	49684-49686	as	_	
215-12	49687-49688	a	_	
215-13	49689-49697	function	_	
215-14	49698-49700	of	_	
215-15	49701-49706	scalp	_	
215-16	49707-49713	region	_	
215-17	49714-49717	and	_	
215-18	49718-49726	rs702859	_	
215-19	49727-49735	genotype	_	
215-20	49735-49736	.	_	

#Text=Bonferroni adjusted multiple comparisons of log-transformed theta power (estimated marginal means) across genotypes [AA/0 = green line; AG/1 = blue line; GG/2 = red line] at frontal, central, and parietal regions during loss (left panel) and gain condition (right panels) in all subjects.
216-1	49737-49747	Bonferroni	_	
216-2	49748-49756	adjusted	_	
216-3	49757-49765	multiple	_	
216-4	49766-49777	comparisons	_	
216-5	49778-49780	of	_	
216-6	49781-49796	log-transformed	_	
216-7	49797-49802	theta	_	
216-8	49803-49808	power	_	
216-9	49809-49810	(	_	
216-10	49810-49819	estimated	_	
216-11	49820-49828	marginal	_	
216-12	49829-49834	means	_	
216-13	49834-49835	)	_	
216-14	49836-49842	across	_	
216-15	49843-49852	genotypes	_	
216-16	49853-49854	[	_	
216-17	49854-49856	AA	_	
216-18	49856-49857	/	_	
216-19	49857-49858	0	_	
216-20	49859-49860	=	_	
216-21	49861-49866	green	_	
216-22	49867-49871	line	_	
216-23	49871-49872	;	_	
216-24	49873-49875	AG	_	
216-25	49875-49876	/	_	
216-26	49876-49877	1	_	
216-27	49878-49879	=	_	
216-28	49880-49884	blue	_	
216-29	49885-49889	line	_	
216-30	49889-49890	;	_	
216-31	49891-49893	GG	_	
216-32	49893-49894	/	_	
216-33	49894-49895	2	_	
216-34	49896-49897	=	_	
216-35	49898-49901	red	_	
216-36	49902-49906	line	_	
216-37	49906-49907	]	_	
216-38	49908-49910	at	_	
216-39	49911-49918	frontal	_	
216-40	49918-49919	,	_	
216-41	49920-49927	central	_	
216-42	49927-49928	,	_	
216-43	49929-49932	and	_	
216-44	49933-49941	parietal	_	
216-45	49942-49949	regions	_	
216-46	49950-49956	during	_	
216-47	49957-49961	loss	_	
216-48	49962-49963	(	_	
216-49	49963-49967	left	_	
216-50	49968-49973	panel	_	
216-51	49973-49974	)	_	
216-52	49975-49978	and	_	
216-53	49979-49983	gain	_	
216-54	49984-49993	condition	_	
216-55	49994-49995	(	_	
216-56	49995-50000	right	_	
216-57	50001-50007	panels	_	
216-58	50007-50008	)	_	
216-59	50009-50011	in	_	
216-60	50012-50015	all	_	
216-61	50016-50024	subjects	_	
216-62	50024-50025	.	_	

#Text=Significant differences in theta power between the genotypes (0, 1, and 2) have been marked with corresponding genotype numbers and asterisks (*p < 0.05 and **p < 0.01).
217-1	50026-50037	Significant	_	
217-2	50038-50049	differences	_	
217-3	50050-50052	in	_	
217-4	50053-50058	theta	_	
217-5	50059-50064	power	_	
217-6	50065-50072	between	_	
217-7	50073-50076	the	_	
217-8	50077-50086	genotypes	_	
217-9	50087-50088	(	_	
217-10	50088-50089	0	_	
217-11	50089-50090	,	_	
217-12	50091-50092	1	_	
217-13	50092-50093	,	_	
217-14	50094-50097	and	_	
217-15	50098-50099	2	_	
217-16	50099-50100	)	_	
217-17	50101-50105	have	_	
217-18	50106-50110	been	_	
217-19	50111-50117	marked	_	
217-20	50118-50122	with	_	
217-21	50123-50136	corresponding	_	
217-22	50137-50145	genotype	_	
217-23	50146-50153	numbers	_	
217-24	50154-50157	and	_	
217-25	50158-50167	asterisks	_	
217-26	50168-50169	(	_	
217-27	50169-50170	*	_	
217-28	50170-50171	p	_	
217-29	50172-50173	<	_	
217-30	50174-50178	0.05	_	
217-31	50179-50182	and	_	
217-32	50183-50184	*	_	
217-33	50184-50185	*	_	
217-34	50185-50186	p	_	
217-35	50187-50188	<	_	
217-36	50189-50193	0.01	_	
217-37	50193-50194	)	_	
217-38	50194-50195	.	_	

#Text=Additive effect of genotype [GG > AG > AA] is seen with significant differences observed between AA and GG [GG > AA] at central (*p < 0.05) and parietal (**p < 0.01) regions during both loss and gain condition, while the gain condition additionally showed a significant difference between AG and GG [GG > AA] at the parietal region (*p < 0.05).
218-1	50196-50204	Additive	_	
218-2	50205-50211	effect	_	
218-3	50212-50214	of	_	
218-4	50215-50223	genotype	_	
218-5	50224-50225	[	_	
218-6	50225-50227	GG	_	
218-7	50228-50229	>	_	
218-8	50230-50232	AG	_	
218-9	50233-50234	>	_	
218-10	50235-50237	AA	_	
218-11	50237-50238	]	_	
218-12	50239-50241	is	_	
218-13	50242-50246	seen	_	
218-14	50247-50251	with	_	
218-15	50252-50263	significant	_	
218-16	50264-50275	differences	_	
218-17	50276-50284	observed	_	
218-18	50285-50292	between	_	
218-19	50293-50295	AA	_	
218-20	50296-50299	and	_	
218-21	50300-50302	GG	_	
218-22	50303-50304	[	_	
218-23	50304-50306	GG	_	
218-24	50307-50308	>	_	
218-25	50309-50311	AA	_	
218-26	50311-50312	]	_	
218-27	50313-50315	at	_	
218-28	50316-50323	central	_	
218-29	50324-50325	(	_	
218-30	50325-50326	*	_	
218-31	50326-50327	p	_	
218-32	50328-50329	<	_	
218-33	50330-50334	0.05	_	
218-34	50334-50335	)	_	
218-35	50336-50339	and	_	
218-36	50340-50348	parietal	_	
218-37	50349-50350	(	_	
218-38	50350-50351	*	_	
218-39	50351-50352	*	_	
218-40	50352-50353	p	_	
218-41	50354-50355	<	_	
218-42	50356-50360	0.01	_	
218-43	50360-50361	)	_	
218-44	50362-50369	regions	_	
218-45	50370-50376	during	_	
218-46	50377-50381	both	_	
218-47	50382-50386	loss	_	
218-48	50387-50390	and	_	
218-49	50391-50395	gain	_	
218-50	50396-50405	condition	_	
218-51	50405-50406	,	_	
218-52	50407-50412	while	_	
218-53	50413-50416	the	_	
218-54	50417-50421	gain	_	
218-55	50422-50431	condition	_	
218-56	50432-50444	additionally	_	
218-57	50445-50451	showed	_	
218-58	50452-50453	a	_	
218-59	50454-50465	significant	_	
218-60	50466-50476	difference	_	
218-61	50477-50484	between	_	
218-62	50485-50487	AG	_	
218-63	50488-50491	and	_	
218-64	50492-50494	GG	_	
218-65	50495-50496	[	_	
218-66	50496-50498	GG	_	
218-67	50499-50500	>	_	
218-68	50501-50503	AA	_	
218-69	50503-50504	]	_	
218-70	50505-50507	at	_	
218-71	50508-50511	the	_	
218-72	50512-50520	parietal	_	
218-73	50521-50527	region	_	
218-74	50528-50529	(	_	
218-75	50529-50530	*	_	
218-76	50530-50531	p	_	
218-77	50532-50533	<	_	
218-78	50534-50538	0.05	_	
218-79	50538-50539	)	_	
218-80	50539-50540	.	_	

#Text=Step-wise increase in posterior theta power as a function of minor allele(s) is shown by the difference values between frontal and parietal regions (Frontal – Parietal) within each condition and genotype, positive values represent frontal maxima and negative values parietal maxima (**p < 0.01 and ***p < 0.001).
219-1	50541-50550	Step-wise	_	
219-2	50551-50559	increase	_	
219-3	50560-50562	in	_	
219-4	50563-50572	posterior	_	
219-5	50573-50578	theta	_	
219-6	50579-50584	power	_	
219-7	50585-50587	as	_	
219-8	50588-50589	a	_	
219-9	50590-50598	function	_	
219-10	50599-50601	of	_	
219-11	50602-50607	minor	_	
219-12	50608-50614	allele	_	
219-13	50614-50615	(	_	
219-14	50615-50616	s	_	
219-15	50616-50617	)	_	
219-16	50618-50620	is	_	
219-17	50621-50626	shown	_	
219-18	50627-50629	by	_	
219-19	50630-50633	the	_	
219-20	50634-50644	difference	_	
219-21	50645-50651	values	_	
219-22	50652-50659	between	_	
219-23	50660-50667	frontal	_	
219-24	50668-50671	and	_	
219-25	50672-50680	parietal	_	
219-26	50681-50688	regions	_	
219-27	50689-50690	(	_	
219-28	50690-50697	Frontal	_	
219-29	50698-50699	–	_	
219-30	50700-50708	Parietal	_	
219-31	50708-50709	)	_	
219-32	50710-50716	within	_	
219-33	50717-50721	each	_	
219-34	50722-50731	condition	_	
219-35	50732-50735	and	_	
219-36	50736-50744	genotype	_	
219-37	50744-50745	,	_	
219-38	50746-50754	positive	_	
219-39	50755-50761	values	_	
219-40	50762-50771	represent	_	
219-41	50772-50779	frontal	_	
219-42	50780-50786	maxima	_	
219-43	50787-50790	and	_	
219-44	50791-50799	negative	_	
219-45	50800-50806	values	_	
219-46	50807-50815	parietal	_	
219-47	50816-50822	maxima	_	
219-48	50823-50824	(	_	
219-49	50824-50825	*	_	
219-50	50825-50826	*	_	
219-51	50826-50827	p	_	
219-52	50828-50829	<	_	
219-53	50830-50834	0.01	_	
219-54	50835-50838	and	_	
219-55	50839-50840	*	_	
219-56	50840-50841	*	_	
219-57	50841-50842	*	_	
219-58	50842-50843	p	_	
219-59	50844-50845	<	_	
219-60	50846-50851	0.001	_	
219-61	50851-50852	)	_	
219-62	50852-50853	.	_	

#Text=The vertical error-bars in the line graph represents 1 standard error, shown only for positive or negative direction in order to avoid any overlap with the data lines.
220-1	50854-50857	The	_	
220-2	50858-50866	vertical	_	
220-3	50867-50877	error-bars	_	
220-4	50878-50880	in	_	
220-5	50881-50884	the	_	
220-6	50885-50889	line	_	
220-7	50890-50895	graph	_	
220-8	50896-50906	represents	_	
220-9	50907-50908	1	_	
220-10	50909-50917	standard	_	
220-11	50918-50923	error	_	
220-12	50923-50924	,	_	
220-13	50925-50930	shown	_	
220-14	50931-50935	only	_	
220-15	50936-50939	for	_	
220-16	50940-50948	positive	_	
220-17	50949-50951	or	_	
220-18	50952-50960	negative	_	
220-19	50961-50970	direction	_	
220-20	50971-50973	in	_	
220-21	50974-50979	order	_	
220-22	50980-50982	to	_	
220-23	50983-50988	avoid	_	
220-24	50989-50992	any	_	
220-25	50993-51000	overlap	_	
220-26	51001-51005	with	_	
220-27	51006-51009	the	_	
220-28	51010-51014	data	_	
220-29	51015-51020	lines	_	
220-30	51020-51021	.	_	

#Text=Theta power (in µV2) across genotypes (rs702859) during loss (panel-set A) and gain (panel-set B).
221-1	51022-51027	Theta	_	
221-2	51028-51033	power	_	
221-3	51034-51035	(	_	
221-4	51035-51037	in	_	
221-5	51038-51041	µV2	_	
221-6	51041-51042	)	_	
221-7	51043-51049	across	_	
221-8	51050-51059	genotypes	_	
221-9	51060-51061	(	_	
221-10	51061-51069	rs702859	_	
221-11	51069-51070	)	_	
221-12	51071-51077	during	_	
221-13	51078-51082	loss	_	
221-14	51083-51084	(	_	
221-15	51084-51093	panel-set	_	
221-16	51094-51095	A	_	
221-17	51095-51096	)	_	
221-18	51097-51100	and	_	
221-19	51101-51105	gain	_	
221-20	51106-51107	(	_	
221-21	51107-51116	panel-set	_	
221-22	51117-51118	B	_	
221-23	51118-51119	)	_	
221-24	51119-51120	.	_	

#Text=Within these panel-sets, TF plots (middle panels showing x-axis with time in ms and y-axis with frequency in Hz for the loss and gain conditions at FZ and PZ electrodes) and head maps of absolute (left panels) and Z-scores (right panels) are illustrated.
222-1	51121-51127	Within	_	
222-2	51128-51133	these	_	
222-3	51134-51144	panel-sets	_	
222-4	51144-51145	,	_	
222-5	51146-51148	TF	_	
222-6	51149-51154	plots	_	
222-7	51155-51156	(	_	
222-8	51156-51162	middle	_	
222-9	51163-51169	panels	_	
222-10	51170-51177	showing	_	
222-11	51178-51184	x-axis	_	
222-12	51185-51189	with	_	
222-13	51190-51194	time	_	
222-14	51195-51197	in	_	
222-15	51198-51200	ms	_	
222-16	51201-51204	and	_	
222-17	51205-51211	y-axis	_	
222-18	51212-51216	with	_	
222-19	51217-51226	frequency	_	
222-20	51227-51229	in	_	
222-21	51230-51232	Hz	_	
222-22	51233-51236	for	_	
222-23	51237-51240	the	_	
222-24	51241-51245	loss	_	
222-25	51246-51249	and	_	
222-26	51250-51254	gain	_	
222-27	51255-51265	conditions	_	
222-28	51266-51268	at	_	
222-29	51269-51271	FZ	_	
222-30	51272-51275	and	_	
222-31	51276-51278	PZ	_	
222-32	51279-51289	electrodes	_	
222-33	51289-51290	)	_	
222-34	51291-51294	and	_	
222-35	51295-51299	head	_	
222-36	51300-51304	maps	_	
222-37	51305-51307	of	_	
222-38	51308-51316	absolute	_	
222-39	51317-51318	(	_	
222-40	51318-51322	left	_	
222-41	51323-51329	panels	_	
222-42	51329-51330	)	_	
222-43	51331-51334	and	_	
222-44	51335-51343	Z-scores	_	
222-45	51344-51345	(	_	
222-46	51345-51350	right	_	
222-47	51351-51357	panels	_	
222-48	51357-51358	)	_	
222-49	51359-51362	are	_	
222-50	51363-51374	illustrated	_	
222-51	51374-51375	.	_	

#Text=The dotted vertical line (at 0 ms) in the TF plots represents the onset of outcome stimulus.
223-1	51376-51379	The	_	
223-2	51380-51386	dotted	_	
223-3	51387-51395	vertical	_	
223-4	51396-51400	line	_	
223-5	51401-51402	(	_	
223-6	51402-51404	at	_	
223-7	51405-51406	0	_	
223-8	51407-51409	ms	_	
223-9	51409-51410	)	_	
223-10	51411-51413	in	_	
223-11	51414-51417	the	_	
223-12	51418-51420	TF	_	
223-13	51421-51426	plots	_	
223-14	51427-51437	represents	_	
223-15	51438-51441	the	_	
223-16	51442-51447	onset	_	
223-17	51448-51450	of	_	
223-18	51451-51458	outcome	_	
223-19	51459-51467	stimulus	_	
223-20	51467-51468	.	_	

#Text=The smaller rectangles within the TF plots represent the TFROI of theta power (3.5–7.5 Hz within 200–500 ms) post outcome stimulus.
224-1	51469-51472	The	_	
224-2	51473-51480	smaller	_	
224-3	51481-51491	rectangles	_	
224-4	51492-51498	within	_	
224-5	51499-51502	the	_	
224-6	51503-51505	TF	_	
224-7	51506-51511	plots	_	
224-8	51512-51521	represent	_	
224-9	51522-51525	the	_	
224-10	51526-51531	TFROI	_	
224-11	51532-51534	of	_	
224-12	51535-51540	theta	_	
224-13	51541-51546	power	_	
224-14	51547-51548	(	_	
224-15	51548-51551	3.5	_	
224-16	51551-51552	–	_	
224-17	51552-51555	7.5	_	
224-18	51556-51558	Hz	_	
224-19	51559-51565	within	_	
224-20	51566-51569	200	_	
224-21	51569-51570	–	_	
224-22	51570-51573	500	_	
224-23	51574-51576	ms	_	
224-24	51576-51577	)	_	
224-25	51578-51582	post	_	
224-26	51583-51590	outcome	_	
224-27	51591-51599	stimulus	_	
224-28	51599-51600	.	_	

#Text=During evaluation of loss as well as gain, there is an additive effect of genotypes [GG > AG > AA] with increasing power corresponding the number of minor allele(s) in central and parietal regions.
225-1	51601-51607	During	_	
225-2	51608-51618	evaluation	_	
225-3	51619-51621	of	_	
225-4	51622-51626	loss	_	
225-5	51627-51629	as	_	
225-6	51630-51634	well	_	
225-7	51635-51637	as	_	
225-8	51638-51642	gain	_	
225-9	51642-51643	,	_	
225-10	51644-51649	there	_	
225-11	51650-51652	is	_	
225-12	51653-51655	an	_	
225-13	51656-51664	additive	_	
225-14	51665-51671	effect	_	
225-15	51672-51674	of	_	
225-16	51675-51684	genotypes	_	
225-17	51685-51686	[	_	
225-18	51686-51688	GG	_	
225-19	51689-51690	>	_	
225-20	51691-51693	AG	_	
225-21	51694-51695	>	_	
225-22	51696-51698	AA	_	
225-23	51698-51699	]	_	
225-24	51700-51704	with	_	
225-25	51705-51715	increasing	_	
225-26	51716-51721	power	_	
225-27	51722-51735	corresponding	_	
225-28	51736-51739	the	_	
225-29	51740-51746	number	_	
225-30	51747-51749	of	_	
225-31	51750-51755	minor	_	
225-32	51756-51762	allele	_	
225-33	51762-51763	(	_	
225-34	51763-51764	s	_	
225-35	51764-51765	)	_	
225-36	51766-51768	in	_	
225-37	51769-51776	central	_	
225-38	51777-51780	and	_	
225-39	51781-51789	parietal	_	
225-40	51790-51797	regions	_	
225-41	51797-51798	.	_	

#Text=Subtle topographic differences across genotypes (i.e., minor allele(s) contributing to posteriorization of theta power) are also shown.
226-1	51799-51805	Subtle	_	
226-2	51806-51817	topographic	_	
226-3	51818-51829	differences	_	
226-4	51830-51836	across	_	
226-5	51837-51846	genotypes	_	
226-6	51847-51848	(	_	
226-7	51848-51851	i.e	_	
226-8	51851-51852	.	_	
226-9	51852-51853	,	_	
226-10	51854-51859	minor	_	
226-11	51860-51866	allele	_	
226-12	51866-51867	(	_	
226-13	51867-51868	s	_	
226-14	51868-51869	)	_	
226-15	51870-51882	contributing	_	
226-16	51883-51885	to	_	
226-17	51886-51902	posteriorization	_	
226-18	51903-51905	of	_	
226-19	51906-51911	theta	_	
226-20	51912-51917	power	_	
226-21	51917-51918	)	_	
226-22	51919-51922	are	_	
226-23	51923-51927	also	_	
226-24	51928-51933	shown	_	
226-25	51933-51934	.	_	

#Text=ERP waveforms (panels in columns 2, 3, and 4) flanked by P3 topography (panels in columns 1 and 5) across the genotypes (panels in rows) during loss and gain outcome.
227-1	51935-51938	ERP	_	
227-2	51939-51948	waveforms	_	
227-3	51949-51950	(	_	
227-4	51950-51956	panels	_	
227-5	51957-51959	in	_	
227-6	51960-51967	columns	_	
227-7	51968-51969	2	_	
227-8	51969-51970	,	_	
227-9	51971-51972	3	_	
227-10	51972-51973	,	_	
227-11	51974-51977	and	_	
227-12	51978-51979	4	_	
227-13	51979-51980	)	_	
227-14	51981-51988	flanked	_	
227-15	51989-51991	by	_	
227-16	51992-51994	P3	_	
227-17	51995-52005	topography	_	
227-18	52006-52007	(	_	
227-19	52007-52013	panels	_	
227-20	52014-52016	in	_	
227-21	52017-52024	columns	_	
227-22	52025-52026	1	_	
227-23	52027-52030	and	_	
227-24	52031-52032	5	_	
227-25	52032-52033	)	_	
227-26	52034-52040	across	_	
227-27	52041-52044	the	_	
227-28	52045-52054	genotypes	_	
227-29	52055-52056	(	_	
227-30	52056-52062	panels	_	
227-31	52063-52065	in	_	
227-32	52066-52070	rows	_	
227-33	52070-52071	)	_	
227-34	52072-52078	during	_	
227-35	52079-52083	loss	_	
227-36	52084-52087	and	_	
227-37	52088-52092	gain	_	
227-38	52093-52100	outcome	_	
227-39	52100-52101	.	_	

#Text=The group with minor allele(s) have displayed higher P3 amplitude than the group homozygous for the major allele [GG/AG > AA], prominently at the posterior region, during evaluation of loss as well as gain.
228-1	52102-52105	The	_	
228-2	52106-52111	group	_	
228-3	52112-52116	with	_	
228-4	52117-52122	minor	_	
228-5	52123-52129	allele	_	
228-6	52129-52130	(	_	
228-7	52130-52131	s	_	
228-8	52131-52132	)	_	
228-9	52133-52137	have	_	
228-10	52138-52147	displayed	_	
228-11	52148-52154	higher	_	
228-12	52155-52157	P3	_	
228-13	52158-52167	amplitude	_	
228-14	52168-52172	than	_	
228-15	52173-52176	the	_	
228-16	52177-52182	group	_	
228-17	52183-52193	homozygous	_	
228-18	52194-52197	for	_	
228-19	52198-52201	the	_	
228-20	52202-52207	major	_	
228-21	52208-52214	allele	_	
228-22	52215-52216	[	_	
228-23	52216-52218	GG	_	
228-24	52218-52219	/	_	
228-25	52219-52221	AG	_	
228-26	52222-52223	>	_	
228-27	52224-52226	AA	_	
228-28	52226-52227	]	_	
228-29	52227-52228	,	_	
228-30	52229-52240	prominently	_	
228-31	52241-52243	at	_	
228-32	52244-52247	the	_	
228-33	52248-52257	posterior	_	
228-34	52258-52264	region	_	
228-35	52264-52265	,	_	
228-36	52266-52272	during	_	
228-37	52273-52283	evaluation	_	
228-38	52284-52286	of	_	
228-39	52287-52291	loss	_	
228-40	52292-52294	as	_	
228-41	52295-52299	well	_	
228-42	52300-52302	as	_	
228-43	52303-52307	gain	_	
228-44	52307-52308	.	_	

#Text=Peak P3 amplitude values (in µV) for gain (green) and loss (red) are shown within the panels of ERP waveforms.
229-1	52309-52313	Peak	_	
229-2	52314-52316	P3	_	
229-3	52317-52326	amplitude	_	
229-4	52327-52333	values	_	
229-5	52334-52335	(	_	
229-6	52335-52337	in	_	
229-7	52338-52340	µV	_	
229-8	52340-52341	)	_	
229-9	52342-52345	for	_	
229-10	52346-52350	gain	_	
229-11	52351-52352	(	_	
229-12	52352-52357	green	_	
229-13	52357-52358	)	_	
229-14	52359-52362	and	_	
229-15	52363-52367	loss	_	
229-16	52368-52369	(	_	
229-17	52369-52372	red	_	
229-18	52372-52373	)	_	
229-19	52374-52377	are	_	
229-20	52378-52383	shown	_	
229-21	52384-52390	within	_	
229-22	52391-52394	the	_	
229-23	52395-52401	panels	_	
229-24	52402-52404	of	_	
229-25	52405-52408	ERP	_	
229-26	52409-52418	waveforms	_	
229-27	52418-52419	.	_	

#Text=The dotted vertical line (at 0 ms) in the waveform panels represents the onset of outcome stimulus.
230-1	52420-52423	The	_	
230-2	52424-52430	dotted	_	
230-3	52431-52439	vertical	_	
230-4	52440-52444	line	_	
230-5	52445-52446	(	_	
230-6	52446-52448	at	_	
230-7	52449-52450	0	_	
230-8	52451-52453	ms	_	
230-9	52453-52454	)	_	
230-10	52455-52457	in	_	
230-11	52458-52461	the	_	
230-12	52462-52470	waveform	_	
230-13	52471-52477	panels	_	
230-14	52478-52488	represents	_	
230-15	52489-52492	the	_	
230-16	52493-52498	onset	_	
230-17	52499-52501	of	_	
230-18	52502-52509	outcome	_	
230-19	52510-52518	stimulus	_	
230-20	52518-52519	.	_	

#Text=Uniform color scales have been used for all the head plots.
231-1	52520-52527	Uniform	_	
231-2	52528-52533	color	_	
231-3	52534-52540	scales	_	
231-4	52541-52545	have	_	
231-5	52546-52550	been	_	
231-6	52551-52555	used	_	
231-7	52556-52559	for	_	
231-8	52560-52563	all	_	
231-9	52564-52567	the	_	
231-10	52568-52572	head	_	
231-11	52573-52578	plots	_	
231-12	52578-52579	.	_	

#Text=Theta power (in µV2) across genotypes (rs702859) and age groups during loss (left columns) and gain condition (right columns).
232-1	52580-52585	Theta	_	
232-2	52586-52591	power	_	
232-3	52592-52593	(	_	
232-4	52593-52595	in	_	
232-5	52596-52599	µV2	_	
232-6	52599-52600	)	_	
232-7	52601-52607	across	_	
232-8	52608-52617	genotypes	_	
232-9	52618-52619	(	_	
232-10	52619-52627	rs702859	_	
232-11	52627-52628	)	_	
232-12	52629-52632	and	_	
232-13	52633-52636	age	_	
232-14	52637-52643	groups	_	
232-15	52644-52650	during	_	
232-16	52651-52655	loss	_	
232-17	52656-52657	(	_	
232-18	52657-52661	left	_	
232-19	52662-52669	columns	_	
232-20	52669-52670	)	_	
232-21	52671-52674	and	_	
232-22	52675-52679	gain	_	
232-23	52680-52689	condition	_	
232-24	52690-52691	(	_	
232-25	52691-52696	right	_	
232-26	52697-52704	columns	_	
232-27	52704-52705	)	_	
232-28	52705-52706	.	_	

#Text=Additive effect of genotypes [GG > AG > AA] with increasing power corresponding the number of minor allele(s) in adolescent (17–18 years) and adult (19–25 years) groups is shown during evaluation of loss as well as gain.
233-1	52707-52715	Additive	_	
233-2	52716-52722	effect	_	
233-3	52723-52725	of	_	
233-4	52726-52735	genotypes	_	
233-5	52736-52737	[	_	
233-6	52737-52739	GG	_	
233-7	52740-52741	>	_	
233-8	52742-52744	AG	_	
233-9	52745-52746	>	_	
233-10	52747-52749	AA	_	
233-11	52749-52750	]	_	
233-12	52751-52755	with	_	
233-13	52756-52766	increasing	_	
233-14	52767-52772	power	_	
233-15	52773-52786	corresponding	_	
233-16	52787-52790	the	_	
233-17	52791-52797	number	_	
233-18	52798-52800	of	_	
233-19	52801-52806	minor	_	
233-20	52807-52813	allele	_	
233-21	52813-52814	(	_	
233-22	52814-52815	s	_	
233-23	52815-52816	)	_	
233-24	52817-52819	in	_	
233-25	52820-52830	adolescent	_	
233-26	52831-52832	(	_	
233-27	52832-52834	17	_	
233-28	52834-52835	–	_	
233-29	52835-52837	18	_	
233-30	52838-52843	years	_	
233-31	52843-52844	)	_	
233-32	52845-52848	and	_	
233-33	52849-52854	adult	_	
233-34	52855-52856	(	_	
233-35	52856-52858	19	_	
233-36	52858-52859	–	_	
233-37	52859-52861	25	_	
233-38	52862-52867	years	_	
233-39	52867-52868	)	_	
233-40	52869-52875	groups	_	
233-41	52876-52878	is	_	
233-42	52879-52884	shown	_	
233-43	52885-52891	during	_	
233-44	52892-52902	evaluation	_	
233-45	52903-52905	of	_	
233-46	52906-52910	loss	_	
233-47	52911-52913	as	_	
233-48	52914-52918	well	_	
233-49	52919-52921	as	_	
233-50	52922-52926	gain	_	
233-51	52926-52927	.	_	

#Text=The adolescents show more theta power and more diffused posterior topography than adults in each genotype group (top three rows) and in the combined sample (bottom row of head maps).
234-1	52928-52931	The	_	
234-2	52932-52943	adolescents	_	
234-3	52944-52948	show	_	
234-4	52949-52953	more	_	
234-5	52954-52959	theta	_	
234-6	52960-52965	power	_	
234-7	52966-52969	and	_	
234-8	52970-52974	more	_	
234-9	52975-52983	diffused	_	
234-10	52984-52993	posterior	_	
234-11	52994-53004	topography	_	
234-12	53005-53009	than	_	
234-13	53010-53016	adults	_	
234-14	53017-53019	in	_	
234-15	53020-53024	each	_	
234-16	53025-53033	genotype	_	
234-17	53034-53039	group	_	
234-18	53040-53041	(	_	
234-19	53041-53044	top	_	
234-20	53045-53050	three	_	
234-21	53051-53055	rows	_	
234-22	53055-53056	)	_	
234-23	53057-53060	and	_	
234-24	53061-53063	in	_	
234-25	53064-53067	the	_	
234-26	53068-53076	combined	_	
234-27	53077-53083	sample	_	
234-28	53084-53085	(	_	
234-29	53085-53091	bottom	_	
234-30	53092-53095	row	_	
234-31	53096-53098	of	_	
234-32	53099-53103	head	_	
234-33	53104-53108	maps	_	
234-34	53108-53109	)	_	
234-35	53109-53110	.	_	

#Text=Uniform color scales have been used for all the head plots.
235-1	53111-53118	Uniform	_	
235-2	53119-53124	color	_	
235-3	53125-53131	scales	_	
235-4	53132-53136	have	_	
235-5	53137-53141	been	_	
235-6	53142-53146	used	_	
235-7	53147-53150	for	_	
235-8	53151-53154	all	_	
235-9	53155-53158	the	_	
235-10	53159-53163	head	_	
235-11	53164-53169	plots	_	
235-12	53169-53170	.	_	

#Text=Number and percentage of participants categorized by genotypes across gender and family type (CC = community comparison family; AD = alcoholism dense family).
236-1	53171-53177	Number	_	
236-2	53178-53181	and	_	
236-3	53182-53192	percentage	_	
236-4	53193-53195	of	_	
236-5	53196-53208	participants	_	
236-6	53209-53220	categorized	_	
236-7	53221-53223	by	_	
236-8	53224-53233	genotypes	_	
236-9	53234-53240	across	_	
236-10	53241-53247	gender	_	
236-11	53248-53251	and	_	
236-12	53252-53258	family	_	
236-13	53259-53263	type	_	
236-14	53264-53265	(	_	
236-15	53265-53267	CC	_	
236-16	53268-53269	=	_	
236-17	53270-53279	community	_	
236-18	53280-53290	comparison	_	
236-19	53291-53297	family	_	
236-20	53297-53298	;	_	
236-21	53299-53301	AD	_	
236-22	53302-53303	=	_	
236-23	53304-53314	alcoholism	_	
236-24	53315-53320	dense	_	
236-25	53321-53327	family	_	
236-26	53327-53328	)	_	
236-27	53328-53329	.	_	

#Text=Groups(Age range =17–25 years)\tGenotype\tTotal\t \t0 (AA)Mean age = 19.29\t1 (AG/GA)Mean age = 19.25\t2 (GG)Mean age = 19.41\t \tGender\tMale\t426 (50.84%)\t298 (48.77%)\t76 (50.00%)\t800 (49.97%)\t \tFemale\t412 (49.16%)\t313 (51.23%)\t76 (50.00%)\t801 (50.03%)\t \tTotal\t838 (100%)\t611 (100%)\t152 (100%)\t1601 (100%)\t \tFamilyType\tCC\t95 (11.34%)\t98 (16.04%)\t31 (20.39%)\t224 (13.99%)\t \tAD\t743 (88.66%)\t513 (83.96%)\t121 (79.61%)\t1377 (86.01%)\t \tTotal\t838 (100%)\t611 (100%)\t152 (100%)\t1601 (100%)\t \t
#Text=Significant main and interaction effects of theta power (Bonferroni corrected) as revealed by the RM-ANOVA analysis.
237-1	53330-53336	Groups	_	
237-2	53336-53337	(	_	
237-3	53337-53340	Age	_	
237-4	53341-53346	range	_	
237-5	53347-53348	=	_	
237-6	53348-53350	17	_	
237-7	53350-53351	–	_	
237-8	53351-53353	25	_	
237-9	53354-53359	years	_	
237-10	53359-53360	)	_	
237-11	53361-53369	Genotype	_	
237-12	53370-53375	Total	_	
237-13	53378-53379	0	_	
237-14	53380-53381	(	_	
237-15	53381-53383	AA	_	
237-16	53383-53384	)	_	
237-17	53384-53388	Mean	_	
237-18	53389-53392	age	_	
237-19	53393-53394	=	_	
237-20	53395-53400	19.29	_	
237-21	53401-53402	1	_	
237-22	53403-53404	(	_	
237-23	53404-53406	AG	_	
237-24	53406-53407	/	_	
237-25	53407-53409	GA	_	
237-26	53409-53410	)	_	
237-27	53410-53414	Mean	_	
237-28	53415-53418	age	_	
237-29	53419-53420	=	_	
237-30	53421-53426	19.25	_	
237-31	53427-53428	2	_	
237-32	53429-53430	(	_	
237-33	53430-53432	GG	_	
237-34	53432-53433	)	_	
237-35	53433-53437	Mean	_	
237-36	53438-53441	age	_	
237-37	53442-53443	=	_	
237-38	53444-53449	19.41	_	
237-39	53452-53458	Gender	_	
237-40	53459-53463	Male	_	
237-41	53464-53467	426	_	
237-42	53468-53469	(	_	
237-43	53469-53475	50.84%	_	
237-44	53475-53476	)	_	
237-45	53477-53480	298	_	
237-46	53481-53482	(	_	
237-47	53482-53488	48.77%	_	
237-48	53488-53489	)	_	
237-49	53490-53492	76	_	
237-50	53493-53494	(	_	
237-51	53494-53500	50.00%	_	
237-52	53500-53501	)	_	
237-53	53502-53505	800	_	
237-54	53506-53507	(	_	
237-55	53507-53513	49.97%	_	
237-56	53513-53514	)	_	
237-57	53517-53523	Female	_	
237-58	53524-53527	412	_	
237-59	53528-53529	(	_	
237-60	53529-53535	49.16%	_	
237-61	53535-53536	)	_	
237-62	53537-53540	313	_	
237-63	53541-53542	(	_	
237-64	53542-53548	51.23%	_	
237-65	53548-53549	)	_	
237-66	53550-53552	76	_	
237-67	53553-53554	(	_	
237-68	53554-53560	50.00%	_	
237-69	53560-53561	)	_	
237-70	53562-53565	801	_	
237-71	53566-53567	(	_	
237-72	53567-53573	50.03%	_	
237-73	53573-53574	)	_	
237-74	53577-53582	Total	_	
237-75	53583-53586	838	_	
237-76	53587-53588	(	_	
237-77	53588-53592	100%	_	
237-78	53592-53593	)	_	
237-79	53594-53597	611	_	
237-80	53598-53599	(	_	
237-81	53599-53603	100%	_	
237-82	53603-53604	)	_	
237-83	53605-53608	152	_	
237-84	53609-53610	(	_	
237-85	53610-53614	100%	_	
237-86	53614-53615	)	_	
237-87	53616-53620	1601	_	
237-88	53621-53622	(	_	
237-89	53622-53626	100%	_	
237-90	53626-53627	)	_	
237-91	53630-53640	FamilyType	_	
237-92	53641-53643	CC	_	
237-93	53644-53646	95	_	
237-94	53647-53648	(	_	
237-95	53648-53654	11.34%	_	
237-96	53654-53655	)	_	
237-97	53656-53658	98	_	
237-98	53659-53660	(	_	
237-99	53660-53666	16.04%	_	
237-100	53666-53667	)	_	
237-101	53668-53670	31	_	
237-102	53671-53672	(	_	
237-103	53672-53678	20.39%	_	
237-104	53678-53679	)	_	
237-105	53680-53683	224	_	
237-106	53684-53685	(	_	
237-107	53685-53691	13.99%	_	
237-108	53691-53692	)	_	
237-109	53695-53697	AD	_	
237-110	53698-53701	743	_	
237-111	53702-53703	(	_	
237-112	53703-53709	88.66%	_	
237-113	53709-53710	)	_	
237-114	53711-53714	513	_	
237-115	53715-53716	(	_	
237-116	53716-53722	83.96%	_	
237-117	53722-53723	)	_	
237-118	53724-53727	121	_	
237-119	53728-53729	(	_	
237-120	53729-53735	79.61%	_	
237-121	53735-53736	)	_	
237-122	53737-53741	1377	_	
237-123	53742-53743	(	_	
237-124	53743-53749	86.01%	_	
237-125	53749-53750	)	_	
237-126	53753-53758	Total	_	
237-127	53759-53762	838	_	
237-128	53763-53764	(	_	
237-129	53764-53768	100%	_	
237-130	53768-53769	)	_	
237-131	53770-53773	611	_	
237-132	53774-53775	(	_	
237-133	53775-53779	100%	_	
237-134	53779-53780	)	_	
237-135	53781-53784	152	_	
237-136	53785-53786	(	_	
237-137	53786-53790	100%	_	
237-138	53790-53791	)	_	
237-139	53792-53796	1601	_	
237-140	53797-53798	(	_	
237-141	53798-53802	100%	_	
237-142	53802-53803	)	_	
237-143	53807-53818	Significant	_	
237-144	53819-53823	main	_	
237-145	53824-53827	and	_	
237-146	53828-53839	interaction	_	
237-147	53840-53847	effects	_	
237-148	53848-53850	of	_	
237-149	53851-53856	theta	_	
237-150	53857-53862	power	_	
237-151	53863-53864	(	_	
237-152	53864-53874	Bonferroni	_	
237-153	53875-53884	corrected	_	
237-154	53884-53885	)	_	
237-155	53886-53888	as	_	
237-156	53889-53897	revealed	_	
237-157	53898-53900	by	_	
237-158	53901-53904	the	_	
237-159	53905-53913	RM-ANOVA	_	
237-160	53914-53922	analysis	_	
237-161	53922-53923	.	_	

#Text=Factor(s)\tdf\tF\tp\tη2\t \tGenotype\t2 / 1465\t3.68\t0.0255*\t0.0050\t \tCondition\t1 / 1465\t4.07\t0.0439*\t0.0028\t \tRegion\t2 / 1465\t3.77\t0.0233*\t0.0051\t \tGenotype × Condition\t2 / 1465\t0.91\t0.3386\t0.0012\t \tGenotype × Region\t4 / 2930\t2.49\t0.0411*\t0.0034\t \tCondition × Region\t2 / 1465\t3.08\t0.0462*\t0.0042\t \tGenotype × Condition × Region\t4 / 2930\t0.46\t0.7636\t0.0006\t \t
#Text=Degrees of freedom (df) for hypothesis and error, F-value, p-value, level of significance (*p < 0.05, ** p < 0.01), and effect size (partial eta square, η2) are shown.)
238-1	53924-53930	Factor	_	
238-2	53930-53931	(	_	
238-3	53931-53932	s	_	
238-4	53932-53933	)	_	
238-5	53934-53936	df	_	
238-6	53937-53938	F	_	
238-7	53939-53940	p	_	
238-8	53941-53943	η2	_	
238-9	53946-53954	Genotype	_	
238-10	53955-53956	2	_	
238-11	53957-53958	/	_	
238-12	53959-53963	1465	_	
238-13	53964-53968	3.68	_	
238-14	53969-53975	0.0255	_	
238-15	53975-53976	*	_	
238-16	53977-53983	0.0050	_	
238-17	53986-53995	Condition	_	
238-18	53996-53997	1	_	
238-19	53998-53999	/	_	
238-20	54000-54004	1465	_	
238-21	54005-54009	4.07	_	
238-22	54010-54016	0.0439	_	
238-23	54016-54017	*	_	
238-24	54018-54024	0.0028	_	
238-25	54027-54033	Region	_	
238-26	54034-54035	2	_	
238-27	54036-54037	/	_	
238-28	54038-54042	1465	_	
238-29	54043-54047	3.77	_	
238-30	54048-54054	0.0233	_	
238-31	54054-54055	*	_	
238-32	54056-54062	0.0051	_	
238-33	54065-54073	Genotype	_	
238-34	54074-54075	×	_	
238-35	54076-54085	Condition	_	
238-36	54086-54087	2	_	
238-37	54088-54089	/	_	
238-38	54090-54094	1465	_	
238-39	54095-54099	0.91	_	
238-40	54100-54106	0.3386	_	
238-41	54107-54113	0.0012	_	
238-42	54116-54124	Genotype	_	
238-43	54125-54126	×	_	
238-44	54127-54133	Region	_	
238-45	54134-54135	4	_	
238-46	54136-54137	/	_	
238-47	54138-54142	2930	_	
238-48	54143-54147	2.49	_	
238-49	54148-54154	0.0411	_	
238-50	54154-54155	*	_	
238-51	54156-54162	0.0034	_	
238-52	54165-54174	Condition	_	
238-53	54175-54176	×	_	
238-54	54177-54183	Region	_	
238-55	54184-54185	2	_	
238-56	54186-54187	/	_	
238-57	54188-54192	1465	_	
238-58	54193-54197	3.08	_	
238-59	54198-54204	0.0462	_	
238-60	54204-54205	*	_	
238-61	54206-54212	0.0042	_	
238-62	54215-54223	Genotype	_	
238-63	54224-54225	×	_	
238-64	54226-54235	Condition	_	
238-65	54236-54237	×	_	
238-66	54238-54244	Region	_	
238-67	54245-54246	4	_	
238-68	54247-54248	/	_	
238-69	54249-54253	2930	_	
238-70	54254-54258	0.46	_	
238-71	54259-54265	0.7636	_	
238-72	54266-54272	0.0006	_	
238-73	54276-54283	Degrees	_	
238-74	54284-54286	of	_	
238-75	54287-54294	freedom	_	
238-76	54295-54296	(	_	
238-77	54296-54298	df	_	
238-78	54298-54299	)	_	
238-79	54300-54303	for	_	
238-80	54304-54314	hypothesis	_	
238-81	54315-54318	and	_	
238-82	54319-54324	error	_	
238-83	54324-54325	,	_	
238-84	54326-54333	F-value	_	
238-85	54333-54334	,	_	
238-86	54335-54342	p-value	_	
238-87	54342-54343	,	_	
238-88	54344-54349	level	_	
238-89	54350-54352	of	_	
238-90	54353-54365	significance	_	
238-91	54366-54367	(	_	
238-92	54367-54368	*	_	
238-93	54368-54369	p	_	
238-94	54370-54371	<	_	
238-95	54372-54376	0.05	_	
238-96	54376-54377	,	_	
238-97	54378-54379	*	_	
238-98	54379-54380	*	_	
238-99	54381-54382	p	_	
238-100	54383-54384	<	_	
238-101	54385-54389	0.01	_	
238-102	54389-54390	)	_	
238-103	54390-54391	,	_	
238-104	54392-54395	and	_	
238-105	54396-54402	effect	_	
238-106	54403-54407	size	_	
238-107	54408-54409	(	_	
238-108	54409-54416	partial	_	
238-109	54417-54420	eta	_	
238-110	54421-54427	square	_	
238-111	54427-54428	,	_	
238-112	54429-54431	η2	_	
238-113	54431-54432	)	_	
238-114	54433-54436	are	_	
238-115	54437-54442	shown	_	
238-116	54442-54443	.	_	
238-117	54443-54444	)	_	

#Text=Highlights
#Text=The effects of a single nucleotide polymorphism (SNP) of the KCNJ6 gene, rs702859, on theta oscillations during reward processing was examined
#Text=Theta power increased significantly across genotypes as a function of minor allele dose (GG > AG > AA) in posterior regions in both loss and gain conditions
#Text=The subgroups with minor allele(s) (GG and AG) showed less frontalization than those with the AA genotype, perhaps suggesting a delay in brain maturation
#Text=Growing evidence from studies suggests that KCNJ6 may be a promising therapeutic target for alcoholism and related disorders
#Text=Functional studies on the KCNJ6 system may shed further light on neurogenetic mechanisms underlying cognitive processes and disorders
239-1	54445-54455	Highlights	_	
239-2	54456-54459	The	_	
239-3	54460-54467	effects	_	
239-4	54468-54470	of	_	
239-5	54471-54472	a	_	
239-6	54473-54479	single	_	
239-7	54480-54490	nucleotide	_	
239-8	54491-54503	polymorphism	_	
239-9	54504-54505	(	_	
239-10	54505-54508	SNP	_	
239-11	54508-54509	)	_	
239-12	54510-54512	of	_	
239-13	54513-54516	the	_	
239-14	54517-54522	KCNJ6	_	
239-15	54523-54527	gene	_	
239-16	54527-54528	,	_	
239-17	54529-54537	rs702859	_	
239-18	54537-54538	,	_	
239-19	54539-54541	on	_	
239-20	54542-54547	theta	_	
239-21	54548-54560	oscillations	_	
239-22	54561-54567	during	_	
239-23	54568-54574	reward	_	
239-24	54575-54585	processing	_	
239-25	54586-54589	was	_	
239-26	54590-54598	examined	_	
239-27	54599-54604	Theta	_	
239-28	54605-54610	power	_	
239-29	54611-54620	increased	_	
239-30	54621-54634	significantly	_	
239-31	54635-54641	across	_	
239-32	54642-54651	genotypes	_	
239-33	54652-54654	as	_	
239-34	54655-54656	a	_	
239-35	54657-54665	function	_	
239-36	54666-54668	of	_	
239-37	54669-54674	minor	_	
239-38	54675-54681	allele	_	
239-39	54682-54686	dose	_	
239-40	54687-54688	(	_	
239-41	54688-54690	GG	_	
239-42	54691-54692	>	_	
239-43	54693-54695	AG	_	
239-44	54696-54697	>	_	
239-45	54698-54700	AA	_	
239-46	54700-54701	)	_	
239-47	54702-54704	in	_	
239-48	54705-54714	posterior	_	
239-49	54715-54722	regions	_	
239-50	54723-54725	in	_	
239-51	54726-54730	both	_	
239-52	54731-54735	loss	_	
239-53	54736-54739	and	_	
239-54	54740-54744	gain	_	
239-55	54745-54755	conditions	_	
239-56	54756-54759	The	_	
239-57	54760-54769	subgroups	_	
239-58	54770-54774	with	_	
239-59	54775-54780	minor	_	
239-60	54781-54787	allele	_	
239-61	54787-54788	(	_	
239-62	54788-54789	s	_	
239-63	54789-54790	)	_	
239-64	54791-54792	(	_	
239-65	54792-54794	GG	_	
239-66	54795-54798	and	_	
239-67	54799-54801	AG	_	
239-68	54801-54802	)	_	
239-69	54803-54809	showed	_	
239-70	54810-54814	less	_	
239-71	54815-54829	frontalization	_	
239-72	54830-54834	than	_	
239-73	54835-54840	those	_	
239-74	54841-54845	with	_	
239-75	54846-54849	the	_	
239-76	54850-54852	AA	_	
239-77	54853-54861	genotype	_	
239-78	54861-54862	,	_	
239-79	54863-54870	perhaps	_	
239-80	54871-54881	suggesting	_	
239-81	54882-54883	a	_	
239-82	54884-54889	delay	_	
239-83	54890-54892	in	_	
239-84	54893-54898	brain	_	
239-85	54899-54909	maturation	_	
239-86	54910-54917	Growing	_	
239-87	54918-54926	evidence	_	
239-88	54927-54931	from	_	
239-89	54932-54939	studies	_	
239-90	54940-54948	suggests	_	
239-91	54949-54953	that	_	
239-92	54954-54959	KCNJ6	_	
239-93	54960-54963	may	_	
239-94	54964-54966	be	_	
239-95	54967-54968	a	_	
239-96	54969-54978	promising	_	
239-97	54979-54990	therapeutic	_	
239-98	54991-54997	target	_	
239-99	54998-55001	for	_	
239-100	55002-55012	alcoholism	_	
239-101	55013-55016	and	_	
239-102	55017-55024	related	_	
239-103	55025-55034	disorders	_	
239-104	55035-55045	Functional	_	
239-105	55046-55053	studies	_	
239-106	55054-55056	on	_	
239-107	55057-55060	the	_	
239-108	55061-55066	KCNJ6	_	
239-109	55067-55073	system	_	
239-110	55074-55077	may	_	
239-111	55078-55082	shed	_	
239-112	55083-55090	further	_	
239-113	55091-55096	light	_	
239-114	55097-55099	on	_	
239-115	55100-55112	neurogenetic	_	
239-116	55113-55123	mechanisms	_	
239-117	55124-55134	underlying	_	
239-118	55135-55144	cognitive	_	
239-119	55145-55154	processes	_	
239-120	55155-55158	and	_	
239-121	55159-55168	disorders	_	
